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Abstract 
The liver has a major role in the metabolism of both endogenous and exogenous compounds. 
In drug development, reliable and reproducible results regarding the toxicity of a new 
compound must be obtained. The gold standard is freshly isolated primary human 
hepatocytes; however, these are costly, difficult to obtain regularly and cannot be cultured 
extensively. Secondary hepatocyte cell lines are cheaper with a much longer lifespan in culture 
but do not accurately reflect the expression profile of a hepatocyte. The aim of this work was 
to promote differentiation of hepatic carcinoma cell lines towards the in vivo hepatic profile 
and potentially create a well defined and easily accessible model for early stage drug testing. 
Initial profiling of HepG2 and Huh7 for differentiation markers, transporters and enzymes was 
carried out by qPCR. Differentiation was attempted by use of growth factors and dimethyl 
sulfoxide (DMSO) for periods of up to thirty days. Analysis of differentiation markers by qPCR 
indicated that 1% DMSO treatment for at least 15 days promoted maturation most effectively. 
Cells treated with 1% DMSO were analysed for mRNA expression of selected transporters and 
enzymes, followed by treatment with typical inducers, Western blotting and functional assays 
to assess the presence and function of certain proteins. 
Although initial results showed potential, further analyses of the 1% DMSO treated cells were 
less promising. Analysis of transporter and enzyme mRNA expression revealed that many 
levels did not change favourably towards those observed in liver, or significantly changed from 
control but remained vastly removed from liver. Results from protein and induction 
experiments also indicated no benefit of 15-day DMSO treatment in either cell line. In 
conclusion, 1% DMSO treatment does not promote differentiation towards a more 
representative hepatic profile in either cell line; alternative methods are needed to develop a 
more heptocyte-like model using these cells. 
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Chapter 1 – Introduction 
1.1 – General introduction 
Drugs and other xenobiotics undergo metabolism and/or elimination as part of the body’s 
mechanism to avoid toxicity. A large number of systems and pathways combine to flush these 
xenobiotics from the body and the liver plays a central role in this process, utilising a variety of 
uptake and excretion systems as well as conducting phase I and phase II metabolism. It is often 
during uptake and metabolism of compounds that toxicity can occur. This is a major hurdle 
during development of new drugs; a compound producing an unacceptable toxic effect in the 
body cannot be used. 
 A high percentage of drug withdrawals from the market are due to toxicity issues. Lasser et al. 
(Lasser et al., 2002) found that during the previous 40 years, 2.9% of drugs released on to the 
market were withdrawn as a result of causing severe adverse effects. With the pre-approval 
cost of drug development estimated to range from $800 million to $2 billion (Orloff et al., 
2009; DiMasi et al., 2003), it is vital that toxicity and drug-drug interactions (DDIs) are 
identified as early as possible during testing. Any potential model must have certain features in 
order to be useful to the drug development industry. These include being readily available, 
easy to use, giving reproducible results and allowing high throughput testing. It would also be 
beneficial for any potential model to be human-based as differences in species metabolism of 
compounds does occur, which has been reviewed in several publications (Bode et al., 2010; 
Strom et al., 2010; Singh, 2006; Lin and Yamazaki, 2003; Lin, 1995). A system which will 
accurately predict toxicity during the early stages of testing is therefore a key area for 
development and would be an extremely valuable tool in industry. 
Hepatocytes play a key role in the metabolism of xenobiotics so a system to predict toxicity 
and DDIs would ideally be focused on these cells. Specific enzymes and transporters which play 
important roles in uptake, transformation and efflux of xenobiotics should be present in an 
effective model in order to be of relevance to hepatocytes in vivo. These are classified as phase 
І and phase ІІ drug metabolizing enzymes (DMEs) and phase ІІІ transporters and although there 
is a basal and/or inducible level of these proteins in most tissues, they are most abundant in 
metabolizing tissues such as intestine and liver. This introduction to the thesis will provide a 
background on the groups of transporters and enzymes and then outline the currently 
available hepatocyte models along with their advantages and disadvantages. 
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1.2 – Liver physiology 
1.2.1 – Overview of liver structure and function 
The liver is a key organ involved in a variety of physiological processes including synthesis, 
storage, distribution and metabolism of molecules such as amino acids, urea, proteins and 
carbohydrates. It is also a key method in the detoxification of xenobiotics introduced into the 
body and waste products of the body itself such as haemoglobin and insulin. The liver itself is 
divided into hexagonal lobules which have a hepatic artery, portal vein and bile duct at each 
corner; blood flow into the liver originates from both the hepatic artery, which supplies 
oxygenated blood from the heart, and the portal vein which carries venous blood from the 
intestines, spleen and pancreas. Blood exits the liver via the central vein. During transit 
through the liver, xenobiotics, hormones and other substances can be taken up into the 
hepatocytes and subjected to metabolic processes resulting in exit of the metabolites back 
into the blood or into the bile ducts. Various cell types in the liver allow this process to occur 
efficiently – parenchymal cells (hepatocytes) account for up to 65% of the liver cell population 
and up to 80% of the liver volume (Tanaka et al., 2011; Zheng et al., 2009; Gebhardt, 1992), 
with the remaining 20% of non-parenchymal cells consisting of lymphocytes, Kupffer cells, 
stellate cells, epithelial cells and oval cells. Figure 1.1 shows the structure and placement of 
these cell types within the liver. 
As well as being the main drug-metabolising component of the liver, hepatocytes also perform 
functions such as glycogen storage and bile acid synthesis which are essential for normal 
homeostasis. Hepatocytes are highly polarised cells which form tight junctions and can be bi-
nuclear. They contain many important drug-metabolising enzymes such as members of the 
cytochrome P450 family and transporters such as those belonging to the ATP-binding cassette 
(ABC) superfamily. Under-expression of metabolic enzymes can result in an accumulation of 
toxic substances, whereas over-expression of efflux transporters can lead to drugs being 
removed from the body before they can act – this can be the case where resistance to 
chemotherapy treatments is observed. Pro-drugs which require cleavage before they attain 
their active form can also be affected by altered expression levels of both enzymes and 
transporters. 
Lining the vascular channels (sinusoids) are hepatic sinusoidal epithelial cells. These constitute 
approximately 50% of the non-parenchymal hepatic cell population and provide a barrier 
between the blood and hepatic cells which allows diffusion of substances through a 
fenestrated monolayer, the average pore size being 120 nm (Zheng et al., 2009; Oda et al., 
2003). These cells play a role in the metabolism of substances such as glycoproteins, 
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lipoproteins, immune complexes and transferrin and the secretion of substances such as 
hepatocyte growth factor (HGF) and cytokines (Mohammed and Khokha, 2005; Kmiec, 2001). 
Biliary epithelial cells (cholangiocytes) line the bile ducts in the liver. These cells are thought to 
transport water, ions and solutes while also being involved in secretion of molecules involved 
in cell-cell signalling such as growth factors and cytokines (Tietz and Larusso, 2006; 
Mohammed and Khokha, 2005). The Canals of Herring separate the hepatocytes along the bile 
canaliculus and the cholangiocytes of the bile duct – this is thought to be where hepatic 
progenitor cells originate (Zheng et al., 2009). 
Between the hepatocytes and the hepatic sinusoidal epithelial cells is the space of Disse where 
hepatic stellate cells can be found. In a healthy liver, these cells are quiescent and constitute 
approximately 5-8% of liver cells and are responsible for controlling the contractility of the 
sinusoids as well as being a major storage site for retinol (vitamin A) homeostasis (Senoo et al., 
2010; Winau et al., 2007; Mohammed and Khokha, 2005; Kmiec, 2001). In a damaged liver, for 
example during liver fibrosis or cirrhosis, the stellate cells emerge from their quiescent state 
after activation by hepatocytes, release their vitamin A stores and instead generate 
extracellular matrix components and secrete substances such as HGF and fibroblast growth 
factor (FGF) (Senoo et al., 2010; Henderson and Forbes, 2008; Mohammed and Khokha, 2005). 
Kupffer cells can also be found in the liver within the sinusoids (Winau et al., 2007). These cells 
are macrophages and so play an important role in clearing waste products such as old or 
damaged red blood cells. If the liver becomes damaged or unhealthy, these cells are activated 
and proceed to release agents such as cytokines which in turn promote a response in 
hepatocytes and aid in the process of liver regeneration (Malato et al., 2008). 
1.2.2 – Liver development and regeneration 
Foetal liver development occurs when endoderm cells in the foregut are exposed to a number 
of signals prompting hepatic development. In mice this process occurs at embryonic day 8.5, 
while studies in several animal models have shown that this occurs after exposure to FGF from 
the heart and bone morphogenic protein (BMP) from the septum transversum mesenchyme 
(Shin et al., 2007; Zhang et al., 2004; Deutsch et al., 2001; Rossi et al., 2001; Jung et al., 1999). 
Foetal liver development in the mouse is continued between 9 and 9.5 days when expression 
of liver specific genes such as alpha-fetoprotein (AFP) and albumin occurs, while in the rat this 
expression occurs one day later.  At this stage cells are referred to as hepatoblasts and 
proliferate in response to a variety of growth factors such as HGF, FGF, epidermal growth 
factor (EGF), transforming growth factor (TGF)-β and the cytokine interleukin-6 (IL-6). Many of 
these factors originate from the surrounding endothelial cells which are essential for normal 
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liver development at this stage (Tanaka et al., 2011; Kung et al., 2010; Oertel and Shafritz, 
2008). After hepatoblasts are formed two developmental routes are possible; hepatocytes and 
cholangiocytes. Exposure to oncostatin M, which is a member of the IL-6 family, has proved to 
be effective for the induction of the hepatoblast to hepatocyte transition and is thought to 
help co-ordinate liver development (Kinoshita et al., 1999).  
Less is known about human foetal liver development as appropriate samples are more difficult 
to procure and so a definition of human foetal liver as determined by expression of markers 
remains an area of discussion (Kung et al., 2010). Although groups have claimed to use other 
sources of stem cells to create hepatocytes, it is unknown whether these truly represent the 
path or indeed the endpoint of a genuine foetal liver stem cell. Success in isolating liver 
progenitor cells has been achieved by selection of cells expressing the epithelial cell adhesion 
molecule (EpCAM) which could be directed into either cholangiocytes or hepatocytes in 
culture and could also be transplanted into immunodeficient mice, resulting in the presence of 
functioning mature human liver tissue (Schmelzer et al., 2007). 
The liver has a remarkable capacity to regenerate. Studies in rodents have demonstrated that 
removal of two thirds of the liver, leaving one third undamaged, allows for regeneration of the 
total liver mass in five to seven days in the rat and eight to fifteen days in humans 
(Michalopoulos, 2007). Using the rat model has allowed for reliable and reproducible study of 
the liver regeneration process. Normal regeneration does not involve stem cells; instead, the 
remaining hepatocytes undergo one mitotic cycle with a smaller proportion of cells undergoing 
a second cycle of mitosis followed by some apoptosis which is thought to reduce any over-
proliferation back to the original liver mass (Sakamoto et al., 1999; Stocker et al., 1973; Stocker 
and Heine, 1971). This hepatic proliferation in the rat peaks at 24 hours after partial 
hepatectomy, whereas proliferation of other cell types occurs later than that of hepatocytes; 
endothelial cell proliferation occurs from two to five days after partial hepatectomy while that 
of stellate cells is not yet fully understood (Michalopoulos, 2007). Although normal liver mass 
has been attained at the end of this period, the architecture is not identical to that of the 
original liver; the individual liver lobules are much larger and fewer in number and the normal 
single cell thickness of the hepatocytes is lost in some places (Michalopoulos and DeFrances, 
1997). Liver re-organisation then takes place over several weeks, eventually becoming identical 
to the original liver structure (Wagenaar et al., 1993). 
1.2.3 – Signalling in liver regeneration 
Clearly the understanding of this process of tightly controlled hepatocyte proliferation would 
be extremely useful if it could be applied in vitro, where isolated primary hepatocytes have a 
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limited lifespan. Investigations into the processes governing proliferation have been 
undertaken, in particular using the model of partial hepatectomy in rats as outlined earlier. 
HGF plays a key role in promoting hepatocyte proliferation – plasma levels of HGF are known 
to increase up to 20-fold after partial hepatectomy (Lindroos et al., 1991) and the HGF 
receptor, cMET, is activated within 30-60 minutes of the procedure (Monga et al., 2002). 
Experiments looking into the effects of siRNA to block cMET expression resulted in stalling of 
the cell cycle until the siRNA effect was active, indicating a key role for HGF signalling in liver 
regeneration (Michalopoulos, 2010; Paranjpe et al., 2007). The production of HGF affecting 
hepatic proliferation by non-parenchymal cells has been observed, predominantly by stellate 
cells but also by sinusoidal epithelial cells (LeCouter et al., 2003; Schirmacher et al., 1993). 
Although HGF production is not the first signal observed to occur in hepatic regeneration, it is 
thought to be key in initiating this cascade of events and is generally considered to be one of 
the most important, irreplaceable steps in the process (Michalopoulos, 2007). 
Although HGF is a key factor it is only one of a multitude of signalling mechanisms involved in 
heptic regeneration. Ligands of the epidermal growth factor receptor (EGFR) such as EGF itself, 
TGF-α, heparin binding EGF (HB EGF) and amphiregulin have had their importance proven in 
terms of liver regeneration. The EGFR is phosphorylated within an hour of partial 
hepatectomy; however, the ability of the liver to regenerate in the absence of this receptor by 
suppression or targeted elimination has not been investigated (Michalopoulos, 2007). EGF is 
consistently available via the portal vein of the liver and changes in expression levels have not 
been directly studied during regeneration, although catecholamines such as epinephrine are 
known to stimulate EGF production and are raised after partial hepatectomy (Michalopoulos, 
2007; Bucher et al., 1977). It has been shown that TGFα is raised from two hours after partial 
hepatectomy and remains highly expressed for over 48 hours (Mead and Fausto, 1989). TGFα 
is produced by the hepatocyte itself, indicating that an autocrine loop may be involved. It has 
also been shown that although overexpression of TGFα promotes liver enlargement in mice, a 
knockout of the gene does not affect regeneration (Webber et al., 1994). Other cell types 
affected by TGFα include the sinusoidal epithelial cells and the biliary epithelium 
(Michalopoulos, 2007). HB EGF increases within 90 minutes of partial hepatectomy, originating 
from both endothelial and Kupffer cells (Kiso et al., 1995). HB EGF knockout mouse models 
have a reduced capacity for regeneration, whereas overproduction leads to enhanced 
regeneration (Mitchell et al., 2005; Kiso et al., 1995). Reduced expression of the final EGFR 
ligand studied, amphiregulin, has also been shown to result in less efficient regeneration of the 
liver in mouse models (Berasain et al., 2005). 
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Other compounds such as tumour necrosis factor (TNF), IL-6, epinephrine, norepinephrine and 
bile acids are thought to be important in properly functioning homeostasis and regeneration 
without having a leading role in regeneration itself. TNF itself does not result in mitosis if 
applied to primary hepatocytes in culture; however, it does enhance the response to HGF and 
TGFα (Pierce et al., 2000; Webber et al., 1998). Plasma levels of TNF do increase after partial 
hepatectomy with the source thought to be Kupffer cells (Michalopoulos, 2007). IL-6 itself 
does not initiate hepatic mitosis nor does it enhance the effects of mitotic activators such as 
HGF, however, it is known to affect biliary cell proliferation (Liu et al., 1998). Epinephrine and 
norepinephrine both increase in plasma concentration after partial hepatectomy and enhance 
the proliferative effects of both HGF and EGF (Cruise et al., 1985), while depletion of bile acids 
in the blood after partial hepatectomy results in decreased regeneration (Huang et al., 2006). 
1.2.4 – Progenitor cells in the liver 
True stem cells are ones which have the capacity to proliferate indefinitely and can 
differentiate into a number of defined lineages. Although stem cells are clearly involved during 
initial foetal liver development, this is not the case in adult liver. Regeneration, as discussed 
previously, involves proliferation of the remaining hepatocytes. However, if the liver is too 
damaged to regenerate using the normal methods observed after partial hepatectomy, 
another cell type can contribute to the process of rebuilding. These cells reside in the Canals of 
Herring (see figure 1.1) and are known as hepatic progenitor cells (HPCs) or oval cells. HPCs are 
not true stem cells in that they do not have the capacity to generate any cell lineage but they 
are capable of differentiating into both hepatocytes and cholangiocytes. 
In order for HPCs to become activated there must be injury to the liver above that which can 
be healed by the normal process of regeneration, such as continuous damage of the mature 
epithelial cells, inhibited replication of the hepatocytes or where there has been severe loss 
over that seen in partial hepatectomy, where roughly one third of the liver remains. Activation 
of HPCs has been shown to require loss of at least 50% of the hepatocyte mass along with 
severely inhibited replication capacity; significant activation of HPCs has also been observed in 
the majority of advanced chronic liver diseases (Bird et al., 2008; Katoonizadeh et al., 2006; 
Libbrecht and Roskams, 2002). In these scenarios the HPCs begin to expand into either 
intermediate hepatocytes, which mature into true hepatocytes, or into immature 
cholangiocytes, after which differentiation into mature cholangiocytes takes place (Gaudio et 
al., 2009). HPC proliferation occurs within one week of extensive liver damage, with 
differentiation into mature hepatocytes occurring two weeks post-injury (Gaudio et al., 2009). 
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As with hepatic regeneration, HPC activation requires specific signalling. Hepatic stellate cells 
(HSCs) are known to interact with HPCs as they release growth factors pertinent to HPC 
activation such as TGFα, HGF and acidic fibroblast growth factor (Kuwahara et al., 2008; 
Sanchez-Munoz et al., 2007; Santoni-Rugiu et al., 2005). The pattern of activation is not as 
clearly understood as that for hepatic regeneration; although it is known that HSC activation 
occurs alongside that of HPCs, it is unknown which occurs first, or indeed whether a common 
factor activates both followed by HSCs affecting HPCs (Svegliati-Baroni et al., 2008). 
Compounds known to affect proliferation of HPCs include steroid hormones, growth factors 
(insulin-like growth factor (IGF1) and vascular endothelial growth factor (VEGF)), bile acids and 
neurotransmitters, although at the present time more is known about compounds affecting 
differentiation towards the cholangiocyte rather than the hepatocyte lineage (Tanaka et al., 
2011; Gaudio et al., 2009; Glaser et al., 2009; Oertel and Shafritz, 2008; Alvaro et al., 2002a; 
Alvaro et al., 2002b).  
1.3 – Key enzymes and transporters in hepatocytes 
1.3.1 – Uptake transporters 
In order for drug metabolism and elimination to occur within a hepatocyte, the compounds 
must first be taken into the cell. Although it is possible for this to occur via diffusion across the 
lipid membrane, the majority of compounds enter the cell via transporters. An overview of 
some influx transporters and their expression and function in the body can be found in table 
1.1. Major uptake transporters in hepatocytes include the organic anion transporters (OATs), 
the organic cation transporters (OCTs/OCTNs) and the organic anion transporting polypeptides 
(OATPs). Clearly, for xenobiotics to be able to enter efficiently, physiological levels of 
functional influx transporters would be required in any hepatic model. 
Members of the solute carrier family (SLC) in the basolateral membrane of the hepatocyte play 
a major role in transporting organic anions and cations both into the hepatocyte from the 
blood and from the hepatocyte to the blood. Different classes of transporter provide sodium 
dependent and independent uptake of compounds into the cell. Sodium dependent uptake is 
carried out via the Na+-taurocholate co-transporting polypeptide (NTCP), which is expressed 
solely in the liver and transports conjugated bile salts from the blood into the hepatocyte 
(Schroeder et al., 1998; Boyer et al., 1994).  
Sodium independent transport of organic anions is conducted by organic anion transporting 
polypeptides (OATPs) and organic anion transporters (OATs), while transport of organic cations 
is carried out by organic cation transporters (OCTs). The OATP transporter family has five 
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members expressed in the liver, with OATPB, OATPC and OATP8 being the predominant 
isoforms expressed in liver (Konig et al., 2000a; Konig et al., 2000b; Tamai et al., 2000). Protein 
levels of OATP8 and C are known to be reduced in hepatocellular carcinoma (Oswald et al., 
2001). Substrate specificity of the OATP family members is known to overlap and cover a broad 
spectrum of compounds such as bile acids and thyroxine (OATPC and 8), bilirubin and 
rifampicin (OATPC), benzylpenicillin (OATPB), monoglucuronosyl bilirubin and digoxin (OATP8) 
(Hagenbuch and Meier, 2004; Cui et al., 2001; Kullak-Ublick et al., 2001; Tamai et al., 2000). 
Five family members belonging to OAT have been described, with three, OAT2, OAT4 and 
OAT5, expressed in the liver (Anzai et al., 2006; Sun et al., 2001; Sekine et al., 1998). The OAT 
transporters are located at the basolateral membrane of the hepatocyte and have overlapping 
substrate specificities, transporting organic anions between the hepatocyte and the blood. 
OAT2 transports compounds such as indomethacin; both OAT2 and OAT4 transport 
tetracycline and prostaglandin, while OAT4 alone transports methotrexate and ketoprofen 
(Koepsell and Endou, 2004; Enomoto et al., 2002; Takeda et al., 2002a; Sekine et al., 2000). 
OAT5 is known to transport NSAIDS and penicillin (Koepsell and Endou, 2004). 
Organic cations are transported by the OCT family which has three family members. Of these, 
OCT1 and OCT3 are expressed in the liver while OCT2 is expressed primarily in the kidney 
(Koepsell et al., 2003; Zhang et al., 1997). Human OCT1 is located on the sinusoidal membrane 
of the hepatocyte and is predominantly expressed in the liver. Substrates include N-
methylquinine, N-methylquinidine, tetraethylammonium (TEA), desipramine and 
prostaglandins E2 and F2α (Molderings et al., 2003; Kimura et al., 2002; Takeda et al., 2002b; 
Zhang et al., 1999). OCT3 is also located at the sinusoidal membrane of the hepatocyte and is 
expressed in skeletal muscle, placenta, kidney and heart as well as in the liver (Koepsell et al., 
2003). OCT3 does have some substrate overlap with OCT1; for example, both transport TEA, 
while OCT3 alone transports substance such as dopamine, noradrenaline and histamine 
(Kekuda et al., 1998; Wu et al., 1998). 
1.3.2 – Phase I drug metabolising enzymes 
After uptake of substances into the hepatocyte drug metabolism can take place in two stages, 
the first of which is phase I drug metabolism. Phase I metabolising enzymes are largely located 
in the endoplasmic reticulum, while phase II enzymes are often cytosolic, a notable exception 
being the UDP glucuronosyltransferase (UGT) family which is located in the endoplasmic 
reticulum alongside many phase I enzymes. Metabolism alters the initial compound to produce 
either a new functional group or modifies an existing functional group to make it more 
accessible to phase II enzymes. This first stage of metabolism generally contributes to making 
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the compound more polar by oxidation, reduction, hydrolysis or hydration; however, this 
alone may not be sufficient to enable excretion from the cell. If this is the case, the compound 
passes on to phase II metabolism. Typical phase I drug metabolising enzymes include the 
cytochrome P450 (CYP) superfamily of enzymes and the flavin containing mono-oxygenases 
(FMOs).  
Human genome sequencing of the CYP superfamily has revealed a total of 107 genes, with 48 
of these being pseudogenes. This leaves a total of 59 active CYP genes divided into 18 families, 
although not all of these contribute to hepatic metabolism of xenobiotics. An overview of the 
CYP superfamily can be seen in table 1.2, with more information on expression and substrates 
of selected enzymes in table 1.3. Briefly, CYP families 5 to 51 are known to have mainly 
endogenous substrates and remain highly conserved during evolution (Bozina et al., 2009). CYP 
families 1 to 3 are less well conserved through evolution and also have a much broader 
substrate range; these are more involved in the metabolism of xenobiotics, while CYP4 
enzymes metabolise fatty acids along with some xenobiotics (Bozina et al., 2009). Enzymes 
important in metabolism of xenobiotics are CYP2C9, -2C19, -2D6 and -3A4, while chemical 
biotransformation and activation of pre-carcinogens are carried out mainly by CYP1A2, -1B1, -
2A6, -2E1, and -3A4 (Bozina et al., 2009; Lewis et al., 1998). One CYP enzyme in particular, 
CYP3A4, can comprise up to 60% of all hepatic CYP content and is responsible for full or partial 
metabolism of up to 50% of all therapeutic drugs, while CYP2C8/9/18, CYP1A2 and CYP2E1 
comprise 20%, 15% and 10% of expression respectively (Guengerich, 1999; Shimada et al., 
1994). All CYP enzymes, CYP3A4 in particular, are known to show a large degree of inter-
individual variation in activity which can be caused by both variations in expression levels and 
polymorphisms (Bozina et al., 2009).  
 While the FMO enzymes may not be as well-known as the CYP superfamily for their 
involvement in drug metabolism, they do play an important role. There are five genes and six 
pseudogenes currently identified in this family; the five functional genes share 55-60% amino 
acid homology (Zhou and Shephard, 2006). Of the five genes (FMO1-5), FMO1 is 
predominantly expressed in foetal liver with FMO3 as the main isoform expressed in adult liver 
(Hines, 2006; Zhou and Shephard, 2006). FMO3 is known to have expression levels in adult 
liver similar to those of the most abundant CYP enzymes and metabolises xenobiotics such as 
cimetidine, ranitidine and tamoxifen, agricultural compounds such as organophosphates and 
carbamates as well as dietary compounds such as trimethylamine (Bain et al., 2005; Chung et 
al., 2000; Hodgson et al., 2000; Ziegler-Skylakakis et al., 1998; Hodgson et al., 1995; Al-Waiz et 
al., 1987). The metabolism of trimethylamine is particularly pertinent as mutations in FMO3 
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can result in the failure of oxidation of the compound, causing the disease trimethylaminurea, 
more commonly known as “fish-odour” syndrome (Zhou and Shephard, 2006). 
1.3.3 – Phase II drug metabolising enzymes 
Phase II drug metabolism is based around the premise of a polar group being present on a 
molecule inside the cell. This can either be present on the compound initially or it can have 
been introduced via phase I metabolism. Generally phase II metabolism creates a more polar 
compound by conjugation with a hydrophilic molecule, enabling excretion from the cell either 
via biliary or renal routes. This mechanism is also helpful in reducing toxicity in the cell, as 
products are generally less toxic than the initial compounds or the products of phase I 
metabolism. Typical examples of phase II drug metabolising enzymes are UDP-
glucuronosyltransferases (UGTs), sulphotransferases (SULTs) and glutathione-S-transferases 
(GSTs). The conjugation reactions carried out by these enzymes, such as glucuronidation and 
sulphonation, result in a compound which is much more easily excreted from the cell and thus 
eliminated from the body. These phase II DMEs are important to a hepatocyte model, 
especially if it is being used for toxicity or elimination investigations. An overview of some of 
the enzymes involved in phase II metabolism is given in tables 1.4 and 1.5. 
The UGT superfamily of enzymes catalyses the conjugation of alpha-D-glucuronic acid to a 
wide range of both xenobiotics and endogenous compounds, allowing subsequent excretion 
from the cell (Tukey and Strassburg, 2000). There are two UGT families, UGT1 and UGT2, with 
a total of 19 isoforms between them; of these, 10 are expressed in adult human liver (Bock, 
2010; Tukey and Strassburg, 2000). Although liver levels of UGT2B4 and -2B10 are particularly 
high, these are mainly involved in maintenance of homeostasis by metabolism of eicosaniods 
and bile acids (Bock, 2010). The UGT1A1 enzyme is known to be responsible for metabolism of 
a wide range of xenobiotics, including paracetamol, irinotecan and its toxic metabolite SN38, 
as well as being the only mechanism for metabolism of the heme metabolite bilirubin (Tukey 
and Strassburg, 2000). This is particularly important as bilirubin accumulation is toxic; lack of 
functional UGT1A1 results in Crigler-Najjar syndrome which is fatal if untreated, although 
treatment of the disease is difficult and a limited lifespan of 30 years is expected, with brain 
damage caused by persistent jaundice (Bock, 2010). UGT2B7 is also an important drug-
metabolising enzyme with a wide range of substrates including morphine, as well as 
endogenous substrates like retinoids, eicosanoids and bile acids (Burchell et al., 2005; Court, 
2005; Little et al., 2004; Samokyszyn et al., 2000; Wietholtz et al., 1996). Other UGT enzymes 
such as UGT1A4, -1A6, -2B4, 2B10 and -2B15 also have a role in drug metabolism, although the 
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range of substrates in these proteins is thought to be smaller (Bock, 2010; Tukey and 
Strassburg, 2000). 
The SULT family of enzymes includes four gene families, SULT1, -2, -4 and -6. As a family, 
sulfotranseferases are responsible for the sulphate conjugation of a wide range of xenobiotics, 
neurotransmitters and hormones and are thought to be the major detoxification method used 
in the foetal liver, where SULT expression is high and UGT expression low (Strassburg et al., 
2002). SULT1A1 is expressed in the liver and catalyses the conjugation of sulphate to many 
phenolic compounds, with substrates such as phenol, p-nitrophenol, estradiol, minoxidil and 
tamoxifen (Jancova et al., 2010; Adjei et al., 2008; Hines, 2008). SULT1A2 is an example of an 
enzyme which can increase toxicity through metabolism rather than decreasing it; the 
conjugation of sulphates to some aromatic hydroxylamines results in compounds which are 
considerably more reactive and mutagenic than the original compound (Meinl et al., 2002). 
SULT1B1 is expressed in the liver and GI tract and has a fairly narrow substrate specificity, 
conjugating substrates such as thyroid hormones and small phenols (Jancova et al., 2010). 
SULT1E1 is expressed in the liver and jejunum and was also known as estrogen 
sulfotransferase (EST) due to its high affinity for estrogen sulfation; this enzyme is also known 
to have some metabolic activity for compounds such as 1-naphtol and genistein (Gamage et 
al., 2006; Falany et al., 1995). Of the SULT family members, SULT2A1 is the most highly 
expressed in the liver as well as being expressed in the adrenal glands and duodenum (Jancova 
et al., 2010). This enzyme increases in expression from foetal to adult liver unlike SULT1E1 
which is more highly expressed in foetal liver tissue (Hines, 2008). SULT2A1 was also known by 
an alternative name, dehydroepiandrosterone-sulfotransferase (DHEA ST) as it is known to 
conjugate hydroxysteroids such as DHEA as well as bile acids and androgens (Comer et al., 
1993). 
Glutathione conjugation is catalysed by the GST family of transporters which are of high 
importance in protecting the cells from reactive oxygen species (ROS) produced through 
normal cellular processes such as phase I drug metabolism by CYP enzymes (Jancova et al., 
2010; Sheehan et al., 2001). Two GST superfamiles have been identified, one of soluble 
enzymes and the other of membrane bound proteins designated MAPEGs (Jancova et al., 
2010). GSTs are divided into five groups, GSTA, GSTM, GSTP, GSTK and GSTT – these families 
have up to 30% sequence homology between classes and over 60% within a class (Jancova et 
al., 2010). GSTs are expressed in the brain, pancreas, liver, kidney, testis, heart, lung, intestine, 
skeletal muscle and spleen (Hayes and Strange, 2000) and are known to metabolise a wide 
range of compounds such as quinones, peroxides, ozonides, esters and sulfoxides (Jancova et 
al., 2010). Over-expression of GST enzymes can result in resistance to certain drugs; for 
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example, many anticancer and antiasthmatic treatments are metabolised by a member of the 
GST family (Hayes and Pulford, 1995).  GSTA1, -A2, -A3 and -A4 are expressed in a variety of 
tissues including liver, whereas in liver GSTA5 is undetectable (Lo and Ali-Osman, 2007; 
Desmots et al., 2001). GSTA1 is expressed in liver and kidney and catalyses the conjugation of 
many anti-cancer drugs such as chloroambucil, doxorubicin, melphalan and busulfan (Lo and 
Ali-Osman, 2007; Kusama et al., 2006; Tew, 1994; Ciaccio et al., 1991). GSTA2 is expressed in 
liver, kidney, lung, prostate and pancreas and metabolises substrates such as chloroambucil, 
chloroquine, ceramide and busulfan (Lo and Ali-Osman, 2007; Hayes et al., 2005). GSTA3 plays 
a role in the production of the steroid hormones testosterone and progesterone as well as 
contributing to the conjugation of glutathione to both endogenous and exogenous compounds 
(Lo and Ali-Osman, 2007; Hayes et al., 2005). GSTA3 is expressed in the lung, liver, kidney, 
pancreas and prostate (Lo and Ali-Osman, 2007; Hayes et al., 2005). GSTA4 is expressed at low 
levels in a wide range of tissues including the liver and expression has been shown to increase 
with liver injury such as cirrhosis (Desmots et al., 2001).  
The N-acetyltransferase (NAT) family of enzymes includes two isoforms, NAT1 and NAT2, 
which catalyze the activation and detoxification of amines (Hein et al., 2000). NAT1 expression 
has been determined to be ubiquitous whereas NAT2 expression is localised to the liver, colon 
and intestine (Jancova et al., 2010). Despite having 85% sequence homology, NAT1 and 2 have 
different substrate specificities with NAT2 in particular being an important metabolic route for 
some drugs including sulphonamides and isoniazid (Kawamura et al., 2005). 
1.3.4 – Phase III drug transporters 
After compounds have been taken up into the cell from the blood they are effluxed into either 
bile or blood for excretion from the system. This can be done immediately after uptake or after 
phase I or II metabolism by enzymes. Major transporters involved in this process are mainly 
from the ATP-binding cassette superfamily (ABC superfamily), which hydrolyse ATP in order to 
facilitate transport. These include P-glycoprotein (alternatively known as ABCB1 and multidrug 
resistance protein 1 (MDR1)), the ABCC family (multidrug resistance-associated proteins (MRP 
proteins)) and ABCG2 (also known as breast cancer resistance protein (BCRP)). P-gp and MRP 
proteins have an extremely broad range of substrates including amino acids, sugars, lipids, 
xenobiotics and many drugs (Dean et al., 2001). As a result, a lot of these transporters have 
overlapping substrate specificities. It is also common for one or more of these proteins to be 
over-expressed in drug-resistant carcinoma cells, which can result in drugs being effluxed too 
quickly from the cell to have the desired effect. These transporters are vital to a hepatocyte 
model but must be present in the correct quantities – an over-expressed transporter could just 
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as easily give erroneous results as an under-expressed one. An overview of expression and 
substrate specificity of some transporters in this group is shown in table 1.6. 
P-gp is one of the most well-known drug efflux transporters in the cell as a result of its role in 
conferring multidrug resistance in multiple cell types (Gerlach et al., 1986a; Gerlach et al., 
1986b). It is located on the canalicular membrane and transports a wide range of substances 
such as steroid hormones, digoxin, verapamil and cyclosporine A from the cell into the bile 
(Leslie et al., 2005). Over-expression of this transporter is particularly prevalent in 
chemotherapy-resistant cancer cells, making any potential inhibitor of this transporter 
particularly interesting in terms of medical use. However, potential drug-drug interactions 
must also be considered under normal physiological conditions as with such a broad range of 
substrates accumulation could easily result due to lack of available transporters. The only 
family member of P-gp, MDR3, is known to be a phospholipid transporter rather than a broad 
substrate one and is not thought to have a significant role in drug transport or to confer 
multidrug resistance (Smit et al., 1993). The bile salt export pump (BSEP) is predominantly 
expressed in liver and does have a role in drug transport. It is known to aid in the disposition of 
drugs such as vinblastine, but its major role is to efflux bile salts from the hepatocyte (Childs et 
al., 1998).  
BCRP (ABCG2) is a fairly new addition to the ABC superfamily which was discovered in 1998, 
and is located on the canalicular membrane of the hepatocyte (Doyle et al., 1998). This 
transporter is known to confer multi-drug resistance but to a lesser extent then either P-gp or 
the MRPs 1 and 2. Although substrates of these four proteins do overlap, BCRP has a narrower 
range and includes substances such as anthracyclines, mitoxantrone and topoisomerase I 
inhibitors (Allen and Schinkel, 2002; Allen et al., 2002). 
The human ABCC family includes nine MRPs, the cystic fibrosis transmembrane conductance 
regulator (CFTR) plus two sulfonylurea receptors (SUR1 and SUR2A/B). MRP1 is not expressed 
at detectable levels in a healthy human liver but is present at the basolateral membrane in the 
kidney, lung, muscle, testis and placenta. However, this expression pattern can change 
dramatically in a liver carcinoma where increased MRP1 protein levels can confer multidrug 
resistance to a cell. MRP1 was the second protein discovered to confer multidrug resistance 
when over-expressed after P-gp (Cole et al., 1992). Typical substrates of MRP1 include 
leukotrines, verapamil, vincristine, folate and oxidised glutathione (Loe et al., 2000; Keppler et 
al., 1998; Jedlitschky et al., 1997; Jedlitschky et al., 1996; Loe et al., 1996; Leier et al., 1994). 
MRP2 is expressed in several tissues including liver, kidney, small intestine, colon and placenta 
(Keppler, 2011). Expression of this protein is localised to the apical (canalicular) membrane and 
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the substrate spectrum is quite similar to that of MRP1, although differing kinetic properties 
have been observed (Cui et al., 1999). MRP2 is responsible for the secretion of a wide range of 
conjugated xenobiotics and endogenous substances such as leukotrines, conjugated bilirubin 
and estradiol (Cui et al., 1999; Kamisako et al., 1999). 
MRP3, 4 and 6 are also known to be expressed at the basolateral membrane of the 
hepatocyte. All three transporters are also expressed in the kidney, while MRP3 also shows 
expression in the cholangiocytes, gallbladder, pancreas, GI tract and spleen (Keppler, 2011). 
MRP4 is expressed in the prostate, blood-brain barrier and the epithelial cells of the pancreatic 
duct (Keppler, 2011). Less is known about MRP6 expression and action, although leukotrines 
are known to be substrates (Ilias et al., 2002). MRP3 substrates include leukotrines, conjugated 
bilirubin and estradiol, while MRP4 has a longer list of known substrates, including cGMP, 
cAMP, leukotrines, prostaglandins, thromboxane, cholate, folate and ADP (Rius et al., 2008; 
Rius et al., 2005; Jedlitschky et al., 2004; Lee et al., 2004b; Rius et al., 2003; Chen et al., 2001; 
Zeng et al., 2000). 
1.4 – Model systems for hepatic transport and metabolism 
1.4.1 – Enzyme only systems 
These allow enzyme-specific actions on a compound to be seen which can make it easier to 
identify metabolites and the metabolic pathway for a particular substance. There are several 
different enzyme preparations which are used for this purpose: S9 liver fractions, liver 
microsomes and recombinant CYPs e.g. Supersomes™. 
1.4.1.1 – Liver fractions 
S9 human liver fractions consist of both microsomal and cytosolic fractions from cells. Most 
phase І enzymes are found in the microsome, while phase ІІ enzymes are often found in the 
cytosol. This S9 fraction therefore contains most of the enzymes which would combine to form 
the metabolic profile of a compound. However, a lot of the co-factors they require to function 
properly will not be there as they are found outside of the cell environment. This can affect 
any results obtained via this system. Another drawback of there being no whole cells in this 
model is that there is no guarantee that a compound would ever come into contact with any of 
the enzymes represented here. It is entirely possible that a new compound could fail to enter 
the cell, or be effluxed so quickly that very little metabolism occurs, and these interactions 
would not be seen in this model. 
15 
 
1.4.1.2 – Liver microsomes 
Microsomes are obtained by differential centrifugation (Raucy and Lasker, 1991) and only 
contain enzymes located in the endoplasmic reticulum (CYPs, UGTs and FMOs). Clearly this 
does not represent the full metabolic complement found in a whole cell, and so all the possible 
metabolites of a compound cannot be reliably detected using this model. However there are 
advantages to using this model as human liver microsomes are widely available from 
commercial sources at relatively low cost. There is also the option of choosing the origin of the 
microsomes; for example they can be a mixed sample from several donors to eliminate inter-
individual variation or specifically chosen to have a certain profile, allowing examination of 
ethnicity, age or sex-specific responses to a compound. However, this system cannot be used 
to definitively determine the outcome of a compounds metabolism as cytosolic enzymes are 
not included in the fraction. 
1.4.1.3 – Supersomes™ 
Supersomes are derived from yeast or insect cells which have been engineered to express a 
single human drug metabolising enzyme (DME), allowing cellular fractions containing a specific 
DME for testing a drug’s metabolic pathway to be obtained (Asseffa et al., 1989). As the 
endogenous yeast/insect DMEs are very different from human ones it is effectively a system to 
see how a single human DMEs interacts with a compound. This has a benefit over microsomes 
as any co-factors that the DME needs to function correctly can also be engineered into the cell, 
allowing the true interaction between enzyme and compound to be observed. As with 
microsomes, only enzymes found in the endoplasmic reticulum can be studied with this 
system, and of course any contribution to metabolism by other DMEs is excluded from these 
studies. The major use of Supersomes™ is therefore to support findings from other systems 
with regard to the role of a single DME. 
1.4.2 – Liver slices 
Liver slices were first used in the early 20th century but were not used for metabolic studies 
until the 1970s when advances in technology meant that slices of a consistent thickness with 
little damage from harvesting were able to be produced (as reviewed in Vermeir (Vermeir et 
al., 2005)). A major advantage is that the cell architecture, cell-cell contacts and metabolic co-
operation between cell types are preserved as they appear in vivo. These are particularly 
useful when looking at the route of metabolism of a compound as additional information can 
be gained over what would be observed in, for example, a hepatocyte-only system. As is also 
the case for most isolated whole cell systems, enzyme levels in liver slices quickly decrease 
following isolation and preparation. It has been observed that the activity of some CYPs drop 
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by ≥64% after just 24 hours and are undetectable after 96 hours (VandenBranden et al., 1998). 
Olinga et al. (Olinga et al., 2008) successfully demonstrated expression and induction of phase 
I and II metabolising enzymes plus phase III transporters after both 5 and 24 hours incubation 
with typical inducers in liver slices, including that of several CYP enzymes. Some studies have 
looked at methods of maintaining slices in culture to minimise loss of activity; for example, 
Martin et al. (Martin et al., 2002) showed that incubation in a rotating culture system with a 
70% oxygen concentration improved both structure and expression in comparison to slices 
incubated with 20% oxygen. However, studies with liver slices are still restricted by their 
sustainability in culture, with estimates that they remain viable for three to four days in 
optimal conditions (Van de Bovenkamp et al., 2007). Difficulties in obtaining fresh liver slices 
are comparable to those concerning isolation of primary hepatocytes, resulting in the model 
being low throughput and not readily available. 
1.4.3 – Hepatocytes 
As the majority of drugs and xenobiotic compounds are metabolised in the liver, specifically in 
hepatocytes, an ideal model would be a hepatocyte itself. Although there are many such 
models in existence none are perfect. The following section looks at the range of hepatocyte 
systems available and their various advantages and disadvantages. 
1.4.3.1 – Primary hepatocytes 
Primary hepatocytes are isolated from liver tissue, cultured and used for metabolic studies. 
These are currently considered to be the most appropriate model for investigating drug 
metabolism as they initially retain a large proportion of the DMEs and transporters that are 
involved. The cell structure is maintained so transport into and out of the hepatocytes can also 
be taken into account and any co-factors required for proper enzyme function should be 
present. The use of primary hepatocytes for drug metabolism, induction and interaction 
studies is well known and has been reviewed in several publications (Hewitt et al., 2007; Soars 
et al., 2007a; Soars et al., 2007b; Vermeir et al., 2005; Gomez-Lechon et al., 2004; Gomez-
Lechon et al., 2003a; Gomez-Lechon et al., 2003b). 
Although primary hepatocytes are considered to be the closest in vitro model to the in vivo 
liver, they do have many features which restrict their use. Supply is a major issue; tissue from 
human liver cannot be easily sourced on a regular basis and there are legal and ethical issues 
tied to their use (Skett et al., 1995). Inter-individual variability is also a factor; this can be 
overcome to an extent by pooling donor hepatocytes, and can prove useful if variations such 
as age or sex are factors which need to be considered (Parkinson et al., 2004). 
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The metabolic profile of primary hepatocytes can change within 7 days of culture due to de-
differentiation. This is especially true for some of the CYP enzymes and limits the usefulness of 
primary hepatocytes after this period, as CYP activity accounts for a large proportion of drug 
metabolism within the cell (Gomez-Lechon et al., 2004; Parkinson et al., 2004; Gomez-Lechon 
et al., 2003a; Gomez-Lechon et al., 2003b). Attempts at altering culture conditions in order to 
preserve the metabolic profile have met with varying amounts of success. A common addition 
to culturing conditions is to overlay an extracellular matrix of matrigel or collagen I and create 
a sandwich culture; this has been reported to preserve the metabolic profile of a hepatocyte 
more effectively than standard culture and to potentially restore de-differentiated cells to a 
more mature phenotype (Gkretsi et al., 2007; Olsavsky et al., 2007; Page et al., 2007; Sidhu et 
al., 2004). This was measured by features such as increased albumin production, enhanced 
connexin-32 expression (a gap junction marker), increased CYP levels and improved responses 
to typical inducers such as phenobarbital (Gkretsi et al., 2007; Olsavsky et al., 2007; Page et al., 
2007; Sidhu et al., 2004). Improved results from co-culture with epithelial, stellate and Kupffer 
cells, which mimic the role played by non-parenchymal cells in the in vivo liver, have also been 
reported and showed improvements in the longevity and functional expression of hepatocytes 
(as reviewed in Dash et al. (Dash et al., 2009)). For example, primary hepatocytes cultured 
alongside hepatic stellate cells have been shown to retain CYP and albumin expression after 
two months of culture (Riccalton-Banks et al., 2003). This could be as a result of growth factors 
such as hepatocyte growth factor (HGF) secreted by stellate cells having a positive impact on 
the hepatocytes. 
1.4.3.2 – Cryopreserved human hepatocytes 
Ideally primary hepatocytes would be used routinely in drug development, but as discussed 
above, de-differentiation in culture and unpredictable availability means this is not possible 
using fresh hepatocytes. Attempts to increase the usefulness of these cells have looked at 
cryopreservation as a means of improving availability and consistency. Initially, yields upon 
resuscitation were very low but the advent of better cryopreservation techniques (Lloyd et al., 
2003) has led to several recent studies on the potential uses of cryopreserved human 
hepatocytes (CHHs) in drug metabolism and induction assays. Roymans et al. (Roymans et al., 
2005) examined levels of CYP activity and found that the induction response was of the same 
magnitude as is seen in fresh primary hepatocytes, although for some enzymes basal activity 
was lower. However, cryopreservation does not yet yield the readily available source of 
healthy hepatocytes that is desired and results in changes in both cell structure and function, 
as reviewed by Stephenne et al. (Stephenne et al., 2010). Li et al. (Li, 2007) reviewed 
cryopreserved hepatocytes as a model in comparison to primary hepatocytes and observed 
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that although levels of important enzymes and transporters are similar initially, limitations of 
the model include having to culture in suspension for the majority of cryopreserved lots. This 
not only limits the type of experiment which can be performed, but expression deteriorates 
very quickly and cells last hours rather than days. This review also reports that when using cells 
which can be successfully plated, the useful lifespan is approximately three days, with 
reductions in CYP1A2 and 3A4 expression of approximately 50% every 24 hours. Although 
cryopreserved hepatocytes are certainly more readily available than freshly isolated ones, the 
associated limitations of the model mean that fresh primary hepatocytes remain more true to 
the in vivo hepatic state. CHHs may not provide the definitive metabolic data that can be 
obtained with primary hepatocytes but are still useful for applications such as ranking test 
compounds in order of toxicity where a comparative rather than an absolute measure is 
required. 
1.4.3.3 – Immortalised hepatocytes 
Another technique to try and overcome de-differentiation of human hepatocytes is to 
artificially immortalise the cells. This can be done by transfection with SV40 large T-antigen, 
which inactivates tumour suppressor genes such as p53 and results in a senescent state where 
replication is no longer limited to a few population doublings (Pfeifer et al., 1993). 
Immortalised human hepatocytes are useful in that they proliferate indefinitely and the 
sample variation seen with fresh hepatocytes is eliminated. These two features could allow 
immortalised hepatocytes to be used in industry as a high-throughput screening model for 
drug development. However, these cell lines do not always express the full metabolic profile of 
the in vivo liver so thorough investigation of expression is needed at several points to ensure 
that expression is maintained during cell expansion. Two notable lines of immortalised 
hepatocytes are Fa2N-4 and HC-04, which are looked at in more detail in the following 
paragraphs. 
The Fa2N-4 cell line was generated by transfection of human hepatocytes with SV40 large T-
antigen (Mills et al., 2004). Expression and induction of proteins in these cells has been 
investigated with varied results. As stated previously, CYP1A2 and -3A4 account for a large 
proportion of drug metabolism in the body. The mRNA of both of these enzymes was found to 
be inducible to a similar extent as in primary human hepatocytes (Mills et al., 2004). This paper 
also showed that CYP2C9 and MDR1 were induced by prototypical inducing agents (e.g. 
rifampicin, phenobarbital) with a similar level of response to primary hepatocytes. These initial 
characterisations were built upon by Ripp et al. (Ripp et al., 2006) who examined the effects of 
known inducers and non-inducers of CYPs in primary hepatocytes and Fa2N-4 cells. The results 
suggested that Fa2N-4 cells have a very similar response to that of primary hepatocytes when 
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looking at CYP3A4 induction. Hariparsad et al. (Hariparsad et al., 2008) looked at basal mRNA 
levels of genes involved in drug metabolism and at CYP3A4 induction in Fa2N-4 in comparison 
to CHHs. It was observed that the basal level of constitutive androstane receptor (CAR) was a 
lot lower in Fa2N-4 cells than in CHHs; this is significant as CAR is one of the pathways of 
induction of CYP3A4. The other route of CYP3A4 activation, the pregnane X receptor (PXR), 
was seen at a similar level in Fa2N-4 cells and CHHs. The study found that CAR-only activators 
(e.g. artemisinin) failed to provoke a response in Fa2N-4, while other activators which act via 
both CAR and PXR (e.g. phenobarbital) evoked a lower response in Fa2N-4 than in CHHs. 
Rifampicin induced CYP3A4 mRNA to a similar level in both Fa2N-4 and CHHs and is a PXR-only 
activator. These results, suggesting reduced or absent CAR function, cast some doubt over 
whether Fa2N-4 can be used as a predictor of DDIs and drug metabolism. 
The HC-04 cell line is slightly different from Fa2N-4 in that it spontaneously immortalised 
rather than being treated to achieve that state. Lim et al. (Lim et al., 2007) found that CYP1A2, 
-3A4 and -3A5 but not -1A1, -2C9 or -2E1 transcripts were expressed in HC-04 cells and it was 
observed that CYP3A4, -1A2, -2C9 and -2E1 could all be induced at the protein level. Functional 
assays for these enzymes also demonstrated CYP-dependent metabolism and toxicity in this 
cell line. These are promising results for this cell line, but the absence of some of the CYPs and 
transporters such as OATPC may limit its usefulness (Lim et al., 2007). More investigations into 
the level of functionality achievable in HC-04 cells needs to be undertaken before any 
significant conclusions can be drawn. 
1.5 – Hepatic tumour-derived cell lines 
Cell lines can be derived from hepatocarcinomas, specifically from primary tumours of the liver 
parenchymal cells which occur after cirrhosis or chronic hepatitis. The levels of DMEs and drug 
transporters found in cell lines of this type tend to be low compared to those seen in in vivo 
liver and in primary hepatocytes. This is especially true of the CYP enzymes, which can often 
show little or no expression in a tumour-derived cell line.  
1.5.1 – HepG2 cells 
The most commonly-used hepatoma cell line is HepG2 which was derived in 1979 (Aden et al., 
1979) and has since been extensively characterised in terms of both phase 1 and phase 2 
enzymes. Numerous studies have shown that the basal levels of several of the major CYPs are 
severely reduced in HepG2 (Westerink and Schoonen, 2007a; Elizondo and Medina-Diaz, 2003) 
but other enzymes and transporters are present at levels which resemble an in vivo 
hepatocytes more closely although they remain at a reduced level in many cases (Sivertsson et 
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al., 2010; Olsavsky et al., 2007; Westerink and Schoonen, 2007b; Westerink and Schoonen, 
2007a; Hewitt and Hewitt, 2004; Elizondo and Medina-Diaz, 2003). Other changes in 
comparison to primary hepatocytes are also evident; for example, the detection of alpha-
fetoprotein is reported in HepG2 and other cell line systems but not in primary or in vivo 
hepatocytes, as AFP is known to be a marker of a more foetal liver phenotype and is not 
expressed in the mature adult liver, while albumin and transferrin (markers of maturation) are 
usually lower in cell lines than primary hepatocytes (Page et al., 2007; Sainz and Chisari, 2006; 
Snykers et al., 2006; Sidhu et al., 2004; Raul Cassia, 1997).  
The low expression levels of some proteins in this cell line prevent it from being used as a 
definitive model for drug metabolism and DDIs, resulting in several studies looking to enhance 
the function of HepG2 cells. An example of this is a study by Bokhari et al. (Bokhari et al., 
2007a) which looked at the effect of growing the cells in a 3D culture system rather than a 2D 
one. Under 3D conditions HepG2 cells formed spherical aggregates which maintained an 
improved liver function as determined by albumin production and also showed improved cell 
viability compared to 2D cell growth. This study also looked at the cytotoxic effect of 
methotrexate (MTX) on cells grown in both 2D and 3D configurations and found that the 3D-
cultured cells reacted to a similar concentration of MTX as in vivo cells, whereas 2D-cultured 
cells reacted to a much lower level of the compound, indicating that a 3D culture system may 
be more suitable for HepG2 culture in terms of producing a realistic response to utilise in drug 
testing. Another study by Dannenberg et al. (Dannenberg and Edenberg, 2006) investigated 
the effect of DNA methylation on expression in HepG2 cells by inhibition of the methylation 
process using the compound 5-aza-dC. Assessment of the treated cells by microarray revealed 
increases in levels of important metabolising genes such as CYP3A4, -3A5 and -3A7 along with 
CCAAT element-binding proteins including C/EBPβ, which has been implicated in 
transdifferentiation studies as being involved in liver development (Al-Adsani et al., 2010; 
Wallace et al., 2009; Shen et al., 2000). 
1.5.2 – Huh7 cells 
Another cell line with potential for use as a realistic in vivo hepatocyte model is Huh7, derived 
in 1982 by Nakabayashi et al. (Nakabayashi et al., 1982). This has been characterised to a much 
lesser extent than HepG2 and therefore needs to be investigated in more depth to determine 
whether it can be useful as a model. Some studies have looked at the expression profile in 
these cells and have found that they are similar to the HepG2 cell line at confluence 
(Sivertsson et al., 2010; Bokhari et al., 2007a; Bokhari et al., 2007b; Olsavsky et al., 2007). As 
with HepG2 cells, studies have been undertaken using Huh7 cells to attempt to create a cell 
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line with an expression profile more resembling that in vivo. An example of this is in work 
published by Sivertsson et al. (Sivertsson et al., 2010), which reports that levels of many 
hepatic differentiation markers, enzymes and transporters are very similar at the mRNA level 
in confluent HepG2 and Huh7 cells, but prolonged growth in standard media for up to four 
weeks results in an increase in the level of some major enzymes. A major observation here is 
the increase in CYP3A4 mRNA which is accompanied by an increase in function within the cell, 
resulting in expression more comparable to primary hepatocytes. Other published data has 
stated that Huh7 cells have no detectable CYP3A4 mRNA at confluence, highlighting possible 
differences in the expression profiles of Huh7 and other cells from different sources (Olsavsky 
et al., 2007). These could be due to passage number, media differences, culturing and 
experimental techniques among other things. Data showing that Huh7 cells become more 
differentiated towards the in vivo hepatic profile when incubated with 1% dimethyl sulfoxide 
(DMSO) for 20 days, with increased expression of albumin, CYP1A2, -2E1 and -3A4 and UGT1A1 
at mRNA level accompanied by functional increases in CYP metabolism (Choi et al., 2009; Sainz 
and Chisari, 2006). Although more work will need to be done in order to validate these cells as 
a suitable in vitro model, prolonged growth in standard media or media supplemented with 1% 
DMSO appear to produce promising results. 
1.5.3 – Additional cell lines 
The last hepatoma-derived cell line I will be looking at is HepaRG which was developed by 
Gripon et al. in 2002 (Gripon et al., 2002). Although this is only a recently developed cell line, 
there have been several papers published on its metabolic profile and functionality which 
indicate that HepaRG may be a good in vitro liver model. A striking difference in this cell line 
compared to many others is the requirement for a differentiation period consisting of at least 
two weeks culture in media containing 2% DMSO after high-density seeding. Aninat et al. 
(Aninat et al., 2006) looked at expression and function of various CYPs in these cells and 
reported that expression was comparable to those seen in primary human hepatocytes with 
evidence of appropriate functionality of these proteins. Two studies by Kanebratt et al.  
(Kanebratt and Andersson, 2008a; Kanebratt and Andersson, 2008b) evaluated levels of CYPs 
and other enzymes and transporters involved in liver metabolism. This found that mRNA levels 
for CYPs, transporter proteins and transcription factors were stable in HepaRG cells over six 
weeks when cultured in media containing 2% DMSO. Although expression tended to be lower 
than in primary hepatocytes (with a few exceptions e.g. levels of CYP3A4 mRNA were higher), 
it was consistently higher than in HepG2 cells. The whole genome expression profile of 
HepaRG has been analysed and compared to both primary hepatocytes and the HepG2 cell 
line; results revealed that HepaRG exhibited an expression profile which more closely matched 
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primary hepatocytes than HepG2 cells did and were more suited to identifying the biological 
consequences of exposure to toxic substances than were HepG2 cells (Hart et al., 2010; Jennen 
et al., 2010). Overall results indicate that HepaRG may be a good candidate for the 
development of a representative hepatocyte cell line. 
1.6 – Stem cell-derived hepatocytes 
A recent development in the search for an in vitro liver model is the use of stem cells (SC); 
once isolated stem cells can be differentiated into hepatocyte-like cells. Stem cells are capable 
of self-renewal, going through multiple cycles of cell division and remaining undifferentiated, 
and are able to differentiate into a variety of specialised cell types. This technology is relatively 
new and at the moment a lot of the work in this area is centred around the process of 
differentiation into hepatocyte-like cells rather than metabolic studies.  
As stem cells can be grown indefinitely without de-differentiation, one of the major 
requirements of an in vitro model could be fulfilled – the ability to create a sustainable source 
of cells for experimentation. Once differentiation has taken place this will most likely not be 
the case, but before the stem cells are directed towards becoming hepatocyte-like cells they 
are a sustainable source. Specific protocols vary for different sources of stem cells and 
between laboratories, but there are a few basic steps which are followed in all cases. The stem 
cells are isolated from the relevant source and kept in sustaining media until the time comes 
for differentiation to be induced. This is typically done by the addition of various supplements 
which direct the cells to differentiate into the appropriate cell type. The three main sources of 
stem cells used for this type of work are human embryonic stem cells (hESCs), adult stem cells, 
and stem cells derived from umbilical cord blood (UCB). Several reviews on this technology and 
the state of development at the moment have been recently published (Wobus and Loser, 
2011; Greenhough et al., 2010; Medine et al., 2010; Phillips and Crook, 2010); a brief outline of 
current developments using embryonic, adult and umbilical cord blood derived-stem cells is 
given below. 
1.6.1 – Human embryonic stem cell-derived hepatocyte-like cells 
Stem cells are isolated from the inner mass of a blastocyst and cultured along with feeder cells 
for one to two weeks. At this point the cells growing outwards from the initial cell masses are 
removed and further cultured or differentiated into various cell types. Ameen et al. (Ameen et 
al., 2008) reviews various techniques employed in culture and differentiation of hESCs in more 
detail. 
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In order for hESC derived hepatocyte-like cells to be useful as a model they must be validated 
in terms of phase І and ІІ DMEs and the phase ІІІ transporters along with their induction 
potential and functionality. This technology is quite new (spontaneous differentiation was first 
shown in the year 2000 (Schuldiner et al., 2000)) and so only a few studies have been carried 
out in this area. As techniques of expansion and differentiation improve, so will the level of 
validation of DMEs and transporters in these cells. 
Hay et al. (Hay et al., 2007) have looked at basic functional characterisation of hESC derived 
hepatocyte-like cells and found some promising results. Typical hepatocellular morphology 
was observed, along with hepatic markers such as alpha-feto protein and albumin. Functional 
CYPs and the storage of glycogen in cells were also seen. Similar findings to these have also 
been reported by Ameen et al. (Ameen et al., 2008) and by Ek et al. (Ek et al., 2007). The latter 
study also looked at expression and function of specific CYPs in more detail. In the three cell 
lines tested, protein levels and functionality of CYPs were lower than in primary hepatocytes. 
However, in one of the lines the mRNA levels of CYPs, various transporters and transcription 
factors were consistently higher than those found in HepG2 cells. This shows promise for 
future uses of these hepatocyte-like cells in drug metabolism and drug-drug interaction (DDI) 
studies once improvements in differentiation quality and quantity of hESCs has been achieved. 
However, the issues of availability, ethical considerations and regulations remain and could 
hinder widespread use of this technology. 
1.6.2 – Adult stem cell-derived hepatocyte-like cells 
The main source for adult stem cells for differentiation into hepatocyte-like cells is bone 
marrow. This has been found to be the source of hepatic progenitor cells and so is the best 
option to date as hepatic stem cells have been difficult to isolate (Vessey and de la Hall, 2001). 
The isolated adult stem cells are cultured and differentiated in a similar way to hESCs (see Lee 
et al. (Lee et al., 2004a) for more detail). As with hESC-derived hepatocyte-like cells, these 
show hepatic cell morphology and testing of DMEs and transporters has produced some 
promising results. Both Lee et al. (Lee et al., 2004a) and Schwartz et al. (Schwartz et al., 2002) 
showed that the cells expressed albumin, showed glycogen storage and some CYP functional 
activity. These preliminary results led to the same conclusions as for hESC-derived hepatocyte-
like cells. Bone marrow stem cells (BMSCs) have also been used by Snykers et al. (Snykers et 
al., 2006), where differentiation using specific growth factor combinations at different time 
points during culture resulted in increases in albumin secretion, glycogen storage, urea 
production and levels of CYP enzymes along with a decrease in AFP, all of which are indicative 
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of a more mature hepatocyte-like cell. As there are fewer ethical issues when using adult SCs 
rather than hESCs this source of cells may be the preferred option for future development. 
1.6.3 – Umbilical cord blood-derived hepatocyte-like cells 
Stem cells can also be extracted from umbilical cord blood. This is a less controversial source 
than hESCs and has the advantage over adult SCs in that the cells are in a less differentiated 
state at the time of harvest. The procedures used for generation of embryonic-like cells from 
the cord blood and subsequent differentiation into hepatocyte-like cells are still being refined. 
In 2005 McGuckin et al. (McGuckin et al., 2005) reported the first reproducible generation of 
embryonic-like SCs from UCB. Within this study there were also some results concerning 
differentiation of the UCB SCs towards hepatocyte-like cells. However, as this procedure is 
extremely new and still requires refining, very little data from testing of expression levels and 
functionality of various proteins in these cells has been published. If these UCB-derived 
hepatocyte-like cells do show promise in terms of being a useful model the implications could 
be far-reaching as the availability of UCB is much greater than that of both hESCs and adult 
SCs; with 100 million births worldwide every year UCB could be a huge potential source of 
stem cells. 
1.7 – Differentiation of existing models 
The differentiation of an existing model to show a more in vivo hepatic profile could be 
another route through which an acceptable model may be created. Two of the more promising 
experimental processes are briefly described below. 
1.7.1 – Dimethyl sulfoxide treatment 
Dimethyl sulfoxide (DMSO) is a compound which has been used in several different 
circumstances to try to aid in differentiation of a hepatic cell line. DMSO applied at a 
concentration of 1% v/v to Huh7 cells resulted in higher expression of hepatic markers and 
higher mRNA and protein expression of some metabolising enzymes such as CYP1A2 (Choi et 
al., 2009; Sainz and Chisari, 2006) indicating a higher level of differentiation and promising in 
terms of creating a realistic hepatic model. A higher concentration of DMSO (2% v/v) is 
routinely applied to the cell line HepaRG to differentiate the cells to a state more closely 
resembling that of a mature hepatocyte. These differentiated cells have been shown to be 
closer in mRNA, protein and functional assessments to primary hepatocytes than either the 
parental cell line or other secondary hepatocytes and may be a promising avenue to explore 
for the development of a toxicity prediction model (Antherieu et al., 2010; Kanebratt and 
Andersson, 2008a; Le Vee et al., 2006). 
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1.7.2 – Transdifferentiation 
Transdifferentiation is the reprogramming of one cell type to another. Several publications 
describing attempts to transdifferentiate pancreatic to hepatic cells have shown some 
promising results. Human foetal pancreatic cells have been reported to have 
transdifferentiated into cells with more hepatic expression markers, although these have not 
been fully tested as a hepatic model (Sumitran-Holgersson et al., 2009). Another route which 
has been explored is to attempt to differentiate an established cell line, in particular the 
pancreatic exocrine line AR42J-B13, into cells more resembling a hepatocyte. This has also met 
with some success with the potential signalling mechanisms for differentiation being 
identified, but again have not been fully tested as a hepatocyte model (Al-Adsani et al., 2010; 
Shen and Tosh, 2010; Wallace et al., 2009; Shen et al., 2000). 
Mouse tail-tip fibroblasts (TTFs) have also been subjected to attempted transdifferentiation 
into hepatocyte-like cells. Huang et al. (Huang et al., 2011) attempted to do this and named 
the induced hepatocyte-like cells produced iHep cells. This was done by lentiviral infection 
with the transcription factors Gata4, Hnf1 and Foxa3, along with inactivation of p19Arf in order 
to bypass the proliferative limitations of the cells in culture. After 15 days cells showed 
expression of liver markers such as albumin, alpha fetoprotein and transferring at RNA level 
and metabolism of compounds using the Cyp1a2, Cyp2a and Cyp3a enzymes at roughly one 
third of the metabolic capacity of primary hepatocytes. This is a good indication that the cells 
are progressing towards hepatic functionality. These iHep cells have also been used to restore 
liver function to Fah-/- mice, indicating that with the correct signalling induction can be 
continued to create a fully representative hepatocyte model using this method (Huang et al., 
2011). 
1.7.3 – Oxygen rich environments 
As discussed previously, although primary hepatocytes are the gold standard model for 
investigations into drug metabolism and toxicity, they cannot be maintained indefinitely in 
culture due to de-differentiation. Attempts at increasing the longevity of this model have 
included culture in different formats, for example co-culture with non-parenchymal cells, 3D 
culture and sandwich culture (Bhatia et al., 1999; Bhatia et al., 1997; Dunn et al., 1992; Dunn 
et al., 1989; Morin and Normand, 1986; Landry et al., 1985). Another attempted strategy to 
prolong the useful life of primary heptocytes has been to culture in a high oxygen environment 
as the oxygen levels available to cells in standard culture conditions are far lower than those 
found in vivo (Nahmias et al., 2007; Nahmias et al., 2006). However, although metabolic rates 
were shown to decrease under restricted oxygen conditions, increased oxygen availability 
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alone did not improve on the model (Tilles et al., 2001; Yanagi and Ohshima, 2001; Rotem et 
al., 1994; Suleiman and Stevens, 1987). Kidambi et al. (Kidambi et al., 2009) described a 
combination of these techniques which appear to increase the longevity of the primary 
hepatocytes as a useful model in culture. This work combined co-culture of primary 
hepatocytes with endothelial cells on collagen coated plates cultured in a high oxygen 
environment in serum-free media. Results revealed that levels of mRNA expression, albumin 
and urea production and metabolic function were improved over those from cells cultured 
with serum or in suspension and were more comparable to those in primary hepatocytes for 
prolonged periods of time; for example, albumin production peaked and stabilised after 11 
days of culture. Another notable finding was that hepatocytes cultured in this fashion were 
able to be used before hepatocytes cultured in suspension with metabolic stability obtained 
earlier. Culturing techniques such as these are promising for extending the life of a primary 
hepatic model, although they still rely on the cells being available for isolation and culture 
initially. 
1.8 – Summary 
Studying drug metabolism and DDIs effectively requires a reproducible model which has 
functional expression of hepatic proteins at a relevant physiological level. Although there are 
many systems which have some of these desired features, as yet none have them all. Liver 
microsomes and Supersomes™ allow the study of a particular enzyme in great detail but fail to 
take into account physiological factors, such as where the enzyme is located in the cell and the 
transporters it encounters in vivo. Liver slices maintain cell structure, cell-cell contacts and 
reflect protein location in vivo but protein levels, especially those of CYPs, decrease 
dramatically. As a result liver slices have a limited time frame of use, affecting the potential for 
use in induction assays which in turn limits their usefulness in DME and DDI testing. 
Primary hepatocytes are deemed to be the “gold standard” model for use in DME and DDI 
assays. They are the model which most consistently represents the in vivo liver when freshly 
isolated. However, these cells tend to lose expression of some proteins after a short time in 
culture which affects reproducibility of results. Additionally, supply is unpredictable as a good 
quality source of fresh human liver tissue cannot be obtained regularly. To try and combat the 
downfalls of primary hepatocytes, attempts at cryopreservation and immortalisation have 
been tried and are partially successful. Although the metabolic profile of these cells is never 
quite as good a match to in vivo liver as primary hepatocytes are, the relative responses to 
inducers can often be useful in DME and DDI assays. The longevity of these cells also allows for 
reproducibility between assays and a more permanent source of cells than primary 
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hepatocytes. A more complete set of proteins with expression levels matching in vivo liver 
would be preferred in order to reliably use these models. 
Cell lines derived from hepatic tumours have been in use for a number of decades now, the 
most established being the HepG2 cell line. Although this does have the benefit of indefinite 
growth and so provides a constant source of cells, the metabolic profile is lacking when 
compared to primary hepatocytes. Cell lines of this type are still being developed, with the 
recent HepaRG line looking like it has the potential to be of use in drug metabolism and DDI 
assays. 
A future possibility is the use of stem-cell derived hepatocyte-like cells. Although adult stem 
cells have been differentiated into hepatocyte-like cells they are a few steps further into the 
differentiation process to begin with than are hESCs. As yet there is no evidence to indicate 
whether this will alter the phenotype or genotype of the hepatocyte-like cells produced. Adult 
stem cells may be more readily available than hESCs and would also carry fewer ethical issues, 
making them more acceptable for use in the drug industry if they were ever to be validated as 
a model. Potentially an even greater source for stem cells could be UCB; umbilical-cord blood-
derived embryonic-like stem cells have been produced and further differentiated into 
hepatocyte-like cells. Extensive validation of any hepatocyte-like cell would be needed before 
use as a high-throughput model for industry could be considered. 
In conclusion, the ideal model for a high-throughput system of analysis for potential drug 
toxicity and DDIs would contain a full metabolic profile of phase І and ІІ DMEs and phase ІІІ 
transporters. It would also need to have appropriate expression levels and functional 
properties of the in vivo liver, to give reproducible results and be in ready supply. This model 
does not currently exist; the closest available at this time are freshly isolated primary 
hepatocytes. However, current work with cell lines and stem cells does point towards this goal 
drawing closer with future studies. 
1.9 – Aims 
The main aim of the series of experiments described in this thesis was to test the hypothesis 
that the cell lines HepG2 and Huh7 can be successfully differentiated into a more mature 
hepatic state. If the hypothesis is positive, this would potentially allow easy access to a well 
defined and easily accessible model for early stage drug testing and could potentially help to 
define culture conditions with which to generate a hepatocyte-like cell from other sources 
such as adult and embryonic stem cells. The hypothesis was investigated by attempting 
differentiation of the cells utilising a variety of treatment strategies, including growth factor 
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treatments applied to stem cells from different sources and the DMSO treatments which have 
already been reported to be producing good results in secondary hepatocyte cell lines. Treated 
cells have been analysed for a wide range of genes of interest including hepatic differentiation 
markers, influx and efflux transporters and both phase I and II drug metabolising enzymes by 
qPCR. Following this, more specific analysis was carried out using protein and functional tests 
to analyse the extent of treatments on the function of the cells. 
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Figure 1.1 – Structure of a liver lobule. Diagram reproduced with permission from 
Tanaka et al. (Tanaka et al., 2011).  
 
30 
 
 
  
OATPs
OCTs
OATs
NTCP
MRP3
MRP4
MRP5
MDR1
MRP2
BCRP
BSEP
MDR3
MRP1
MRP6
Hepatocyte
Cholangiocyte
Bile duct
B
lo
o
d
 F
lo
w
Figure 1.2 – Hepatic drug transportersFigure 1.2 – Drug transporters and their location in the hepatocyte 
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Protein Name Alternate names Tissue expression Substrates 
OATP1A2 OATPA, OATP, 
SLCO1A2, 
SLC21A3 
Brain, liver, 
kidney, ciliary 
body 
Bile salts, organic 
cations and anions 
OATP1B1 OATPC, OATP2, 
SLCO1B1, 
SLC21A6 
Liver Bile salts, organic 
anions 
OATP1B3 OATP8, SLCO1B3, 
SLC21A8 
Liver, cancer cell 
lines 
Bile salts, organic 
anions, digoxin 
OATP1C1 OATPF, SLCO1C1, 
SLC21A14 
Brain, testis, 
intestine, kidney 
Bromosulphophathanlin 
(BSP) 
OATP2A1 PGT, SLCO2A1, 
SLC21A2 
Ubiquitous Prostaglandin 
OATP2B1 OATPB, SLCO2B1, 
SLC21A9 
Liver, placenta, 
intestine, ciliary 
body 
BSP 
OCT1 SLC22A1 Liver (sinusoidal) Organic cations 
OCT2 SLC22A2 Kidney, brain Organic cations 
OCT3 SLC22A3 Liver, muscle, 
placenta, kidney, 
heart, lung, brain 
Organic cations 
OAT1 SLC22A6 Kidney, placenta, 
brain 
Organic anions 
OAT2 SLC22A7 Liver, kidney Organic anions 
OAT3 SLC22A8 Kidney, brain, 
muscle, 
developing bone 
Organic anions 
OAT7 SLC22A9, OAT4 Liver Estrone sulfate 
NTCP SLC10A1 Liver 
(basolateral), 
pancreas 
Bile acids 
 
  
Table 1.1 – Influx transporters. Information from the following sources (Schroeder 
et al., 1998; Boyer et al., 1994; Hagenbuch and Meier, 2004; Cui et al., 2001; Kullak-
Ublick et al., 2001; Tamai et al., 2000; Koepsell and Endou, 2004; Enomoto et al., 
2002; Takeda et al., 2002; Sekine et al., 2000; Molderings et al., 2003; Kimura et al., 
2002; Takeda et al. 2002b; Zhang et al., 1999; Kekuda et al., 1998; Wu et al., 1998). 
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Family Subfamilies Genes Function 
CYP1 3 subfamilies, 3 
genes, 1 pseudogene 
CYP1A1, -1A2, -1B1 Drug and steroid 
metabolism, in 
particular estrogen 
CYP2 13 subfamilies, 15 
genes, 16 
pseudogenes 
CYP2A6, -2A7, -2A13, 
-2B6, -2C8, -2C9, -
2C18, -2C19, -2D6, -
2E1, -2F1, -2J2, -2R1, 
-2S1, -2U1, -2W1 
Drug and steroid 
metabolism 
CYP3 1 subfamily, 4 genes,2 
pseudogenes 
CYP3A4, -3A5, -3A6, -
3A43 
Drug and steroid 
metabolism, including 
testosterone 
CYP4 6 subfamilies, 12 
genes, 10 
pseudogenes 
CYP4A11, -4A22, -
4B1, -4F2, -4F3, -4F8, 
-4F11, -4F12, -4F22, -
4V2, -4X1, -4Z1 
Fatty acid metabolism  
CYP5 1 subfamily, 1 gene CYP5A1 Thromboxine A2 
synthesis 
CYP7 2 subfamilies, 2 genes CYP7A1, CYP7B1 Bile acid biosynthesis 
CYP8 2 subfamilies, 2 genes CYP8A1, CYP8B1 Bile acid and 
prostacyclin synthesis 
CYP11 2 subfamilies, 3 genes CYP11A1, -11B1, -
11B2 
Steroid biosynthesis 
CYP17 1 subfamily, 1 gene CYP17A1 Steroid biosynthesis 
CYP19 1 subfamily, 1 gene CYP19A1 Steroid biosynthesis 
CYP20 1  subfamily, 1 gene CYP20A1 Unknown function 
CYP21 2 subfamilies, 1 gene, 
1 psseudogene 
CYP21A2 Steroid biosynthesis 
CYP24 1 subfamily, 1 gene CYP24A1 Vitamin D 
degradation 
CYP26 3 subfamilies, 3 genes CYP26A1, -26B1, -
26C1 
Retinoic acid 
hydroxylase 
CYP27 3 subfamilies, 3 genes CYP27A1, -27B1, -
27C1 
Bile acid biosynthesis, 
vitamin D activation 
CYP39 1 subfamily, 1 gene CYP39A1 Cholesterol 
hydroxylase 
CYP46 1 subfamily, 1 gene CYP46A1 Cholesterol 
hydroxlyase 
CYP51 1 subfamily, 1 gene, 3 
pseudogenes 
CYP51A1 Cholesterol 
biosynthesis 
 
  
Table 1.2 – CYP450 families. Information from the following sources (Bozina et al., 2009; Lewis 
et al., 1998; Guengerich, 1999; Shimada et al., 1994). 
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Protein name Alternate names Tissue expression Substrates 
CYP1A1 CYP1, CP11, P1-
450 
Extrahepatic Pre-carcinogens, PAHs 
CYP1A2 CP12, P3-450 Liver Aromatic amines 
CYP1B1 CP1B, P4501B1 Extrahepatic Oestradiol 
CYP2A6 CPA6, P450C2A Liver Nicotine 
CYP2A7 CYPA7, P450-IIA4 Liver Steroids, fatty acids, some 
xenobiotics 
CYP2B6 CPB6, P450-IIB6 Liver, lower levels 
in other tissues 
Xenobiotics, in particular 
anti-cancer drugs 
CYP2C9 CPC9, P450-IIC9 Liver Many xenobiotics 
CYP2C19 CPCJ, P450-IIC19 Liver Many xenobiotics 
CYP2D6 CPD6 Liver Many xenobiotics 
CYP2E1 CPE1, P450C2E Liver Many xenobiotics, 
solvents, pre-carcinogens 
CYP3A4 CP34, P450C3N 
P450PCN1 
Liver, intestine Many xenobiotics, pre-
carcinogens, dietary 
components 
CYP3A5 CP35, P450PCN3 Liver, intestine Many xenobiotics, pre-
carcinogens, dietary 
components 
CYP3A7 CP37, P450-HFLA Mainly foetal liver Many xenobiotics, pre-
carcinogens, dietary 
components 
CYP7A1 CP7A, CYP7 Liver Bile acid synthesis 
CYP7B1 CP7B Extrahepatic Cholesterol to bile acid 
conversion 
FMO1 None Foetal liver and 
kidney, adult 
kidney 
Anti-histamine 
promethazine, insecticide 
alicarb 
FMO2 FMO1B1 Unknown – high 
prevalence of 
polymorphism 
causing non-
function 
Unknown 
FMO3 FMOII, TMAU Adult liver, kidney 
and lung 
Xenobiotics such as 
cimetidine, agricultural 
chemicals such as 
organophosphates, dietary 
trimethylamine 
FMO4 FMO2 Very low levels in 
foetal and adult 
tissues 
Variety of xenobiotics and 
pesticides 
FMO5 None Adult liver (low 
levels) 
Unknown – possibly not a 
DME 
 
  
Table 1.3 – Phase I metabolising enzymes. Information from the following sources (Bozina 
et al., 2009; Lewis et al., 1998; Guengerich, 1999; Shimada et al., 1994; Zhou and Shepard, 
2006; Hines, 2006; Bain et al., 2005; Chung et al., 2000; Hodgson et al., 2000; Ziegler-
Skylakakis et al., 1998; Hodgson et al., 1995, Al-Waiz et al., 1987). 
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Protein 
name 
Alternate names Tissue expression Substrates 
UGT1A1 UGT1, UDPGT 1-
1 
Liver, kidney Bilirubin, estradiol, thyroxin, 
paracetamol 
UGT1A3 UGT1C, UDPGT 
1-3 
Liver, kidney Estrogens, bile acids 
UGT1A4 UGT1D, UDPGT 
1-4 
Liver, kidney Estrogens, eicosaniods, nicotine 
UGT1A6 UGT1F, UDPGT 1-
6 
Liver, kidney Serotonin, paracetamol 
UGT1A7 UGT1G, UDPGT 
1-7 
GI tract Phenols, irinotecan, uridine 
UGT1A8 UGT1H, UDPGT 
1-8 
GI tract Phenols, flavones, opioids 
UGT1A9 UGT1I, UDPGT 1-
9 
Liver, kidney Estrogens, eicosanoids 
UGT1A10 UGT1J, UGT 1.10 GI tract Mycophenolic acid, coumarins 
UGT2A1 None Nasal tissue Unknown 
UGT2B4 UGT2B11, 
UDPGT2B4 
Liver Bile acids, arachidonic acid, 
codeine 
UGT2B7 UGT2B9, 
UDPGT2B7 
Liver, kidney Bile acids, estradiol, progesterone, 
glucocorticoids 
UGT2B10 UDPGT2B10 Liver, kidney Eicosanoids, nicotine 
UGT2B15 UGT2B8, 
UDPGT2B15 
Liver, pancreas, 
prostate, kidney 
Testosterone, paracetamol 
UGT2B17 UDPGT2B17 Liver Testosterone 
Table 1.4 – Phase II metabolising enzymes (UGT enzymes). Information from the following 
sources (Bock, 2010; Tukey and Strassburg, 2000; Burchell et al., 2005; Court, 2005; Little et al., 
2004; Samokyszyn et al., 2000; Wietholtz et al., 1996; Jancova et al., 2010). 
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Protein 
name 
Alternate 
names 
Tissue expression Substrates 
SULT1A1 ST1A1 Liver, pancreas, prostate, 
kidney, lung 
Phenolic compounds 
SULT1A2 ST1A2 Liver, pancreas, prostate, 
kidney, lung 
Aromatic amines 
SULT1B1 ST1B1 Liver, GI tract Thyroid hormones, small phenols 
SULT1E1 ST1E1 Liver, jejunum Estrogen, genistein, 1-naphtol 
SULT2A1 ST2A1 Liver, adrenal glands, 
duodenum 
Hydroxysteroids 
SULT4A1 SULTX3 Brain Unknown 
SULT6B1 None Testis, kidney Unknown 
GSTA1 GSTA1-1, 
GST2, GTH1 
Liver, kidney Anti-cancer drugs e.g. 
chloroambucil, doxorubicin, 
busulfan 
GSTA2 GSTA2-2, 
GST2, GTH2 
Liver, kidney, lung, 
prostate, pancreas 
Chloroambucil, chloroquinine, 
ceramide, busulfan 
GSTA3 GSTA3-3, 
GTA3 
Lung, liver, kidney, 
pancreas, prostate 
Steroid hormone production, 
endogenous and exogenous 
conjugation 
GSTA4 GSTA4-4, 
GTA4 
Wide range of tissues 
including liver 
4-hydroxyalkenals such as 4-
hydroxynonenal (4-HNE) 
GSTA5 None Unknown Unknown 
GSTM1-5 GSTM1-1 to 
5-5, GST4 
Wide range including liver, 
heart, kidney and testis 
Endogenous and exogenous 
conjugation 
GSTP1 GSTP, GST3 Wide range including 
kidney, lung, liver, heart 
and pancreas 
Endogenous and exogenous 
conjugation 
GSTT1/2 None Wide range including 
kidney, lung, liver, heart 
and pancreas 
Endogenous and exogenous 
conjugation 
NAT2 AAC2, PNAT Liver, GI tract Sulphonamides, isoniazid 
Table 1.5 – Phase II metabolising enzymes (SULT, GST and NAT enzymes). Information from the 
following sources (Jancova et al., 2010; Strassburg et al., 2002; Adjei et al., 2008; Hines, 2008; 
Meinl et al., 2002; Gamage et al., 2006; Falany et al., 1995; Comer et al., 1993; Hayes and 
Strange, 2000; Hayes and Pulford, 1995; Lo and Ali-Osman, 2007; Desmots et al., 2001; Kusama 
et al., 2006; Tew, 1994; Ciaccio et al., 1991; Hayes et al., 2005; Hein et al., 2000; Kawamura et al., 
2005). 
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Protein name Alternate names Tissue expression Substrates 
MRP1 ABCC1 Kidney, lung, 
muscle, testis, 
placenta, multi-
drug resistant 
carcinoma 
Conjugated drugs, 
verapamil, 
vincristine, folate 
MRP2 ABCC2 Liver, kidney, GI 
tract, placenta 
Conjugated 
bilirubin, estradiol, 
leukotrines 
MRP3 ABCC3 Kidney, 
cholangiocytes, 
pancreas, GI 
tract, spleen 
Conjugated 
bilirubin, 
leukotrines, 
estradiol 
MRP4 ABCC4 Kidney, prostate, 
brain, pancreas 
Conjugated 
nucleosides, cGMP, 
cAMP, ADP, folate 
MRP5 ABCC5 Wide range 
including liver, 
kidney, lung and 
muscle 
Thiopurine 
anticancer drugs, 
some anti-HIV drugs 
MRP6 ABCC6 Kidney, lower 
liver levels 
Drugs such as 
doxorubicin, 
cisplatin, probenacid 
BCRP ABCG2 Blood-brain 
barrier, placenta, 
kidney, intestine, 
liver 
Hydrophobic drugs, 
mitoxantrone, 
anthracycline 
BSEP ABCB11 Liver Bile salts, vinblastine 
P-gp MDR1, ABCB1 Blood-brain 
barrier, kidney, 
intestine, liver 
Hydrophobic drugs – 
digoxin, verapamil, 
cyclosporin A, 
steroid hormones 
MDR3 ABCB4 Liver, colon Phosphatidylcholine, 
phospholipids 
 
  
Table 1.6 – Efflux transporters. Information from the following sources (Rius et al., 
2008; Rius et al., 2005; Jedlitschky et al., 2004; Lee et al., 2004b; Rius et al., 2003; 
Chen et al., 2001; Zeng et al., 2000; Keppler, 2011; Ilias et al., 2002; Cui et al., 1999; 
Kamisako et al., 1999; Allen and Schinkel, 2002; Allen et al., 2002; Loe et al., 2000; 
Keppler et al., 1998; Jedlitschky et al., 1997; Jedlitschky et al., 1996; Loe et al., 1996; 
Leier et al., 1994; Childs et al., 1998; Leslie et al., 2005). 
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Chapter 2 – Materials and Methods 
Detailed in this section is the methodology used in obtaining the experimental results shown in 
the following chapters. All reagents and cell culture media were purchased from Sigma 
(Dorset, UK) unless otherwise stated. Buffer recipes can be found in Appendix 1. 
2.1 – Cell culture 
2.1.1 – Routine culture of HepG2 and Huh7 cells 
All manipulations were carried out in the sterile environment of a class ІІ laminar flow cabinet 
(S@feflow 1.2, BIOAIR, Italy) using aseptic techniques to avoid contamination. Sterility was 
maintained by UV irradiation and spraying with 70% ethanol and TriGene (Starlab, UK). All 
glassware was autoclaved at 121oC for 20 minutes before use and nitrile gloves were worn at 
all times. Sterile plastics were purchased from Corning Costar. All medium was stored at 40C 
and warmed to 370C prior to use. 
HepG2 cells (passages 71-90) were originally obtained from American Type Culture Collection 
(ATCC  HB-8065). HepG2 cells were maintained in high glucose DMEM supplemented with 10% 
foetal calf serum (v/v), penicillin/streptomycin (100U/ml and 100μg/ml respectively), 1% 
glutamine (v/v) and 1% non-essential amino acids (v/v). This cell line was grown in 75cm2 flasks 
at 37oC in 5% CO2 in air until confluent (approximately 7 days, determined by light microscopy), 
at which time they were sub-cultured and re-seeded at a density of 2.5 x106 cells per flask. 
Growth medium was replaced every three to four days. 
Huh7 cells (passages 5-18) were kindly donated by Paul Sharp (Kings College, London, UK). 
These were maintained in high glucose DMEM supplemented with 10% foetal calf serum (v/v), 
penicillin/streptomycin (100U/ml and 100μg/ml respectively) and 1% glutamine (v/v). This cell 
line was grown in 162cm2 flasks at 37oC in 5% CO2 in air until 90% confluent (approximately 7 
days, determined by light microscopy), at which time they were sub-cultured and re-seeded at 
a density of 1.8 to 2.5 x106 cells per flask. Growth medium was replaced every three to four 
days. 
2.1.2 – Subculture of HepG2 and Huh7 cells 
When ready to be subcultured, cells were washed twice with PBS and incubated at 37oC in 
trypsin-EDTA (10ml/162cm2, 5ml/75cm2) for approximately 5 minutes. Once detached they 
were transferred into a sterile universal tube and the flask was washed with medium to 
retrieve any remaining cells. Addition of serum-containing medium deactivated the trypsin. 
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Cells were then centrifuged at 400 xg for 3 minutes, after which the supernatant was discarded 
and the cell pellet resuspended in 10mls of fresh medium using a wide-bore needle and 
syringe. The number of cells was quantified using a Coulter Particle Counter Z1 (Beckman 
Coulter, UK) and seeded accordingly into sterile culture flasks at the previously stated 
densities. For experimental purposes HepG2 cells were seeded onto 6, 12 and 24 well plates at 
densities of 5 x105 (6 well) or 1 x105 (12 and 24 well) cells per well. Huh7 cells were seeded 
onto 6 well and 24 well plates at densities of 4 x105 and 8 x104 cells per well respectively. 
Medium was changed every two to three days at which point all cells were visually assessed 
for effects of treatment on viability and morphology using a light microscope. 
2.1.3 – Cell cryopreservation 
Periodically cells from both lines were frozen in liquid nitrogen in order to maintain a low 
passage stock. Cells ready to be subcultured were dissociated from the flask with trypsin and a 
count obtained as previously described, after which the cells in suspension were re-pelleted by 
centrifugation. The pellet was resuspended in freezing medium consisting of 80% growth 
medium, 10% serum and 10% DMSO) so that 1ml of medium contained 3 to 5x106 cells. 1ml 
aliquots of cell suspension in 2ml cryopreservation vials were slowly frozen at a rate of 
1oC/min until a temperature of -196oC was reached, at which point the vials were transferred 
into a liquid nitrogen storage facility. 
In order to grow cells from frozen stocks, a vial was removed from the liquid nitrogen store 
and immediately thawed in a water bath at 37oC whilst being vigorously shaken to minimise 
bursting of the cells. Once thawed, cells were added to a new sterile culture flask along with 
prewarmed growth medium. The following day the medium was changed to remove any traces 
of the freezing medium. Culturing was then commenced as previously described, allowing at 
least one passage before cells were used for experimental purposes. 
2.2 – Differentiation treatments 
2.2.1 – Initial growth factor treatments 
HepG2 and Huh7 cells were seeded onto 6 well plates at the previously stated densities and 
allowed to grow for two days. HepG2 cells were also seeded onto 3 cm diameter plastic plates 
at the same density to allow imaging on the stage of a confocal microscope. On the third day 
cells were at approximately 90% confluence (acceptable range was approximately 85% to 95%, 
cells not meeting this criteria or showing signs of infection were discarded) and the applicable 
growth factor cocktail was added to the standard growth medium, passed through a sterile 
0.22 μm syringe-driven filter (Millipore, Ireland) and added to the growing cells (for growth 
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factor treatments see table 4.2). Every two days medium was changed and images were taken 
of HepG2 cells using a Zeiss LSM 510 inverted confocal microscope (Zeiss, Germany) at 20x 
zoom and excitation wavelength of 633 nm using an HeNe2 laser. On day five of treatment 
(day eight total growth) total RNA was extracted from the cells as described in chapter 2.4. 
However, as no clear changes were observed in morphology with this treatment and it was not 
feasible to conduct this in prolonged treatments due to the time the cells were out of the 
sterile environment, no images from this method are included. 
2.2.2 – Dimethyl sulfoxide (DMSO) treatments 
HepG2 and Huh7 cells were seeded onto 6 well plates at the previously described densities 
and allowed to grow for two days. On the third day the cells were at approximately 90% 
confluence and treatment began with the addition of either 1% or 2% DMSO (v/v) to the 
standard growth medium. Medium was changed every two to three days and total RNA was 
extracted at specific time points. Untreated Huh7 cells were grown and extracted at the same 
time points. The timing of treatments and RNA or protein extraction for both HepG2 and Huh7 
cell lines can be seen in figures 2.1 and 2.2 respectively. 
2.2.3 – Extended growth factor treatments 
HepG2 and Huh7 cells were seeded onto 6 well plates at the previously described densities 
and allowed to grow for two days. On the third day the cells were at approximately 90% 
confluence and treatment commenced with the addition of growth factor treatment 1, 2 or 3 
(see table 4.3). The cocktail was added to standard growth medium and passed through a 
sterile 0.22 μm syringe-driven filter before being added to the cells. Medium was changed 
every two to three days and total RNA was extracted at specific time points (figures 2.1 and 
2.2). 
2.2.4 – HepatoZYME medium 
HepatoZYME is a specialised medium designed for long term maintenance of primary 
hepatocytes which can be purchased from Invitrogen (UK). It is designed to be used in a 
serum-free state and contains carefully balanced growth factor mixtures. This medium was 
tested on both HepG2 and Huh7 cells as an alternative to standard growth medium or 
supplemented medium using combinations of growth factors to attempt to produce a more 
heptocyte-like cell using a widely available commercial product. Normal growth conditions for 
both HepG2 and Huh7 cells require the addition of 10% foetal calf serum; however, adding 
10% serum to this medium would reduce its specificity so various methods of growing both cell 
lines with a lower serum content were attempted. Both cell lines were grown on 6 well plates 
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to confluence in standard growth medium which was subsequently replaced by HepatoZYME 
containing no serum or with 2% serum. In both media, cells began to dissociate from the flask 
surface very quickly and after four to five days very few whole cells were present. Next, in an 
attempt to habituate the cells to low serum concentrations, both cell lines were cultured in 
standard growth medium with gradual reductions in serum content from 10% to 2% over a 
period of two weeks. Both cell lines grew more slowly at low serum concentration but still 
appeared healthy. After five to seven days of growth at 2% serum, cells were subcultured and 
seeded into 6 well plates with the continuation of growth medium at 2% serum. When cells 
were confluent this was replaced with HepatoZYME medium with or without 2% serum. 
Unfortunately cells did not survive in serum-supplemented or standard HepatoZYME medium 
for more than ten days, and after approximately five days there were so few viable cells 
present that only small quantities of RNA could be extracted and what was obtained was of 
too poor quality to be of use. In view of these results it was concluded that the HepatoZYME 
medium with a low serum concentration was not suitable for prolonged growth of these cell 
lines and no further experiments were conducted using this medium. 
2.3 – Induction treatments 
Rifampicin, phenobarbital and β-naphthoflavone (BNF) were added to HepG2 and Huh7 cells in 
6 well plates at confluency and after 15 days of 1% DMSO treatment. Each experiment 
included a control and three different concentrations of the inducing agent. Phenobarbital was 
dissolved in water to a stock concentration of 30mM; control cells were incubated in standard 
growth medium with the maximal volume of water added to treated cells; treated cells 
contained either 0.5, 1.5 or 3 mM phenobarbital in standard growth media with the maximum 
vehicle volume (water) in each concentration (i.e. the vehicle volume in each of the lower 
concentrations and the control was equal to that present in the 3 mM treatment). Rifampicin 
and BNF were both dissolved in DMSO to stock concentrations of 30 mM and 10 mM 
respectively. Control cells were incubated with growth medium plus the maximum volume of 
DMSO added to treated cells. When used as a vehicle DMSO concentration was always <1%. 
Cells were treated with 10 μM, 50 μM or 100 μM rifampicin, and with 1 μM, 10 μM or 100 μM 
BNF. All treatments were applied for 24 hours, after which total RNA was extracted. 
2.4 – RNA extraction and reverse transcription 
Total RNA was isolated from HepG2 and Huh7 cells using the SV Total RNA Isolation System 
according to the manufacturer’s instructions (Promega). RNA was quantified and purity 
assessed using a spectrophotometer with a quartz cuvette at absorbances 260 nm, 230 nm 
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and 280 nm. RNA concentration was determined by the measurement of absorbtion at 260 
nm, while the ratios 260/280 and 260/230 were recorded to detect contamination by phenols, 
proteins and other organic compounds – ideally in pure RNA preparations both of these ratios 
would give a value of 2. Where values under 1.8 were observed for either ratio the sample was 
not used. Total RNA (1 μg and 0.5 μg for HepG2 cells and Huh7 cells respectively) was reverse 
transcribed into cDNA. A lower concentration of RNA was reverse transcribed for Huh7 
samples due to the lower RNA yield from the cells, allowing the sample to be used for more 
experiments; this concentration still allowed subsequent PCR experiments to be carried out 
reliably. Reverse transcription was carried out using random priming and Moloney murine 
leukaemia virus (MMLV) reverse transcriptase (RT) (Promega), in a reaction volume of 20 μl. 
This RT also has an endogenous RNase H+ function which ensures degradation of the RNA 
template after it has been subjected to reverse transcription; RNase inhibitor (RNAsin, 
Promega) was included to ensure that RNA degradation did not occur in the mixture before 
reverse transcription has taken place. This enzyme inhibits common eukaryotic RNases and 
does not affect MMLV reverse transcriptase or RNase H+ function. Negative control reactions 
from which either MMLV-RT enzyme or RNA were omitted were included to check for genomic 
DNA contamination in the samples and other contaminants in the RT components. Briefly, RNA 
was mixed with 1 μl of 0.5 mg/ml random hexamers and heated for 5 minutes at 65oC in order 
to remove any secondary structure, then cooled on ice for a further 2 minutes to ensure that 
the secondary structure did not reform. The rest of the reaction mixture was then added (0.5 
μl MMLV-RT (200 U/μl), 4 µl 5xRT buffer, 5 µl 2mM dNTPs and 0.25 μl RNase inhibitor (40 U/μl, 
Promega)) and samples incubated at 42oC for 2 hours, followed by 10 minutes at 70oC. Reverse 
transcription products and negative controls were subject to end point PCR to ensure that the 
reverse transcription had worked and that no contamination was present. 
2.5 – End point PCR, cloning and qPCR 
Details of primer sequences, annealing temperatures, exon locations, product length 
sequencing results and qPCR parameters such as melting temperatures, assay efficiency and 
error used in this work are included in chapter 3. All primers were designed using the LUX 
primer design program by Invitrogen (www.invitrogen.com) with the criteria of a product size 
of around 100 base pairs, primer length of approximately 20 base pairs, a melting temperature 
of between 55 and 60oC and ideally would cross an exon:exon boundary. The inclusion of an 
exon:exon boundary is particularly useful as the intron which would be included in the 
genomic DNA sequence would create a longer product during PCR. This can both help with 
identifying potential genomic DNA amplification during end-point PCR and can prevent 
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genomic amplification during the much shorter amplification stage in qPCR. As part of the 
design program predicted product sequences were tested for specificity using the BLAST 
program (http://blast.ncbi.nlm.nih.gov/Blast.cgi). Primers were ordered from either VHBio 
(Gateshead, UK) or IDT (Belgium). Primers were initially purchased with standard desalting 
purification; if these proved to be unsuitable for either end-point or qPCR due to mispriming, 
lack of product or poor qPCR efficiency, HPLC purified primers were ordered. If primers were 
still found to be unsuitable they were redesigned. 
End point PCRs were carried out for all primer pairs. Reaction volumes were 20 μl, comprised 
of 0.25 μl GoTaq DNA polymerase (5 U/μl, Promega), 2 μl 2mM dNTPs, 0.5 μM of each primer 
(1 μl of a 10 μM stock) and 4 μl 5x Green GoTaq Flexibuffer. Amplification protocol was as 
follows: 95oC for 2minutes, 35 cycles of 95oC (30 seconds), χoC (30 seconds, χ = annealing 
temperature) and 72oC (30 seconds), then an end stage of 72oC for 10 minutes (carried out on 
a Px2 Thermo Cycler, Thermo Scientific, USA). Cycle number was increased to 40 if insufficient 
amplification was seen. PCR products were separated by gel electrophoresis using 1.5% 
agarose gels and visualised with SafeView (5 μl per 100 ml of agarose, NBS Biologicals Ltd, UK) 
under UV light (Alphaimager, Flowgen). Products were excised, cloned using pGem T-easy 
vector system 2 with JM109 competent cells according to manufacturers instructions 
(Promega), and sequenced to verify that the correct product had been amplified. Sequencing 
was outsourced to Cogenics (Essex, UK).  
Quantitative PCR (qPCR) was carried out on a Roche LightCycler 480 using LightCycler 480 
SYBR-green Master Mix (Roche, UK). The suitability of six reference genes to be used in data 
normalisation was determined using GeNorm software ((Vandesompele et al., 2002), website 
medgen.ugent.be/genorm/, PrimerDesign, Southampton, UK) using cDNA samples harvested 
at confluence over several passages of each cell line. Of the six, the two most stable reference 
genes were chosen for each cell line; these were GAPDH and hATP5b for HepG2 cells and 
GAPDH and TOP1 for Huh7 cells. Pre-designed primer mixes for these genes were purchased 
from Primer Design (Southampton, UK) and used in PCR with LightCycler 480 SYBR-green 
Master Mix. For amplification of genes of interest the protocol was as follows: 95oC for 10 
minutes, 45 cycles of 95oC (10 seconds), χoC (20 seconds, χ = annealing temperature) and 72oC 
(10 seconds), followed by melt curve analysis (cooling to 65oC followed by heating to 97oC 
during which a continuous fluorescent reading is recorded) and a cooling step. For reference 
genes the protocol was as follows: 95oC for 10 minutes, 35 cycles of 95oC (15 seconds), 60oC 
(30 seconds) and 72oC (10 seconds), followed by melt curve analysis and a cooling step. All 
data was normalised to a geometric mean derived from the two appropriate reference genes. 
Coefficient of variation (CV) calculations were carried out for each assay to ensure 
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reproducibility using the first and second clone dilutions from standard curves which were 
repeated up to ten times. An average value for each clone dilution from each repetition was 
calculated, from which an overall mean and standard deviation was generated for each clone 
dilution. These values were used to generate a CV for each assay (standard deviation/mean) 
with a smaller value being representative of a more stable, consistent assay. 
2.6 – Functional studies 
2.6.1 – Hoechst 33342 experiments 
Hoechst 33342 dye is effluxed from cells mainly by MDR1 and BCRP. The functionality of these 
transporters in cells can be investigated using inhibitors such as cyclosporin A (CSA, vehicle 
100% methanol), verapamil (vehicle 100% ethanol) (both MDR1) and Ko143 (vehicle DMSO) 
(BCRP). Both confluent and 15 day 1% DMSO-treated HepG2 and Huh7 cells plus prolonged 
untreated Huh7 cells were subject to Hoechst 33342 accumulation experiments. Huh7 cells 
were grown on 24 well plates for confluent, prolonged untreated and DMSO Hoechst 
experiments. HepG2 cells were grown on 24 well plates for confluent experiments and on 12 
well plates for 15 day 1% DMSO experiments, as a larger volume of medium was needed to 
sustain the cells than the 24 well plates could hold. Cells were treated with DMSO as 
previously stated.  
For experiments, cells were washed with warm Krebs buffer and incubated for 30 minutes in 
Krebs with or without inhibitors (10 μM CSA, 100 μM verapamil or 10 μM Ko143) on a heating 
plate at 37oC. Krebs containing Hoechst dye at concentrations ranging from 0.1 μM to 30 μM 
(vehicle water) was applied with or without inhibitors (matching those applied in the previous 
30 minutes) for 60 minutes. Cells were then washed twice with ice cold Krebs buffer and lysed 
in lysis buffer (appendix A) for at least 30 minutes at 37oC, harvested and collected. 
Fluorescence was measured in one of two ways; either in UV grade cuvettes (Fisher) and 
analysed in a Perkin-Elmer LS-5 luminescence spectrometer (Perkin Elmer, Massachusetts, 
USA) at excitation wavelength 360 nm and emission wavelength 480 nm or in black plastic 96 
well plates (Sterilin, purchased through Fisher Scientific, UK) and analysed on a fluorescent 
plate reader (FLUOstar Omega, BMG Labtech, Germany) using excitation filter 355 ± 10 nm and 
emission filter 480 ± 20 nm. For analysis, background fluorescence measured in cuvettes or 
wells containing lysis buffer only was subtracted from sample readings. Protein concentration 
of each sample was determined using Bradford reagent and measured in 96 well clear plastic 
plates on a spectrometer at 595 nm (FLUOstar Omega, BMG Labtech, Germany). For each well, 
fluorescent data was normalised to protein concentration. 
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2.6.2 – Calcein-AM experiments 
Confluent and 1% DMSO treated HepG2 and Huh7 cells were grown as described for Hoechst 
33342 experiments. Calcein-AM is not fluorescent but is cleaved by cellular esterases into 
calcein, which does fluoresce. The uncleaved form, calcein-AM, is lipid soluble and is effluxed 
by MDR1 and MRP1. Calcein is not lipid soluble and is effluxed from the cell by MRP1 and 
MRP2. Verapamil at 100 μM was used to inhibit MDR1 and MRP1 function and MK571 (Sigma) 
at 20 μM was used to inhibit MRP1 and MRP2 efflux. All solutions were made in Krebs buffer 
and heated to 37oC before use. All experiments were carried out on a heated surface. Cells 
were washed in warm Krebs and incubated for 30 minutes with 2 μM calcein-AM (vehicle 
DMSO) with or without MDR1 inhibitors (verapamil and CSA), washed with Krebs and 
incubated in 500 μl Krebs solution with or without inhibitors (verapamil, CSA and MK571). 
After 20 minutes either all Krebs solution was collected and kept for analysis in cuvettes or 200 
μl was collected for analysis in 96 well plates with the remaining solution being removed and 
discarded. Warm Krebs buffer (with or without inhibitors) was added again and the process 
repeated. Solutions were collected at four time points (0-20, 20-40, 40-60 and 60-80 minutes) 
in order to minimise the influx of calcein back into the cells and to enable the rate of efflux to 
be calculated if necessary. After the final collection water was added, the samples were 
protected from light and left overnight to lyse at 4oC. Lysed cells were harvested into 1.7 ml 
microcentrifuge tubes, centrifuged at 9660 xg for 10 minutes and the supernatant analysed for 
calcein fluorescence and protein content.  
Fluorescent samples were analysed using optical grade cuvettes on a fluorimeter at excitation 
wavelength 492 nm and emission wavelength 518 nm, or on black plastic plates in a 
fluorescent plate reader with excitation filter 480 ± 20 nm and emission filter 520 ± 10 nm. 
Background fluorescence was subtracted from readings for all samples before analysis and 
corrected readings were normalised to protein concentration for each well. Before 
experiments were commenced, the effects of overnight storage on calcein fluorescence were 
assessed and it was determined to be stable while protected from light at 4oC for at least 72 
hours. Total calcein content was determined by adding efflux and lysate fluorescence values. 
Calcein influx was assessed by loading the cells for 20 minutes with concentrations of calcein 
(vehicle water) from 0.2 μM to 2 μM in warm Krebs, representing 10% to 100% of calcein-AM 
cleavage. Cells were then washed twice with cold Krebs, lysed in water overnight and treated 
as previously described. Analysis of all samples and loading solutions was carried out on a 
fluorescent plate reader using black plastic 96 well plates. Protein levels were assessed using 
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Bradford reagent and read on a spectrometer. Background fluorescence was subtracted and 
data normalised to protein levels. 
2.7 – Western blotting 
Protein was extracted from HepG2 and Huh7 cells at confluence and at 10, 15 and 20 days of 
1% DMSO treatment. Cells treated at confluence and for 15 days with 1% DMSO were treated 
with BNF at the same concentrations as previously described (section 2.3) and protein 
harvested. Cells were washed twice with ice-cold 1x PBS and incubated at 4oC for 45 minutes 
with lysis buffer (recipe in appendix A). After being scraped and collected into 1.7 ml 
eppendorf tubes, samples were passed through a 25G needle three times, centrifuged at 9660 
xg for 15 minutes and the supernatant collected, aliquoted and stored at -80oC. Sample protein 
values were obtained by Bradford assay using a spectrometer at 595 nm. Protein 
concentration by acetone precipitation was carried out when necessary; this was done by 
adding acetone to the protein sample in a ratio of 1:4 (e.g. 25 µl acetone for every 100 µl of 
sample). This was incubated at room temperature for 20 minutes followed by centrifugation at 
9660 xg for 15 minutes. Supernatant was discarded and samples air-dried for 5 minutes before 
being re-suspended in an appropriate volume of sample loading buffer (Invitrogen). 
All reagents used in the process of Western blotting were from Invitrogen unless otherwise 
stated. Samples were thawed on ice; initially, maximum sample loading volume (13 μl) was 
used which was later refined to 20 µg of sample per well. Pre-cast NuPAGE Novex 4-12% Bis-
Tris Gels (1.0 mm, 12 well) were used as per the manufacturer’s instructions (NuPAGE 
technical guide, www.invitrogen.com). Denaturing conditions using SDS and reducing agents 
were applied and gels were run for 50-55 minutes at 200V. Transfer of the protein from gel to 
nitrocellulose membrane (0.45 μm pore, Invitrogen) was in a semi-dry transfer tank (OWL HEP-
1, Thermo Scientific, USA), for 24 minutes at 20V, again as per manufacturer’s instructions. 
Membranes were air dried for 30 minutes, re-wet in 1x PBS and incubated in Odyssey blocking 
buffer (Licor, Cambridge, UK) diluted 1:1 with 1x PBS at room temperature for 1 hour prior to 
addition of antibodies. 
Antibodies used were as follows; transferrin (1:1000), GAPDH (1:1000 and 1:5000), ADPGK 
(1:500) (all Genetex, Texas, USA), UGT1A1 (1:30 D-16, Santa Cruz, California, USA), albumin 
(1:100 AbCam, Cambridge, UK), BCRP (1:50 BXP-21, Santa Cruz, California, USA), MDR1 (1:100 
C219, Santa Cruz, California, USA) and actin (I-19, 1:2000 Santa Cruz, California, USA). 
Secondary IRDye antibodies were purchased from Licor as follows; donkey anti-rabbit IgG 
(680LT, red), goat anti-mouse IgG (680LT, red) and donkey anti-goat IgG (800CW, green). All 
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were used at 1:5000 dilution. All antibodies were diluted in blocking buffer with 0.1% Tween-
20; secondary antibodies also had 0.1% SDS added. Membranes were scanned using an 
Odyssey Licor v1.2 and bands were quantified using ImageJ software (version 1.44p, 
http://imagej.nih.gov/ij). After use membranes were stored in 1x PBS at 4oC until being air 
dried. Membranes were protected from light at all times after the secondary antibody had 
been added. 
2.8 – Extraction of cells from umbilical cord blood 
Umbilical cord blood was obtained from patients undergoing Caesarean section and kindly 
donated to us by Jola Weaver (Queen Elizabeth Hospital, Gateshead, UK and Newcastle 
University, UK) with full consent and ethical approval. The process of cell extraction is detailed 
below. 
UCB was decanted into 50 ml Falcon tubes and diluted 1:1 with 1x PBS (maximum total volume 
of 35ml). Into a separate 50 ml tube, 15 ml of Biocoll Separating Solution (density 1.077 g/ml, 
Biochrom AG, Germany) was added and all of the UCB:PBS from one Falcon (35 mls) was 
decanted by pipetting so that the Biocoll solution remained as a separate layer in the bottom 
of the tube. This was centrifuged at 800 xg for 20 minutes with no brake applied at the end of 
the spin as this disturbs the layers formed. Following centrifugation, four layers should be 
apparent – from the top, serum; a small layer of cells; biocoll and finally red blood cells. The 
cell layer must be transferred to a new tube. Serum can be transferred with the cells but no 
Biocoll. At this point, cells were amalgamated into as few tubes as possible and centrifuged 
again at 800 xg for 10 minutes, this time with the brake on full. The supernatant was discarded 
and the pellet resuspended in 5ml of PBS; all cells were collected into one Falcon if not already 
in one tube, which was filled with PBS and centrifuged again at 800 xg for 10 minutes. Once 
again, the supernatant was discarded and the cells resuspended in PBS and counted. Cells can 
be seeded at this point; a typical seeding density is 15 x106 cells in 5ml of media. However, the 
suspension contains all cells except red blood cells at this point, so platelets, white blood cells 
and so on are still present. If seeded these should detach within two weeks; if further 
separation is required before seeding, magnetic beads must be used.  
Unfortunately UCB was only provided once. Cells were extracted and grown in 25cm2 flasks 
with either HepatoZYME plus 2% serum (10% serum for the first 3 days to help cells attach) or 
DMEM HEPES plus 10% serum. Cells were split at confluence using trypsin which proved to be 
too strong an agent and the cells did not thrive afterwards. This resulted in few cells surviving 
and no RNA could be extracted for analysis. 
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2.9 – Statistical analysis 
Data is shown as mean ± SEM. Statistical analysis by one-way ANOVA with Dunnett’s or 
Bonferroni’s post test and using Student’s T-test were also carried out with Prism. All graphs 
and statistics were produced using GraphPad Prism v5.00 (www.graphpad.com). 
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Cells seeded
3 days of growth to 90% confluence.
Media changed Day 0
Control cells 
harvested
1 day of growth to 100% confluence.
Day 1
Treated cells Harvested Day 5
Treated cells Harvested Day 10
Treated cells Harvested Day 15
Treated cells Harvested Day 20
Treated cells Harvested Day 25
Figure 2.1 – Experimental protocol for HepG2 cells. Cells were seeded and grown in
standard growth medium on six well plastic plates. On day 0 media was changed to either
fresh standard growth medium (control cells) or growth medium plus the applicable
treatment. Following this, media was replaced every two to three days. Cells were harvested
at the indicated points for either protein or total RNA dependent on the experiment.
 
Figure 2.1 – Experimental protocol for HepG2 cells. Cells were seeded and grown in 
sta ar  gr t  e i   six ell plastic plates. n day 0 media was changed to either 
   i  (c tr l cel s) or growth medium plus the ap licable 
treat ent. Following this, media was replaced every two to three days. Cells were 
harvested at the indicated points for either protein or total RNA dependent on the 
experiment. Matched controls of untreated cells were not sustainable for the duration of 
the experiment, with widespread cell death due to overgrowth observed after 5 to 7 days. 
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Figure 2.2 – Experimental protocol for Huh7 cells. Cells were seeded and grown in standard
growth medium on six well plastic plates. On day 0 media was changed to either fresh standard
growth medium (control and untreated cells) or growth medium plus the applicable treatment.
Following this, media was changed every two to three days. Cells were harvested at the indicated
points for either protein or total RNA dependent on the experiment. In addition to the control at
confluence, matched controls of untreated cells grown in standard growth media are harvested at
each time point of the experiment.
Cells seeded
3 days of growth to 90% confluence.
Media changedDay 0
Control cells 
harvested
1 day of growth to 100% confluence.
Day 1
Treated cells Harvested Day 5
Treated cells Harvested Day 10
Treated cells Harvested Day 15
Treated cells Harvested Day 20
Treated cells Harvested Day 25
Untreated cells
Untreated cells
Untreated cells
Untreated cells
Untreated cells
  
Figure 2.2 – Experimental protocol for Huh7 cells. Cells were seeded and grown in 
standard growth medium on six well plastic plates. On day 0 media was changed to 
either fresh standard growth medium (control and untreated cells) or growth edium 
plus the applicable treatment. Following this, media was changed every two to three 
days. C lls were harvested at he indicated poin s fo  either protein or to al RNA 
dependent on the experiment. In addition to the control at confluence, matched 
controls of untreated cells grown in standard growth media were harvested at each 
time point of the experiment.  
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Chapter 3 – Characterisation of HepG2 and 
Huh7 cells: PCR assay development 
Chapter aim: To develop quantitative PCR assays for a variety of differentiation markers, 
transporters and drug metabolising enzymes in order to characterise the hepatic carcinoma 
cell lines HepG2 and Huh7 relative to liver. 
3.1 – Introduction 
Hepatic carcinoma cell lines are known to have markedly different mRNA and protein 
expression profiles to those found in healthy in vivo hepatocytes. As well as being initially 
altered due to their carcinogenic nature, the repeated passaging necessary to maintain these 
cells in vitro is known to contribute to genetic drift, further changing the expression profile of 
transporters and enzymes.  
The two human hepatocarcinoma cell lines being characterised in this chapter are HepG2 and 
Huh7. HepG2 cells are sometimes used in the pharmaceutical industry in the very early stage 
assessment of drug toxicity; however, these cells are known to be hugely different from in vivo 
hepatocytes in the expression and activity of a number of major enzymes and transporters 
(Sivertsson et al., 2010; Ek et al., 2007; Hilgendorf et al., 2007; Olsavsky et al., 2007; Westerink 
and Schoonen, 2007a; Westerink and Schoonen, 2007b; Elizondo and Medina-Diaz, 2003). A 
key example of this is the drug metabolising enzyme CYP3A4, which is reported to have 
expression levels 100-fold lower than both liver and primary hepatocytes in HepG2 cells at 
best; some variants of the cell line have no detectable CYP3A4 at mRNA or protein level 
(Sivertsson et al., 2010; Olsavsky et al., 2007). HepG2 cells have been extensively characterised 
by a large number of groups; however, due to the variability between the same cell lines when 
grown in different laboratories the HepG2 cells used here have been assessed for basal mRNA 
expression levels of several differentiation markers, enzymes and transporters. 
Huh7 cells were isolated in 1982 and were found to excrete hepatocyte-specific plasma 
proteins such as albumin, transferrin and alpha 1-antitrypsin (Nakabayashi et al., 1982). Recent 
studies have since reported a similar mRNA expression profile for hepatic markers, 
transporters and enzymes in these cells as in HepG2s (Sivertsson et al., 2010; Olsavsky et al., 
2007). The mRNA expression profile of key transporters and enzymes in Huh7 cells used in 
these experiments has been examined due to both the lack of reported expression profiles and 
to characterise them under the conditions employed. 
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In order to characterise the cell lines in question the mRNA levels of several hepatocyte 
differentiation markers, transporters and enzymes were analysed. These genes of interest 
(GOI) were chosen to provide an overview of the maturation status of HepG2 and Huh7 cells at 
confluence in comparison to a human whole liver cDNA sample comprised of a pool of three 
human liver samples (37 year old Caucasian male, 64 year old Caucasian male, 70 year old 
Caucasian female; purchased from Primer Design, UK). Five markers of differentiation were 
selected for initial observations of differentiation status; these were albumin, transferrin, 
alpha-fetoprotein (AFP), serpin peptidase inhibitor, clade A, member 1 (SERPINA1 or alpha-1 
antiproteinase, antitrypsin (A1AT)) and hepatocyte nuclear factor 4, alpha (HNF4a). These will 
be discussed in more detail later in this chapter and in chapter 4.  
Both influx and efflux transporters along with phase I and II metabolising enzymes are vital for 
hepatic function; a selection of key genes were selected for characterisation by assessment of 
mRNA levels. Four influx transporters were selected; three from the solute carrier organic 
anion transporter family (OATPB, C and 8) and solute carrier family 22 (extraneuronal 
monoamine transporter) member 3 (OCT3) which transports organic cations into the cell. 
Members of the ATP-binding cassette (ABC) superfamily comprise the majority of efflux 
transporters in the hepatocyte and four were chosen for this study. These were multidrug 
resistance protein 1, also known as P-glycoprotein (MDR1, P-gp or ABCB1), multidrug 
resistance associated proteins 1 and 2 (MRP1 and 2, or ABCC1 and 2) and breast cancer 
resistance protein (BCRP or ABCG2). 
Finally, several drug metabolising enzymes were chosen for analysis. These included three 
cytochrome P450 (CYP) enzymes, CYP1A2, 2E1 and 3A4 which are well known phase I 
metabolising enzymes and are critical for hepatic function. Phase II conjugating enzymes were 
also included for assessment – members of the glutathione S-transferase alpha (GSTA) family 
were assessed in two reactions, one specifically targeting GSTA4 and one which detected 
GSTA1, 2 and 5. UDP glucuronosyltransferase 1 family polypeptide A1 (UGT1A1) and flavin 
containing monooxygenase 3 (FMO3) were the other two enzymes assayed.  
Quantitative PCR (qPCR) was chosen as the method to analyse basal mRNA levels of this range 
of differentiation markers, enzymes and transporters for several reasons. It is a high 
throughput analytical method, allowing large numbers of samples generated in subsequent 
experiments to be quickly assessed. Accuracy of quantification in each PCR assay can be 
verified by inclusion of a standard curve (Larionov et al., 2005). 
Within qPCR there are several choices to be made in the design of an assay. These include 
probe type, detection method, quantification method and data analysis. There are several 
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types of qPCR probes to choose from, some of which incorporate a fluorescent signal either as 
a primer or a probe. The simplest and one of the most commonly used detection systems 
available is the use of an intercalating dye which binds to double stranded DNA (dsDNA) whilst 
utilising standard primers; the SYBR green system is an example of this. When the SYBR green 
dye binds to dsDNA its fluorescence significantly increases, resulting in the fluorescent 
intensity increasing proportionally to the amount of dsDNA present. An advantage of this 
method is that multiple fluorophore molecules bind along the whole product rather than just a 
single primer or probe-bound fluorophore, allowing more sensitive detection of low expression 
products. SYBR green detection also allows for melting temperature (Tm) analysis which is 
important for verification of a single assay-specific product. A disadvantage of this method is 
that products of non-specific amplification are more likely to be detected and therefore 
carefully designed primer pairs and good quality reagents are essential.  
Primer-based detection systems such as LUX fluorogenic primers (Invitrogen 
(www.invitrogen.com:  D-Lux assays) incorporate a fluorophore bound to the 3’ end of one 
primer in a hairpin structure. This hairpin effectively quenches the fluorescent signal so no 
separate quenching molecule is required; the fluorescent signal is slightly increased upon 
deformation of the secondary structure and increases significantly upon extension during PCR. 
An advantage of this system is that multiplexes composed of two or more assays can be 
conducted simultaneously by utilising fluorophores which emit fluorescence at different 
wavelengths; this method of detection also allows for Tm analysis. Disadvantages are that the 
assays are not as sensitive as SYBR green when detecting low level expression and the labelled 
primers are more expensive.  
Finally, probe based detection methods such as the TaqMan® system utilise two primers 
alongside a probe with both fluorophore and quencher attached. The probe is designed to 
bind to the template between the two primers and as the Taq enzyme travels along the DNA 
during extension, the fluorescent reporter is cleaved from the probe and dequenched, 
resulting in an increase in fluorescence. As this detection method requires both primer pairs 
and a probe, assay design is more complex and usually more costly than the previous two 
methods. Advantages are also imposed by the necessary specificity of designing three binding 
elements rather than only two as this ensures more accuracy in product detection. As with the 
primer-bound assays, multiplexing here is possible if different fluorophores are employed. 
Other choices in qPCR involve quantification method and analysis of the data. Two types of 
quantification, absolute and relative, are commonly used. Absolute quantification requires a 
standard with a known copy number and a robust assay which shows identical amplification 
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efficiencies between runs in order to extrapolate an exact copy number value for an unknown 
sample. Relative quantification assigns values to samples to enable comparison between them; 
this can be done either using the crossing point (CP) value (the cycle number at which 
fluorescence is deemed to be first significantly increased from background) or by using a 
standard curve to extrapolate relative abundance in arbitrary units rather than exact copy 
number. Absolute quantification is much more difficult to utilise and is more often employed 
in applications such as determining viral titre. For most instances relative quantification allows 
sufficient data to be collected to provide an answer to the question and is often the method of 
choice in gene expression studies. Data analysis for relative quantification depends upon which 
data output has been generated. If CP values are solely being used, the method of choice is 
PCR efficiency assessment, commonly referred to as ΔΔCt quantification (Fleige et al., 2006). 
Standard curve quantification of data has been shown to be a viable and arguably more simple 
alternative to this calculation, and despite its more common use in absolute quantification, 
there is no reason it cannot be employed in relative quantification assays (Larionov et al., 
2005). 
With careful consideration of the positives and negatives discussed previously for all stages of 
qPCR assay design, several conclusions were reached regarding techniques best suited to this 
study. Firstly, SYBR green detection was utilised for all assays. This allows for detection of low 
expression genes of interest and is the most cost-effective option when designing and running 
multiple assays for a potentially large number of samples. This detection method also allows 
for generation of Tm data to ensure that a single product is being generated. Relative 
quantification of data was employed with a standard curve of positive controls generated by 
cloning of PCR products; derivation of absolute copy number is unnecessary here. A standard 
curve was used over ΔΔCt calculations to extract data as it is simple, minimising the 
opportunity for mistakes to occur, and the generation of the standard curve allows efficiency 
of the PCR reaction to be accurately assessed as well as being an automatic inclusion of a 
positive control for use in Tm analysis. 
When designing primers for use in qPCR it is recommended to aim to generate products which 
are around 100 base pairs in length to ensure that the whole product is amplified in every 
cycle thus improving PCR efficiency. This is also important as in assays utilising SYBR green the 
fluorescence reading is taken at the end of the extension step in each cycle; this is how the 
amount of DNA is quantified and an accurate assay will not be produced if whole length PCR 
products are not guaranteed. It is also beneficial to design the primers so that an exon-exon 
boundary is encompassed where possible. As these assays are aiming to quantify mRNA levels, 
genomic DNA (gDNA) amplification must be avoided. Although a DNase step was included in 
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the sample generation process to eradicate gDNA, the PCR environment is intentionally ideal 
for amplification so any small amount of gDNA remaining could interfere with the true results. 
Inclusion of an exon-exon boundary within a primer minimises the chance of it binding to 
gDNA as the binding site itself will be interrupted by an intron. Where the exon-exon 
boundaries occur within the product but between primers, amplification from gDNA rather 
than cDNA will be clear due to the much larger product, which can be seen in end point PCR as 
a larger band on the gel, and in qPCRs utilising SYBR green as a second product with a different 
melting temperature to that of the correct product. Conditions of the PCR can also be altered 
to ensure that genomic amplification does not occur, such as keeping the extension time 
relatively short. For example, a Taq polymerase which amplifies at a rate of 25 base pairs per 
second coupled with an extension time of 10 seconds allows for an amplicon 250 base pairs in 
length to be produced, which would eliminate effective gDNA amplification if the target 
sequence spanned an intron greater than this in size. 
In order to ensure that the correct PCR product was being amplified, products from all primer 
pairs were cloned and sequenced as described in chapter 2. Briefly, sequence fragments were 
amplified from HepG2, Huh7 and whole liver cDNA by end point PCR, separated on an agarose 
gel and the products excised.  Products were eluted from the gel and pooled to ensure enough 
template was recovered to allow cloning. Clones were produced and purified and the insert 
was sequenced from at least two clone preparations. Sequencing results are shown in the 
figures of this chapter (figures 3.1 – 3.20), along with end point PCR and qPCR assessment of 
GOI mRNA levels in HepG2 and Huh7 cells and human whole liver cDNA for comparison. Once 
clones had been produced and verified they were used in qPCR to create the standard curves 
for assay verification. This served two purposes; the range of standards was much wider than 
could be produced using cDNA generated from experimental samples and so could be altered 
to encompass crossing points (CPs) of the samples in order to produce a relevant standard 
curve, and the melting point analysis at the end of the PCR allows verification of the correct 
product being amplified. Each standard curve was run several times, at which point the 
suitability of the assay was evaluated by looking at the calculated efficiency and error of the 
amplification. These are generated by the inbuilt Lightcycler 480 software (version 1.4.2) by 
comparing dilution factors assigned to samples identified as standards and assessing them 
with regard to the recorded CP value. These data are used to assess whether a doubling of the 
product occurs with each cycle – the software gives a standard curve showing an exact 
doubling a value of 2, with numbers above or below this representing more or less template 
being generated with each cycle. Error values are calculated both from replicates within the 
standard curve and from variation of points on the curve from the overall efficiency calculated. 
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If efficiency is consistently around 2 with a small error margin, the amount of DNA in the PCR is 
doubling in every cycle which is what would be expected in a truly exponential reaction. Values 
outside the range 1.7-2.3 can be potentially improved upon by altering variables such as 
annealing temperature and primer concentration. 
Melting point analysis functions by slowly heating the final PCR products up to 95oC whilst 
constantly taking a fluorescence reading in each well – this cannot be utilised with all qPCR 
systems and is an advantage of using SYBR green as a fluorescent probe. This heat causes the 
secondary structures within the DNA to deform and the double stranded DNA to become 
single stranded. In qPCR assays using SYBR green the fluorescence of the probe is maximal 
when bound to double stranded DNA. The failing of secondary structure results in a decrease 
in fluorescence which occurs at a specific temperature and is diagnostic for the product of a 
PCR amplification generated using a specific set of primers. For this reason, a positive control 
in the form of a diluted sample of the cloned PCR product was included in every qPCR assay so 
verification of the PCR product from each sample could be performed. This is especially crucial 
if non-specific amplification such as primer-dimer formation occurs. The inclusion of a positive 
control also helps to assess whether each assay is performing as expected in terms of 
efficiency; a control which is suddenly significantly different from previous runs points to an 
error in that particular plate and if this occurred was repeated.  
To analyse qPCR data for the GOI, reference gene levels must be quantified in every sample. A 
reference gene is one that has constant, stable expression in the cell regardless of treatment 
or growth stage. Historically only one reference gene was used, often GAPDH, 18S ribosomal 
RNA or β-actin. However, this method has been proven to be less accurate than the use of 
multiple reference genes which have been tested and selected for each applicable cell line 
(Gutierrez et al., 2008). Assessment of reference gene suitability for HepG2 and Huh7 cells was 
carried out using the geNorm software ((Vandesompele et al., 2002), website 
medgen.ugent.be/genorm/), which allows determination of the required number and the most 
stable high and low expression reference genes from a panel of at least six primer pairs.  
This chapter outlines the process of assay design for each GOI used in qPCR experiments in 
subsequent chapters. Included are the details of primer sequences, exon positions, sequences 
of the inserts in clones created for validation, and both end point and qPCR assessment of 
mRNA levels in whole liver cDNA and confluent HepG2 and Huh7 cells. 
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3.2 – Methods 
Collection and processing of RNA samples from six-well plates for both cell lines was executed 
as described in materials and methods (chapter 2.4). End point PCR assays were developed 
and products analysed by gel electrophoresis and characterised by cloning and sequencing; 
from these qPCR assays were developed and evaluated using SYBR green fluorescence on a 
Roche LightCycler 480. Pre-designed reference gene primers and human whole liver cDNA 
were purchased from Primer Design. LightCycler 480 SYBR Green 1 Master mix (Roche) was 
used in all assays. 
3.3 – Results 
3.3.1 – Primer design 
All primer sets incorporate an exon-exon boundary either in the forward or reverse primer or 
within the product between primers with three exceptions. OATP8, CYP3A4 and UGT1A1 
assays all have both forward and reverse primers located on the same exons. The OATP8 assay 
was already in use and validated within the laboratory; in the latter two cases this was 
unavoidable. The CYP3A family includes CYP3A4, A5, A7 and A43; these are very closely related 
with amino acid homologies within a subfamily typically over 55% (Nelson et al., 1996) and so 
it was difficult to design primers which only detect one family member. As a result several 
primer pairs were tested before finding ones which uniquely bound to CYP3A4 and the less 
desirable single exon binding and 200bp+ product length were overlooked in favour of the 
specific product. The UGT1A family has nine members that each have a unique first exon 
followed by four common exons. This made it necessary to design primers to anneal to the 
first exon only. GSTA primers were initially designed to anneal only to GSTA1; however, after 
cloning and sequencing it was found that products from GSTA1, 2 and 5 were generated and it 
was decided that the cumulative information from these three genes would be useful to this 
analysis. 
3.3.2 – End point PCR 
End point PCR assays were executed as described in chapter 2.5 using cDNA from confluent 
HepG2 and Huh7 cells along with a purchased whole human liver cDNA sample. In all assays 
the end point PCR showed only one band with occasional instances of faint primer-dimers 
being observed where there was low gene expression in template cDNA. An example of this 
was the CYP3A4 assay, where more primer-dimer was observed with HepG2 and Huh7 
template cDNA due to the lesser amount of target cDNA present. Product band sizes ranged 
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from 54 to 226 base pairs, with specific band sizes identified for each assay in figures 3.1 to 
3.20. The bands were excised and pooled before being cloned and sequenced. As the qPCR 
cycling protocols differ from those used in end point PCR, primer-dimers are not certain to 
form if they are seen in end point PCR and so this was not considered a reason to re-design 
assays unless very strong non-specific bands were produced. 
3.3.3 – Sequence and BLAST results 
Two clones for each assay were sequenced externally (Cogenics, Essex, UK) and the results are 
displayed in figures 3.1 to 3.20. Each clone was analysed using the Basic Local Alignment 
Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.cgi) which searches for areas of 
similarity between the input sequence and NCBI reference sequences. The alignment output 
from this service is shown as part E in all of the figures in this chapter and reveals any 
mismatches between the input and reference sequences. Occasional mismatches can be seen 
in a few of the alignments, probably due to PCR or sequencing errors or polymorphisms, 
however none of these are registered in the NCBI SNP database as being known SNPs (Single 
Nucleotide Polymorphisms). As these mismatches do not occur in more than one or two 
positions per product they do not significantly affect overall specificity of the cloned sequence. 
BLAST outputs also show which reference sequences a particular clone matches. In order to be 
a valid assay, PCR products must only match to the desired sequence or sequences. In the case 
of the assays assessed here, all PCR products only matched with the appropriate reference 
sequences – in most cases this is just one sequence. In the case of the GSTA primers (figure 
3.17) the product matched to all three expected genes (GSTA1, 2 and 5).  
In cases where the pooled end point PCR samples used to generate the clone had a much 
stronger product band in liver than in the cell lines, it is likely that the clones analysed have an 
insert from only the liver cDNA. By including melting point analysis, it was possible to confirm 
that even though the sequence may represent only one source of cDNA, the products 
generated during PCR for other templates were correct. 
3.3.4 – qPCR assay validation 
For all assays a standard curve generated using serial dilutions of the cloned PCR products was 
run on multiple occasions. Very little optimisation was required whilst developing these assays 
as the LightCycler 480 SYBR Green I mastermix was developed to allow for ease of use with 
most templates and primers. Occasionally a slight alteration in annealing temperature was 
necessary to eliminate non-specific amplification. Once an assay produced consistent results 
over several runs as determined by coefficient of variation (CV) calculations (table 3.1, method 
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of calculation as described in chapter 2.5) to show variation between runs was less than 10% 
and replicates of samples within runs were within 10% of each other, the assay was deemed 
suitable to use. From that point onwards one representative standard curve was selected for 
calculating sample concentrations in every subsequent run of that assay. Two clone dilutions 
corresponding to points on the standard curve were included on every plate as positive control 
samples. Data from the relevant standard curve are displayed in part F of each figure. These 
show efficiency and error values along with the range of values seen in melting temperature 
analysis. The melting temperatures are typically within 0.5oC of each other across the plate. 
The diagram of melting temperatures generated from the qPCR assay is shown in part G of 
each figure. Most assays typically show one peak indicating amplification of a single product, 
for example as shown in figure 3.1 for albumin. Some assays show an additional smaller peak 
at a lower melting temperature than the main peak; this usually indicates the presence of 
primer-dimer in the reaction product; an example of this can be seen in figure 3.16 for CYP3A4. 
The presence of primer-dimers is not a problem if it is occurring in negative reactions as seen 
for CYP3A4, where it is clear that any sample which has the lower Tm peak does not also have 
a major peak known to be the correct product. Occasionally other unidentified peaks were also 
seen, such as those in figures 3.10 and 3.19 (OCT3 and UGT1A1). If this occurred, the relevant 
samples were identified from the data output, excluded from analysis and repeated at a later 
date. Usually samples which were repeated for this reason produced a similar result during the 
second analysis and further inspection regarding levels of reference genes revealed lower 
mRNA levels throughout the expression profile, which resulted in some non-specific 
amplification in low expression GOI assays. The few samples in which this occurred were 
excluded from analysis. 
For each cell line a high and low expression reference gene was chosen; GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase, NM_001082253) and hATP5b (ATP synthase, H+ 
transporting, mitochondrial F1 complex, beta polypeptide, NM_001686) in HepG2, and GAPDH 
and TOP1 (topoisomerase (DNA) I, NM_003286) in Huh7. GAPDH and hATP5b reference genes 
were used to normalise whole liver cDNA. When all data had been collected for a specific 
sample, that from the two reference genes were used to determine a geometric mean; the 
data from the gene in question were divided by this geometric mean in order to take into 
account the amount of cDNA originally in the sample. This process was applied to all data 
presented in this and the following chapters. Graph H on all figures in this chapter shows the 
results from qPCR assays comparing these normalised values for a whole liver cDNA sample 
and samples from each cell line extracted from confluent cells. Confluence was reached after 
four days of growth as defined in figures 2.1 and 2.2 for HepG2 and Huh7 cells, respectively.  
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In all assays reverse transcription (RT) controls containing no reverse transcriptase enzyme 
were included in the qPCR as well as being tested by end-point PCR to ensure that no gDNA 
was present in the initial RNA samples. This was especially important in the three assays that 
have both primers on the same exon, where it is possible for gDNA to be amplified and 
unidentified by melting point analysis. RT negative controls and negative controls containing 
water plus qPCR mastermix were always a minimum of five cycles away from sample results; 
failing this the plate or individual samples were repeated at another time. Melting 
temperature analysis was always performed for every sample and compared to the positive 
control; any samples which did not match the positive control were excluded to be repeated at 
another time as this indicates non-specific amplification. As stated previously, this rarely 
occurred and was usually observed in samples which had low overall mRNA expression 
combined with an assay for a low expression GOI, in which case repetition produced a similar 
result and the sample was excluded from analysis. 
3.3.5 – Summary of gene expression 
Table 3.2 shows basal expression of all GOI in confluent HepG2 and Huh7 cells expressed 
relative to liver (liver = 1). These data have been calculated from qPCR results (graph H) shown 
in figures 3.1 to 3.20 in this chapter. The cell lines are represented by data compiled from two 
experiments at passages 73 and 75 for HepG2 cells and 6 and 11 for Huh7 cells. All data have 
been normalised to two reference genes as described. It is clear that the majority of genes 
assessed have lower mRNA levels in both HepG2 and Huh7 than in liver. Albumin and 
transferrin mRNAs were lower in both cell lines than liver and transferrin levels appeared 
comparable in HepG2 and Huh7 cells; albumin mRNA was slightly higher in HepG2 cells than in 
Huh7 cells but still 19-fold lower than in liver. Alpha fetoprotein mRNA levels were much 
higher in HepG2 cells (93-fold) than in liver and 19-fold greater in Huh7 cells in comparison to 
liver. Alpha-1-antitrypsin mRNA was only 6-fold reduced in HepG2 cells but almost 30-fold 
lower in Huh7 than in liver, while HNF4a mRNA levels were largely similar to liver, with 
approximately 2-fold greater and 2-fold lower levels seen in HepG2 and Huh7 cells, 
respectively. 
Of the influx transporters assessed, MRP1 mRNA showed the largest variation from liver. 
Approximately 2100-fold greater expression was seen in HepG2 cells compared to liver while 
in Huh7 cells expression was 89-fold greater, which while not as dramatic is still highly over-
expressed in comparison to liver. MRP2 mRNA levels were largely similar to liver in HepG2 cells 
(1.6-fold greater), while Huh7 cells were 12-fold lower. HepG2 cells also showed relatively 
similar levels of MDR1 and BCRP mRNAs, being 2.7-fold greater and 2.8-fold lower, 
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respectively. Huh7 cells were more removed from liver for these two transporters, having 5.6- 
and 21-fold lower MDR1 and BCRP mRNA levels, respectively. 
mRNA levels of four influx transporters OCT3 and OATPB, C and 8 were also measured. HepG2 
cells showed relatively similar levels of OCT3 and OATPB mRNA with 1.4-fold and 4.8-fold 
decreases compared with liver, respectively. However, OATPC and 8 mRNA levels were much 
lower in comparison to liver; 51000-fold and 19000-fold lower, respectively. In Huh7 cells the 
genes closest to liver in expression levels were OATPB and 8, which were 11- and 82-fold 
lower, respectively. OCT3 mRNA levels were 24-fold decreased and OATPC mRNA 363-fold 
decreased in Huh7 cells in comparison to liver. 
Of the phase I and II drug metabolising and conjugating enzymes assessed, only GSTA and 
GSTA4 mRNAs in HepG2 cells show levels approaching those in liver (6.2-fold and 1.6-fold 
lower, respectively). In Huh7 cells both transcripts were much lower than in HepG2 – GSTA 
mRNA was 357-fold lower while GSTA4 mRNA showed a 13-fold decrease from liver. All three 
of the cytochrome P450 enzymes (CYP1A2, 2E1 and 3A4) showed much lower mRNA levels 
than liver in each cell line. For example, the closest in expression to liver levels was CYP1A2 
mRNA in Huh7, which was decreased by 44000-fold. A similar situation was seen with UGT1A1 
and FMO3 mRNAs with extremely large decreases from liver seen in both HepG2 and Huh7 
cells. 
3.4 – Discussion 
The information included in the figures of this chapter is as required in the MIQE guidelines 
(Bustin et al., 2009), which outline the minimum information required for publication of qPCR 
experiments. Primers were designed as per the specifications outlined in the introduction to 
this chapter where possible, which was the case in the majority of assays. End-point PCRs were 
optimised and products were cloned and sequenced. All products were proved to be specific 
to the desired genes bar a few sequencing errors, which did not introduce any similarity to 
other genes when subjected to BLAST analysis. Parameters for standard curve variables for all 
assays were within acceptable limits and assays all amplified only a single product, with some 
rare instances of primer-dimer seen in negative controls. CV values for each assay showed 
variation below 10% when all values were taken into account (table 3.1 part A) and little 
difference was observed in the CV recorded for clone dilutions 1 and 2. Changes in CV over 
time are displayed in table 3.1 part B for both clone dilutions and no significant differences 
were seen between runs 1-5 and 6-10 in either dilution. Sample dilution series for high, 
medium and low expression GOI (figure 3.21, albumin, BCRP and CYP2E1 assays respectively) 
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revealed that dilutions of RT products of 1:30 for high expression genes and 1:3 for medium 
and low expression genes were acceptable as exponential increases were seen at these points. 
In conclusion, these qPCR assays are validated sufficiently to allow use in further analysis of 
experimental samples.  
This preliminary work allowed an approximate comparison of mRNA levels of genes of interest 
between the two cell lines used and a human liver sample. Although the comparison with 
human liver rather than hepatic cells alone does have its limitations, it remains a useful 
indicator of cellular maturity. Hepatocytes make up approximately 65% of the cells in the liver 
and occupy 80% of the cellular volume (Gebhardt, 1992). However, the bi-nuclear nature of a 
proportion of hepatocytes means that in terms of DNA abundance, the hepatocyte contributes 
approximately 69% of the DNA found in a sample of whole liver (Carlile et al., 1997). This 
suggests that whilst a sample of whole liver is not ideal, it will provide an indication of hepatic 
expression within the liver. The fact that this liver sample is comprised of three donors which 
include a wide age range and both genders also contributes to its suitability as an indicator of 
hepatic expression in the population. Of course, ideally comparisons would be drawn with an 
isolated hepatocyte population from a large number of donors but in reality these would be 
difficult and costly to obtain. In a study such as this where an overview of hepatic maturity is 
required a definitive hepatocyte-only sample is not essential. If this preliminary data was to 
indicate much improved hepatic expression in these carcinoma cell lines, a truly hepatic 
sample would be vital to continuing the investigation. 
The five markers of differentiation analysed in this chapter, albumin, transferrin, AFP, A1AT 
and HNF4a have given a picture of the differentiation status of these cells which will be 
discussed further in later chapters. Comparison of this data with other papers describing 
relative mRNA levels of these genes draws a similar picture, but with some notable differences 
in magnitude of change from liver to cell line. Albumin mRNA is reported to be lower in HepG2 
cells than in liver by anything from 1000- to 10-fold (Sivertsson et al., 2010; Ek et al., 2007) and 
4-fold higher than liver by Olsavsky et al. (Olsavsky et al., 2007). Huh7 cells have been reported 
as having albumin mRNA levels from 100- to 2-fold lower than liver (Sivertsson et al., 2010; 
Olsavsky et al., 2007). This range of changes does fit with those observed here, with levels 19-
fold and 27-fold lower than liver in HepG2 and Huh7 cells, respectively. Transferrin has been 
verified as a useful marker of hepatic differentiation in several publications (Page et al., 2007; 
Hengstler et al., 2005; Sidhu et al., 2004; Raul Cassia, 1997) but has not yet been analysed 
relative to liver. Results found here indicate that both HepG2 and Huh7 cells express 
transferrin mRNA at levels approximately 10-fold lower than liver. AFP is a well known 
indicator of reversion to a more foetal rather than adult liver state (Page et al., 2007; Snykers 
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et al., 2007) and has been shown to be around 100,000-fold higher in both HepG2 and Huh7 
cells than in liver (Olsavsky et al., 2007). The results obtained here agree that AFP is increased 
in both cell lines but not to such extremes as this; data indicate that HepG2 and Huh7 are 92-
fold and 18-fold higher than in liver respectively, showing Huh7 cells to be closer to liver 
expression. A1AT mRNA is described as being between 100- and 10-fold lower than liver in 
both HepG2 and Huh7 cells (Olsavsky et al., 2007), which is approximately the same as seen 
here. Huh7 cells had a 29-fold decrease in expression relative to liver, while HepG2 cells are 
closer to liver with only a 6-fold decrease. The final differentiation marker, HNF4a, has been 
reported to have equal expression in liver and Huh7 cells (Sivertsson et al., 2010; Olsavsky et 
al., 2007) and in HepG2 cells to be between that of liver and a 10-fold reduction (Sivertsson et 
al., 2010; Ek et al., 2007; Olsavsky et al., 2007). Data here show approximately 2-fold greater 
levels in HepG2 cells than in liver and 2-fold lower levels in Huh7 cells; neither of these is 
better than the other with regard to similarity to liver expression. Taking into consideration all 
five differentiation markers measured here, neither cell line appears to be more hepatocyte-
like than the other. 
Four influx transporters, MRP1, MRP2, MDR1 and BCRP were assessed for expression in HepG2 
and Huh7 cells and compared to liver. MRP1 has been reported to be up to 10-fold higher in 
HepG2 cells than in liver and only slightly increased from liver in Huh7 cells (Hilgendorf et al., 
2007; Olsavsky et al., 2007). However, the data obtained here shows a much larger increase in 
both cell lines, with expression over 2000-fold higher in HepG2 cells and around 89-fold higher 
in Huh7 cells. Although Huh7 expression is closer to that of liver, it is still an extremely large 
increase and if it is mirrored by an increase in functionality would be expected to drastically 
alter the efflux function of the cell. MRP2 is reported to have expression either comparable to 
or 10-fold lower than liver in both cell lines (Sivertsson et al., 2010; Ek et al., 2007; Olsavsky et 
al., 2007). Data here agree with the literature, showing a very slight increase in HepG2 MRP2 
mRNA expression and a 12-fold decrease in Huh7 cells compared to liver. MDR1 mRNA is 
reported to be expressed either at levels seen in liver or up to 10-fold lower in both HepG2 and 
Huh7 cells (Sivertsson et al., 2010; Ek et al., 2007; Hilgendorf et al., 2007; Olsavsky et al., 
2007). Data obtained here show an increase of 2.6-fold in HepG2 cells, while Huh7 cells 
express MDR1 mRNA at levels approximately 5-fold lower than liver; again, both are close to 
previously reported levels. BCRP mRNA levels are reported to be slightly lower than liver in 
HepG2 cells (Hilgendorf et al., 2007); data comparing Huh7 cells to liver have not been 
published. Data obtained here indicate that HepG2 cells are the closest of the two to liver in 
terms of BCRP mRNA expression, with HepG2 having 2-fold lower and Huh7 21-fold lower 
transcript levels in comparison to liver. Overall, Huh7 cells are probably the most suitable 
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system for efflux analysis in an hepatocyte-like system as neither of the major drug-resistance 
conferring proteins, MDR1 and MRP1, are over-expressed; however, Huh7 remains a less than 
ideal model for hepatic efflux transporters. 
Expression levels of four influx transporters were analysed – OCT3 and OATPB, C and 8. OCT3 is 
reported to have approximately equal mRNA expression in liver and HepG2 cells (Hilgendorf et 
al., 2007; Olsavsky et al., 2007) while Huh7 cells have been shown to express OCT3 at levels 
approximately 4-fold lower than those seen in liver (Olsavsky et al., 2007). Data obtained here 
agree with predictions for HepG2 cells which show a small reduction of 1.4-fold from liver but 
Huh7 cells expressed OCT3 mRNA approximately 124-fold lower than levels seen in liver, a 
much lower figure than expected. OATPB mRNA is reported to be expressed in Huh7 cells at 3-
fold lower levels than in liver (Olsavsky et al., 2007), which is slightly higher than results 
obtained here that show 11-fold lower OATPB mRNA expression. HepG2 cells are variable in 
their expression of OATPB mRNA, with one paper reporting similar expression to liver 
(Hilgendorf et al., 2007) and another stating that no transcript at all could be detected 
(Olsavsky et al., 2007); data here suggests a 4.8-fold lower expression than in liver. OATPC and 
8 transcripts are both reported to be much lower in HepG2 cells than in liver (Hilgendorf et al., 
2007) and in two publications OATPC is said to be undetected at mRNA level (Sivertsson et al., 
2010; Ek et al., 2007). Huh7 cells are also reported to have no detectable OATPC transcripts 
(Sivertsson et al., 2010), while no data are available at this time for comparison of OATP8 
expression in liver. mRNA was detected for both OATPC and 8 in both cell lines here, although 
in HepG2 cells this was at a very reduced level; expression of mRNA stood at 51000- and 
19000-fold lower than liver for OATPC and OATP8, respectively. Huh7 cells also showed 
reduced expression of these transcripts, although they were markedly higher than levels 
observed in HepG2 cells. OATPC mRNA expression was approximately 363-fold lower than that 
in liver, while OATP8 mRNA expression was 82-fold lower than seen in liver. Overall, neither 
cell line appears improved over the other in expression of influx transporters, with HepG2 
closer to liver in expression of OCT3 and OATPB and Huh7 closer to liver expression of OATPC 
and -8, albeit at substantially reduced levels. 
Cytochrome P450 enzymes are responsible for a large proportion of drug metabolism within 
the cell. Three CYP enzymes have been quantified here – CYP1A2, 2E1 and 3A4, all of which 
have low expression in HepG2 and Huh7 cells. Both HepG2 and Huh7 cells are reported to have 
either no or very low (over 1000-fold lower than liver) CYP1A2 expression (Sivertsson et al., 
2010; Ek et al., 2007; Olsavsky et al., 2007). Data here show CYP1A2 mRNA as being 1.4x106-
fold lower than liver in HepG2 cells and 4.4x104-fold lower in Huh7 cells, so although Huh7 
cells do show the higher expression level of the two cell lines, levels are still extremely reduced 
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relative to liver – both of these figures agree with previously published data. CYP2E1 mRNA 
expression in HepG2 cells is reported to be either undetectable or over 1000-fold reduced 
from liver (Sivertsson et al., 2010; Ek et al., 2007; Olsavsky et al., 2007). In Huh7 cells estimates 
range from 400-fold to over 1000-fold decrease relative to liver expression (Sivertsson et al., 
2010; Olsavsky et al., 2007). Data obtained here suggest that transcript levels for both cell lines 
are extremely low, with HepG2 and Huh7 cells having a 2.6x106-fold and a 1.9x106-fold 
decrease respectively. Published data available for CYP3A4 record HepG2 cells as having 
anywhere between 100-fold and over 1000-fold decrease from liver (Sivertsson et al., 2010; Ek 
et al., 2007; Olsavsky et al., 2007) and Huh7 cells as having either undetectable mRNA levels or 
expression 1000-fold lower than seen in liver (Sivertsson et al., 2010; Olsavsky et al., 2007). 
From results obtained here, CYP3A4 mRNA levels appear very low in both cells lines, with 
HepG2 showing expression 1.2x105-fold lower than liver and Huh7 cells with expression 
3.1x105-fold lower than those seen in liver, values which agree with data in the literature. 
Neither cell line could be considered closer to hepatocyte-like expression of these three CYP 
enzymes as levels are so severely reduced from those in vivo that any differences are not likely 
to be physiologically relevant and would not be useful in measuring drug metabolism in any 
potential drug development model. 
As well as the phase I CYP enzymes several phase II metabolising enzymes were assessed for 
mRNA levels relative to liver. The GSTA mRNA assay which assesses levels of GSTA1, 2 and 5 
expression shows HepG2 cells as having mRNA levels 6-fold lower than that of liver, while 
Huh7 cells have much lower expression with a 350-fold decrease relative to liver. Data specific 
to GSTA1 mRNA levels in these cell lines have been published and show that HepG2 cells have 
around 3-fold lower expression than liver with that in Huh7 cells approximately 50-fold lower 
than liver levels (Olsavsky et al., 2007) – here mRNA levels in HepG2 cells were very close to 
published data but in Huh7 cells much lower levels of expression were found than stated in the 
literature. Published data for GSTA4 mRNA levels are not available; data here show that HepG2 
expression is very similar to that in liver, with only a 1.6-fold decrease observed. Huh7 cells 
showed a 13-fold decrease relative to liver levels and so is further away from the ideal than 
HepG2; however, bearing in mind the extremes which have been observed in previous assays 
this still seems comparatively close to liver levels. Published data for the UGT1A family of 
enzymes show mRNA expression in HepG2 cells as over 1000-fold lower than in liver and in 
Huh7 cells as between 100- and 1000-fold decreased relative to liver (Sivertsson et al., 2010; 
Ek et al., 2007). The data obtained here specifically relate to UGT1A1 mRNA rather than the 
whole family and show a 2800-fold decrease in expression in HepG2 and a 1000-fold decrease 
in Huh7 cells, both of which agree with previously published data. Finally, for FMO3 there are 
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no published data for analysis; data here show extreme decreases from liver mRNA levels in 
both HepG2 and Huh7 cells, which have a 4.6x109-fold decrease and a 3.9x105-fold decrease in 
expression respectively. HepG2 cells appear to be more useful in assessment of GSTA 
functions, whereas Huh7 cells have more hepatocyte-like expression of UGT1A1 and FMO3 
although both are expressed at levels far lower than those seen in vivo. 
The variation observed between reported levels of mRNA in the literature and levels observed 
here are quite marked for some GOI; for example, albumin mRNA levels in HepG2 cells are 
reported as being anywhere from 1000-fold lower to 4-fold higher than liver. These differences 
between cells which are identically named are important in a project such as this where 
differentiation to a more hepatic profile is the aim, as basal levels of genes and thus the 
starting point is potentially very variable. These differences could be due to variations in 
culture conditions, plating density and passage number to name a few. For example, HepG2 
cells used here were cultured in high glucose DMEM with 10% FCS, 1% glutamine, 1% NEAA 
and penicillin/streptomycin. Sivertsson et al. (Sivertsson et al., 2010) cultured HepG2 cells in 
DMEM with 10% heat inactivated FCS, NEAA, penicillin/streptomycin and 1mM sodium 
pyruvate, while Olsavsky et al. (Olsavsky et al., 2007) used DMEM with 10% FCS, 0.1mM NEAA, 
penicillin/streptomycin, 10mM HEPES and 1mM sodium pyruvate. These are but two examples 
from the literature; many other papers for both HepG2 and Huh7 cells describe culture 
conditions with very slight differences from each other which could potentially affect basal 
expression of some or all genes and result in the variable results published in the literature. 
Details of other variables are not so easily extracted from the literature such as source and 
batch of foetal calf serum used, frequency of mycoplasma testing (carried out periodically on 
cells used here), number of passages the cells were grown for after removal from liquid 
nitrogen stocks before commencement of experiments and intervals between feeding and 
passaging the cells. Genetic drift of cells can also become a factor if the passage number of 
cells used is high, particularly in carcinoma-derived cell lines, which can result in an expression 
profile differing from that in the original ATCC cells. All of these could affect cellular phenotype 
and lead to the variations in expression described here. Evidence that HepG2 cells do have the 
potential to form distinct subtypes is seen in the existence of the clonal cell line HepG2/C3A 
(ATCC number CRL-10741) which shows some differences to the original HepG2 cells such as 
the ability to grow in glucose deficient medium, strong contact inhibition of growth and high 
levels of albumin and AFP secretion. 
Table 3.2 also shows which of the two cell lines express the mRNA for each gene at a level 
most resembling that of liver. Neither cell line is closer to liver mRNA levels in transferrin or 
HNF4a, with transferrin being approximately 10-fold lower in both cell lines and HNF4a being 
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2-fold higher in HepG2 and 2-fold lower in Huh7. Comparison of the two cell lines with regard 
to the remaining GOIs reveals that neither is more suitable as a hepatocyte model than the 
other. HepG2 cells have eleven genes which are closer in expression to those in liver, whereas 
Huh7 cells are closer in the remaining seven GOIs. It could be argued that, for example, Huh7 
cells are more suitable than HepG2 if OATP transporters are specifically of interest, or that 
HepG2 cells could be useful for efflux transporter analysis if an effective MRP1 inhibitor was 
employed. However, as both cell lines have severe limitations in enzyme mRNA levels with at 
least some transporters expressed at low levels it would be difficult to prove that any effects 
seen were not contributed to by the absence of a fully functioning hepatic profile. The 
conclusion can therefore be drawn that it would be highly beneficial to attempt to increase the 
similarity of one or both of these cell lines to the in vivo hepatocyte by means of 
differentiation to a more mature hepatic phenotype. 
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Albumin (NM_000477)
P
ri
m
e
rs Forward CTTATTCCAGGGGTGTGTTTCG
Reverse CGATGAGCAACCTCACTCTTGTG
Ex
o
n
Lo
ca
ti
o
n Forward 1
Reverse 1, 2
Product length 
(bp)
55
Annealing 
temperature (oC)
59
200 bp
100 bp Albumin
Li
ve
r
H
ep
G
2
H
u
h
7
-v
e
Reference sequence (5’ – 3’). Exon-exon boundary is located at position 152-153.
120 – CTTATTCCAGGGGTGTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCG – 174
BLASTresults for cloned sequence against reference sequence.
Reference
Clone
B
A
C
D
E
Clone sequence – insert is in the forward orientation
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Albumin qPCR assay
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Figure 3.1 – Albumin PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the albumin qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.1 – Albumin PCR assay dev lopment. Primer sequences, ex  l , product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned nd sequenc d as describ d in hapt r 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the albumin qPCR 
assay normalised to two reference genes.  
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Transferrin (NM_001063)
P
ri
m
e
rs Forward GTCAACTGTGTCCAGGGTGTGG
Reverse TCAGACACTTGAAGGCTCCCG
Ex
o
n
Lo
ca
ti
o
n Forward 5
Reverse 5, 6
Product length 
(bp)
75
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 943-944. 
877 – GTCAACTGTGTCCAGGGTGTGGCTGCTCCACCCTTAACCAATACTTCGGCTACTCGGGAGCCT
TCAAGTGTCTGA – 951
Li
ve
r
H
ep
G
2
H
uh
7
-v
e
200 bp
100 bp TF
Clone sequence – insert is in the reverse orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
A
B
C
D
E
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Transferrin qPCR assay
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Figure 3.2 – Transferrin PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the transferrin qPCR assay for confluent
HepG2 and Huh7 cells (both n = 12) normalised to two reference genes and displayed
as mean ± SEM.
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Figure 3.2 – Transferrin PCR assay development. Primer sequences, exon location, 
product length and annealing temperature for both end point and quantitative PCR are 
shown in the table A. The reference s quence with primers highlighted is displayed in B. 
End point PCR products visualised on an ag rose gel under UV light are shown in C. These 
products were excised, cloned and sequenced as described in chapter 2; the 
chromatogram of the cloned sequence  can be seen in D, with results from a BLAST 
analysis shown in E. Data from qPCR assays is displayed in parts F, G and H. Table F 
includes standard curve details and product melting temperatures, with figure G being an 
example of a typical melt point plot obtained through this assay. Finally, graph H shows 
data from the transferrin qPCR assay normalised to two reference genes.  
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Alpha-fetoprotein (NM_001134)
P
ri
m
e
rs Forward GGAGCGGCTGACATTATTATCG
Reverse GGCCAACACCAGGGTTTACTG
Ex
o
n
Lo
ca
ti
o
n Forward 11, 12
Reverse 12
Product length 
(bp)
72
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is  located at position 1475-1476.
1471 – GGAGCGGCTGACATTATTATCGGACACTTATGTATCAGACATGAAATGACTCCAGTAAA
CCCTGGTGTTGGCC – 1542
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e
200 bp
100 bp AFP
Clone sequence – insert is in the reverse orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
E
A
B
C
D
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AFP qPCR assay
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Figure 3.3 – AFP PCR assay development. Primer sequences, exon location, product
length and annealing temperature for both end point and quantitative PCR are shown
in the table A. The reference sequence with primers highlighted is displayed in B. End
point PCR products visualised on an agarose gel under UV light are shown in C. These
products were excised, cloned and sequenced as described in chapter 2; the
chromatogram of the cloned sequence can be seen in D, with results from a BLAST
analysis shown in E. Data from qPCR assays is displayed in parts F, G and H. Table F
includes standard curve details and product melting temperatures, with figure G
being an example of a typical melt point plot obtained through this assay. Finally,
graph H shows data from the AFP qPCR assay for confluent HepG2 and Huh7 cells
(both n = 12) normalised to two reference genes and displayed as mean ± SEM.
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Figure 3.3 – AFP PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference s quence with primers highlighted is displayed in B. E d point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. T ble F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the AFP qPCR assay 
normalised to two reference genes.  
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A1AT (NM_000295)
P
ri
m
e
rs Forward GGTCTGCCAGCTTACATTTACCC
Reverse CCCATTGCTGAAGACCTTAGTG
Ex
o
n
Lo
ca
ti
o
n Forward 4, 5
Reverse 5
Product length 
(bp)
103
Annealing 
temperature (oC)
55
Reference sequence (5’-3’). Exon-exon boundary is located at position 1178-1179.
1176 – GGTCTGCCAGCTTACATTTACCCAAACTGTCCATTACTGGAACCTATGATCTGAAGAG
CGTCCTGGGTCAACTGGGCATCACTAAGGTCTTCAGCAATGGG – 1278
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r
H
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G
2
H
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7
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e
200 bp
100 bp A1AT
Clone sequence – insert is in the reverse orientation
BLASTresults for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
E
D
C
B
A
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A1AT qPCR assay
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Figure 3.4 – A1AT PCR assay development. Primer sequences, exon location, product
length and annealing temperature for both end point and quantitative PCR are shown
in the table A. The reference sequence with primers highlighted is displayed in B. End
point PCR products visualised on an agarose gel under UV light are shown in C. These
products were excised, cloned and sequenced as described in chapter 2; the
chromatogram of the cloned sequence can be seen in D, with results from a BLAST
analysis shown in E. Data from qPCR assays is displayed in parts F, G and H. Table F
includes standard curve details and product melting temperatures, with figure G
being an example of a typical melt point plot obtained through this assay. Finally,
graph H shows data from the A1AT qPCR assay for confluent HepG2 and Huh7 cells
(both n = 12) normalised to two reference genes and displayed as mean ± SEM.
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Figure 3.4 – A1AT PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The ref r nce sequ nc  with primers highlighted is displayed in .  point 
PCR products visuali ed on an agarose gel und r UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G eing an example of  typical melt point 
plot obtained through this assay. Finally, graph H shows data from the A1AT qPCR assay 
normalised to two reference genes.  
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HNF4a (NM_000457)
P
ri
m
e
rs Forward CCTGTCCCGACAGATCACCTC
Reverse TGGACTCACACACATCTGCG
Ex
o
n
Lo
ca
ti
o
n Forward 5, 6
Reverse 6
Product length 
(bp)
92
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). Exon-exon boundary is located at position 581-582.
569 – CCTGTCCCGACAGATCACCTCCCCCGTCTCCGGGATCAACGGCGACATTCGGGCGAAGAA
GATTGCCAGCATCGCAGATGTGTGTGAGTCCA – 660
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r
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G
2
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e
200 bp
100 bp HNF4a
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
E
D
C
B
A
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HNF4a qPCR assay
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Figure 3.5 – HNF4a PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the HNF4a qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.5 – HNF4a PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel nd r UV light re shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includ s standard curv  details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the HNF4a qPCR assay 
normalised to two reference genes.  
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MRP1 (NM_004996)
P
ri
m
e
rs Forward TGGCATCACCTTCTCCATCC
Reverse GAGAGCAGGGACGACTTTCCG
Ex
o
n
Lo
ca
ti
o
n Forward 15, 16
Reverse 16
Product length 
(bp)
81
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 2163-2164.
2161 – TGGCATCACCTTCTCCATCCCCGAAGGTGCTTTGGTGGCCGTGGTGGGCCAGGTGGGC
TGCGGAAAGTCGTCCCTGCTCTC – 2241
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e
200 bp
100 bp
MRP1
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
C
D
E
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MRP1 qPCR assay
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Figure 3.6 – MRP1 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the MRP1 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.6 – MRP1 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel nder UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includ s standard curv  details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the MRP1 qPCR assay 
normalised to two reference genes.  
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MRP2 (NM_000392)
P
ri
m
e
rs Forward CACCATCATGGACAGTGACAAGG
Reverse GAGAGCAGGGACGACTTTCCG
Ex
o
n
Lo
ca
ti
o
n Forward 31, 32
Reverse 32
Product length 
(bp)
60
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 4647-4648.
4627 – CACCATCATGGACAGTGACAAGGTAATGGTCCTAGACAACGGGAAGATTATAGAGT
GCGG – 4686
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200 bp
100 bp
MRP2
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
A
B
C
D
E
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MRP2 qPCR assay
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Figure 3.7 – MRP2 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the MRP2 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.7 – MRP2 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The ref renc  sequence with prim rs highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR ssays s displayed in parts F, G and H. Table F includes standard c ve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the MRP2 qPCR assay 
nor alised to two reference genes.  
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MDR1 (NM_000927)
P
ri
m
e
rs Forward TTCACTTCAGTTACCCATCTCG
Reverse GTCTGCCCACTCTGCACCTTC
Ex
o
n
Lo
ca
ti
o
n Forward 12
Reverse 13
Product length 
(bp)
77
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 1642-1643.
1607 – TTCACTTCAGTTACCCATCTCGAAAAGAAGTTAAGATCTTGAAGGGTCTGAACCTG
AAGGTGCAGAGTGGGCAGAC – 1683
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200 bp
MDR1100 bp
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
C
D
E
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MDR1 qPCR assay
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Figure 3.8 – MDR1 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the MDR1 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.8 – MDR1 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highli hted is displayed in B. End point 
PCR products visualised n an agaros  gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an ex mple of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the MDR1 qPCR assay 
normalised to two reference genes.  
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BCRP (NM_004827)
P
ri
m
e
rs Forward CAGGTGGAGGCAAATCTTCG
Reverse TTGGATCTTTCCTTGCAGCTAA
Ex
o
n
Lo
ca
ti
o
n Forward 3, 4
Reverse 4
Product length 
(bp)
54
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 756-757
738 – CAGGTGGAGGCAAATCTTCGTTATTAGATGTCTTAGCTGCAAGGAAAGATCCAA – 791 
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e
100 bp
BCRP
Clone sequence – insert is in the reverse orientation
BLASTresults for cloned sequence against reference sequence.
Reference
Clone
A
B
C
D
E
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BCRP qPCR assay
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Figure 3.9 – BCRP PCR assay development. Primer sequences, exon location, product
length and annealing temperature for both end point and quantitative PCR are shown
in the table A. The reference sequence with primers highlighted is displayed in B. End
point PCR products visualised on an agarose gel under UV light are shown in C. These
products were excised, cloned and sequenced as described in chapter 2; the
chromatogram of the cloned sequence can be seen in D, with results from a BLAST
analysis shown in E. Data from qPCR assays is displayed in parts F, G and H. Table F
includes standard curve details and product melting temperatures, with figure G
being an example of a typical melt point plot obtained through this assay. Finally,
graph H shows data from the BCRP qPCR assay for confluent HepG2 and Huh7 cells
(both n = 12) normalised to two reference genes and displayed as mean ± SEM.
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Figure 3.9 – BCRP PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for bot   oint and quanti ative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data fro  the BCRP qPCR assay 
normalised to two reference genes.  
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OCT3 (NM_021977)
P
ri
m
e
rs Forward CCAAGCCATCCTGAACCTCG
Reverse TGCCATACCTGTCTGCTGCAT
Ex
o
n
Lo
ca
ti
o
n Forward 2
Reverse 2, 3
Product length 
(bp)
71
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 560-561.
498 – CCAAGCCATCCTGAACCTCGGCTTCCTGACTGGAGCATTCACCTTAGGCTATGCAGCAG
ACAGGTATGGCA – 568
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h
7
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e
200 bp
OCT3100 bp
Clone sequence – insert is in the reverse orientation
BLASTresults for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
C
D
E
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OCT3 qPCR assay
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Figure 3.10 – OCT3 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the OCT3 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.10 – OCT3 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are show  in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard c rve details 
and product melting temp r tures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the OCT3 qPCR assay 
normalised to two reference genes.  
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OATPB (NM_007256)
P
ri
m
e
rs Forward CCTGCCGCTCTTCTTTATCG
Reverse CATGCAGCTTGGAGACAGCTC
Ex
o
n
Lo
ca
ti
o
n Forward 10
Reverse 11
Product length 
(bp)
100
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). Exon-exon boundary is located at position 1820-1821.
1758 – CTGCCGCTCTTCTTTATCGGCTGCTCCAGCCACCAGATTGCGGGCATCACACACC
AGACCAGTGCCCACCCTGGGCTGGAGCTGTCTCC AAGCTGCATG – 1857
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h7
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e
200 bp
OATPB100 bp
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
C
D
E
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OATPB qPCR assay
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Figure 3.11 – OATPB PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the OATPB qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.11 – OATPB PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is di played in parts F, G and H. Table F inclu es standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the OATPB qPCR assay 
normalised to two reference genes.  
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OATPC (NM_006446)
P
ri
m
e
rs Forward TGTGTTCATGGGTAATATGCTTCG
Reverse AGATCCCAGGGTAAAGCCAATG
Ex
o
n
Lo
ca
ti
o
n Forward 6
Reverse 7
Product length 
(bp)
166
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). Exon-exon boundary is located in position 732-733.
623 – TGTGTTCATGGGTAATATGCTTCGTGGAATAGGGGAGACTCCCATAGTACCATTGGG
GCTTTCTTACATTGATGATTTCGCTAAAGAAGGACATTCTTCTTTGTATTTAGGTATATTGAAT
GCAATAGCAATGATTGGTCCAATCATTGGCTTTACCCTGGGATCT – 788
Clone sequence – insert is in the reverse orientation
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e
200 bp
OATPC100 bp
A
B
C
D
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BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
Reference
Clone
OATPC qPCR assay
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Figure 3.12 – OATPC PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the OATPC qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.12 – OATPC R ass y development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised n an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as d scribed in ch pter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example f a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the OATPC qPCR assay 
normalised to two reference genes.  
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OATP8 (NM_019844)
P
ri
m
e
rs Forward TACTCAGCACACTTGGGTGAATG
Reverse CCTCCTGTTGCAGAGAACAAAGA
Ex
o
n
Lo
ca
ti
o
n Forward 12
Reverse 12
Product length 
(bp)
107
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). 
1675 – TACTCAGCACACTTGGGTGAATGCCCAAGAGATAATACTTGTACAAGGAAATTTTTCAT
CTATGTTGCAATTCAAGTCATAAACTCT TTGTTCTCTGCAACAGGAGG – 1781
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200 bp
OATP8100 bp
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
C
D
E
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OATP8 qPCR assay
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Figure 3.13 – OATP8 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the OATP8 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.13 – OATP8 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel und r UV light are show  in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temp r tures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the OATP8 qPCR assay 
normalised to two reference genes.  
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CYP1A2 (NM_000761)
P
ri
m
e
rs Forward GACTTTGACAAGAACAGTGTCCG
Reverse TTCTCCTGTGGGATGAGGTTGC
Ex
o
n
Lo
ca
ti
o
n Forward 2, 3
Reverse 3
Product length 
(bp)
98
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). Exon-exon boundary is located at position 895-896.
884 – GACTTTGACAAGAACAGTGTCCGGGACATCACGGGTGCCCTGTTCAAGCACAGCAA
GAAGGGGCCTAGAGCCAGCGGCAACCTCATCCCACAGGAGAA – 981
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200 bp
CYP1A2100 bp
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
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D
E
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CYP1A2 qPCR assay
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Figure 3.14 – CYP1A2 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the CYP1A2 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.14 – CYP1A2 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The ref rence sequence with prim rs highligh ed is displayed n B. End point 
PCR products visualised on an agarose gel under UV light are show  in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the CYP1A2 qPCR 
assay normalised to two reference genes.  
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CYP2E1 (NM_000773)
P
ri
m
e
rs Forward ATAGCCGACATCCTCTTCCG
Reverse GTAAAGCTGGAGCCAGGGAGTG
Ex
o
n
Lo
ca
ti
o
n Forward 4
Reverse 4, 5
Product length 
(bp)
117
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). Exon-exon boundary is located at position 681-682.
571 – ATAGCCGACATCCTCTTCCGCAAGCATTTTGACTACAATGATGAGAAGTTTCTAAGGCT
GATGTATTTGTTTAATGAGAACTTCCACCTAC TCAGCACTCCCTGGCTCCAGCTTTAC – 687
Clone sequence – insert is in the reverse orientation
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200 bp
CYP2E1100 bp
BLAST results for cloned sequence against reference sequence.
Reference
Clone
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CYP2E1 qPCR assay
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Figure 3.15 – CYP2E1 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the CYP2E1 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.15 – CYP2E1 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The ref rence sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR ssays is displayed in parts F, G and H. Table F includ s standard curv  details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the CYP2E1 qPCR 
assay normalised to two reference genes.  
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CYP3A4 (NM_017460)
P
ri
m
e
rs Forward TGTGCCTGAGAACACCAGAG
Reverse GTGGTGGAAATAGTCCCGTG
Ex
o
n
Lo
ca
ti
o
n Forward 13
Reverse 13
Product length 
(bp)
226
Annealing 
temperature (oC)
58
Sequence 5’-3’. 
1655 – TGTGCCTGAGAACACCAGAGACCTCAAATTACTTTGTGAATAGAACTCTGAAATGAAGAT
GGGCTTCATCCAATGGACTGCATAAATAACCGGGGATTCTGTACATGCATTGAGCTCTCTCATTGTCT
GTGTAGAGTGTTATACTTGGGAATATAAAGGAGGTGACCAAATCAGTGTGAGGAGGTAGATTTGG
CTCCTCTGCTTCTCACGGGACTATTTCCACCAC – 1880 
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CYP3A4
500 bp
200 bp
Clone sequence – insert is in the forward orientation
A
B
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BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
Reference
Clone
Reference
Clone
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Figure 3.16 – CYP3A4 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the CYP3A4 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.16 – CYP3A4 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G nd H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the CYP3A4 qPCR 
assay normalised to two reference genes.  
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GSTA
Primers anneal to GSTA1, 2 and 5
(NM_145740, NM_000846, 
NM_153699)
P
ri
m
e
rs Forward AATCGCTACTTCCCTGCCTTTG
Reverse ACCAGATGAATGTCAGCCCG
Ex
o
n
Lo
ca
ti
o
n Forward 5
Reverse 6
Product length 
(bp)
95
Annealing 
temperature (oC)
59
Reference sequence (5’-3’). Exon-exon boundary is located at position 526-527.
500 – AATCGCTACTTCCCTGCCTTTGAAAAAGTCTTAAAGAGCCATGGACAAGACTACCTTGTT
GGCAACAAGCTGAGCCGGGCTGACATTCA TCTGGT – 594
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e
200 bp
GSTA100 bp
Clone sequence – insert is in the forward orientation
BLAST results for cloned sequence against reference sequence.
Reference
Clone
Reference
Clone
A
B
C
D
E
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GSTA qPCR assay
St
an
d
ar
d
C
u
rv
e Efficiency 2.242
Error 0.0217
Melting temperature range 
(oC)
81.7 – 82.1
Li
ve
r
H
ep
G
2
H
uh
7
0
50
100
150
200
1000
1500
G
S
T
A
 m
R
N
A
 c
o
n
c
e
n
tr
a
tio
n
 (
a
rb
itr
a
ry
 u
n
its
)
Figure 3.17 – GSTA PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the GSTA qPCR assay for confluent HepG2 and
Huh7 cells (both n = 12) normalised to two reference genes and displayed as mean ±
SEM.
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Figure 3.17 – GSTA PCR assay development. Primer sequences, exon location, product 
length and an ealing temp rature for both nd p int and quantitative PCR ar  shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be een in D, with results from a BLAST anal sis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the GSTA qPCR assay 
normalised to two reference genes.  
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GSTA4(NM_001512)
P
ri
m
e
rs Forward ATGGTAACCACCTGCTGTTCC
Reverse GTCTGTACCAACTTCATCCCG
Ex
o
n
Lo
ca
ti
o
n Forward 3, 4
Reverse 4
Product length 
(bp)
67
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 289-290.
287 – ATGGTAACCACCTGCTGTTCCAACAAGTGCCCATGGTTGAAATTGACGGGATGAAGTT
GGTACAGAC – 353
Clone sequence – insert is in the forward orientation
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GSTA4
100 bp
BLAST results for cloned sequence against reference sequence.
Reference
Clone
A
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GSTA4 qPCR assay
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Figure 3.18 – GSTA4 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the GSTA4 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.18 – GSTA4 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel nd r UV light e shown in C. These p oducts 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a ypical melt point 
plot obtained through this assay. Finally, graph H shows data from the GSTA4 qPCR assay 
normalised to two reference genes.  
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UGT1A1 (NM_000463)
P
ri
m
e
rs Forward AAATAGTTGTCCTAGCACCTGACG
Reverse GGAATGGCACAGGGTACGTCTT
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n Forward 1
Reverse 1
Product length 
(bp)
84
Annealing 
temperature (oC)
56
Reference sequence (5’-3’).
182 – AAATAGTTGTCCTAGCACCTGACGCCTCGTTGTACATCAGAGACGGAGCATTTTACACCT
TGAAGACGTACCCTGTGCCATTCC – 265
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Clone sequence – insert is in the forward orientation
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UGT1A1 qPCR assay
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Figure 3.19 – UGT1A1 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the UGT1A1 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.19 – UGT1A1 PCR assay development. Primer sequences, exon location, product 
length and annealing temperature for both end point and quantitative PCR are shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be seen in D, with results from a BLAST analysis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F in lud s standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the UGT1A1 qPCR 
assay normalised to two reference genes.  
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FMO3 (NM_006894)
P
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e
rs Forward TATTCAATGGAAAGCGTGTCCTG
Reverse ATGACCTGTTCTGCTGTGCG
Ex
o
n
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ti
o
n Forward 5
Reverse 5, 6
Product length 
(bp)
91
Annealing 
temperature (oC)
58
Reference sequence (5’-3’). Exon-exon boundary is located at position 721-722.
636 – TATTCAATGGAAAGCGTGTCCTGGTGGTTGGCCTGGGGAATTCGGGCTGTGATATTGCC
ACAGAACTCAGCCGCACAGCAGAAC AGGTCAT – 726
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FMO3100 bp
Clone sequence – insert is in the reverse orientation
BLAST results for cloned sequence against reference sequence.
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FMO3 qPCR assay
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Figure 3.20 – FMO3 PCR assay development. Primer sequences, exon location,
product length and annealing temperature for both end point and quantitative PCR
are shown in the table A. The reference sequence with primers highlighted is
displayed in B. End point PCR products visualised on an agarose gel under UV light are
shown in C. These products were excised, cloned and sequenced as described in
chapter 2; the chromatogram of the cloned sequence can be seen in D, with results
from a BLAST analysis shown in E. Data from qPCR assays is displayed in parts F, G
and H. Table F includes standard curve details and product melting temperatures,
with figure G being an example of a typical melt point plot obtained through this
assay. Finally, graph H shows data from the FMO3 qPCR assay for confluent HepG2
and Huh7 cells (both n = 12) normalised to two reference genes and displayed as
mean ± SEM.
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Figure 3.20 – FMO3 PCR ass y development. Primer sequ nc s, exon location, product 
length and annealing temperature for both end point and quantitative PCR ar  shown in 
the table A. The reference sequence with primers highlighted is displayed in B. End point 
PCR products visualised on an agarose gel under UV light are shown in C. These products 
were excised, cloned and sequenced as described in chapter 2; the chromatogram of the 
cloned sequence  can be see  i  D, wi h results from a BLAST anal sis shown in E. Data 
from qPCR assays is displayed in parts F, G and H. Table F includes standard curve details 
and product melting temperatures, with figure G being an example of a typical melt point 
plot obtained through this assay. Finally, graph H shows data from the FMO3 qPCR assay 
normalised to two reference genes.  
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Assay Number of runs Clone 1 CV Clone 2 CV 
Albumin 10 0.041 0.037 
Transferrin 10 0.042 0.057 
AFP 10 0.050 0.051 
HNF4a 5 0.052 0.057 
A1AT 5 0.047 0.046 
OATPB 5 0.085 0.051 
OATPC 5 0.060 0.067 
OATP8 5 0.038 0.042 
OCT3  5 0.020 0.032 
MRP1 5 0.061 0.095 
MRP2 7 0.021 0.051 
MDR1 10 0.068 0.068 
BCRP 8 0.034 0.026 
CYP1A2 10 0.057 0.081 
CYP2E1 6 0.047 0.079 
CYP3A4 10 0.029 0.037 
FMO3 5 0.041 0.071 
UGT1A1 10 0.059 0.043 
GSTA 5 0.075 0.065 
GSTA4 10 0.094 0.068 
Assay Clone 1 CV 1-5 Clone 1 CV 6-10 Clone 2 CV 1-5 Clone 2 CV 6-10 
Albumin 0.034 0.051 0.025 0.050 
Transferrin 0.020 0.048 0.030 0.078 
AFP 0.053 0.029 0.026 0.055 
MDR1 0.034 0.092 0.082 0.044 
CYP1A2 0.048 0.056 0.069 0.081 
CYP3A4 0.015 0.035 0.034 0.041 
UGT1A1 0.071 0.052 0.037 0.052 
GSTA4 0.120 0.036 0.098 0.025 
A 
B 
Table 3.1 – Coefficient of Variation (CV) for qPCR assays. Table A shows CV values for all assays 
detailed in figures 3.1-3.20 calculated using data from two dilutions of the cloned PCR product 
over the number of runs specified. Table B shows data from those assays which had ten data 
points available (ten runs) with the first and second five data points analysed separately to 
highlight any changes over time for both clone dilutions. 
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Figure 3.21 – Sample dilution series for high, medium and low expression assays.
Samples were serially diluted and used in three assays representative of high
(albumin), medium (BCRP) and low (CYP2E1) expression GOIs.
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Liver HepG2 Huh7
Albumin 1.0 0.05 0.04
Transferrin 1.0 0.10 0.10
AFP 1.0 93 19
A1AT 1.0 0.16 0.03
HNF4a 1.0 2.1 0.42
MRP1 1.0 2110 89
MRP2 1.0 1.6 0.08
MDR1 1.0 2.7 0.18
BCRP 1.0 0.35 0.05
OCT3 1.0 0.69 8.0 x10-3
OATPB 1.0 0.21 0.08
OATPC 1.0 1.9 x10-5 2.8 x10-3
OATP8 1.0 5.1 x10-5 0.01
CYP1A2 1.0 7.1 x10-7 2.2 x10-5
CYP2E1 1.0 3.8 x10-7 5.3 x10-7
CYP3A4 1.0 7.9 x10-6 3.2 x10-6
GSTA 1.0 0.16 2.8 x10-3
GSTA4 1.0 0.61 0.07
UGT1A1 1.0 3.5 x10-4 9.1 x10-4
FMO3 1.0 2.2 x10-10 2.5 x10-6
Gene
Expression relative to liver
Table 3.2 – Summary of gene expression in confluent HepG2 and Huh7 cells. This table 
summarises the results of the qPCR data displayed as part of figures 3.1 to 3.21. Confluent 
HepG2 and Huh7 cells were harvested for RNA and cDNA obtained as described in chapter 
2. Whole liver cDNA was purchased and used as an indicator of in vivo hepatic levels. 
Results shown for HepG2 cells are from two experiments with a minimum of eight total 
replicates (N = 2, n = 8) and for Huh7 cells are from two experiments with a minimum of 
ten total replicates (N = 2, n = 10). All data has been normalised to two housekeeping 
genes and is displayed as relative change to liver. Numbers highlighted in grey denote 
mRNA levels closest to those observed in liver. 
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Chapter 4 – Differentiation of secondary hepatic 
cell lines to show a more in vivo hepatic profile 
Chapter aim: To analyse the suitability of the previously identified differentiation markers and 
subsequently investigate whether various treatment regimes can be used to differentiate 
HepG2 and Huh7 cells into a more mature, hepatocyte-like cell. 
4.1 – Introduction 
As shown in the previous chapter, HepG2 and Huh7 cells are far from being ideal hepatocyte 
models showing both higher and lower mRNA levels of major enzymes and transporters 
compared to liver. In order to try and improve these cell lines several treatments were applied 
to attempt to differentiate them and induce a profile more resembling the in vivo hepatocyte. 
These treatments have been adapted from methods published in the literature and will be 
explained in more detail in this chapter. 
A major area of development in recent years is the process of differentiating hepatocyte-like 
cells from stem cells. These attempts at creating a functional hepatocyte have been applied to 
cells from various sources such as human embryonic stem cells (hESCs) (Agarwal et al., 2008; 
Hay et al., 2008; Hay et al., 2007; Jun Cai, 2007), umbilical cord blood derived stem cells (UCB-
SCs) (Sensken et al., 2007; Teramoto et al., 2005) and adult sources such as adipose tissue and 
bone marrow stem cells (BMSCs) (Philippe A. Lysy, 2008; Snykers et al., 2006). Interesting 
results have also been obtained using the rat pancreatic cell line AR42J treated with 
dexamethasone to create transdifferentiated hepatocytes (Eberhard et al., 2010; Shen and 
Tosh, 2010; Burke et al., 2006) and with human fetal pancreatic cells treated with fibroblast 
growth factor 2 and dexamethasone to generate hepatocyte-like cell (Sumitran-Holgersson et 
al., 2009). Results from these attempts at differentiation have been studied in order to 
develop potential differentiation protocols applicable to HepG2 and Huh7 cells. Other more 
direct attempts at creating a more desirable hepatic profile in cell lines have met with some 
success, such as treatment of cell lines with dimethyl sulfoxide (DMSO) (Choi et al., 2009; Sainz 
and Chisari, 2006) and inhibition of DNA methylation and histone deacetylation (Dannenberg 
and Edenberg, 2006); ideas from these studies have also been implemented in treatment 
development here. 
A number of different protocols have been published by many separate groups regarding stem 
cell differentiation from human embryos, umbilical cord blood and adult cell sources. A 
common feature of these attempts at creating hepatocyte-like cells is a multi-step protocol 
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where treatments are applied at specific time points for a pre-determined period of time. 
These treatments typically last at least ten days and extend up to thirty days with two or three 
changes of growth-factor cocktails being applied. It would be expected that secondary 
hepatocyte cell lines such as HepG2 and Huh7 will already be pre-programmed towards 
hepatic development, compared with freshly isolated stem cells. Therefore, where a multiple-
step protocol was described only the final maturation cocktail was applied to the cell lines. 
An alternative protocol to application of growth factor cocktails is to use DMSO to induce 
hepatic differentiation. DMSO is used in primary hepatocyte culture to maintain the hepatic 
profile (Le Vee et al., 2009), and with the hepatocarcinoma cell line HepaRG to create a more 
differentiated cell which more closely resembles the hepatocyte (Aninat et al., 2006; Le Vee et 
al., 2006; Gripon et al., 2002). Both of these applications utilise DMSO at 2% v/v in the growth 
medium. Sumida et al. (Sumida et al., 2011) have shown that DMSO at a concentration of up to 
2% is not cytotoxic to either rat or human primary hepatocytes and that concentrations over 
0.75% were required to significantly alter expression of the majority of probe sets assayed. 
Some genes which were shown to be up-regulated by DMSO included the cytochrome-P450 
enymes (CYP) CYP3A4 and CYP2B6, whereas genes including multidrug-resistance associated 
proteins (MRPs) -2 to -5 and UDP glucuronosyltransferase (UGT) -1A6 were seen to be down-
regulated with higher DMDO concentrations. Primary human hepatocytes have also been 
treated with concentrations of DMSO up to 2.5% and assessed for mRNA levels of several 
different enzymes and transporters by Nishimura et al. (Nishimura et al., 2003). Results 
indicated that some genes were upregulated as a result of incubation with higher DMSO 
concentrations; these included CYP3A4, CYP2E1 and CYP1B1. 
A study by Sainz et al. in 2006 (Sainz and Chisari, 2006) demonstrated that 1% DMSO applied 
to Huh7 cells resulted in a more differentiated cell line. This was supported by a further 
publication from the same group in 2009 (Choi et al., 2009) which examined more thoroughly 
the expression of drug metabolising enzymes and found that in these DMSO-treated cells, both 
mRNA levels and functional activity were enhanced towards those seen in an in vivo 
hepatocyte. Use of DMSO at 1-2% has been described for HepG2 cells, however the effects on 
differentiation were not assessed (Chodon et al., 2007; Galbraith et al., 1986). Although this 
treatment does seem to have potential for use in Huh7 cells, results have been reported by 
one group only. As described earlier in chapter 3, there are high levels of variation between 
the same cell lines under different culture conditions so it is unknown whether this treatment 
would be effective on all Huh7 cells or indeed on all hepatic carcinoma cell lines. The precise 
mechanism through which DMSO functions is currently unknown (Aninat et al., 2006; Sainz 
and Chisari, 2006) but several studies have been conducted which show some effects of the 
112 
 
compound on a cell. DMSO has been shown to be a scavenger of reactive oxygen species (ROS) 
(Villa et al., 1991) and an anti-apoptotic agent (Gilot et al., 2002), both in primary rat 
hepatocytes. It has also been shown to alter intracellular signalling in Chinese hamster ovary 
(CHO) cells (Fiore and Degrassi, 1999) and to affect cell membrane integrity in a variety of cells 
(Melkonyan et al., 1996) and alternative splicing in HeLa cell nuclear extracts (Bolduc et al., 
2001). A combination of these factors or other unknown effect(s) of DMSO may be responsible 
for any differentiation seen in cell lines or maintenance of primary hepatocyte profiles in vitro. 
In order to assess the extent of differentiation, the mRNA levels of five known markers of 
hepatic maturation were studied – albumin, transferrin, AFP, A1AT and HNF4a. Albumin and 
transferrin are both expected to be increased in the mature hepatocyte in comparison to the 
immature one, whereas AFP should decrease as maturation increases (Page et al., 2007; Sainz 
and Chisari, 2006; Snykers et al., 2006; Sidhu et al., 2004; Raul Cassia, 1997). A1AT and HNF4a 
mRNA levels are also expected to increase with differentiation to a more mature hepatocyte 
(Sainz and Chisari, 2006). Although these alone do not define a hepatocyte, they can be used 
to indicate potential maturation of the cell towards a more hepatocyte-like profile. By 
quantifying mRNA changes in treated cells over time, the effectiveness of the treatments can 
be assessed for the specific differentiation markers and cell lines used here. Subsequently, 
marker expression can be used to predict potential maturation of a cell.  
In the previous chapter, basal levels of these differentiation markers were assessed in 
comparison to liver. These indicated that neither cell line could be considered more 
hepatocyte-like than the other, with relatively equal levels of albumin and transferrin mRNA at 
approximately 20-fold and 10-fold lower expression than liver respectively, AFP mRNA levels 
closer to liver in Huh7 cells at 19-fold higher expression in comparison to 93-fold higher 
expression in HepG2 cells, A1AT mRNA levels closer in HepG2 cells at approximately 6-fold 
lower than liver and HNF4a mRNA levels 2-fold higher than liver in HepG2 cells and 2-fold 
lower than liver in Huh7 cells. The aims of this chapter were to identify the most suitable 
markers for preliminary assessment of differentiation and subsequently use this information to 
analyse the effects of a variety of potential differentiation protocols utilising combinations of 
growth factors and DMSO on both HepG2 and Huh7 cells, giving an indication as to whether a 
more hepatic phenotype was produced. 
4.2 – Methods 
All cells were seeded, grown and treated as described in chapter 2. Briefly, cells were seeded 
in six-well plastic plates. Treatments were initiated at 90% confluence as described by Sainz et 
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al. (Sainz and Chisari, 2006) and continued for the number of days specified for each 
experiment with a medium change every two to three days. Preliminary and extended growth 
factor treatments are detailed in tables 4.1 and 4.2 respectively. Total RNA was extracted at 
specific time points, reverse transcribed into cDNA and utilised in qPCR assessment of gene 
expression. Figures 2.1 and 2.2 detail experimental layout for each cell line. qPCR assays were 
conducted as described in chapters 2 and 3. Whole liver data are shown relative to control 
HepG2 and Huh7 cells (untreated confluent); these were calculated relative to all control cells 
for each particular cell line and the mean displayed on each figure in this chapter. 
4.3 – Results 
4.3.1 – Selection of differentiation markers 
Five markers of hepatic maturation were assessed for their usefulness in indicating 
differentiation in treated cells. Criteria that were required to be met were that the assay was 
accurate and reliable in both treated and untreated cells and that as a result of treatment with 
DMSO, which produces a more hepatic phenotype in Huh7 cells (Sainz and Chisari, 2006), 
expression of the marker mRNA moved towards that in adult liver. A single experiment in 
which three identical samples were treated with 1% DMSO was used for each cell line in order 
to make these preliminary observations. HepG2 cells were treated for 20 days with RNA 
extracted every five days; Huh7 cells were treated for 25 days and RNA was extracted every 
five days. Both experiments included a control of 100% confluent cells consisting of a pool of 
six samples harvested after a total of four days of growth from seeding – see figures 2.1 and 
2.2 for experimental layout. A1AT, albumin and transferrin mRNAs are predicted to increase if 
cells become more differentiated towards the in vivo hepatocyte, whereas AFP mRNA level is 
predicted to decrease. HNF4a mRNA expression is reported to increase with differentiation in 
the literature but data from chapter 3 showed that HepG2 cells already have HNF4a expression 
exceeding that in liver by 2.1-fold. 
Results from treated HepG2 cells analysed by qPCR for these five markers of differentiation are 
shown in figure 4.1 where data from a sample of human liver cDNA are included for 
comparison. A1AT mRNA was significantly increased at 15 and 20 days of 1% DMSO treatment, 
with the level at 15 days approximately two thirds of liver expression and approximately 4-fold 
higher than control (figure 4.1 A). This indicated that cells were becoming differentiated by 15 
days of treatment and that this was sustained through to 20 days. HNF4a mRNA in HepG2 
control cells showed double the expression of HNF4a mRNA found in liver (figure 4.1 B). 
Significant increases over control were seen at 5 and 15 days, but these were not sustained at 
10 and 20 days which remained much closer to control level. Both albumin and transferrin 
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mRNA levels (figure 4.1 C and E) in treated HepG2 cells increased significantly after 15 days 
and were sustained through to 20 days. AFP mRNA (figure 4.1 D) showed an initial significant 
increase at both 5 and 10 days of treatment but decreased to control level by 15 and 20 days; 
liver AFP mRNA level was notably lower than in control and treated cells. 
Results from Huh7 cells treated with 1% DMSO for 25 days and analysed by qPCR for levels of 
maturation markers are shown in figure 4.2. A1AT mRNA level in control cells was roughly 30-
fold lower than in liver and did not increase throughout the experiment. HNF4a results are 
much the same as were seen in HepG2 cells, with significant increases at 5 and 20 days which 
are not evident at other time points. Albumin mRNA level increases steadily throughout the 
1% DMSO treatment, with significant increases from control level at 10, 20 and 25 days. AFP 
mRNA level would be expected to decrease as maturation increases, and in these treated Huh7 
cells an initial increase was seen at 10 days followed by significant decreases compared to 
control at 15 and 20 days. The level increased slightly at 25 days but was still lower than 
control. The decreases in AFP mRNA observed at 15 to 20 days were to levels approaching 
those seen in liver. Transferrin mRNA showed significant increases from control at 15 and 20 
days as would be expected in a more hepatocyte-like cell but still remained at a level 
approximately 75% lower than that in liver (figure 4.2 E). 
These results are summarised in table 4.3 which shows fold change from control at 15 days of 
treatment for both cell lines along with expression in liver shown normalised to that in 
confluent HepG2 and Huh7 cells (data recalculated from table 3.1). In HepG2 cells, A1AT and 
albumin mRNA levels approached those seen in liver. HNF4a and transferrin data showed that 
mRNA levels of these genes increased above liver levels obtained in chapter 3. However, 
transferrin level in liver relative to the HepG2 control from this particular experiment remained 
higher than that in treated cells at all time points. This discrepancy is probably due to relatively 
low sample numbers in these initial experiments and transferrin levels are analysed with a 
larger sample number in figure 4.5. AFP mRNA levels in both cell lines were higher than liver 
and in HepG2 cells remained noticeably higher than in Huh7 cells – AFP should decrease with 
maturation. Huh7 cells had lower expression of A1AT at confluence than HepG2 cells as 
indicated by comparison of values for liver relative to confluent cells; liver expression relative 
to confluent Huh7 cells was 29.8-fold increased, whereas liver relative to HepG2 cells was 6.4-
fold increased. Huh7 cells also failed to show significantly increased A1AT expression as a 
result of DMSO treatment, although levels were approximately 3-fold higher than control. 
HNF4a mRNA levels were very similar in 15 day treated Huh7 cells and liver, but these levels 
were not stable throughout the treatment. Albumin mRNA level in Huh7 cells increased  
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 Dexamethasone 10 ng/ml FGF4 20 ng/ml HGF 10 ng/ml OSM 1% ITS 0.2 mM Sodium pyruvate 
Treatment  1  X (5-8M) - X  - X  X  
Treatment  2  X (10-6M) -  - X X  X  
Treatment  3  X (10-7M) - X  X   -  - 
Treatment  4  X (5-8M) X X   - X X 
Treatment  5  X (10-7M) X  X  X  - - 
Treatment  6  X (10-7M) - X X  X  X  
Treatment  7  X (10-7M) X  X  X  X  X  
 
 Table 4.1 – Preliminary growth factor treatments adapted from published protocols (Agarwal et al., 2008; Hay et al., 2008; Hossein 
Baharvand, 2008; Philippe A. Lysy, 2008; Hay et al., 2007; Jun Cai, 2007; Snykers et al., 2006; Kurash et al., 2004) and applied to HepG2 and 
Huh7 cells. Hepatocyte growth factor (HGF), oncostatin M (OSM) and insulin-transferrin-selenium (ITS) were purchased from Invitrogen, UK. 
Dexamethasone, fibroblast growth factor 4 (FGF4) and sodium pyruvate were purchased from Sigma, UK.  
1
1
5
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relative to control after 15 days of treatment but did not approach liver expression, while 
transferrin levels increased and by 15 days of treatment were closer to levels observed in liver. 
AFP mRNA expression decreased with treatment as would be expected in a more mature cell 
and became close to liver expression. This analysis of differentiation markers by a single 
experiment for each cell line gave an indication as to which of the markers would be most 
informative in terms of helping to indicate maturation of hepatic cells. For subsequent 
treatments, mRNA levels of albumin, transferrin and AFP were assessed to indicate whether 
further hepatic maturation occurred. HNFa was not selected as levels in both cell lines were 
already close to those in liver and any significant differences to control were not sustained in 
adjacent time points. A1AT was also omitted due to a lack of significant response observed in 
Huh7 cells when both albumin and transferrin did increase with treatment – in HepG2 cells, 
A1AT, albumin and transferrin all increased simultaneously, indicating a possible discrepancy in 
the response of A1AT in Huh7 cells. 
Summary 
 HepG2 – significant increases in albumin, transferrin and A1AT after 15 days of 
treatment. HNF4a and AFP did not decrease closer to liver levels. 
 Huh7 – significant increases in albumin and transferrin, significant decreases in AFP 
with prolonged DMSO treatment. No sustained effect on HNF4a and A1AT. 
 Overall, albumin, transferrin and AFP markers were determined to be the most 
informative of differentiation status after 1% DMSO treatment of at least 15 days. 
4.3.2 – Preliminary growth factor treatments 
Initially, seven treatments were adapted from published protocols describing generation of 
hepatocyte-like cells from sources such as hESCs, BMSCs and the rat pancreatic cell line AR42J 
(Agarwal et al., 2008; Hay et al., 2008; Hossein Baharvand, 2008; Philippe A. Lysy, 2008; Jun 
Cai, 2007; Snykers et al., 2006; Kurash et al., 2004). These are described in table 4.1 and were 
applied to both HepG2 and Huh7 cell lines. Cells were allowed to grow for three days after 
seeding to 90% confluence at which point treatments one to seven were applied for four 
additional days with media changed after two days. Control cells remained in standard growth 
medium without additional supplements for the whole seven days, with medium changes 
applied alongside treated cells. During this time frame control cells were able to maintain 
confluence and remain attached to the plate surface. RNA was extracted from all samples on 
the final day. These samples were analysed by qPCR for albumin, transferrin and AFP mRNA 
levels, the results of which are shown in figures 4.3 and 4.4 for HepG2 and Huh7 cells 
117 
 
respectively. If hepatic maturation had occurred an increase in both albumin and transferrin 
levels and a decrease in AFP levels compared to control would be expected. A human liver 
sample was included as an indication of in vivo levels.  
In HepG2 cells no large increases in albumin or transferrin mRNA levels were seen; only 
treatments 4 and 5 resulted in significantly increased albumin and transferrin mRNAs 
respectively. These are not large changes when compared to levels in the liver. AFP mRNA 
level in control HepG2 cells was much higher than in liver; however, none of the treated cells 
showed a significant reduction in AFP. Treatments 6 and 7 produced an AFP mRNA level 
approximately half that of control but these decreases were not statistically significant.  The 
effect of treatments 1 to 7 on Huh7 cells are shown in figure 4.4. Although albumin mRNA level 
in control cells was much lower than in liver, no increase was seen in any of the treated cells. 
In fact, treatments 3, 5, 6 and 7 resulted in significantly reduced expression compared to 
control. Transferrin mRNA level in Huh7 control cells was approximately 1.5 times that in 
HepG2 control cells and only one tenth of liver expression, but again no increases were 
observed in the treated cells; levels were generally lower than in control cells, although none 
of the changes were statistically significant. The AFP mRNA level in Huh7 control cells was 
approximately 10-fold lower than in HepG2 control cells but still three times higher than that 
in liver. Although none of the treatments resulted in levels which were significantly lower than 
control, neither did they increase AFP mRNA above control level. It is notable that the two 
treatments which produced the lowest AFP levels, 3 and 6, also resulted in significantly 
decreased albumin mRNA levels and lowered transferrin levels, indicating that perhaps the 
decrease in AFP is due to an overall decrease in global mRNA expression and not an indicator 
of increased hepatic maturation. 
Summary 
 Growth factor treatments did not result in a markedly more differentiated cell in either 
HepG2 or Huh7 cells; the short treatment time of four days was not sufficient. 
4.3.3 – 1% DMSO treatment on HepG2 and Huh7 cells 
Figure 4.5 shows results from HepG2 cells treated with 1% DMSO and analysed for the 
differentiation markers albumin, transferrin and AFP. Unlike the data used for differentiation 
marker assessment in figure 4.1, these data are compiled from three experiments with 
treatment extended to 25 days to allow for the possibility of maturation only after an 
extended period of treatment. Although matched controls could be generated for Huh7 cells 
(prolonged untreated growth), HepG2 cells did not survive for the duration of the experiment 
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in standard media, becoming over-confluent to such an extent that widespread cell death 
occurred. 1% DMSO is therefore required for prolonged growth of HepG2 cells, arresting the 
cell cycle and preventing over-growth. Albumin mRNA level increased significantly after 15 
days of treatment and remained at a similar, but not significantly increased, level after 20 days 
before returning to control level at 25 days. Transferrin mRNA levels showed a similar pattern, 
with increases at both 15 and 20 days of treatment (significant at 20 days). At 25 days the 
expression of transferrin mRNA was reduced to control level. HepG2 cells treated with 1% 
DMSO showed no sustained or significant change in AFP mRNA level at any point. 
Results from Huh7 cells treated with 1% DMSO and analysed for albumin, transferrin and AFP 
levels are shown in figure 4.6. As is the case with the previous figure, this displays data for 
three 1% DMSO experiments rather than just one as in figure 4.2. This figure displays data 
from both confluent control cells (as in HepG2 experiments) along with untreated cells 
matched to each time point, which were grown for the specified number of days in standard 
growth medium. The experimental layout used in this treatment can be seen in figure 2.2. 
Albumin mRNA levels showed a steady increase throughout the experiment in both treated 
and untreated cells, with the 1% DMSO treatment resulting in a significant increase from 10 
days onwards and untreated cells showing significant increases from 15 days onwards. No 
difference between treated and untreated cells was seen at any time point when assessed by 
Student’s t-test. Transferrin mRNA levels were significantly increased after 15 and 20 days of 
1% DMSO treatment but remained at control level in untreated cells. Significant differences 
between untreated and DMSO-treated cells were seen at 10 to 25 days inclusive; in all cases 
1% DMSO treated cells had increased expression over untreated cells. The difference in levels 
of transferrin mRNA between treated and untreated cells indicate an effect of DMSO rather 
than of prolonged or arrested growth. AFP mRNA levels decreased steadily throughout both 
experiments and were significantly different from control at all time points in both untreated 
and DMSO-treated Huh7 cells. DMSO treated cells had significantly lower AFP mRNA than 
untreated cells at 25 days; at all other time points there was no difference between treated 
and untreated cells.  
Summary 
 HepG2 – significant increases in albumin and transferrin after 15 days of treatment, no 
significant changes in AFP level. 1% DMSO is required for prolonged treatment. 
 Huh7 – 1% DMSO treatment produced significant increases in albumin and transferrin 
plus significant decreases in AFP. Prolonged untreated growth also resulted in 
significant albumin and AFP changes but no effect on transferrin was observed. 
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 Huh7 1% DMSO treatment appears to be more effective at differentiation than 
prolonged untreated growth, indicating DMSO is inducing maturation as well as 
slowing growth. 
4.3.4 – 2% DMSO treatment on HepG2 and Huh7 cells 
In figure 4.7 data are shown from the 1% DMSO HepG2 experiments previously displayed in 
figure 4.5 alongside results from cells treated with 2% DMSO; this allows direct comparison of 
the two treatments. The 2% DMSO treatment produced a significant increase in albumin 
mRNA over control level at both 10 and 15 days, while with 1% DMSO the level only became 
significantly higher at 15 days. A significant difference between the two treatments was seen 
at 10 days, with 2% DMSO treated cells showing a higher level of albumin mRNA than cells 
treated with the lower concentration of DMSO. The trend in 2% DMSO treated cells followed 
that observed in earlier experiments where the increase was not sustained throughout the 
later time points.  
Transferrin mRNA level in 2% DMSO treated cells increased steadily from initiation of the 
experiment until 15 days when a significant increase from control was observed. Again, the 
effect of 1% DMSO lagged slightly behind with increases at 15 and 20 days. Significantly higher 
levels in 2% treated cells over 1% treated cells were seen at 5 and 10 days. A decrease in 
transferrin mRNA to a level comparable to that in control was apparent from 20 days in 2%, 
and at 25 days in 1% DMSO treated cells respectively. AFP mRNA level increased initially with 
2% DMSO treatment and returned to control level from 10 days onwards. In general, AFP 
mRNA levels were higher in 2% DMSO treated cells than in 1% DMSO treated cells at matched 
time points, with significant increases at 5, 10 and 20 days. AFP mRNA level was significantly 
lower in 2% than in 1% DMSO treated cells at 25 days. 
Figure 4.8 displays data from Huh7 cells treated with 2% DMSO for up to 25 days and analysed 
for albumin, transferrin and AFP mRNA levels. This is displayed alongside data from figure 4.6 
showing mRNA levels of these genes in untreated and 1% DMSO treated cells. Albumin mRNA 
levels were increased by 2% DMSO and reached significance compared to control at 15 days of 
treatment, although the standard error was large. No significant differences between 
untreated, 1% and 2% DMSO treated cells were seen at any time point. Transferrin mRNA 
levels in 2% DMSO treated cells increased earlier than with either 1% DMSO or extended 
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 DMSO 
(1%) 
Dexamethasone 
(10-7M) 
HGF 
(20 ng/ml) 
OSM 
(10 ng/ml) 
Control and 
untreated cells 
- - - - 
DMSO (1%) X - - - 
DMSO (2%) X (2%) - - - 
Treatment  1  X    X X  - 
Treatment  2  X  X - X 
Treatment  3  X  X X X  
Table 4.3 – Extended treatments applied to HepG2 and Huh7 cells for up to 25 days. 
Treatments 1-3 were adapted from preliminary growth factor experiments. 
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 growth, with significant increases compared to control at 5, 10, 15 and 25 days. Cells treated 
with 2% DMSO had significantly raised transferrin mRNA compared to untreated cells at 5 and 
10 days, the mRNA level was significantly increased over 1% DMSO treated cells at day 10 only. 
2% DMSO treated cells had a similar level of transferrin to untreated cells after 20 days when 
1% DMSO treatment resulted in transferrin mRNA levels significantly higher than both of the 
other treatments. AFP mRNA level in 2% DMSO treated Huh7 cells did not significantly 
decrease in comparison to control at any time. This was in contrast to both untreated and 1% 
treated cells, which both showed significant decreases from control at all time points. The level 
of AFP mRNA in 2% DMSO treated cells was significantly higher than in both untreated and 1% 
treated cells at 5, 10 and 20 days of treatment and higher than 1% DMSO treated cells at 25 
days of treatment. 
Summary 
 HepG2 – albumin and transferrin levels increased earlier with 2% DMSO treatment 
than with 1% DMSO. AFP levels in 2% DMSO cells were higher than in 1% at 5, 10 and 
20 days, indicating no advantage over 1% treatment. 
 Huh7 – significant increases over control were seen in albumin after 15 days and 
transferrin at all times points except 20 days. AFP did not decrease significantly. 
 2% DMSO treatment also resulted in a less healthy cell population than 1% DMSO with 
cell detatchment and lower RNA yields. Results from differentiation marker analysis 
combined with this observation reveal no advantage in 2% over 1% DMSO treatment. 
4.3.5 – HepG2 cells plus treatment 1 
Treatments 1, 2 and 3 are detailed in Table 4.2. Figure 4.9 shows data for HepG2 cells with 
treatment 1 (Tr1). Tr1 consisted of 1% DMSO, 10-7M dexamethasone and 20 ng/ml hepatocyte 
growth factor (HGF) in standard growth medium. These data are displayed alongside 
previously presented data for 1% DMSO treated cells. A significant increase in albumin mRNA 
level was seen at 10 days both in comparison to control and to 1% DMSO treated cells. 
However, this increase was not sustained at later time points. Transferrin mRNA levels in Tr1 
cells were increased from control throughout the experiment, with significant changes from 
control at 10 and 15 days and significant increases from 1% DMSO treated cells at 10 and 25 
days. AFP mRNA levels remained largely unchanged from control with the only significant 
difference observed being a slight increase in 1% DMSO treated cells transferrin level over that 
in Tr1 cells at 25 days. 
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Summary 
 Although significant increases in transferrin were apparent earlier than in 1% 
treatment, no advantage was observed in albumin and AFP expression with Tr1. 
4.3.6 – HepG2 cells plus treatment 2 
Treatment 2 (Tr2) consisted of 1% DMSO, 10-7M dexamethasone and 10 ng/ml oncostatin M 
(OSM) in standard growth medium; data for HepG2 cells plus Tr2 are shown in figure 4.10. 
Again, data for 1% DMSO treated cells are displayed alongside these results for comparison. 
No change from control level of albumin mRNA was seen at any time point for Tr2 cells, while 
significant increases from control were observed in transferrin mRNA levels at 15, 20 and 25 
days of treatment. This increase in transferrin level was maintained at 25 days unlike with the 
1% DMSO treatment, where mRNA level was significantly lower than in Tr2 treated cells. In 
contrast to the 1% DMSO treated cells where no decrease in AFP mRNA was detected, Tr2 cells 
showed a significant and time-dependent decrease compared to control from 10 days 
onwards. Tr2 treated cells were also significantly lower in AFP mRNA than 1% DMSO treated 
cells from 15 days onwards. 
Summary 
 AFP was significantly decreased in comparison to both control and 1% DMSO from 10 
days onwards; however, no increase in albumin and lower increases in transferrin 
indicate that a more mature cell type was not produced with Tr2. 
4.3.7 – HepG2 cells plus treatment 3 
Treatment 3 (Tr3) consisted of 1% DMSO, 10-7M dexamethasone, 20 ng/ml HGF and 10 ng/ml 
OSM in standard growth medium; data for HepG2 cells plus Tr3 alongside data from 1% DMSO 
treated cells are shown in figure 4.11. Albumin mRNA levels increased slightly at 10 and 15 
days with Tr3 but do not reach significance. Transferrin mRNA was consistently above control 
levels and reached significance at 10 and 15 days. Tr3 treated cells also showed significantly 
higher transferrin mRNA levels than 1% DMSO treated cells at all time points except 20 days. 
AFP mRNA levels in Tr3 cells were lower than control from day 15 onwards but only reached 
significance at 25 days. Tr3 AFP mRNA levels were significantly lower than those in 1% DMSO 
treated cells at 15 and 25 days. 
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Summary 
 Transferrin was increased over both control and 1% DMSO at 10 and 15 days; 
however, no significant albumin increases occurred, with AFP significantly decreasing 
only after 25 days. No clear advantage of Tr3 over 1% DMSO was apparent. 
4.3.8 – Huh7 cells plus treatment 1 
Treatments 1 to 3 are as described in Table 4.2, and are identical to those applied to HepG2 
cells. Treatment 1 (Tr1) consisted of 1% DMSO, 10-7M dexamethasone and 20 ng/ml HGF; data 
for Huh7 cells plus Tr1 are shown in figure 4.12. Displayed alongside results for this treatment 
are those previously described for prolonged untreated culture and 1% DMSO alone. Albumin 
mRNA levels were significantly increased compared to control in Tr1 cells at 15 and 25 days 
but were at control level at day 20. At 15 days albumin mRNA level was significantly increased 
over both untreated and 1% DMSO treated cells by Tr1; however, at 20 days the level was 
significantly lower than that seen in 1% DMSO treated cells. Transferrin mRNA levels in Tr1 
cells appeared to increase in comparison to control throughout the experiment (similar to 
results with 1% DMSO), but did not reach significance at any time point. Significant differences 
were seen between untreated and Tr1 cells at 5, 10 and 25 days, while 1% DMSO treated cells 
had higher levels of transferrin mRNA than both untreated and Tr1 treated cells at 20 days. 
Although AFP mRNA levels steadily decreased from 5 days onwards in Tr1 cells they did not 
decrease significantly in comparison to control levels and remained substantially higher than in 
untreated and 1% DMSO treated cells. The AFP level in Tr1 cells was significantly increased 
over that in untreated cells at 5, 10 and 15 days, and in 1% DMSO treated cells at 10 and 15 
days.  
Summary 
 Albumin and transferrin levels were generally similar to both untreated and 1% DMSO 
but AFP did not significantly decrease from control as was observed with untreated 
and 1% DMSO cells. No advantage of Tr1 over 1% DMSO was observed. 
4.3.9 – Huh7 cells plus treatment 2 
Treatment 2 (Tr2) consisted of 1% DMSO, 10-7M dexamethasone and 10 ng/ml OSM in 
standard growth medium; data for Huh7 cells plus Tr2 along with data from untreated and 1% 
DMSO treated cells are shown in figure 4.13. Albumin mRNA levels remained around control 
level except at 15 days, at which point a statistically significant but unsustained increase was 
observed. At this time point, Tr2-treated cells showed a significantly higher level of albumin 
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mRNA than both untreated and 1% DMSO treated cells. At 25 days the reverse was observed 
as Tr2 cells had a significantly lower level of albumin mRNA than the two other data sets. 
Transferrin mRNA in Tr2 cells was significantly raised at 5 and 15 days compared to control. At 
20 days 1% DMSO treated cells showed significantly increased transferrin mRNA level over 
both untreated and Tr2 cells. AFP mRNA levels in Tr2 cells generally decreased from control 
level and all (except the 15 day time point increase) reached significance. AFP mRNA level at 
day 15 appeared to be an anomalous result as data from 10 and 20 days did not support this 
value, which was almost as high as the original control level and was significantly higher than 
that in both untreated and 1% DMSO treated cells.  
Summary 
 Significant increases in both albumin and AFP occurred with Tr2 at 15 days but were 
not sustained – AFP was not significantly lower than that in untreated or 1% DMSO 
cells. No benefit of Tr2 over 1% DMSO was observed. 
4.3.10 – Huh7 cells plus treatment 3 
Treatment 3 (Tr3) consisted of 1% DMSO, 10-7M dexamethasone, 20 ng/ml HGF and 10 ng/ml 
OSM in standard growth medium; data for Huh7 cells plus Tr3 alongside data from untreated 
and 1% DMSO treated cells are shown in figure 4.14. Tr3 cells showed albumin mRNA levels 
largely unchanged from control with no significant increases or decreases. At 10 and 20 days of 
treatment, cells were significantly lower in albumin mRNA than 1% DMSO treated cells and 
significantly lower than untreated cells at 20 and 25 days. Transferrin mRNA levels in Tr3 cells 
also remained close to control level with no significant increase or decrease. After 20 days of 
treatment, 1% DMSO treated cells had higher transferrin mRNA level than both untreated and 
Tr3 cells and Tr3 cells were significantly lower in transferrin than both 1% DMSO and untreated 
cells. After 25 days of treatment Tr3 cells had a significantly lower level of transferrin mRNA 
than 1% DMSO treated cells. AFP mRNA levels steadily decreased from control in Tr3 cells and 
were significantly reduced at 15 and 25 days. Tr3 cells also showed significantly lower AFP level 
at 25 days than both untreated and 1% DMSO treated cells. 
Summary 
 Neither albumin nor transferrin levels were significantly increased over control; AFP 
levels did decrease but only reached significance after 15 and 25 days of treatment. 
Tr3 did not show a significant advantage over 1% DMSO. 
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4.3.11 – Comparison of treatments in HepG2 and Huh7 cells 
Figure 4.15 shows results from each treatment at 15 days plus control levels and liver data. 
Control and treated data were taken from figures 4.5, 4.7, 4.9, 4.10 and 4.11. Liver data have 
been included from previous figures in this chapter (labelled ‘liver’) and recalculated from 
table 3.1 (labelled ‘liver 3.1’) to be displayed as relative to confluent HepG2 levels. The time 
point of 15 days was chosen for this analysis as the majority of treatments that showed an 
effect exhibited a change in differentiation marker mRNA levels at this stage of treatment. 
Results for one-way ANOVA with Dunnett’s post test to enable comparison to control are 
included as displayed on the original figures. Results for one-way ANOVA with Bonferroni’s 
post test are also displayed; these were calculated for 15 day treated cells only, excluding 
values for control and liver samples. 
When compared to control, the only treatments which resulted in significantly higher albumin 
mRNA levels were 1% and 2% DMSO. No differences were seen between 1- or 2% DMSO and 
treatments 1-3. With regard to transferrin mRNA, the only treatment which did not produce a 
significant change from control at 15 days was 1% DMSO. However, the mean value for this 
treatment was extremely close to that calculated for 2% DMSO treated cells and was higher 
than that seen in Tr2 cells, both of which were significant. A comparison between the effects 
of 1- and 2% DMSO and treatments 1-3 showed a significant difference between Tr2 and Tr3, 
with Tr3 having the greater effect of the two. AFP mRNA level was significantly decreased from 
control by both Tr2 and Tr3 but remained higher than that in liver. Tr2 also produced a 
significantly lower AFP mRNA level than both 1% and 2% DMSO treatments.  
In Huh7 cells, albumin mRNA levels were significantly increased in comparison to control by all 
treatments except Tr3, with no significant differences between the differently treated cells (fig 
4.16). Transferrin mRNA levels were increased over control in 1%- and 2%- DMSO and in Tr2-
treated cells after 15 days of treatment. Again, no significant differences in effect were seen 
between 1 and 2% DMSO and treatments 1-3. AFP mRNA levels were significantly decreased in 
1-and 2% DMSO- and in Tr3-treated cells. Significant increases in AFP mRNA level were seen in 
cells with Tr2 when compared to untreated cells and those exposed to 1% DMSO. Tr3 treated 
cells had significantly lower AFP mRNA levels than Tr1 and Tr2 cells. 
Summary 
 HepG2 – overall, 1% DMSO is the preferable differentiation treatment with increases 
in both albumin and transferrin. Tr1, 2 and 3 did not increase albumin, while 2% DMSO 
caused some cell death. 
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 Huh7 – only prolonged untreated growth, 1% DMSO and Tr3 produced significant AFP 
decreases; of these, only 1% DMSO also showed significant increases in albumin and 
transferrin. Therefore, 1% DMSO is the preferable treatment for Huh7 cells. 
 Relative liver levels were stable from the cells analysed at confluence in chapter 3 to 
the confluent cells used in experiments here, indicating that basal levels of the 
differentiation markers were stable with passaging of both cell lines. 
4.4 – Discussion 
In order to assess the hepatic maturation status of HepG2 and Huh7 cells, measurement of 
informative markers was required. Five potential markers of differentiation, albumin, 
transferrin, AFP, A1AT and HNF4a were assessed in both cell lines treated with 1% DMSO. All 
five of these markers had previously been reported in the literature as being indicative of a 
more mature hepatic cell when an appropriate increase or decrease in expression was seen 
(Page et al., 2007; Sainz and Chisari, 2006; Snykers et al., 2006; Sidhu et al., 2004; Raul Cassia, 
1997). Results are shown in figures 4.1 and 4.2 for HepG2 and Huh7 cells respectively. Changes 
observed in these experiments indicated that of the five markers selected, three were more 
suitable for assessment of maturation status in these cell lines; these were albumin, transferrin 
and AFP as the responses observed matched those reported in the literature as being those 
expected in a more mature hepatic cell. 
Preliminary experiments with seven different growth factor mixtures applied to HepG2 and 
Huh7 cells (figures 4.3 and 4.4) showed no clear effect on differentiation. This may be because 
treatments were only applied for four days whereas the literature demonstrates that extended 
exposure to specific cocktails of growth factors are ideally required for differentiation, e.g. at 
least 10 days (Agarwal et al., 2008; Hay et al., 2008; Hossein Baharvand, 2008; Philippe A. Lysy, 
2008; Jun Cai, 2007; Snykers et al., 2006). Extended treatment durations with these mixes 
were attempted but continued proliferation led to cells overgrowing and dying soon after the 
4 day time point. As very little informative data were gained from this restricted growth time, 
the literature was re-assessed to see which treatments may be most beneficial. As a result of 
this analysis, treatments 1, 2 and 3 were adapted and selected for further investigation. All 
further treatments included dexamethasone as it is essential for liver maturation (Kinoshita 
and Miyajima, 2002; Zaret, 2002) and is included in the majority of protocols attempting to 
differentiate hepatocytes. HGF was used in the final stage of a stepped protocol by Snykers et 
al. (Snykers et al., 2006) using rat BMSCs, which resulted in raised albumin levels, alongside a 
transient increase then decrease of AFP as the cells matured. OSM has been used in the 
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differentiation of pancreatic cells into hepatocytes (Kurash et al., 2004) and with hESCs (Hay et 
al., 2008) with promising results. HGF and OSM have been used together on hESCs by 
Baharvand et al. (Hossein Baharvand, 2008), which reported promising results in terms of 
hepatic marker expression. Sodium pyruvate and ITS (insulin-selenium-transferrin) were 
omitted from prolonged treatments as they are intended for use in serum-free medium as 
partial replacement of the hormones and other additives usually contributed by serum 
supplementation (Sigma datasheet I2521, appendix B); as all treatments contained 10% serum 
this was unnecessary. 
In order to prolong the duration of growth factor treatments on both cell lines, a mechanism 
of slowing or halting growth was required, particularly for HepG2 cells. Several compounds 
have been described that slow growth of HepG2 and Huh7 cells including vitamin K2 
(Yamamoto et al., 2009) and vitamin K2 analogues such as menatetrenone (Ozaki et al., 2007) 
and panaxydol (Guo et al., 2009). 1% DMSO treatment has been reported to halt growth after 
approximately 6 days of treatment and to induce differentiation in Huh7 cells (Choi et al., 
2009; Sainz and Chisari, 2006). This treatment seemed to be the most promising and had 
already been seen to effectively enable prolonged incubation and induce differentiation in 
both cell lines here. As extended treatment periods were required with growth factor 
cocktails, 1% DMSO was added in order to prolong treatments one, two and three (table 4.3). 
A 2% DMSO treatment is used in the cell line HepaRG to induce differentiation to a more 
mature hepatic profile (Aninat et al., 2006; Le Vee et al., 2006; Gripon et al., 2002); both 
concentrations were applied experimentally here. 
Thus, following the initial experiments, further treatments of 1% and 2% DMSO were applied 
to both cell lines. HepG2 cells showed significant increases in albumin and transferrin mRNA 
levels after 15 and 20 days respectively with 1% DMSO treatment, while 2% DMSO produced 
significant increases in expression of both genes earlier than observed following 1% DMSO. 
Taken alone, these results indicate that 2% DMSO enhances maturation after shorter 
incubation times than 1% DMSO. AFP mRNA levels were generally lower in 1%- than in 2% 
DMSO treated HepG2 cells but did not reach significance in comparison to control. 
Observations of the cells made during treatment revealed that HepG2 cells appeared 
unhealthier when subject to 2% DMSO than untreated or 1% DMSO treated cells with 
noticeable cell death and unattached cells. Comparison of results combined with these 
observations led to the conclusion that the higher concentration of DMSO treatment provided 
no discernable advantage.  
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As it was possible to culture Huh7 cells for the duration of the experiment without addition of 
DMSO, effects of DMSO inclusion over those observed with prolonged untreated growth were 
able to be assessed. Both untreated Huh7 cells and those with 1% DMSO showed a steady 
increase in albumin mRNA levels with statistical significance first achieved at 15 and 10 days of 
treatment respectively. While 2% DMSO treated cells also showed a significant increase in 
albumin after 15 days of treatment, no further significant changes were observed. Despite the 
mean level in 2% DMSO treated cells (figure 4.8) not being vastly different from that seen in 
untreated or 1%-treated cells, a large standard error resulting from widespread data points 
prevents it from reaching significance at time points other than 15 days. These increased error 
margins are likely due to the adverse effects of 2% DMSO on the cells, which as in HepG2 cells, 
caused some cell death and detachment of cells from the growth surface. Transferrin mRNA 
levels in untreated Huh7 cells did not increase significantly above control; this was not the case 
in either DMSO experiment, with significant increases recorded at 15 and 20 days in 1% DMSO 
treated cells and at all time points except 20 days with 2% DMSO. This indicates that DMSO is 
having an effect above that seen solely by prolonging growth in standard medium. Untreated 
and 1% DMSO treated Huh7 cells had similar AFP mRNA levels throughout the experiment with 
significant decreases in comparison to control at all time points. However, 2% DMSO 
treatment did not follow this pattern and no significant change from control was observed. 
Overall, results for these three experiments indicate that 1% DMSO is the treatment most 
likely to produce a more mature hepatic cell, with transferrin levels above those seen in 
untreated cells and AFP levels below those in 2% DMSO treated cells. 
Increases in albumin mRNA with 1% DMSO treatment in DMSO-treated Huh7 cells were 
observed by Choi et al. (Choi et al., 2009) and Sainz et al. (Sainz and Chisari, 2006) where a 
maximal increase in albumin mRNA was observed after 14 days of treatment and were shown 
to be comparable to levels in primary human hepatocytes after 20 days of growth. While 
neither cell line here showed comparable albumin levels to those in liver, maximal expression 
was observed at 15 to 20 days which agrees with the published data. Increased albumin levels 
were also observed after 4 weeks of prolonged untreated growth of both HepG2 and Huh7 
cells in comparison to control but did not quite reach levels in liver (Sivertsson et al., 2010). 
This publication also indicated that Huh7 cells reached the maximal level of albumin 
expression observed after 2 weeks of culture, while data between 0 and 4 weeks of growth for 
HepG2 cells was not shown. Albumin mRNA increases have also been observed in HepaRG 
cells, where DMSO is included in routine culture over a prolonged period of time in order to 
produce a more mature cell and levels 70% of those observed in freshly isolated human 
hepatocytes were recorded after 30 days of culture with DMSO (Aninat et al., 2006). AFP 
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mRNA levels in HepaRG cells lower than those observed in freshly isolated hepatocytes were 
also recorded, whereas the confluent HepG2 cells analysed for AFP in this publication showed 
an 89-fold increase in comparison to those in fresh hepatocytes (Aninat et al., 2006). These 
comparisons to published data indicate that the observed time period required for significant 
changes to take place is as would be expected, and the response in terms of an increase in 
albumin and a decrease in AFP mRNA levels, while perhaps not as close to liver levels as 
observed in some publications, remains substantial enough to indicate that some degree of 
maturation may be taking place. 
Both HepG2 and Huh7 cells were subsequently treated with 1% DMSO plus growth factors for 
prolonged periods of time; these three treatments are described in table 4.3. In HepG2 cells, 
albumin mRNA level in cells exposed to Treatment one was significantly higher than control 
after 10 days but this was not sustained; following Treatments two and three no significant 
increase or decreases from control were observed. Although all three treatments significantly 
increased transferrin levels, the absence of increases in albumin mRNA by Tr2 and 3 cast doubt 
upon whether they have truly induced a more hepatic profile in HepG2 cells. The only 
treatment which resulted in significantly decreased AFP mRNA level was Tr2 but this did not 
produce a corresponding increase in albumin levels. Tr1, 3 and 1% DMSO all showed little 
effect on AFP level – Tr3 did result in a significant decrease from control after 25 days of 
treatment but this did not correspond with increases in either albumin or transferrin mRNA. 
Overall, 1% DMSO treated HepG2 cells showed the most promising result in terms of 
differentiation towards a more mature hepatic phenotype. The changes became apparent at 
around 15 days of treatment, when albumin mRNA levels were significantly raised over control 
with increases in transferrin mRNA following soon after. However, AFP mRNA levels did not 
decrease from control, indicating that treated cells had not yet achieved a fully mature hepatic 
profile. 
Treatments one and two on Huh7 cells produced significant increases in albumin mRNA level 
from control by day 15 which were not sustained at further time points; treatment three 
resulted in no increase in albumin or transferrin mRNA at any time point. Treatment one also 
showed no significant effect on transferrin, whilst treatment two only increased expression at 
15 days of treatment. However, Tr2 also showed a solitary increase in AFP mRNA at 15 days 
which questions whether these albumin and transferrin increases are truly indicative of a more 
mature hepatic profile, or if a global RNA increase in mRNAs of all types has resulted in these 
observations; however, levels of housekeeping genes GAPDH and TOP1 remained stable. Tr1 
resulted in no significant AFP mRNA decrease at any time point, whereas Tr3 had significantly 
lower levels of AFP than control at 15 and 25 days of treatment. Overall, none of the three 
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growth factor treatments produced results surpassing those of 1% DMSO alone. This could 
indicate that the growth factors selected for treatment were not applicable for the maturation 
level already seen in these cell lines. Although growth factor combinations were purposely 
selected from the literature as those which were used in the latter stages of differentiation 
protocols, it could be that for carcinoma cell lines different factors are required to induce 
maturation. Alternatively, the growth factors may not have had the desired effect on the cell 
due to low receptor levels or the factors themselves being masked by the serum included in all 
media recipes used here. Expression of cMET (HGF receptor), FGF receptors and OSMR (OSM 
receptor) was checked via end-point PCR and were determined to be expressed at least at the 
mRNA level in both cell lines. 
Figures 4.15 and 4.16 show overall results for HepG2 and Huh7 cells respectively after 15 days 
of treatment with 1% and 2% DMSO and treatments 1-3. The 15 day time point was chosen as 
in most treatments any effect that occurred was manifest by this time. Values for ‘liver’ levels 
of these three genes were taken from previous figures in this chapter, and ‘liver 3.1’ values are 
from table 3.1 calculated relative to confluent control cells for each cell line and are displayed 
on the appropriate graph. Results for albumin, transferrin and AFP mRNA levels in treated 
HepG2 cells indicate that there is not much difference in the effect of 1% and 2% DMSO. Of the 
three growth factor treatments, Tr2 and 3 look promising in terms of AFP decrease and 
transferrin increase, but neither show a significant increase in albumin mRNA levels. This 
indicates that an ingredient in these treatment media is suppressing the response which 
increases albumin expression in DMSO-only treated cells. As a result of this, 1% DMSO treated 
HepG2 cells will be analysed further to determine the extent of maturation which has taken 
place.  
Data from Huh7 cells after 15 days of treatment are shown in figure 4.16. Here, 1% DMSO does 
stand out clearly as the preferred method of differentiation – this is the only treatment which 
resulted in a significant increase in both albumin and transferrin mRNA and a decrease in AFP 
mRNA levels. It is also worth noting that for both HepG2 and Huh7 cells the expression levels 
in liver of all three genes are approximately the same in samples from these experiments and 
in those from earlier experiments displayed in table 3.1. The cells used in these two sets of 
experiments were at a different passage number and had undergone one cycle of freeze-thaw 
between the experiments. This indicates that the basal levels of the three markers in these 
cells are stable throughout a range of passages and following storage in liquid nitrogen. It was 
also observed that confluent HepG2 cells are closer to liver in respect of albumin and 
transferrin mRNA concentrations than confluent Huh7 cells are. The two cell lines appear to 
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have comparable AFP mRNA levels in confluent cells; with the addition of 1% DMSO for 15 
days Huh7 cells display an AFP mRNA level more comparable to liver than HepG2 cells. 
In conclusion, both cell lines show the most promising results with application of 1% DMSO for 
a minimum of 15 days. However, this is based only on mRNA expression of three 
differentiation markers. In order to assess the maturation status of the treated cells further, 
hepatic features such as levels of transporters and enzymes which contribute to the function 
of a fully differentiated hepatocyte need to be analysed. Results from this assessment are 
shown in the following chapter. 
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Figure 4.1 – Analysis of markers of differentiation in HepG2 cells. Results for
five markers of hepatic maturation are shown in graphs A to E – A1AT, HNF4a,
albumin, AFP and transferrin respectively. Cells were seeded and grown for
three days to 90% confluence and treated with 1% DMSO for up to twenty
days. RNA was harvested every five days, reverse transcribed and analysed for
the appropriate gene using qPCR. Cells grown to confluence were used as a
control. Whole liver cDNA is included as an indicator of in vivo hepatic mRNA
levels. Results shown are from one experiment with three replicates (N = 1, n
= 3), confluent cells have six replicates (n = 6). Data is displayed as mean ±
SEM and analysed statistically using one-way ANOVA with Dunnett’s post test.
* = p<0.05, ** = p<0.01.
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Figure 4.2 – Analysis of markers of differentiation in Huh7 cells. Results for five
markers of hepatic maturation are shown in graphs A to E – A1AT, HNF4a, albumin,
AFP and transferrin respectively. Cells were seeded and grown for three days to 90%
confluence and treated with 1% DMSO for up to twenty five days. RNA was
harvested, reverse transcribed and analysed for the appropriate gene using qPCR.
Cells grown to confluence were used as a control. Whole liver cDNA was included as
an indicator of in vivo hepatic mRNA levels. Results shown are from one experiment
with three replicates (N = 1, n = 3), confluent cells have six replicates (n = 6). Data is
displayed as mean ± SEM and analysed statistically using one-way ANOVA with
Dunnett’s post test. * = p < 0.05, ** = p < 0.01.
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respectively. Cells were seeded and grown for three days to 90% confluence and treated 
with 1% DMSO for up to twenty five days. RNA was harvested, reverse transcribed and 
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* Experimental control cells are confluent, control values are set at 1. 
** Data recalculated from table 3.1
 HepG2 levels at 
15 days relative 
to control * 
Liver levels 
relative to HepG2 
cells at 
confluence ** 
Huh7 levels at 
15 days relative 
to control * 
Liver levels 
relative to Huh7 
cells at 
confluence ** 
A1AT 4.0 6.4 2.2 29.8 
HNF4a 2.0 0.49 2.5 2.4 
Albumin 11.4 19.4 2.0 27.6 
AFP 1.5 0.01 0.08 0.05 
Transferrin 18.4 10.4 6.4 10.4 
     
Table 4.3 – Markers of differentiation in HepG2 and Huh7 cells relative to control at 15 days. 
Data from figures 4.1 and 4.2 has been amalgamated into this table and altered to be displayed 
relative to control in order to better demonstrate the effects of treatment. Data for liver levels 
compared to confluent cells has been recalculated from table 3.1 and is included for comparison 
in order to provide a larger sample number for more accurate data. 
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Figure 4.3 – Preliminary growth factor treatments on HepG2 cells. Graphs A, B and C
show mRNA levels of albumin, transferrin and AFP respectively in HepG2 cells treated for
four days with seven different growth factor treatments as detailed in Table 4.2. Briefly,
cells were grown for three days to 90% confluence, at which point the appropriate
treatment was applied for four days and RNA harvested after a total of seven days
growth. Control cells remained in media without growth factors for the entire seven
days. Whole liver cDNA is included as an indicator of in vivo hepatic levels. Results are
from two experiments, each with two replicates (N = 2, n = 4). Data is displayed as mean
±SEM and analysed using one-way ANOVA with Dunnett’s post test. * = p<0.05.
 
  
Figure 4.3 – Preli i r  r   t ts n 2 ce ls. Graphs A, B and C 
show mRNA levels of albumin, transferrin and AFP respectively in HepG2 cells treated 
for four days with seven different growth factor treatments as detailed in Table 4.2. 
Briefly, cells were grown for three days to 90% confluence, at which point the 
appropriate treatment was applied for four days and RNA harvested after a total of 
seven days growth. Control cells remaine  in media without growth factor  for the 
entire seven days. Whole liver cDNA is included as an indicator of in vivo  hepatic levels. 
Results are from two experiments, each with two replicates (N = 2, n = 4). Data is 
displayed as mean ±SEM and analysed using one-way ANOVA with Dunnett’s post test. 
* = p<0.05.  
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Figure 4.4 – Preliminary growth factor treatments on Huh7 cells. Graphs A, B and C
show mRNA levels of albumin, transferrin and AFP respectively in Huh7 cells treated for
four days with seven different growth factor treatments as detailed in Table 4.2. Briefly,
cells were grown for three days to 90% confluence, at which point the appropriate
treatment was applied for four days and RNA harvested after a total of seven days
growth. Control cells remained in media without growth factors for the entire seven
days. Whole liver cDNA is included as an indicator of in vivo hepatic levels. Results are
from one experiment with two replicates (N = 1, n = 2). Data is displayed as mean ±SEM
and analysed using one-way ANOVA with Dunnett’s post test. * = p<0.05, ** = p<0.01.
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Figure 4.4 – Preli inary growth factor treatments on Huh7 cells. Graphs A, B and C 
show mRNA levels of albumin, transferrin and AFP respectively in Huh7 cells treated for 
four days with seven different growth factor treatments as detailed in Table 4.2. Briefly, 
cells were grown for three days to 90% confluence, at which point the appropriate 
t eatment was applied for four days and RNA ha ves ed after a to al of seven days 
growth. Control cells remaine  in media without growth factors for the entire sev n 
days. Whole liver cDNA is included as an indicator of in vivo  hepatic levels. Results are 
from one experiment with two replicates (N = 1, n = 2). Data is displayed as mean ±SEM 
and analysed using one-way ANOVA with Dunnett’s post test. * = p<0.05, ** = p<0.01.  
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Figure 4.5 – HepG2 cells treated with 1% DMSO and analysed for differentiation
markers. Results for albumin, transferrin and AFP are shown in graphs A, B and C
respectively. Cells were seeded and grown for three days until 90% confluent then
treated with 1% DMSO for up to 25 days. RNA was harvested, reverse transcribed and
analysed for the appropriate genes using qPCR. Cells grown to confluence were used
as a control. Whole liver cDNA is included as an indication of in vivo hepatic mRNA
levels. Results shown are from three experiments with a minimum of nine total
replicates (N = 3, n = 9), confluent cells having twelve replicates (N = 3, n = 12). Data is
displayed as mean ± SEM and analysed statistically using one-way ANOVA with
Dunnett’s post test. * = p < 0.05.
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Figure 4.6 – Prolonged untreated culture and 1% DMSO treatment of Huh7
cells analysed for differentiation markers. Results for albumin, transferrin and
AFP are shown in graphs A, B and C respectively. Cells were seeded and grown
for three days until 90% confluent then treated with 1% DMSO for up to 25 days;
untreated cells were allowed to continue growing without DMSO treatment and
extracted at the same time points. RNA was harvested, reverse transcribed and
analysed for the appropriate genes using qPCR. Cells grown to confluence were
used as a control. Whole liver cDNA is included as an indication of in vivo hepatic
mRNA levels. Results shown for both untreated and 1% DMSO treated cells are
from three experiments with a minimum of nine total replicates (N = 3, n = 9).
Control data was pooled and experiments normalised to this pool of data; total
control replicates number a minimum of 30 from six experiments (N = 6, n = 30).
Data is displayed as mean ± SEM and analysed statistically against control using
one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of
untreated against treated data was by Student’s t-test (# = p < 0.05, ## = p
<0.01).
 
  
Figure 4.6 – Prolonged untreated culture and 1% DMSO treatment of Huh7 cells 
analysed for differentiation markers. Results for albumin, transferrin and AFP are 
shown in graphs A, B and C respectively. Cells were seeded and grown for three days 
until 90% conflue t then treated with 1% DMSO for up to 25 days; untreated cells were 
allowed to ontinu  growing without DMSO treatment and ex racted at the same time 
points. RNA was harvested, r verse transcribed and analysed for the appropriat  genes 
using qPCR. Cells grown to confluence were used as a control. Whole liv r cDNA is 
included as an indication of in vivo hepatic mRNA levels. Results shown for both 
untreated and 1% DMSO treated cells are from three experiments with a minimum of 
nine total replicates (N = 3, n = 9). Control data was pooled and experiments normalised 
to this pool of data; total control replicates number a minimum of 30 from six 
experiments (N = 6, n = 30). Data is displayed as mean ± SEM and analysed statistically 
against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 
0.01). Analysis of untreated against treated data was by Student’s t-test (# = p < 0.05, 
## = p <0.01).  
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Figure 4.7 – HepG2 cells treated with DMSO and analysed for differentiation markers.
Results for albumin, transferrin and AFP are shown in graphs A, B and C respectively.
Cells were seeded and grown for three days until 90% confluent then treated with 1 or
2% DMSO for up to 25 days. RNA was harvested, reverse transcribed and analysed for
the appropriate genes using qPCR. Cells grown to confluence were used as a control.
Data from 1% DMSO is included for comparison. Whole liver cDNA is included as an
indication of in vivo hepatic mRNA levels. Results shown for 2% DMSO treated cells are
from two experiments with a minimum of five total replicates (N = 2, n = 5). Control data
from 2% DMSO experiments was pooled with that from 1% DMSO data and experiments
normalised to this pool of data; total control replicates number a minimum of 21 from
five experiments (N = 5, n = 21). Data is displayed as mean ± SEM and analysed
statistically against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05,
** = p < 0.01). Analysis of 1% DMSO against 2% DMSO data was by Student’s t-test (# = p
< 0.05, ## = p <0.01).
C
 
  
Figure 4.7 – HepG2 cells treated with DMSO and analysed for differentiation markers. 
Results for albumin, transferrin and AFP are shown in graphs A, B and C respectively. 
Cells were seeded and grown for three days until 90% confluent then treated with 1 or 
2% DMSO for up to 25 days. RNA was harvested, reverse transcribed and analysed for the 
appropriate genes using qPCR. Cells grown to confluence were used as a control. Data 
from 1% DMSO is included for comparison. Whole liver cDNA is included as an indication 
of in vivo hepatic mRNA levels. Results shown f r 2% DMSO treated cells are from two 
experiments with a minimum of five total replicates (N = 2, n = 5). Control data from 2% 
DMSO experiments was pooled with that from 1% DMSO data and experiments 
normalised to this pool of data; total control replicates number a minimum of 21 from 
five experiments (N = 5, n = 21). Data is displayed as mean ± SEM and analysed 
statistically against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, 
** = p < 0.01). Analysis of 1% DMSO against 2% DMSO data was by Student’s t-test (# = p 
< 0.05, ## = p <0.01).  
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Figure 4.8 – Untreated and DMSO treated Huh7 cells analysed for
differentiation markers. Results for albumin, transferrin and AFP are shown in
graphs A, B and C respectively. Cells were seeded and grown for three days until
90% confluent then treated with 1 or 2% DMSO for up to 25 days; untreated
cells were allowed to continue growing without DMSO treatment and extracted
at the same time points. RNA was harvested, reverse transcribed and analysed
for the appropriate genes using qPCR. Cells grown to confluence were used as a
control. Data from 1% DMSO treatment is included for comparison. Whole liver
cDNA is included as an indication of in vivo hepatic mRNA levels. Results shown
for 2% DMSO treated cells are from three experiments with a minimum of nine
total replicates (N = 3, n = 9). Control data from all three experiments was
pooled and experiments normalised to this pool of data; total control replicates
number a minimum of 42 from nine experiments (N = 9, n = 42) Data is displayed
as mean ± SEM and analysed statistically against control using one-way ANOVA
with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Each time point is analysed
individually testing all data columns against each other by one way ANOVA with
Bonferroni’s post test (a = untreated vs. 1% DMSO is p < 0.05, b = 1% DMSO vs.
2% DMSO is p < 0.05, c = untreated vs. 2% DMSO is p < 0.05).
C
 
  
Figur  4.8 – Untreat d and DMSO treated Huh7 cells analys d for differentiation 
markers. Results for albumin, transferrin and AFP are shown in graphs A, B and C 
respectively. Cells were seeded and grown for three days until 90% confluent then 
treated with 1 or 2% DMSO for up to 25 days; untreated cells were allowed to continue 
growing without DMSO treatment and extracted at the same time points. RNA was 
harvested, reverse transcribed and analysed for the appropriate genes using qPCR. Cells 
grown to confluence were used as a control. Data from 1% DMSO treatment is included 
for comparison. Whole liver cDNA is included as an indication of in vivo hepatic mRNA 
levels. Results shown for 2% DMSO treated cells are from three experiments with a 
minimum of nine total replicates (N = 3, n = 9). Control data from all three experiments 
was pooled and experiments normalised to this pool of data; total control replicates 
number a i  f   i  xperiments (N = 9, n = 2) ta is isplayed as 
mean ± SEM and analysed sta is cally ag inst control using one-way ANOVA with 
Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Each time point is analysed i dividually 
testing all data columns against each other by one way ANOVA with Bonferroni’s post 
test (a = untreated vs. 1% DMSO is p < 0.05, b = 1% DMSO vs. 2% DMSO is p < 0.05, c = 
untreated vs. 2% DMSO is p < 0.05).  
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Figure 4.9 – HepG2 cells with treatment 1 and 1% DMSO analysed for differentiation
markers. Results for albumin, transferrin and AFP are shown in graphs A, B and C
respectively. Cells were grown to 90% confluence and treated with 1% DMSO, 10-7M
dexamethasone and 20 ng/ml hepatic growth factor (HGF). RNA was isolated, reverse
transcribed and analysed for the appropriate genes by qPCR. Cells grown to confluence
were used as a control. Results shown for Tr1 cells are from two experiments with a
minimum of four total replicates (N = 2, n = 4). Control data from both experiments was
pooled and experiments normalised to this pool of data; total control replicates number
a minimum of 18 from five experiments (N = 5, n = 18). Data from 1% DMSO is included
for comparison. Whole liver cDNA is included as an indicator of in vivo hepatic mRNA
levels. Data is displayed as mean ± SEM and analysed statistically against control using
one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of 1%
DMSO against treatment 1 data is by Student’s t-test (# = p < 0.05, ## = p <0.01).
C
 
  
Figure 4.9 – HepG2 cells ith treat ent 1 and 1% DMSO analysed for differentiation 
markers. Results for albumin, transferrin and AFP are shown in graphs A, B and C respectively. 
C lls were grown to 90% confluence and treated with 1% DMSO, 10-7M dexamethasone and 
20 ng/ml hepatic growth factor (HGF). RNA was isolated, reverse transcribed and analysed for 
the appropriate genes by qPCR. Cells grown to confluence were used as a control. Results 
shown for Tr1 cells are from two experiments with a minimum of four total replicates (N = 2, 
n = 4). Control data from both experiments was pooled and experiments normalised to this 
pool of data; total control replicates number a minimum of 18 from five experiments (N = 5, n 
= 18). Dat  fr m 1% DMSO is included for comp rison. Whole liver cDNA is included as an 
indicator of in vivo hepatic RNA levels. Data is di played as mean ± SEM a d analysed 
statistically against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = 
p < 0.01). Analysis of 1% DMSO against treatment 1 data is by Student’s t-test (# = p < 0.05, ## 
= p <0.01).  
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Figure 4.10 – HepG2 cells with treatment 2 and 1% DMSO analysed for
differentiation markers. Results for albumin, transferrin and AFP are shown in graphs
A, B and C respectively. Cells were grown to 90% confluence and treated with 1%
DMSO, 10-7M dexamethasone and 10 ng/ml oncostatin M (OSM). RNA was isolated,
reverse transcribed and analysed for the appropriate genes by qPCR. Cells grown to
confluence were used as a control. Results shown for Tr2 cells are from two
experiments with a minimum of six total replicates (N = 2, n = 6). Control data from
both experiments was pooled and experiments normalised to this pool of data; total
control replicates number a minimum of 21 from five experiments (N = 5, n = 21). Data
from 1% DMSO is included for comparison. Whole liver cDNA is included as an
indicator of in vivo hepatic mRNA levels. Data is displayed as mean ± SEM and
analysed statistically against control using one-way ANOVA with Dunnett’s post test (*
= p < 0.05, ** = p < 0.01). Analysis of 1% DMSO against treatment 2 data is by
Student’s t-test (# = p < 0.05, ## = p <0.01).
C
 
  
Figure 4.10 – HepG2 cells with treatment 2 and 1% DMSO analysed for differentiati n 
mark rs. Results for lbumin, transferrin and AFP a e shown in graphs A, B and C respectively. 
Cells were grown to 90% confluence and treated with 1% DMSO, 10-7M dexamethasone and 
10 ng/ml oncostatin M (OSM). RNA was isolated, reverse transcribed and analysed for the 
appropriate genes by qPCR. Cells grown to confluence were used as a control. Results shown 
for Tr2 cells are from two experiments with a minimum of six total replicates (N = 2, n = 6). 
Control data from both experiments was pooled and experiments normalised to this pool of 
data; total control replicates number a minimum of 21 from five experiments (N = 5, n = 21). 
Data from 1% DMSO is included for comparison. Whole liver cDNA is included as an indicator 
of in vivo hepatic mRNA levels. Data is displayed as mean ± SEM and analysed statistically 
against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). 
Analysis of 1% DMSO against treatment 2 data is by tudent’s t-test (# = p < 0.05, ## = p 
<0.01).  
 
150 
 
Li
ve
r
C
on
tr
ol
5 
da
ys
10
 d
ay
s
15
 d
ay
s
20
 d
ay
s
25
 d
ay
s
0
5
10
15
20
1% DMSO
Treatment 3
*
A
lb
 m
R
N
A
 c
o
n
c
e
n
tr
a
tio
n
 (
re
la
tiv
e
 t
o
 c
o
n
tr
o
l)
Li
ve
r
C
on
tr
ol
5 
da
ys
10
 d
ay
s
15
 d
ay
s
20
 d
ay
s
25
 d
ay
s
0
10
20
30
40
1% DMSO
Treatment 3
*
**
*
#
##
#
#
T
F
 m
R
N
A
 c
o
n
c
e
n
tr
a
tio
n
 (
re
la
tiv
e
 t
o
 c
o
n
tr
o
l)
A
B
 
  
151 
 
Li
ve
r
C
on
tr
ol
5 
da
ys
10
 d
ay
s
15
 d
ay
s
20
 d
ay
s
25
 d
ay
s
0.0
0.5
1.0
1.5
2.0
1% DMSO
Treatment 3
**
#
##
A
F
P
 m
R
N
A
 c
o
n
c
e
n
tr
a
tio
n
 (
re
la
tiv
e
 t
o
 c
o
n
tr
o
l)
Figure 4.11 – HepG2 cells with treatment 3 and 1% DMSO analysed for
differentiation markers. Results for albumin, transferrin and AFP are shown in graphs
A, B and C respectively. Cells were grown to 90% confluence and treated with 1%
DMSO, 10-7M dexamethasone, 20 ng/ml hepatic growth factor (HGF) and 10 ng/ml
oncostatin M (OSM). RNA was harvested, reverse transcribed and analysed for the
appropriate genes by qPCR. Cells grown to confluence were used as a control. Results
shown for Tr3 cells are from two experiments with a minimum of four total replicates
(N = 2, n = 4). Control data from both experiments was pooled and experiments
normalised to this pool of data; total control replicates number a minimum of 18 from
five experiments (N = 5, n = 18). Data from 1% DMSO is included for comparison.
Whole liver cDNA is included as an indicator of in vivo hepatic mRNA levels. Data is
displayed as mean ± SEM and analysed statistically against control using one-way
ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of 1% DMSO
against treatment 3 data is by Student’s t-test (# = p < 0.05, ## = p <0.01).
C
 
  
Figure 4.11 – HepG2 cells with treatment 3 and 1% DMSO analysed for differentiation 
markers. Results for lbumin, transferrin and AFP a e shown in graphs A, B and C respectively. 
Cells were grown to 90% confluence and treated with 1% DMSO, 10-7M dexam thasone, 20 
ng/ml hepatic growth factor (HGF) and 10 ng/ml on ostatin M (OSM). RNA was harvested, 
reverse transcribed and analysed for the appropriate genes by qPCR. Cells grown to 
confluence were used as a control. Results shown for Tr3 cells are from two experiments with 
a minimum of four total replicates (N = 2, n = 4). Control data from both experiments was 
pooled and experiments normalised to this pool of data; total control replicates number a 
minimum of 18 from five experiments (N = 5, n = 18). Data from 1% DMSO is included for 
comparison. Whole liver cDNA is included as an indicator of in vivo hepatic mRNA levels. Data 
is is lay  as mean ± SEM and analysed statistically against control using one-way ANOVA 
with Dunnett’s post t s  (* = p < 0.05, ** = p < . 1). Analysis of 1% DMSO against treatment 
3 data is by Student’s t-test (# = p < 0.05, ## = p <0.01).  
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Figure 4.12 – Untreated and DMSO treated Huh7 cells with treatment 1 analysed for
differentiation markers. Results for albumin, transferrin and AFP are shown in graphs
A, B and C respectively. Cells were grown to 90% confluence and treated with 1%
DMSO, 10-7M dexamethasone and 20 ng/ml hepatic growth factor (HGF) for up to 25
days; untreated cells were allowed to continue growing without treatment and
extracted at the same time points. mRNA was harvested, reverse transcribed and
analysed for the appropriate genes using qPCR. Cells grown to confluence were used
as a control. Data from untreated cells and 1% DMSO treatment is included for
comparison. Whole liver cDNA is included as an indication of in vivo hepatic mRNA
levels. Results for treated cells are from two experiments with a minimum of three
total replicates (N = 2, n = 3). Control data from all three experiments was pooled and
experiments normalised to this pool of data; total control replicates number a
minimum of 36 from eight experiments (N = 8, n = 36). Data is displayed as mean ±
SEM and analysed statistically against the appropriate control using one-way ANOVA
with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Each time point was also
analysed individually testing all data columns against each other by one way ANOVA
with Bonferroni’s post test (a = untreated vs. 1% DMSO is p < 0.05, b = 1% DMSO vs.
treatment 1 is p < 0.05, c = untreated vs. treatment 1 is p < 0.05).
C
 
  
Figure 4.12 – Untreated and DMSO treated Huh7 cel s it  e t   for 
differ ntiation markers. Results for albumin, transferrin and AFP are shown in graphs A, B 
and C respectively. Cells were grown to 90% confluence and treated with 1% DMSO, 10-7M 
dexamethasone and 20 ng/ml hepatic growth factor (HGF) for up to 25 days; untreated cells 
were allowed to continue growing without treatment and extracted at the same time points. 
mRNA was harvested, reverse transcribed and analysed for the appropriate genes using qPCR. 
Cells grown to confluence were used as a control. Data from untreated cells and 1% DMSO 
treatment is included for comparison. Whole liver cDNA is included as an indication of in vivo 
hepatic mRNA levels. Results for treated cells are from two experiments with a inimum of 
three total replicates (N = 2, n = 3). Control d ta from all thre  experiments was pooled a  
experiments normalised to this pool of data; total control replicates number  minimum of 36 
from eight experiments (N = 8, n = 36). Data is displayed as mean ± SEM and analysed 
statistically against the appropriate control using one-way ANOVA with Dunnett’s post test (* 
= p < 0.05, ** = p < 0.01). Each time point was also analysed individually testing all data 
columns against each other by one way ANOVA with Bonferroni’s post test (a = untreated vs. 
1% DMSO is p < 0.05, b = 1% DMSO vs. treatment 1 is p < 0.05, c = untreated vs. treatment 1 
is p < 0.05).  
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Figure 4.13 – Untreated and DMSO treated Huh7 cells with treatment 2 analysed for
differentiation markers. Results for albumin, transferrin and AFP are shown in graphs
A, B and C respectively. Cells were grown to 90% confluence and treated with 1%
DMSO, 10-7M dexamethasone and 10 ng/ml oncostatin M (OSM) for up to 25 days;
untreated cells were allowed to continue growing without treatment and extracted at
the same time points. RNA was harvested, reverse transcribed and analysed for the
appropriate genes using qPCR. Cells grown to confluence were used as a control. Data
from untreated cells and 1% DMSO treatment is included for comparison. Whole liver
cDNA is included as an indication of in vivo hepatic mRNA levels. Results for treated
cells are from two experiments with a minimum of six total replicates (N = 2, n = 6).
Control data from all three experiments was pooled and experiments normalised to
this pool of data; total control replicates number a minimum of 42 from eight
experiments (N = 8, n = 42). Data is displayed as mean ± SEM and analysed statistically
against the appropriate control using one-way ANOVA with Dunnett’s post test (* = p <
0.05, ** = p < 0.01). Each time point was also analysed individually testing all data
columns against each other using one way ANOVA with Bonferroni’s post test (a =
untreated vs. 1% DMSO is p < 0.05, b = 1% DMSO vs. treatment 2 is p < 0.05, c =
untreated vs. treatment 2 is p < 0.05).
C
 
  
Figur  4.13 – Untreated and DMSO treated Huh7 cells with treatment 2 nalysed for 
differentiation arkers. Results for albumin, transferrin and AFP are shown in graphs A, B 
and C respectively. Cells were grown to 90% confluence and treated with 1% DMSO, 10-7M 
dexamethasone  and 10 ng/ml oncostatin M (OSM) for up to 25 days; untreated cells were 
allowed to continue growing without treatment and extracted at the same time points. RNA 
was harvested, reverse transcribed and analysed for the appropriate genes using qPCR. Cells 
grown to confluence were used as a control. Data from untreated cells and 1% DMSO 
treatment is included for comparison. Whole liver cDNA is included as an indication of in vivo 
hepatic mRNA levels. R sults for treated cells are fr m two experimen s with a mi imum of 
six otal replicates (N = 2, n = 6). Control data from all thre  experiments was pooled and 
experiments normalised to this pool of data; total control replicates number a minimum of 42 
from eight experiments (N = 8, n = 42). Data is displayed as mean ± SEM and analysed 
statistically against the appropriate control using one-way ANOVA with Dunnett’s post test (* 
= p < 0.05, ** = p < 0.01). Each time point was also analysed individually testing all data 
columns against each other using one way ANOVA with Bonferroni’s post test (a = untreated 
vs. 1% DMSO is p < 0.05, b = 1% DMSO vs. treatment 2 is p < 0.05, c = untreated vs. treatment 
2 is p < 0.05).  
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Figure 4.14 – Untreated and DMSO treated Huh7 cells with treatment 3 analysed for
differentiation markers. Results for albumin, transferrin and AFP are shown in graphs
A, B and C respectively. Cells were grown to 90% confluence and treated with 1%
DMSO, 10-7M dexamethasone, 20 ng/ml hepatic growth factor (HGF) and 10 ng/ml
oncostatin M (OSM) for up to 25 days; untreated cells were allowed to continue
growing without treatment and extracted at the same time points. RNA was
harvested, reverse transcribed and analysed for the appropriate genes using qPCR.
Cells grown to confluence were used as a control. Data from untreated cells and 1%
DMSO treatment is included for comparison. Whole liver cDNA is included as an
indication of in vivo hepatic mRNA levels. Results for treated cells are from two
experiments with a minimum of three total replicates (N = 2, n = 3). Control data from
all three experiments was pooled and experiments normalised to this pool of data;
total control replicates number a minimum of 36 from eight experiments (N = 8, n =
36). Data is displayed as mean ± SEM and analysed statistically against the appropriate
control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01).
Each time point is analysed individually testing all data columns against each other
using one way ANOVA with Bonferroni’s post test (a = untreated vs. 1% DMSO is p <
0.05, b = 1% DMSO vs. treatment 3 is p < 0.05, c = untreated vs. treatment 3 is p <
0.05).
C
 
  
Figure 4.14 – Untreated and DMSO treated Huh7 cells with treatment 3 analysed for 
differentiation arkers. Results for albu in, transferrin and AFP are shown in graphs A, B 
and C respectively. C lls were grown to 90% confluen e and treated with 1% DMSO, 10-7M 
dexamethasone, 20 ng/ml hepatic growth factor (HGF) and 10 ng/ml oncostatin M (OSM) for 
up to 25 days; untreated cells were allowed to continue growing without treatment and 
extracted at the same time points. RNA was harvested, reverse transcribed and analysed for 
the appropriate genes using qPCR. Cells grown to confluence were used as a control. Data 
from untreated cells and 1% DMSO treatment is included for comparison. Whole liver cDNA is 
included as an indication of in vivo hepatic mRNA levels. Results for treated cells are from two 
experiments with a minimum of three total replicates (N = 2, n = 3). Control data from all 
three experiments was pooled and experiments normalised to this pool of data; total control 
repli ates number  minimum of 36 fro  eight experiments (N = 8, n = 36). Data is displayed 
as mean ± SEM an  analysed statistically against the appropriate control using one-way 
ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Each time point is analysed 
individually testing all data columns against each other using one way ANOVA with 
Bonferroni’s post test (a = untreated vs. 1% DMSO is p < 0.05, b = 1% DMSO vs. treatment 3 is 
p < 0.05, c = untreated vs. treatment 3 is p < 0.05).  
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Figure 4.15 – Albumin, transferrin and AFP mRNA levels in 1% DMSO, 2% DMSO and
treatments 1, 2 and 3 applied to HepG2 cells for 15 days. These graphs are an
amalgamation of data from figures 4.5, 4.7, 4.9, 4.10 and 4.11, showing only data from
15 days of treatment to allow comparison. Data labelled “Liver 3.1” has been
recalculated from table 3.1 to be expressed as relative to confluent HepG2 levels. Data
has been analysed statistically using one way ANOVA with Dunnett’s post test to assess
changes from control (* = p < 0.05, ** = p < 0.01) and also by one way ANOVA with
Bonferroni’s post test to test all treated pairs of columns against each other (control and
liver data excluded) (# = p < 0.05, ## = p < 0.01).
A B
C
 
  
Figure 4.15 – Albumin, transferrin and AFP mRNA levels in 1% DMSO, 2% DMSO and 
treatments 1, 2 and 3 applied to HepG2 cells for 15 days. These graphs are an amalgamation 
of data from figures 4.5, 4.7, 4.9, 4.10 and 4.11, showing only data from 15 days of treatment 
to allow comparison. Data labelled “Liver 3.1” has been recalculated from table 3.1 to be 
expressed as relative o confluent He G2 levels. D ta has been analysed stati tic lly using 
one way ANOVA with Dunnett’s post test to assess changes from control (* = p < 0.05, ** = p 
< 0.01) and also by one way ANOVA with Bonferroni’s post test to test all treated pairs of 
columns against each other (control and liver data excluded) (# = p < 0.05, ## = p < 0.01).  
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Figure 4.16 – Albumin, transferrin and AFP mRNA levels in untreated, 1% DMSO, 2%
DMSO and treatments 1, 2 and 3 applied to Huh7 cells for 15 days. These graphs are an
amalgamation of data from figures 4.6, 4.8, 4.12, 4.13 and 4.14, showing only data from
15 days of treatment to allow comparison between the treatments. Data labelled “Liver
3.1” has been recalculated from table 3.1 to be expressed as relative to confluent Huh7
levels. Data has been analysed statistically using one way ANOVA with Dunnett’s post
test to assess changes from control (* = p < 0.05, ** = p < 0.01) and also by one way
ANOVA with Bonferroni’s post test to test all pairs of treated columns against each other
(control and liver excluded) (# = p < 0.05, ## = p < 0.01).
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Figure 4.16 – Albumin, transferrin and AFP mRNA levels in untreated, 1% DMSO, 2% DMSO 
and treatments 1, 2 and 3 applied to Huh7 cells for 15 days. These graphs are an 
amalgamation of data from figures 4.6, 4.8, 4.12, 4.13 and 4.14, showing only data from 15 
days of treatment to llow c parison betw n the tre tm n s. Data labelled “Liver 3.1” has 
been recalculated from table 3.1 to be expressed as relative to confluent Huh7 levels. Data 
has been analysed statistically using one way ANOVA with Dunnett’s post test to assess 
changes from control (* = p < 0.05, ** = p < 0.01) and also by one way ANOVA with 
Bonferroni’s post test to test all pairs of treated columns against each other (control and liver 
excluded) (# = p < 0.05, ## = p < 0.01).  
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Chapter 5 – Transporter and enzyme levels in 
DMSO-treated HepG2 and Huh7 cells. 
Chapter aim: To characterise the expression levels of selected phase I and II drug metabolising 
enzymes plus influx and efflux transporters in 1% DMSO-treated HepG2 and Huh7 cells. 
5.1 – Introduction 
The results described in the previous chapters indicate that a 15 day or longer exposure to 1% 
DMSO may cause an increase in the differentiation status of both HepG2 and Huh7 cells. 
However, this has only been assessed by measuring mRNA expression of three markers of 
differentiation – albumin, transferrin and AFP. Although these provide valuable information 
regarding the maturation status of the cell, more evidence is required in order to verify that 
these cells are in fact closer to the in vivo hepatocyte in relation to functionality (drug 
processing). Transcript and protein expression levels along with functional capabilities of 
various transporters and metabolising enzymes are extremely important to the overall 
function of a true hepatocyte. An overview of hepatocyte-defining criteria which should always 
be seen in hepatocytes is given by Hengstler et al. (Hengstler et al., 2005) and includes 
synthesis of albumin, functional assessment of both phase I and II metabolic enzymes and 
evidence of enzyme induction. As the next step in satisfying these criteria, the work presented 
in this chapter investigates the basal and DMSO stimulated mRNA levels of several important 
transporters and phase I and II metabolising enzymes and compares these to levels in mature 
human liver.   
Increases in mRNA level and functional activity of CYP3A4 have been observed in 20 day 
DMSO-treated Huh7 cells (Choi et al., 2009) and in CYP1A2 and CYP3A4 in Huh7 cells grown in 
standard media for four weeks (Sivertsson et al., 2010). Sivertsson et al. (Sivertsson et al., 
2010) investigated the effect of prolonged standard (untreated) growth on both HepG2 and 
Huh7 cells. The main finding was an increase in mRNA, protein and functional levels of CYP3A4 
in Huh7 cells grown for 4 weeks. No similar change was observed in corresponding HepG2 
cells. Huh7 cells treated with 1% DMSO for twenty days were assessed for drug metabolising 
enzyme activity and expression by Choi et al. (Choi et al., 2009) with some positive results. 
mRNA levels of several important enzymes including CYP1A2, 2B6, 2D6 and 3A4 and UGT1A1 
were seen to increase towards levels seen in primary hepatocytes (Choi et al., 2009) and 
metabolic rates of several key enzymes including CYP1A2 and 3A4 were also increased in 
comparison to control cells. These two papers give a solid indication that both prolonged 
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untreated growth and 1% DMSO are effective in promoting a more hepatic profile in Huh7 
cells at the mRNA, protein and functional levels.  
5.1.1 – Influx transporters 
General information on influx transporters, their locations and substrates can be found in 
chapter 1.3.1 and in table 1.1. Four influx transporters were chosen to be investigated in 
treated HepG2 and Huh7 cells and in untreated Huh7 cells. These were selected from the 
OATP and the OCT families; namely OATPB, C and 8 plus OCT3. All four of these transporters 
are expressed in the liver on the basolateral membrane of the hepatocyte, transporting 
substrates between the blood and hepatocytes (Koepsell et al., 2007; Tamai et al., 2001; Konig 
et al., 2000a; Konig et al., 2000b).  
Substrates of OATP transporters do overlap; for example, both OATPC and -8 transport 
anticancer drugs such as methotrexate (Abe et al., 2001; Abe et al., 1999) and the 
antihistamine fexofenadine (Matsushima et al., 2008). Within these categories of substrates 
there are some compounds which are specific to each OATP transporter such as the 
antidiabetic drug repaglinide, which utilises the OATPC transporter (Niemi et al., 2005), the 
cardioactive drug digoxin, which is transported by OATP8 (Kullak-Ublick et al., 2001) and the 
leukotriene receptor antagonist montelukast, which is transported by OATPB (Mougey et al., 
2009). A more extensive list of these transporters and their substrates can be found in table 
5.1 (adapted from (Fahrmayr et al., 2010)). Substrates of OCT3 include endogenous 
neurotransmitters such as epinephrine and xenobiotics introduced into the body such as 
nicotine, verapamil and quinine (Koepsell et al., 2007). A more in depth list of these 
transporters and their substrates can be found in table 5.1 (adapted from (Fahrmayr et al., 
2010)). 
Earlier data from chapter 3 analysed basal mRNA levels of these influx transporters in both 
HepG2 and Huh7 cells in comparison to liver (figures 3.10 – 3.13, table 3.2). OCT3 mRNA levels 
were much closer to liver in HepG2 cells (approximately 70% of liver, Huh7 125-fold lower than 
liver), as were OATPB mRNA levels albeit by a smaller margin (HepG2 levels over 4-fold lower 
than liver, Huh7 levels 12-fold lower than liver). Huh7 cells showed levels of OATPC and -8 
which were closer to liver levels than those in HepG2, although levels of OATPC mRNA in both 
cell lines was particularly low. If the 1% DMSO treatment has promoted differentiation of 
HepG2 and Huh7 cells, levels of all four of these transporters must increase with treatment. 
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5.1.2 – Efflux transporters 
Four efflux transporters from the ABC superfamily of transporters, MRP1, MRP2, MDR1 (P-gp) 
and BCRP were assessed in treated HepG2 and Huh7 cells. General information on these 
transporters can be found in section 1.3.4 and in table 1.6. In the hepatocyte, P-gp, MRP2 and 
BCRP are located on the canalicular (apical) membrane, while MRP1 is located on the 
sinusoidal (basolateral) membrane. P-gp is known to confer multidrug resistance to carcinoma 
cells and transports steroid hormones and xenobiotic substrates such as digoxin, verapamil 
and cyclosporin A (Leslie et al., 2005). MRP1 and -2 are known to transport both endogenous 
and xenobiotic substances which are the products of phase II conjugating enzymes (Haimeur et 
al., 2004; Leslie et al., 2004). MRP1 is know to efflux substances such as daunorubicin, a 
chemotherapeutic drug (Leslie et al., 2005), whilst MRP2 effluxes a broad range of conjugated 
drug metabolites along with anticancer drugs such as cisplatin (Nies and Keppler, 2007; Cui et 
al., 1999). The spectrum of substances transported by BCRP is smaller and does overlap with 
the three other efflux transporters studied here. For example, efflux of methotrexate is 
conducted by P-gp and BCRP along with several MRP proteins; however, BCRP also transports 
the polyglutamated forms of methotrexate whereas the MRP proteins are known not to 
(Hooijberg et al., 2004; Ifergan et al., 2004; Hooijberg et al., 2003). Further substrates of these 
four transporters are detailed in table 5.2. 
Basal levels of efflux transporters were analysed in figures 3.6 to 3.9 and displayed relative to 
liver in table 3.2. HepG2 cells had mRNA levels of MDR1 (P-gp), MRP1 and MRP2 higher than 
those in liver and BCRP mRNA levels almost 3-fold lower than liver. MRP1 levels in particular 
were significantly raised from liver, showing over 2100-fold increased mRNA levels. MRP1 and 
-2 were less markedly raised with levels 2.7-fold and 2.6-fold higher than liver respectively. In 
Huh7 cells, only basal levels of MRP1 were increased over those in liver, showing an 89-fold 
increase over liver. Although this is still markedly higher than liver, it is much lower than levels 
observed in HepG2. MDR1, MRP2 and BCRP levels were 5-fold, 12-fold and 20-fold decreased 
from liver respectively. For 1% DMSO treatment induction of a more differentiated cell, HepG2 
levels of MDR1, MRP1 and -2 must be decreased with an increase in BCRP, while all except 
MRP1 need to increase in Huh7 cells. 
5.1.3 – Phase I metabolising enzymes 
Four phase I drug metabolising enzymes (DMEs), cytochrome P450 (CYP) -1A2, -2E1 and -3A4 
and flavin containing mono-oxygense 3 (FMO3) were investigated in treated HepG2 and Huh7 
cells. General information on the CYP and FMO families, locations and substrates can be found 
in section 1.3.3 and tables 1.2 and 1.3. The CYP superfamily, in particular families 1, 2 and 3 are 
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heavily involved in xenobiotic metabolism; for example, CYP3A4 is responsible for full or partial 
metabolism of over 50% of all therapeutic drugs (Guengerich, 1999; Shimada et al., 1994). As a 
result, bottlenecks can occur with CYP enzymes and cause drug-drug interactions as well as 
potentially introducing inhibition and induction problems; inter-individual variations in 
expression may exacerbate this (Lin, 2006). Drugs metabolised by CYP3A4 include verapamil, 
diazepam, cyclosporin and tamoxifen (Kacevska et al., 2008; Lin, 2006). CYP1A2 has been 
shown to increase with maturity and is either absent or present at very low levels in foetal 
liver, with expression still 10-fold lower in post natal liver up to 10 months of age than in adult 
liver (Cazeneuve et al., 1994). Substrates of this enzyme include caffeine, melatonin, 
phenacetin and paracetamol (Zhou et al., 2010). Similarly to CYP1A2, CYP2E1 protein levels 
increase after birth with newborn levels approximately 10% of those seen in adult liver (Vieira 
et al., 1996). Many of the drugs metabolised by CYP2E1 are procarcinogens or release a toxic 
by-product, which can result in a build-up of toxicity if a bottleneck or previous enzyme 
induction event has taken place. Substances metabolised by CYP2E1 include paracetamol, 
benzene (Tanaka et al., 2000) and carbon tetrachloride (Cederbaum, 2006). Like many of the 
genes in the CYP family, FMO3 expression is specific to developmental stage and is absent at 
birth, failing to reach adult levels until after the onset of puberty (Hines, 2006). Mutations in 
FMO3 are responsible for the disorder trimethylaminuria, where the substrate of 
trimethylamine is not broken down correctly. Other substrates of FMO3 include nicotine and 
tamoxifen (Krueger and Williams, 2005). Table 5.3 consists of an overview of substrates of 
these four phase I DMEs. 
Basal levels of these enzymes were analysed in chapter 3 in both HepG2 and Huh7 cells in 
comparison to liver (figures 3.14, 3.15, 3.16 and 3.20, table 3.2). Overall, expression levels 
were much lower than those in liver in both cell lines for all four genes. Although it can be said 
that, for example, expression of CYP1A2 is closer to liver in Huh7 cells, it remains over 45,000-
fold reduced from the in vivo level. These vast reductions are apparent for all of these enzymes 
in both cell lines; increases of several thousand fold would be required with DMSO treatment 
to produce cells with levels that would begin to be comparable to liver. 
5.1.4 – Phase II metabolising enzymes 
Phase II DMEs are mainly conjugating enzymes consisting of families such as the glutathione-S-
transferases (GSTs), sulphotransferases (SULTs) and UDP glucuronosyltransferases (UGTs); 
general information on family, location and substrates can be found in chapter 1.3.3 and tables 
1.4 and 1.5. The three phase II DME assays described in this chapter assess UGT1A1 and GSTA4 
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mRNAs specifically along with a third assay named GSTA which measures GSTA1, 2 and 5 
mRNAs. 
UGT1A1 metabolises a wide range of both xenobiotic and endogenous substrates including 
paracetamol, the chemotherapeutic drug irinotecan and thyroxine (Bock, 2010). It is also a 
major route in the metabolism of bilirubin, an accumulation of which can cause both Crigler-
Najjar and Gilbert’s syndromes (Tukey and Strassburg, 2000). Substrates of individual GST 
enzymes have not been as thoroughly defined as some enzymes such as CYPs and many 
characterisations are related to anti-cancer or cancer-related drugs. GSTA2 polymorphisms are 
known to be associated with cancer of the upper aerodigestive tract cancers (Canova et al., 
2010) and it is known to metabolism the immune system suppressant azathioprine (Eklund et 
al., 2006). GSTA4 is involved in the metabolism of arachidonic acid (Hubatsch et al., 1998) and 
GSTA1 in the metabolism of the chemotherapeutic compound chlorambucil (Hayes et al., 
2005). Known substrates of UGT1A1 and GSTA enzymes are listed in table 5.4. 
In chapter 3 the basal levels of these genes in HepG2 and Huh7 cells in comparison to liver 
were analysed (table 3.2). Levels of GSTA and GSTA4 mRNAs were higher in HepG2 than Huh7 
cells and were reasonably close to liver levels at 6-fold and 1.6-fold lower than liver 
respectively. UGT1A1 mRNA levels were over 1000-fold reduced from liver in both HepG2 and 
Huh7 cells. In order for the DMSO treatment to promote a more hepatocyte-like cell from 
either cell line, levels of these genes would all need to increase. 
In the previous chapter 1% DMSO applied to HepG2 and Huh7 cells appeared to result in 
differentiation to a more mature hepatic state after a minimum of 15 days of treatment. 
However, this was assessed using only three markers of differentiation. While this does 
provide some valuable information it would be unwise to declare these cells more mature 
without further assessment of other salient features of the cell. Assessment of the expression 
levels of these described transport and metabolising GOI in treated HepG2 and Huh7 cells with 
comparison to liver expression will generate a more informative overview of the maturation 
status of these cells and their relevance as a model in drug development regime.  
5.2 – Methods 
Data generated in this chapter utilises the same samples as were assessed for levels of 
differentiation markers in chapter 4. HepG2 and Huh7 cells were cultured in six-well plastic 
plates for up to 30 days while being treated with 1% DMSO. Huh7 cells were also grown for up 
to 30 days in standard growth medium to provide time-matched controls. During these 
experiments Huh7 cells reached confluence after four days of growth as previously described; 
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during a further period of growth (3-6 days) during which cells became over-confluent, cell 
proliferation appeared to slow and eventually cease. Conversely, HepG2 cells did not cease to 
proliferate with prolonged untreated growth, becoming so over-confluent that maintenance 
was impossible and cells began to die after roughly 8-10 days of total growth (4-6 days post-
confluence). Experimental layout is shown in figures 2.1 and 2.2. qPCR assays were conducted 
as outlined in chapters 2 and 3. Data from human liver is shown relative to HepG2 and Huh7 
confluent control cells. Data from days 5 and 30 of treatment are not shown as differentiation 
analysis from the previous chapter revealed that any changes would be expected to take place 
after 15 to 20 days of treatment. Data was analysed by one-way ANOVA with Dunnett’s post 
test when comparisons are to a single control point, and by Student’s T-test for matched time 
points in treated and untreated Huh7 cells. 
5.3 – Results 
5.3.1 – Influx transporters 
The four influx transporters assessed in this chapter were OATPB, C and 8 and OCT3. The 
mRNA levels of these transporters in HepG2 and Huh7 cells following 1% DMSO treatment are 
shown in figures 5.1 and 5.2 respectively. Levels in Huh7 cells in standard growth medium are 
also shown in figure 5.2. Graph A in figure 5.1 shows that OATPB mRNA levels in HepG2 cells 
were almost 5-fold lower in confluent control cells than in liver and remained close to control 
level throughout the treatment period. OATPC mRNA level (graph B) was approximately 
40,000-fold lower in control HepG2 cells than in liver and although there were significant 
increases from control after 20 and 25 days of treatment, these did not result in levels 
approaching that observed in the liver sample. OATP8 mRNA expression (graph C) was also 
much higher in liver with the level approximately 20,000-fold higher than that in control 
HepG2 cells and was not significantly increased in the cells at any point during the 1% DMSO 
treatment. Finally, graph D in figure 5.1 shows that OCT3 mRNA levels in liver and HepG2 
control cells are very similar and that a significant increase is observed in cell expression 
following 25 days of treatment.  
Results for Huh7 cells treated with 1% DMSO or grown in standard media alone for up to 25 
days and subsequently analysed for mRNA levels of the four influx transporters are shown in 
figure 5.2. OATPB mRNA levels were roughly 12-fold lower in control cells than in liver and 
remained stable throughout 1% DMSO treatment (graph A). In untreated cells, OATPB mRNA 
levels were decreased significantly compared to control after 10 days, but increased at 
subsequent time points to become comparable to control after 20 and 25 days of treatment. 
Expression in treated cells tended to be higher than in untreated cells but the difference was 
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significant only after 15 days of treatment and by day 25 levels in treated and untreated cells 
were comparable. OATPC mRNA in liver was approximately 300-fold higher than in Huh7 
control cells and the level of expression in the cells did not change significantly over 25 days of 
untreated growth (graph B). However, 1% DMSO treated cells showed significantly decreased 
mRNA level from the control at every time point and were also significantly lower in OATPC 
mRNA than time-matched, untreated cells. OATP8 mRNA level was roughly 70-fold higher in 
liver than in control Huh7 cells and decreased significantly in both prolonged untreated growth 
and 1% DMSO treated cells in comparison to control at all time points (graph C). t-tests on 
these data revealed that over longer growth periods, 1% DMSO resulted in OATPC mRNA levels 
significantly lower than in time matched untreated cells; however this is unlikely to be of any 
physiological significance since levels in both treated and untreated cells were much lower 
than those in liver. Finally, OCT3 mRNA level was approximately 300-fold higher in liver than in 
control Huh7 cells (graph D). Both prolonged untreated growth and 1% DMSO resulted in cells 
with significant increases in OCT3 levels compared to control after 15-25 days and 25 days 
respectively. The level in untreated Huh7 cells remained significantly higher than that in 
control cells from 15 days onwards and was also significantly increased over the corresponding 
DMSO treated cells at 15 and 20 days. In both sets of cells, OCT3 mRNA expression was roughly 
5-fold higher than in controls after 25 days of growth; however this still did not result in a 
concentration approaching the measured liver level. 
Summary 
 OATPB – no significant change with 1% DMSO treatment in HepG2 cells. Untreated 
Huh7 cells decreased significantly after 10 days but this was not sustained; no change 
in DMSO-treated Huh7 cells. 
 OATPC – significant increase in HepG2 cells after 20 and 25 days of treatment but 
remained much lower than liver. No significant changes in untreated Huh7 cells, 
significant decreases from control at all time points in DMSO-treated Huh7 cells. 
 OATP8 – no significant change with 1% DMSO treatment in HepG2 cells. Both 
untreated and DMSO-treated Huh7 cells were significantly decreased from control at 
all time points; DMSO-treated cells had significantly lower expression than matched 
untreated cells. 
 OCT3 – significant increase in HepG2 cells treated for 25 days with 1% DMSO which 
elevated levels above those in liver. Untreated Huh7 cells showed significant increases 
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from control at 15, 20 and 25 days, while DMSO-treated cells were significantly 
increased from control only after 25 days. 
5.3.2 – Efflux transporters 
The four efflux transporters assayed were MRP1, MRP2, MDR1 and BCRP. The results for these 
assays from 1% DMSO treated HepG2 and Huh7 cells are shown in figures 5.3 and 5.4 
respectively. Prolonged growth of Huh7 cells in standard growth medium is also shown in 
figure 5.4. Graph A in figure 5.3 shows that MRP1 mRNA level in control HepG2 cells was 
calculated to be over 2100-fold higher than in liver and that no significant change from control 
occurred with 1% DMSO treatment Although liver value for MRP1 is too low to be shown 
visually on the graph in comparison to HepG2 values, it was detectable and the actual value 
was 2.7x10-4. MRP2 mRNA level (graph B) in control HepG2 cells was roughly double that in 
liver and did not significantly change with 1% DMSO treatment. MDR1 mRNA (graph C) was 
over 3-fold higher in control HepG2 cells than in liver and treatment with 1% DMSO resulted in 
no significant change from control throughout the experiment. Finally, graph D in figure 5.3 
shows BCRP mRNA levels in liver and HepG2 cells. Control HepG2 cells had roughly half the 
BCRP mRNA of liver and levels decreased significantly from control at 10, 15 and 20 days of 
treatment with 1% DMSO.  
Results from Huh7 cells analysed for mRNA levels of MRP1 are shown in graph A of figure 5.4. 
In control cells the level of MRP1 was approximately 10-fold higher than in liver and extended 
growth either with or without 1% DMSO did not result in a significant change from control 
level. MRP1 mRNA levels in DMSO treated cells were significantly lower at 15 and 25 days than 
in untreated cells of the same age. MRP2 mRNA level in liver was approximately 200-fold 
higher than in control Huh7 cells. No significant changes from control were seen in either 
untreated or 1% DMSO treated cells, nor were any significant differences seen between the 
two treatments at any time point. MDR1 mRNA level was roughly 9-fold higher in liver than in 
control Huh7 cells. Prolonged growth in standard medium resulted in a steady increase in 
MDR1 level culminating in a significant increase after 25 days. However, MDR1 levels in cells 
treated with 1% DMSO remained close to control and did not significantly alter. Finally, graph 
D of figure 5.4 shows that BCRP mRNA level in Huh7 control cells was roughly 20-fold lower 
than liver level and, with prolonged untreated growth, BCRP expression was decreased 
significantly from control at every time point. Following 1% DMSO treatment BCRP mRNA 
levels in Huh7 cells did not change significantly from control but were significantly higher than 
untreated cells at 10 and 15 days of treatment. 
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Summary 
 MRP1 – no significant change from control was observed in HepG2 cells, untreated 
Huh7 or DMSO-treated Huh7 cells. However, levels in untreated Huh7 cells were 
significantly higher at matched timepoints than those in DMSO-treated cells after 15 
and 25 days. 
 MRP2 – no significant change from control was observed in HepG2 cells, untreated 
Huh7 or DMSO-treated Huh7 cells. 
 MDR1 – no significant change from control was observed in HepG2 cells. A significant 
increase was observed after 25 days in untreated Huh7 cells, while no significant 
changes were observed in DMSO-treated Huh7 cells. 
 BCRP – significant decreases from control were observed at 10, 15 and 20 days in 
HepG2 cells. Untreated Huh7 cells were significantly decreased from control at all 
timepoints, while no significant changes from control were observed in DMSO-treated 
Huh7 cells. 
5.3.3 – Phase I metabolising enzymes 
The phase I DMEs assayed in this chapter were CYP1A2, 2E1, 3A4 and FMO3. The results from 
these assays on 1% DMSO treated HepG2 and Huh7 cells are shown in figures 5.5 and 5.6 
respectively. Results for prolonged untreated culture of Huh7 cells in standard growth medium 
are also shown in figure 5.6. Graph A in figure 5.5 shows that the liver level of CYP1A2 mRNA 
was approximately 2000-fold higher than that in control HepG2 cells. CYP1A2 level in HepG2 
cells treated with 1% DMSO decreased from control at all time points, however none reached 
significance. CYP2E1 mRNA level (graph B) was roughly 130-fold higher in liver than in control 
HepG2 cells. In cells treated with 1% DMSO, levels of CYP2E1 increased and reached 
significance compared to control at 20 days; however, this was not sustained at 25 days of 
treatment. CYP3A4 mRNA level (graph C) was approximately 30-fold higher in liver than in 
HepG2 control cells and with 1% DMSO treatment applied to cells for 10, 15 and 20 days 
increased significantly to roughly 4-fold control level. Finally, graph D in figure 5.5 shows that 
the liver level of FMO3 was approximately 2700-fold higher than in control HepG2 cells; 
although 1% DMSO increased mRNA expression, the differences to control did not reach 
significance. 
Results from Huh7 cells assessed for levels of CYP1A2 mRNA are displayed in graph A in figure 
5.6. Liver CYP1A2 level was approximately 40-fold higher than in control Huh7 cells and 
169 
 
prolonged untreated growth of Huh7 cells resulted in an increase in CYP1A2 mRNA expression, 
which was significant at 20 and 25 days. At these time points, CYP1A2 mRNA was 
approximately 60-fold higher than control and exceeded the level observed in liver. Huh7 cells 
treated with 1% DMSO showed no significant change in CYP1A2 mRNA from control level at 
any point during the experiment. CYP1A2 mRNA levels were significantly higher in untreated 
cells in comparison to 1% DMSO treated cells at 15, 20 and 25 days of treatment and were 
markedly increased, being some 40-70 fold higher. CYP2E1 mRNA level in liver was 
approximately 35,000-fold higher than in Huh7 control cells. Following 10 and 20 days of 
untreated growth, cells showed significant increases over control of approximately 3-fold. 1% 
DMSO increased CYP2E1 mRNA throughout the experiment, with the increase reaching 
significance compared to control cells after 25 days when levels were roughly 20-fold greater 
than control. Although all DMSO-treated cells had increases at least equal to those which were 
increased significantly in untreated cells (over 3-fold), bigger error margins prevented the data 
from reaching significance until the much larger increase after 25 days. CYP2E1 mRNA level in 
1% DMSO treated Huh7 cells was significantly higher than in untreated cells at 15 and 25 days 
of treatment. CYP3A4 mRNA level was roughly 72-fold higher in liver than in control Huh7 cells 
and in untreated and 1% DMSO treated cells were roughly 3-fold higher than control at all time 
points, with significant increases compared to control at 15 and 25 days for untreated and 1% 
DMSO treated cells respectively. Comparing time matched DMSO treated and untreated cells 
showed no effect of DMSO treatment at any time point. Finally, FMO3 mRNA level in liver was 
approximately 770-fold higher than that in control Huh7 cells. Extended growth resulted in 
significant decreases from control at all time points, whilst the level in 1% DMSO treated cells 
remained around control level throughout the experiment. 1% DMSO treated Huh7 cells had 
significantly higher levels of FMO3 mRNA than were found in untreated cells of the same age 
at 10 and 15 days of treatment. 
Summary 
 CYP1A2 – mRNA levels in DMSO-treated HepG2 cellsdid not significantly change. 
Untreated Huh7 cells significantly increased from control after 15, 20 and 25 days, 
while DMSO-treatment of Huh7 cells did not result in any significant changes. 
 CYP2E1 – levels in 20-day DMSO-treated HepG2 cells increased significantly. Untreated 
Huh7 cells are significantly increased from control after 10 and 20 days, while levels in 
DMSO-treated Huh7 cells significantly increased after 25 days. 
 CYP3A4 – significant increases were observed after 10, 15 and 20 days of DMSO 
treatment on HepG2 cells. Levels in both untreated and DMSO-treated Huh7 cells 
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were approximately double of those in control at all time points, but only reached 
significance at 15 and 25 days of treatment respectively. 
 FMO3 – no significant changes were observed in DMSO-treated HepG2 cells. Levels in 
untreated Huh7 cells were significantly decreased from control at all time points, while 
those in DMSO-treated Huh7 cells did not significantly change. 
5.3.4 – Phase II metabolising enzymes 
The assays measuring mRNA levels of phase II DMEs included specific assays for GSTA4 and 
UGT1A1 and one assay encompassing GSTA1, 2 and 5, referred to here as GSTA. The results 
from these assays on 1% DMSO treated HepG2 and Huh7 cells are shown in figures 5.7 and 5.8 
respectively. Results for prolonged untreated culture of Huh7 cells in standard growth medium 
are also shown in figure 5.8. Graph A in figure 5.7 shows GSTA mRNA level in liver was almost 
40-fold higher than that in control HepG2 cells and in 1% DMSO treated cells levels decreased 
significantly from control at all time points. GSTA4 mRNA level in liver (graph B) was almost 
double that seen in control HepG2 cells. HepG2 cells with 1% DMSO treatment showed a 
significant increase in GSTA4 over control after 15 days, when the level increased to 
approximately those in liver. At other time points GSTA4 mRNA levels remained around 
control level. UGT1A1 mRNA level in liver (graph C) was approximately 4,600-fold higher than 
in HepG2 control cells. Large increases from control were seen in all 1% DMSO treated cells 
and reached significance at 20 days of treatment with a level approximately 1,500-fold higher 
than control. Although control levels cannot be visualised on the graph whilst displaying the 
much larger HepG2 and liver levels, UGT1A1 mRNA was detectable and control was set at a 
value of 1. 
Results from Huh7 cells treated with 1% DMSO and grown in standard media assayed for 
phase II DMEs are shown in figure 5.8. GSTA mRNA level was over 600-fold higher in liver than 
control Huh7 cells (graph A); untreated Huh7 cells showed significantly reduced GSTA mRNA 
from control at all time points. This was reversed by 1% DMSO treatment, which resulted in 
increased expression over control at all time points, reaching significance at 20 days of 
treatment when a level roughly 12-fold higher than control was observed. Comparing 1% 
DMSO treated to age-matched untreated cells showed that 1% DMSO significantly increased 
GSTA mRNA at 10, 15 and 20 days. GSTA4 mRNA level was approximately 15-fold higher in 
liver than in control Huh7 cells and did not change significantly from control with either 
extended growth or DMSO. Treatment with 1% DMSO for 25 days resulted in a significantly 
higher GSTA4 level than untreated Huh7 cells at the same time point. Finally, UGT1A1 mRNA 
level in liver was approximately 1000-fold higher than in control Huh7 cells. Levels in untreated 
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Huh7 cells did not change significantly from control whereas 1% DMSO treated cells had 
significantly higher UGT1A1 mRNA levels than control after 20 and 25 days of treatment.  
Summary 
 GSTA – levels in DMSO-treated HepG2 cells were significantly decreased from control 
at all time points. Untreated Huh7 cells were significantly decreased from control at all 
time points, while in DMSO-treated cells a significant increase was observed after 20 
days. 
 GSTA4 – levels in DMSO-treated HepG2 cells remained similar at most time points, 
with a solitary significant increase at 15 days. No significant changes were observed in 
either untreated or DMSO-treated Huh7 cells. 
 UGT1A1 – a significant increase in DMSO-treated HepG2 cells was observed at 20 days. 
No significant changes were seen in untreated Huh7 cells, while significant increases 
were observed after 20 and 25 days of DMSO treatment in Huh7 cells. 
5.3.5 – GOI mRNA levels in HepG2 cells 
Table 5.5 shows accumulated data from figures 5.1, 5.3, 5.5 and 5.7 along with data from table 
3.1 recalculated to show liver levels relative to control. Column 1 shows data from table 3.1 – 
these data are from preliminary experiments in assay development (chapter 3) using samples 
from two confluent HepG2 experiments and a pooled liver sample; values have been 
recalculated to show liver levels relative to HepG2 cells. Column 2 shows data for the same 
liver sample relative to different control HepG2 samples. These two data sets essentially allow 
comparison of mRNA levels in confluent control cell samples and indicate how stable basal 
expression is between passages. Columns 3 and 4 show data from HepG2 cells treated with 1% 
DMSO expressed relative to control. In column 3 data from 15 days of treatment is shown as 
this was the time point at which most treatment effects were observed when assaying 
differentiation markers (chapter 4). Column 4 shows the data point for each gene which was 
closest to liver level along with the time point at which this was observed. 
Comparison of the values for columns 1 and 2 which show expression in liver relative to 
control cells shows that influx transporter mRNA levels remained similar in the two separate 
sets of experiments. Although the level of OATPB mRNA was just under 5-fold higher in liver 
than in control cells only a very small increase over control was seen following 15 days of 
growth, which was the biggest difference at any time point. After 15 days of DMSO treatment 
the OATPC mRNA level was over 2-fold higher than control and this increased to over 4-fold 
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higher than control after 25 days of treatment. However, neither of these values approached 
liver level. OATP8 mRNA levels increased slightly from control after 15 days of treatment, 
which was the biggest increase seen throughout the treatment, but this also did not approach 
the level in liver. OCT3 mRNA levels in liver relative to confluent cells were not vastly different 
from each other or from levels seen after 15 days of treatment.  
Efflux transporter mRNA levels are fairly similar in the first two columns of table 5.5 displaying 
liver levels relative to control HepG2 cells and calculated from two separate sets of 
experiments. MRP1 mRNA levels showed a difference between the two values for liver relative 
to confluent cells but both values were much lower than those observed in control and after 
15 days of treatment with 1% DMSO, which was the closest of the treated values to that seen 
in liver. Both liver values show MRP2 mRNA levels of approximately half those seen in control 
HepG2 cells with the closest treated value to liver seen at 10 days. However, none of the time 
points showed large variations from control and at 20 days MRP2 levels were also close to 
those observed at 10 days. MDR1 mRNA levels in liver relative to confluence were roughly one 
third of those seen in control HepG2 cells and values were close, indicating relatively stable 
mRNA levels of this gene between passages. Treated HepG2 cells did show slight decreases in 
MDR1 mRNA at 10 and 15 days but these did not reach liver levels. Finally, BCRP mRNA levels 
in liver relative to confluent HepG2 cells were between 2- to 3-fold increased, remaining 
relatively stable with passaging. With 1% DMSO treatment levels did not increase and were 
consistently lower than control. 
Phase I and II DMEs showed much wider variation in confluent levels of the GOI than were 
seen in the transporters with the exception of GSTA4, which showed fairly stable basal levels. 
Other enzymes varied widely; for example, CYP1A2 mRNA levels varied by over 600-fold when 
measuring liver relative to the two confluent data sets. mRNA levels of CYP2E1, CYP3A4 and 
FMO3 had variations similar to or even larger than this, indicating either that basal levels of 
these genes were very variable or that the genes were expressed at such a low level that 
consistent measurements were difficult to obtain. Of the genes which did show substantial 
increases with DMSO treatment such as CYP2E1 and 3A4, FMO3, GSTA4 and UGT1A1, all 
except UGT1A1 and GSTA4 remained much lower than their respective liver levels even if the 
lowest relative liver level calculated was taken as the true level. The GSTA4 mRNA level in 15 
day treated HepG2 cells was roughly equal to liver. UGT1A1 mRNA after 20 days of treatment 
was almost half of that in liver if the lowest relative liver level is used, and just under one third 
of the higher relative liver level. The CYP1A2 and GSTA assay results both showed mRNA levels 
in treated cells lower than those in control cells whilst liver levels of both genes were higher 
than control. 
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Summary 
 In most cases liver levels relative to HepG2 at confluence were similar in experiments 
in this chapter and previous ones in chapter 3, indicating that basal levels do not 
change with passaging. Some exceptions were CYP2E1, CYP3A4 and FMO3. 
 For most genes the closest expression to liver did occur after at least 15 days of 
treatment which agrees with results from chapter 4. 
 While increases in some low expression genes such as CYP2E1 and -3A4 did increase, 
they remained much lower than liver levels. MRP1, which should have decreased if a 
more mature cell line was produced, did not do so.   
5.3.6 – GOI mRNA levels in Huh7 cells 
The mRNA levels of the three OATP influx transporters assayed were very close in both 
measurements of liver relative to confluent Huh7 levels, indicating that basal expression is 
stable with passage number of the cells (Table 5.6). OCT3 mRNA levels were slightly more 
variable than the OATP levels observed with a 2.4-fold difference seen between the two values 
for liver relative to confluence. Although increases in OCT3 mRNA levels were seen in treated 
and untreated Huh7 cells, neither approached liver values. Of the OATP genes assayed, 
increases were seen in OATPB and C mRNA levels in treated and untreated cells respectively 
but again neither approached levels in liver. Levels of OATPB and 8 in untreated cells and 
OATPC and 8 in treated cells all decreased when an increase was required to match levels in 
liver. 
Levels of MRP1 and MRP2 mRNA differed between the two measurements of liver relative to 
confluent Huh7 cells by approximately 7-fold and 13-fold respectively. MDR1 and BCRP mRNA 
levels were similar in the two measurements indicating a more stable basal level of these 
genes. Notable responses in DMSO treated Huh7 cells were seen at 15 days when MRP1 mRNA 
levels fell from control and were closer to liver levels; untreated cells increased in MRP1 mRNA 
which was the opposite effect to that desired. Slight increases from control were observed in 
MRP2 mRNA in both untreated and treated cells but these did not approach those seen in 
liver. MDR1 mRNA levels in untreated Huh7 cells approached those seen in liver after 25 days; 
in DMSO treated cells the largest increase was observed after 20 days but this was only about 
50% of the magnitude seen in untreated cells. BCRP mRNA levels in both treated and 
untreated cells decreased after 15 days when a minimal increase of 20-fold would be required 
to come close to liver levels. 
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Levels of phase I DMEs in confluent Huh7 cells did appear to differ significantly between 
passages as was observed in HepG2 cells; for example, a 50-fold difference is apparent 
between the two liver calculations in CYP2E1 mRNA levels. The largest differences out of all of 
the GOIs assayed were observed between confluent values for CYP2E1, 3A4 and FMO3 in 
HepG2 cells, and in CYP1A2, 3A4 and FMO3 in Huh7 cells. This demonstrates that the apparent 
variability of expression between passages in confluent cells does have some similarity 
between the two cell lines, noticeably in those GOIs which had low expression. mRNA levels in 
the phase II DMEs appeared to be more stable with only a 2-fold difference between liver 
relative to confluence in the GSTA assay and negligible differences in GSTA4 and UGT1A1 
mRNA levels. Large increases in CYP1A2 mRNA in comparison to control can be seen at 15 and 
10 days of the experiment in untreated and treated cells respectively; however, with the 
discrepancy between the values for liver relative to control it cannot be determined whether 
these are close to true liver levels or not. CYP2E1 and 3A4 mRNA levels increased compared to 
control in both treated and untreated cells but did not approach those in liver, while FMO3 
levels were lower than control with both growth conditions. No real increase from control was 
observed in GSTA4 mRNA levels in either untreated or treated Huh7 cells. This was also true 
for GSTA levels in untreated cells. However, an 11-fold increase in GSTA mRNA level was 
observed in DMSO treated cells after 20 days but this did not approach the 300- to 600-fold 
increase over control cells which was observed in liver. Small increases in UGT1A1 mRNA levels 
were also observed in both untreated and treated Huh7 cells but again these did not approach 
the 1000-fold plus increase shown in liver over confluent cells. 
Summary 
 Gene levels in liver relative to confluent Huh7 cells from data in this chapter and 
chapter 3 showed that most were stable with passaging, the exceptions being the CYPs 
and FMO3 which are also the lowest in expression. 
 The majority of genes showed the closest expression to liver after 15-20 days of 
treatment which agrees with results from chapter 4. 
 As with HepG2 cells, the majority of genes did not markedly change towards liver 
levels either with prolonged untreated or DMSO-treated growth, which indicates that 
a more hepatocyte-like cell has not been produced. 
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5.4 – Discussion 
In the previous chapter it was observed that 1% DMSO prompted changes in the mRNA 
expression levels of certain markers of differentiation in both HepG2 and Huh7 cells indicating 
that a more hepatocyte-like cell resulted from the treatment. The aim of this chapter was to 
determine whether this apparent maturation was also apparent as changes in the mRNA levels 
of selected transporters and enzymes to a more liver-like expression level. HepG2 cells in 
particular are known to have poorly expressed levels of important DMEs such as CYP3A4 (Hart 
et al., 2010; Jennen et al., 2010; Slany et al., 2010; Guillouzo et al., 2007; Cederbaum, 2006; 
Hewitt and Hewitt, 2004). Although Huh7 cells have not been characterised to as great an 
extent as HepG2 cells, published data do indicate that DME levels here and in 
hepatocarcinoma cell lines in general are lower than in primary and in vivo hepatocytes (Hart 
et al., 2010; Jennen et al., 2010; Slany et al., 2010). 
Data from this set of experiments comparing the expression in confluent control cells scaled to 
expression in liver were compared to an earlier set of experiments described in Chapter 3. 
mRNA levels in HepG2 cells for all three CYP enzymes along with FMO3 and GSTA showed wide 
variation between the two sets of data. This may indicate that basal expression of these genes 
varies between cultures, however it was noted that expression levels of these genes were very 
low in HepG2 cells which made measurement difficult, which may account for some of the 
variability.  
In HepG2 cells the majority of genes assessed showed no significant positive change in 
expression from control cells as a result of DMSO treatment. Of those which showed increased 
expression from a starting point below that in liver, such as OATPC and FMO3, the achieved 
expression level remained well below liver level and so the physiological relevance of these 
results is questionable. MRP1, MRP2 and MDR1 levels in HepG2 cells before treatment were 
higher compared to liver but did not decrease to levels similar to liver in response to 1% 
DMSO. UGT1A1 mRNA levels were significantly increased and became a lot closer to liver 
levels as a result of 1% DMSO treatment. Depending on the more likely level of CYP1A2 mRNA 
in liver relative to confluent cells, this may also be true of CYP1A2 levels in 1% DMSO treated 
cells. 
Both prolonged untreated Huh7 cells and 1% DMSO treated Huh7 cells were assessed for 
levels of GOIs. In contrast to what was seen in HepG2 cells, only MRP1 mRNA levels were 
higher in confluent Huh7 cells than in liver. In untreated Huh7 cells, several instances of 
decreases in mRNA levels over time were observed when an increase would be expected with 
a more mature hepatic phenotype – these include OATP8, BCRP and GSTA. Significant 
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increases in MDR1 mRNA over time revealed mRNA levels approaching those in liver. Another 
notable result was a 36-fold increase in CYP1A2 levels which may or may not result in 
expression approaching that in liver depending on the calculated values of liver relative to the 
potentially variable, low expression basal levels in confluent cells. Huh7 cells treated with 1% 
DMSO showed notable increases in OCT3, MDR1, CYP1A2, CYP2E1 and GSTA mRNA levels. 
However, only MDR1 approached liver mRNA level. Interestingly, OATP8 mRNA levels 
decreased significantly from control in both untreated and treated cells while liver expression 
was at least 70-fold higher than that in control cells.  
The results obtained here agree with those published by Choi et al. (Choi et al., 2009) where 
the two data-sets overlap, as increases in the mRNA levels of CYP1A2, CYP3A4 and UGT1A1 
were seen in DMSO treated cells in comparison to confluent Huh7 cells while not reaching 
those measured in primary human hepatocytes. However, this publication showed that 
functional protein levels were vastly improved upon by DMSO in comparison to growing Huh7 
cells, indicating that a small mRNA increase could result in a much more appropriate hepatic 
model being produced. Aspects of the data shown here also agree with that for prolonged 
untreated growth as published by Sivertsson et al. (Sivertsson et al., 2010) such as the slight 
increase in OATPC and MDR1 and the relatively unchanged MRP2 mRNA levels. Although a 3-
fold increase in CYP3A4 was seen, this did not compare to the near in vivo levels of the gene 
with an increase of at least 100-fold over confluence observed in this publication. However, 
other increases observed here such as the 36-fold increase in CYP1A2 mRNA were not 
observed by Sivertsson. This could be due to their classification of changes in expression into 
groups rather than expressing an individual value for each gene, as if a change was not large 
enough to change categories it would not be apparent; for example, if an exceptionally low-
expression gene displayed a large fold change but did not enter the next group (i.e. from 
<0.001 to 0.001-0.01) it would not be seen. Alternatively, the Huh7 cell lines used by the two 
laboratories could be responding differently due to inherent differences in tissue culture and 
laboratory regimes as discussed previously.  
Changes in expression of certain genes as a result of DMSO treatment has been observed in 
both rat and human hepatocytes (Sumida et al., 2011; Nishimura et al., 2003). Some of these 
results do support data presented here; for example, Nishimura et al. (Nishimura et al., 2003) 
reported a 1.5-2 fold increase and a 2-3 fold increase in CYP3A4 mRNA over control with 0.5% 
and 2.5% DMSO treatments respectively, which are comparable to changes observed here in 
both HepG2 and Huh7 cells. Results for induction of CYP1A2 were again much lower than 
those observed in both treated and untreated Huh7 cells with increases less than 2-fold at all 
concentrations. Some inconsistencies are also apparent when comparing with Sumida et al. 
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(Sumida et al., 2011). Although these results are not associated with any fold-change values, 
the data suggest that some genes such as CYP3A4 and CYP2E1 are up-regulated with DMSO 
treatment, which agrees with data presented here. However, their data also suggests that 
MRP2 is down-regulated, while results obtained here suggests there is little change in either 
cell line. Although both of these papers investigate the direct effects of DMSO on a cell system, 
no potential mechanism of action by the compound is discussed. Indeed, it seems that very 
little in general is known about the potential effects of DMSO on signalling pathways or cellular 
systems and communications, which could be a potential avenue for future research.  
Overall, 1% DMSO treatment is not effective at inducing a hepatocyte-like expression profile of 
key transporters and drug metabolising enzymes in either HepG2 or Huh7 cells. There are 
some indications that expression levels of certain genes have been made more like the hepatic 
level, such as UGT1A1 in 1% DMSO treated HepG2 cells, MDR1 in untreated Huh7 cells and 
MRP1 in 1% DMSO treated Huh7 cells. This may indicate that although the mature hepatic 
phenotype has not been induced across all genes there may be certain areas in which these 
cells are more true to the hepatocyte than confluent cells 4-days post plating and suggest that 
the identified treatments or growth regimes may be useful in producing models for studying 
specific aspects of drug metabolism. However, so far only mRNA levels have been investigated 
and it is possible that changes in protein expression or transporter/enzyme activity occur 
independently of changes in mRNA expression, for example in translation, activation or 
translocation of the protein, resulting in a functional hepatocyte-like phenotype. In 
subsequent chapters, effects in these areas are investigated by using induction assays with 
phenobarbital, rifampicin and β-naphthoflavone and by functional assays and Western blots to 
assess protein levels and functionality. 
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Transporter Substrate Class Substrate 
OATPB Antibiotic 
Antihistamine 
Antihypertensive 
Leukotriene receptor-
antagonist 
Statins 
Benzylpenicillin 
Fexofenadine 
Bosentan 
Montelukast 
Atorvastatin 
Fluvastatin 
Rosuvastatin 
OATPC Antibiotic 
 
Anticancer 
 
Antidiabetic 
Antihistamine 
Antihypertensive 
 
Diuretic 
Fungicide 
Statins 
 
 
Endogenous 
Benzylpenicillin 
Rifampicin 
Atrasentan 
Methotrexate 
Repaglinide 
Fexofenadine 
Bosentan 
Valsartan 
Torasemide 
Capsofungin 
Atorvastatin 
Fluvastatin 
Pravastatin 
Bile salts 
Hormone conjugates 
Bilirubin 
OATP8 Analgesic 
Antibiotic 
Anticancer 
 
Antihistamine 
Antihypertensive 
 
 
Cardioactive 
 
Statins 
 
Endogenous 
Deltorphin II 
Rifampicin 
Atrasentan 
Methotrexate 
Fexofenadine 
Bosentan 
Telmisartan 
Valsartan 
Digoxin 
Ouabain 
Fluvastatin 
Pravastatin 
Bile salts 
Hormone conjugates 
Bilirubin 
OCT3 Cholinergic receptor 
antagonist 
Cholinergic receptor agonist 
Adrenergic receptor 
antagonist 
Antimalarial 
Ca2+ channel blocker 
Neurotransmitters 
Atropine 
Nicotine 
Etilefrine 
Quinine 
Verapamil 
Epinephrine 
Histamine 
Norepinephrine 
 
  
Table 5.1 – Substrates of influx transporters. Information adapted from tables presented in 
Koepsell et al. (Tompkins et al., 2010; Koepsell et al., 2007) and Fahrmayer et al. (Fahrmayr et 
al., 2010) and data from Konig et al. (Urquhart et al., 2007; Konig et al., 2000a; Konig et al., 
2000b) and Cui et al. (Cui et al., 2001). 
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Transporter Substrate class Substrate 
MRP1 Anticancer 
 
Daunorubicin 
Etoposide 
Vincristine 
Chlorambucil metabolites 
Cyclophosphamide 
metabolites 
MRP2  
Antidiabetic 
Statins 
Protease inhibitor 
Anticancer 
 
Histamine receptor antagonist 
Endogenous 
Conjugated drug metabolites 
Glibenclamide 
Pravastatin 
Indinavir 
Irinotecan 
Cisplatin 
Cimetidine 
Bilirubin glucouronide 
Leukotrine C4 
MDR1 Antihypertensive 
 
 
 
Antihistamine 
Anticancer 
 
 
 
Protease inhibitor 
Immunosuppressant 
Ca2+ channel blocker 
Endogenous 
Digoxin 
Quinidine 
Losartan 
Mibefradil 
Fexofenadine 
Paclitaxel 
Daunorubicin 
Doxorubicin 
Irinotecan 
Saquinavir 
Cyclosporin A 
Verapamil 
Steroid hormones 
BCRP  
Anticancer 
 
 
 
Statins 
 
Histamine receptor antagonist 
Endogenous 
Sulphate metabolites 
Topotecan 
Daunorubicin 
Irinotecan 
Mitoxantrone 
Rosuvastatin 
Pitavastatin 
Cimetidine 
Estrone sulphate 
Folic acid 
Table 5.2 – Substrates of efflux transporters. Information from Leslie et al. (Urquhart et al., 
2007; Leslie et al., 2005)and Funk (Funk, 2008). 
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Transporter Substrate class Substrate 
CYP1A2 Analgesic 
 
 
CNS stimulant 
 
Anticancer 
Antidepressant 
Anti-inflammatory 
Beta-blocker 
Bronchodilator 
Ca2+ channel blocker 
Paracetamol 
Phenacetin 
Aminopyrine 
Caffeine 
Paraxanthine 
Dacarbazine 
Duloxetine 
Leflunomide 
Propranolol 
Theophylline 
Verapamil 
CYP2E1 Anaesthetic 
 
Analgesic 
Antidepressant 
Anti-epileptic 
CNS stimulant 
Bronchodilator 
Alcohol 
 
Beta-blocker 
Ketones 
Aromatic hydrocarbons 
Halogenated hydrocarbons 
Halothane 
Isoflurane 
Paracetamol 
Fluoxetine 
Phenobarbital 
Caffeine 
Theophylline 
Ethanol 
Methanol 
Propranolol 
Acetone 
Benzene 
Carbon tetrachloride 
CYP3A4 Anticancer 
 
 
 
 
 
 
 
 
Immunosuppressant 
Synthetic opioid, analgesic 
Antihypertensive 
Ca2+ channel blocker 
Anti-anxiety 
Docetaxel 
Irinotecan 
Topotecan 
Mitoxantrone 
Vincristine 
Vinblastine 
Tamoxifen 
Letrozole 
Imatinib 
Cyclosporin A 
Methadone 
Quinidine 
Verapamil 
Diazepam 
FMO3 Endogenous 
 
 
Psychostimulant 
Analgesic 
Alkaloid 
Agonist/antagonist 
Methionine 
Trimethylamine 
Tyramine 
Methamphetamine 
Benzydamine 
Nicotine 
Tamoxifen 
 
  
Table 5.3 – Substrates of phase I metabolising enzymes. Information from Zhou et al. (Zhou 
et al., 2010), Tanaka et al. (Tanaka et al., 2000), Kacevska et al. (Kacevska et al., 2008), Lin 
(Lin, 2006) and Krueger et al. (Krueger and Williams, 2005). 
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Transporter Substrate class Substrate 
UGT1A1 Antihypertensive 
Synthetic thyroxine 
Anticancer 
Analgesic 
Estrogen receptor modulator 
Endogenous 
Carvedilol 
Levothyroxine 
Irinotecan 
Paracetamol 
Raloxifene 
Thyroxine 
Bilirubin 
Eicosanoids 
GSTA1 Anticancer 
 
 
 
 
 
 
 
Glutathione depletion 
Chlorambucil 
Busulfan 
Melphalan 
Thiotepa 
Brostallicin 
Doxorubicin 
Vincristine 
Mitoxantrone 
Chlorodinitrobenzene 
GSTA4 Lipid peroxidation product 
Glutathione depletion 
Anticancer, autoimmune 
disease blockers 
Endogenous 
4-hydroxynonenal 
Chlorodinitrobenzene 
Thiopurines 
 
Arachidonic acid 
Table 5.4 – Substrates of phase II metabolising enzymes. Information from Williams et al. 
(Williams et al., 2004), Bock (Bock, 2010), Lo et al. (Lo and Ali-Osman, 2007) and Hayes et al. 
(Hayes et al., 2005). 
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Figure 5.1 – DMSO treated HepG2 cells – OATPB, OATPC, OATP8 and OCT3 mRNA
levels. Results for these four influx transporters are shown in graphs A to D. Cells were
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by
qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9), confluent cells
having twelve replicates (N = 3, n = 12). Data is displayed as mean ± SEM and analysed
statistically against control using one-way ANOVA with Dunnett’s post test (* = p <
0.05, ** = p < 0.01).
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mRNA levels. Results shown are from three experiments with a minimum of nine total 
replicates (N = 3, n = 9), confluent cells having twelve replicates (N = 3, n = 12). Data is 
displayed as mean ± SEM and analysed statistically against control using one-way ANOVA 
with Dunnett’s post test (* = p < 0.05, ** = p < 0.01).  
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Figure 5.2 – Untreated and DMSO treated Huh7 cells – OATPB, OATPC, OATP8 and
OCT3 mRNA levels. Results for these four influx transporters are shown in graphs A to
D. Cells were treated with 1% DMSO for up to 25 days and assessed for the
appropriate gene by qPCR. Cells grown to confluence are used as a control and whole
liver cDNA is included as an indication of hepatic mRNA levels. Results shown are from
three experiments with a minimum of nine total replicates (N = 3, n = 9). Control data
was pooled and experiments normalised to this pool of data; total control replicates
number a minimum of 30 from six experiments (N = 6, n = 30). Data is displayed as
mean ± SEM and analysed statistically against control using one-way ANOVA with
Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of untreated against treated
cells was done using Student’s t-test (# = p <0.05, ## = p < 0.01).
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Figure 5.2 – Untreated and DMSO treated Huh7 cells – OATPB, OATPC, OATP8 and OCT3 
mRNA levels. Results for these four influx transporters are shown in graphs A to D. Cells were 
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by qPCR. 
Cells grown to confluence are used as a control and whole liver cDNA is included as an 
indication of hepatic mRNA levels. Results shown are from thr e experiments with a 
minimum of nine otal replicates (N = 3,  = 9). Control data was pooled and experiments 
normalised to this pool of data; total control replicates number a minimum of 30 from six 
experiments (N = 6, n = 30). Data is displayed as mean ± SEM and analysed statistically 
against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). 
Analysis of untreated against treated cells was done using Student’s t-test (# = p <0.05, ## = p 
< 0.01).  
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Figure 5.3 – DMSO treated HepG2 cells – MRP1, MRP2, MDR1 and BCRP mRNA
levels. Results for these four efflux transporters are shown in graphs A to D. Cells were
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by
qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9), confluent cells
having twelve replicates (N = 3, n = 12). Data is displayed as mean ± SEM and analysed
statistically against control using one-way ANOVA with Dunnett’s post test (* = p <
0.05, ** = p < 0.01).
 
  
Figure 5.3 – DMSO treated HepG2 cells – MRP1, MRP2, MDR1 and BCRP mRNA levels. 
Res lts for these four efflux transporters are shown in graphs A to . Cells were treated with 
1% DMSO for up to 25 days and assessed f r the appropriate gene by qPCR. Cells grown to 
confluence are used as a control and whole liver cDNA is included as an indication of hepatic 
mRNA levels. Results shown are from three experiments with a minimum of nine total 
replicates (N = 3, n = 9), confluent cells having twelve replicates (N = 3, n = 12). Data is 
displayed as mean ± SEM and analysed statistically against control using one-way ANOVA 
with Dunnett’s post test (* = p < 0.05, ** = p < 0.01).  
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Figure 5.4 – Untreated and DMSO treated Huh7 cells – MRP1, MRP2 MDR1 and BCRP
mRNA levels. Results for these four efflux transporters are shown in graphs A to D.
Cells were treated with 1% DMSO for up to 25 days and assessed for the appropriate
gene by qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9). Control data was
pooled and experiments normalised to this pool of data; total control replicates
number a minimum of 30 from six experiments (N = 6, n = 30). Data is displayed as
mean ± SEM and analysed statistically against control using one-way ANOVA with
Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of untreated against treated
cells was done using Student’s t-test (# = p <0.05, ## = p < 0.01).
i re .   t    treat  Huh  ce ls – MRP1, MRP2 MDR1 and BCRP 
A levels. Results for these four efflux transporters are shown i  graphs A to D. Cells 
were treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by 
qPCR. Cells grown to confluence are used as a control and whole liver cDNA is included as an 
indication of hepatic mRNA levels. Results shown are from three experiments with a 
minimum of nine total replicates (N = 3, n = 9). Control data was pooled and experiments 
normalised to this pool of data; total control replicates number a minimum of 30 from six 
experiments (N = 6, n = 30). Data is displayed as mean ± SEM and analysed statistically 
against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). 
Analysis of u treated against reated cells was done using Student’s t-test (# = p <0.05, ## = p 
< 0.01).  
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Figure 5.5 – DMSO treated HepG2 cells – CYP1A2, 2E1, 3A4 and FMO3 mRNA levels.
Results for these four metabolising enzymes are shown in graphs A to D. Cells were
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by
qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9), confluent cells
having twelve replicates (N = 3, n = 12). Data is displayed as mean ± SEM and analysed
statistically against control using one-way ANOVA with Dunnett’s post test (* = p <
0.05, ** = p < 0.01).
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Figure 5.5 – DMSO treated HepG2 cells – CYP1A2, 2E1, 3A4 and FMO3 mRNA levels. Results 
for these four metabolising enzymes are shown in graphs A to D. Cells were treated with 1% 
DMSO for up to 25 days and assessed for the appropriate gene by qPCR. Cells grown to 
confluence are used as a control and whole liver cDNA is included as an indication of hepatic 
mRNA levels. Results shown are from three experiments with a minimum of nine total 
replicates (N = 3, n = 9), confluent cells having twelve replicates (N = 3, n = 12). Data is 
displayed as mean ± SEM and analysed statistically ag inst control using one-w y ANOVA 
with Dunnett’s post est (* = p < 0.05, ** = p < 0.01).  
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Figure 5.6 – Untreated and DMSO treated Huh7 cells – CYP1A2, 2E1, 3A4 and FMO3
mRNA levels. Results for these four metabolising enzymes are shown in graphs A to D.
Cells were treated with 1% DMSO for up to 25 days and assessed for the appropriate
gene by qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9). Control data was
pooled and experiments normalised to this pool of data; total control replicates
number a minimum of 30 from six experiments (N = 6, n = 30). Data is displayed as
mean ± SEM and analysed statistically against control using one-way ANOVA with
Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of untreated against treated
cells was done using Student’s t-test (# = p <0.05, ## = p < 0.01).
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Figure 5.6 – Untreated and DMSO treat d Huh7 cells – CYP1A2, 2E1, 3A4 and FMO3 mRNA 
levels. Result  for the e four m tabolising enzymes are shown in graphs A to D. Cells were 
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by qPCR. 
Cells grown to confluence are used as a control and whole liver cDNA is included as an 
indication of hepatic mRNA levels. Results shown are from three experiments with a 
minimum of nine total replicates (N = 3, n = 9). Control data was pooled and experiments 
normalised to this pool of data; total control replicates number a minimum of 30 from six 
experiments (N = 6, n = 30). Data is displayed as mean ± SEM and analysed statistically 
against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). 
Analysis of untreated against treated cells was done using Student’s t-test (# = p <0.05, ## = p 
< 0.01).  
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Figure 5.7 – DMSO treated HepG2 cells – GSTA, GSTA4 and UGT1A1 mRNA levels.
Results for these three conjugating enzymes are shown in graphs A to C. Cells were
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by
qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9), confluent cells
having twelve replicates (N = 3, n = 12). Data is displayed as mean ± SEM and analysed
statistically against control using one-way ANOVA with Dunnett’s post test (* = p <
0.05, ** = p < 0.01).
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Figure 5.7 – DMSO treated HepG2 cells – GSTA, GSTA4 and UGT1A1 mRNA levels. Results 
for the e three conjugating enzymes ar  shown in graphs A to C. Cells were treat d with 1% 
DMSO for up to 25 days and assessed for the appropriate gene by qPCR. Cells grown to 
confluence are used as a control and whole liver cDNA is included as an indication of hepatic 
mRNA levels. Results shown are from three experiments with a minimum of nine total 
replicates (N = 3, n = 9), confluent cells having twelve replicates (N = 3, n = 12). Data is 
displayed as mean ± SEM and analysed statistically against control using one-way ANOVA 
with Dunnett’s post test (* = p < 0.05, ** = p < 0.01).  
 
196 
 
 
  
Li
ve
r
C
on
tr
ol
10
 d
ay
s
15
 d
ay
s
20
 d
ay
s
25
 d
ay
s
0
5
10
15
20
500
1000
1500
1% DMSO
Untreated
*
** ** ** **
## ##
#
G
S
T
A
 m
R
N
A
 c
o
n
c
e
n
tr
a
tio
n
 (
re
la
tiv
e
 t
o
 c
o
n
tr
o
l )
Li
ve
r
C
on
tr
ol
10
 d
ay
s
15
 d
ay
s
20
 d
ay
s
25
 d
ay
s
0
1
2
3
10
15
20
1% DMSO
Untreated
##
G
S
T
A
4
 m
R
N
A
 c
o
n
c
e
n
tr
a
tio
n
 (
re
la
tiv
e
 t
o
 c
o
n
tr
o
l )
A
B
197 
 
 
  
Figure 5.8 – Untreated and DMSO treated Huh7 cells – GSTA, GSTA4 and UGT1A1
mRNA levels. Results for these three conjugating enzymes are shown in graphs A to C.
Cells were treated with 1% DMSO for up to 25 days and assessed for the appropriate
gene by qPCR. Cells grown to confluence are used as a control and whole liver cDNA is
included as an indication of hepatic mRNA levels. Results shown are from three
experiments with a minimum of nine total replicates (N = 3, n = 9). Control data was
pooled and experiments normalised to this pool of data; total control replicates
number a minimum of 30 from six experiments (N = 6, n = 30). Data is displayed as
mean ± SEM and analysed statistically against control using one-way ANOVA with
Dunnett’s post test (* = p < 0.05, ** = p < 0.01). Analysis of untreated against treated
cells was done using Student’s t-test (# = p <0.05, ## = p < 0.01).
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Figure 5.8 – Untreated and DMSO treat d Huh7 cells – GSTA, GSTA4 and UGT1A1 mRNA 
levels. R sults for these thre  conjugating enzymes are shown in graphs A to C. Cells were 
treated with 1% DMSO for up to 25 days and assessed for the appropriate gene by qPCR. 
Cells grown to confluence are used as a control and whole liver cDNA is included as an 
indication of hepatic mRNA levels. Results shown are from three experiments with a 
minimum of nine total replicates (N = 3, n = 9). Control data was pooled and experiments 
normalised to this pool of data; total control replicates number a minimum of 30 from six 
experiments (N = 6, n = 30). Data is displayed as mean ± SEM and analysed statistically 
against control using one-way ANOVA with Dunnett’s post test (* = p < 0.05, ** = p < 0.01). 
Analysis of untreated against treated cells was done using Student’s t-test (# = p <0.05, ## = p 
< 0.01).  
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 Liver levels relative to 
HepG2 cells at 
confluence ** 
Liver levels relative to 
control * 
HepG2 + 1% DMSO 
levels at 15 days 
relative to control * 
HepG2 + 1% DMSO –
closest expression to liver 
(days) relative to control * 
OATPB 4.81 4.60 1.68 1.68 (15 days) 
OATPC 5.2x105 3.7x105 2.34 4.31 (25 days) 
OATP8 1.9x105 1.8x105 1.57 1.57 (15 days) 
OCT3 1.44 1.13 1.01 1.01 (15 days) 
MRP1 4.74x10-4 2.7x10-4 1.08 1.08 (15 days) 
MRP2 0.61 0.46 1.31 1.05 (10 days) 
MDR1 0.37 0.28 0.98 0.83 (10 days) 
BCRP 2.86 1.95 0.72 0.83 (25 days) 
CYP1A2 1.4x106 2.1x103 0.36 0.40 (20 days) 
CYP2E1 2.6x106 133 13.05 28.01 (20 days) 
CYP3A4 1.3x105 31.71 4.11 4.11 (15 days) 
FMO3 4.7x109 2.7x103 18.25 45.65 (10 days) 
GSTA 6.29 36.74 0.17 0.41 (25 days) 
GSTA4 1.64 1.94 1.89 1.89 (15 days) 
UGT1A1 2900 4700 841 1428 (20 days) 
     
 
* Experimental control cells are confluent, control values are set at 1. Data taken from figures 5.1, 5.3, 5.5 and 5.7. 
** Data recalculated from table 3.1. 
  Table 5.5 – Transporter and enzyme mRNA levels in HepG2 cells relative to control. This data shows relative change in the level of a gene in 
comparison to control. Control values are always 1. Data for liver in comparison to confluent levels in HepG2 cells has been recalculated from 
table 3.1. 
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 Liver levels relative 
to Huh7 cells at  
confluence ** 
Liver levels relative 
to  
control * 
Untreated Huh7 
levels at 15 days 
relative to  
control * 
Untreated Huh7 –
closest expression to 
liver (days) relative to 
control * 
Huh7 + 1% DMSO 
levels at 15 days 
relative to control * 
Huh7 + 1% DMSO –
closest expression to 
liver (days) relative to 
control * 
OATPB 11.98 12.86 0.42 0.89 (25 days) 1.08 1.48 (20 days) 
OATPC 363 332 0.75 1.47 (20 days) 0.19 0.19 (15 days) 
OATP8 82.64 73.64 0.38 0.43 (20 days) 0.081 0.14 (20 days) 
OCT3 124 300 3.24 4.12 (25 days) 1.92 3.19 (25 days) 
MRP1 0.011 0.085 1.56 1.29 (10 days) 0.69 0.69 (15 days) 
MRP2 12.59 173 1.03 1.68 (25 days) 1.01 1.50 (20 days) 
MDR1 5.68 8.89 2.46 5.34 (25 days) 1.25 2.43 (20 days) 
BCRP 21.46 28.94 0.25 0.37 (20 days) 0.79 1.06 (10 days) 
CYP1A2 4.5x104 37.56 36.57 36.57 (15 days) 2.34 13.27 (10 days) 
CYP2E1 1.9x106 3.7x104 1.76 3.36 (10 days) 4.65 16.83 (25 days) 
CYP3A4 3.2x105 72.45 3.20 3.20 (15 days) 2.44 3.08 (25 days) 
FMO3 4.0x105 773 0.89 0.51 (20 days) 0.89 0.89 (15 days) 
GSTA 357 641 0.26 0.38 (20 days) 3.76 11.35 (20 days) 
GSTA4 13.83 14.39 1.33 1.50 (20 days) 1.07 1.07 (15 days) 
UGT1A1 1095 1055 3.70 6.65 (25 days) 1.35 3.41 (25 days) 
       
 
* Experimental control cells are confluent, control values are set at 1. Data taken from figures 5.2, 5.4, 5.6 and 5.8. 
** Data recalculated from table 3.1. 
  Table 5.6 – Transporter and enzyme mRNA levels in Huh7 cells relative to control. This data shows relative change in the level of a gene in comparison 
to control. Control values are always 1. Data for liver in comparison to confluent levels in Huh7 cells has been recalculated from table 3.1. 
1
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Chapter 6 – Induction via CAR, PXR and AhR 
nuclear receptor pathways 
Chapter aim: To investigate the effects of the model inducing compounds rifampicin, 
phenobarbital and beta-naphthoflavone in confluent and DMSO-treated HepG2 and Huh7 
cells. 
6.1 – Introduction 
The induction of enzymes and transporters is key in a fully functioning cell, enabling it to 
respond to changing levels of endogenous and xenobiotic compounds by altering expression of 
metabolising enzymes and transporters. Appropriate responses to inducing agents are also 
indicative of a high degree of phenotypic differentiation and are achieved by changes in both 
transcription and post-transcriptional mechanisms. Correctly functioning induction is especially 
important in hepatocytes as they are responsible for a large proportion of drug metabolism. 
Although short term responses to stimuli can be managed via post-transcriptional 
mechanisms, more complex, longer term responses require changes in the transcription of 
genes. This involves a ligand interacting with the cell and creating a response via nuclear 
receptors which bind to the genomic DNA and cause either repression or stimulation of 
transcription.  
The effects of typical activating compounds of three nuclear receptor pathways were 
examined in HepG2 and Huh7 cells to enable assessment of induction functionality in both 
confluent and DMSO- treated cells; the receptors selected were the aryl hydrocarbon receptor 
(AhR), the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR). These 
three receptor pathways are well established as being involved in the regulation of many 
important proteins in the hepatocyte. Examples of protein targets of these receptors can be 
seen in table 6.1. However, cross-talk and interaction between nuclear receptor pathways is 
inevitable due to built-in redundancy mechanisms within the cell. Several studies have 
investigated this issue with regard to the three receptors being addressed here and will be 
outlined below. 
The AhR is usually found in the cytoplasm of the cell and translocates into the nucleus in 
response to treatment with a suitable ligand. Here it can form a complex with the AhR nuclear 
translocator (Arnt) and bind to DNA, initiating increases in levels of affected genes (Xu et al., 
2005). One of a number of genes known to respond to AhR stimulation is breast cancer 
restistance protein (BCRP) (Tan et al., 2010; Tompkins et al., 2010; Dauchy et al., 2008) and the 
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compound beta-naphthoflavone (BNF) is known to act predominantly via the AhR pathway 
(Patel et al., 2007; Urquhart et al., 2007; Xu et al., 2005). However, BNF activation of the AhR 
could result in additional pathways besides AhR being activated by an extended cascade of 
events. This is demonstrated by Patel et al. (Patel et al., 2007) where it was found that an 
increase in AhR can result in an increase in CAR levels. This could potentially mean that 
application of BNF results in induction via AhR and CAR even if BNF solely interacted with AhR 
and would be unavoidable with any AhR agonist. As BNF acts predominantly via AhR and AhR 
activating compounds have been routinely used in the literature to increase BCRP levels, cells 
here were treated with three concentrations of BNF and assessed for BCRP mRNA levels. 
PXR and CAR are both orphan nuclear receptors which have two distinctive domains; a DNA 
binding domain and a ligand binding domain (Wang and LeCluyse, 2003). PXR has been studied 
in several organisms and are predominantly expressed in the liver and intestine, whilst CAR is 
found mainly in hepatocytes and to a lesser extent in the intestine (Mottino and Catania, 2008; 
Xu et al., 2005). Cross-talk between the PXR and CAR receptor pathways is recognised and 
many genes have been observed to respond to inducers of both pathways. Many ligands are 
also recognised to activate both pathways, and although some are seen as typical inducers of 
one or the other cross-talk may still be apparent.  
PXR responds to a wide variety of ligands including both endogenous and xenobiotic 
compounds. One of the most widely utilised PXR activators is rifampicin which is used here to 
attempt to induce MDR1 (multidrug resistance protein 1) mRNA levels, a known target of the 
PXR pathway (Mottino and Catania, 2008; Urquhart et al., 2007; Xu et al., 2005; Mills et al., 
2004). Rifampicin itself has been reported as both acting predominantly via PXR and as having 
no activating effect on the CAR receptor (Gibson et al., 2006; Xu et al., 2005; Moore and 
Kliewer, 2000). Although MDR1 is recognised as a PXR pathway target and has been used as 
such alongside rifampicin induction in a number of publications, it is also recognised that it can 
be activated by other mechanisms such as the CAR pathway if activated (Kohle and Bock, 2009; 
Urquhart et al., 2007). Data from Haslam et al. (Haslam et al., 2008) reports that rifampicin 
successfully increased levels of MDR1 mRNA, total protein and apically expressed protein 
alongside increases in functional activity in the T84 epithelial cell line. A similar reduction of 
digoxin accumulation with a rifampicin-induced increase in MDR1 protein expression was 
observed in vivo in humans by Greiner et al. (Greiner et al., 1999). Despite the potential for 
increased expression as a result of activation of more than one pathway, potentially useful 
information can still be extracted from assessment of confluent and DMSO-treated cells 
treated with rifampicin and analysed for MDR1 mRNA levels in comparison to previously 
published data indicating levels of induction in liver and primary hepatocytes. 
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A well-known activator of CAR is phenobarbital (PB) which has been used on multiple 
occasions to analyse gene responses to CAR induction (Mottino and Catania, 2008; Xu et al., 
2005; Sidhu et al., 2004). Sidhu et al. (Sidhu et al., 2004) also suggested that the 
responsiveness of an hepatocyte to phenobarbital may be a reliable indicator of the 
maturation status of the cell. Phenobarbital has been stated to cause induction predominantly 
by CAR activation (Xu et al., 2005) and is known to have the ability to induce several 
transporters in the MRP family (Urquhart et al., 2007). MRP2 (multidrug resistance associated 
protein 2) has been demonstrated in several previous publications as being responsive to 
phenobarbital induction (Antherieu et al., 2010; Mottino and Catania, 2008; Urquhart et al., 
2007; Courtois et al., 2002). As with rifampicin/PXR induction of MDR1, the induction of MRP2 
can be achieved via more than one pathway; for example, Kast et al. (Kast et al., 2002) 
reported MRP2 induction by CAR, PXR and FXR (farnesoid X receptor). It has also been 
observed that CAR and PXR bind to similar response elements once activation has occurred, 
indicating likely cross-talk between these two pathways (Burk et al., 2005; Kast et al., 2002). 
Although phenobarbital could potentially result in activation of more than just the CAR 
pathway and cross-talk between the activated CAR and other response pathways is likely, the 
number of previous publications utilising this compound to analyse MRP2 induction allows a 
useful comparison to be made between results in the literature obtained for primary 
hepatocytes and other hepatic cell lines and the induction profile of the confluent and DMSO-
treated HepG2 and Huh7 cells here. Cells were treated with several concentrations of 
phenobarbital and were subsequently assessed for mRNA levels of MRP2. 
MDR1, MRP2 and BCRP were chosen to be assessed for induction by the three compounds in 
question partly because there is evidence in the literature that thesewill show induction, and 
also because all three are highly expressed in both cell lines both at confluence and after 
DMSO treatment. MDR1 mRNA levels are almost 3-fold higher than liver in confluent HepG2 
cells and approximately 5-fold lower than liver in confluent Huh7 cells. This does not change 
after 15 days of DMSO treatment in either HepG2 or Huh7 cells. MRP2 mRNA levels were 
approximately 2-fold of those in liver in confluent HepG2 cells but were between 170-fold and 
12-fold reduced from liver in confluent Huh7 cells. DMSO treatment for 15 days did not 
significantly change MRP2 levels in HepG2 or Huh7 cells. Finally, BCRP mRNA levels in 
confluent HepG2 cells were between 2- and 3-fold lower than liver, while those in confluent 
Huh7 cells were between 20- and 30-fold lower than liver. A significant reduction in BCRP 
mRNA level was observed in 15-day DMSO-treated HepG2 cells, while no significant difference 
was observed in DMSO-treated Huh7 cells.  
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In the following experiments, both 15 day DMSO-treated cells and untreated confluent cells 
from each cell line were subjected to incubation with rifampicin, phenobarbital and BNF. 
Analysis of mRNA levels by qPCR was used to assess induction of the target genes MDR1, 
MRP2 and BCRP respectively in confluent and DMSO-treated cells, providing more information 
on the maturation status of the cells.  
6.2 – Methods 
HepG2 and Huh7 cells were seeded and grown in 6-well plastic plates as described in chapter 
2.2. Cells were either grown to confluence or treated with 1% DMSO for 15 days (as described 
in chapter 2.2 and figures 2.1 and 2.2) and incubated with rifampicin, phenobarbital or BNF for 
24 hours as described in chapter 2.3. Concentrations used were ones previously reported as 
having an effect in published papers, together with a higher concentration in the event that no 
effect was observed at lower concentrations. Rifampicin at 10, 50 and 100 μM and BNF at 1, 10 
and 100 μM were applied in standard growth medium to confluent cells or in standard growth 
medium supplemented with 1% DMSO to DMSO treated cells, with both compounds dissolved 
in a vehicle of DMSO. DMSO concentration was maintained at a constant level between all 
treated and control cells. Phenobarbital at 0.5, 1.5 and 3.0 mM was applied to cells in standard 
growth media and in media containing 1% DMSO with all containing an equivalent volume of 
vehicle, in this case water. Incubations were continued for 24 hours, after which total RNA was 
extracted, reverse transcribed and mRNA levels of GOI assessed by qPCR (as described 
previously in chapters 2 and 3). Data from a purchased human liver cDNA sample are shown 
relative to HepG2 and Huh7 confluent control cells. 
6.3 – Results 
6.3.1 – Rifampicin treatments 
Figures 6.1 and 6.2 show results for rifampicin treated HepG2 and Huh7 cells respectively. 
MDR1 mRNA levels in confluent and DMSO treated cells are shown in each figure (parts A and 
B respectively). MDR1 mRNA levels in human liver cDNA were less than half of those observed 
in both confluent control and in 1% DMSO control HepG2 cells (fig 6.1). In confluent HepG2 
cells no significant change was seen with 10 or 50 μM rifampicin but at 100 μM a significant 
increase from control level was observed. In cells pre-treated with 1% DMSO for 15 days a very 
different response to rifampicin was observed, as MDR1 mRNA levels decreased to around half 
that seen in control cells at all concentrations of the compound although no significant 
changes were observed.  
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Data from Huh7 cells treated with rifampicin and analysed for MDR1 mRNA levels at 
confluence are shown in figure 6.2 part A, with results from 1% DMSO-treated cells in part B.  
MDR1 mRNA level was higher in liver than in control cells both at confluence and following 
DMSO treatment.  The difference between control and liver levels was slightly less in DMSO-
treated cells than in confluent cells demonstrating the slight induction in MDR1 mRNA level by 
1% DMSO described in Ch5, figure 5.4 part C. No significant changes from control with 
rifampicin at 10 or 50 μM were seen in confluent cells, while a significant increase in MDR1 
mRNA occurred following 100 μM rifampicin treatment. As in HepG2 cells all concentrations of 
rifampicin appeared to decrease the MDR1 mRNA level in DMSO treated Huh7 cells, however 
none of the observed changes were found to be statistically significant. 
Summary 
 MDR1 increased significantly with 100 µM rifampicin in confluent HepG2 cells; levels in 
DMSO-treated HepG2 cells decreased from control at all concentrations but no 
significant changes were observed. 
 MDR1 mRNA increased significantly with 100 µM rifampicin in confluent Huh7 cells but 
no significant changes were observed in DMSO-treated Huh7 cells. 
6.3.2 – Phenobarbital treatments 
Figures 6.3 and 6.4 show results for phenobarbital treated HepG2 and Huh7 cells respectively. 
MRP2 mRNA levels in both confluent and DMSO treated cells are shown in each figure (parts A 
and B respectively). Figure 6.3 shows that liver MRP2 mRNA level was around half of that in 
control confluent and DMSO treated cells. In confluent HepG2 cells, 0.5 and 1 mM 
phenobarbital had no significant effect on MRP2 mRNA levels, however a significant increase 
to approximately two-fold control level was observed with 3 mM phenobarbital. A similar set 
of results was observed for DMSO treated HepG2 cells, with the only significant change 
observed an approximate doubling of expression following 3 mM phenobarbital. 
Results from Huh7 cells treated with phenobarbital are shown in figure 6.4. Comparison of 
MRP2 mRNA level in liver to that in control cells showed similar values for both confluent and 
DMSO treated cells, with the liver level approximately 160-fold that seen in the cells.  Both sets 
of cells, confluent and DMSO treated, showed very similar responses to phenobarbital in terms 
of MRP2 mRNA level, with significant increases, to approximately double that of the respective 
control, seen only following the drug at 3 mM.  
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Summary 
 Results in confluent and DMSO-treated HepG2 cells were very similar, with the only 
significant increases in MRP2 mRNA seen after 3 mM phenobarbital treatment. 
 The only phenobarbital concentration to significantly increase MRP2 mRNA levels in 
both confluent and DMSO-treated Huh7 cells was 3 mM. 
6.3.3 – BNF treatments 
Figures 6.5 and 6.6 show results for BNF treated HepG2 and Huh7 cells respectively. BCRP 
mRNA levels in both confluent and DMSO treated cells are shown in each figure (parts A and B 
respectively). In liver, the BCRP mRNA level was approximately double that of control 
confluent HepG2 cells, whereas it was approximately three-fold that of control DMSO treated 
cells. Although this difference between untreated and DMSO treated cells is relatively small, it 
reflects the change in BCRP mRNA level resulting from 15 days of 1% DMSO treatment shown 
in figure 5.3 part D. In confluent HepG2 cells increases in BCRP mRNA to levels similar to those 
in liver were observed at all concentrations of BNF but none reached significance in 
comparison with the control. In HepG2 cells treated with 1% DMSO for 15 days prior to BNF 
incubation, BCRP mRNA expression was significantly increased compared to that in control 
cells and to a level slightly higher than found in liver when using the compound at 10 μM. This 
was not sustained at 100 μM BNF. 
Results for Huh7 cells treated with three concentrations of BNF are shown in figure 6.6. The 
liver level of BCRP mRNA was approximately 30- and 36-fold higher than that in control 
confluent and DMSO treated cells respectively. Again, this mirrors results shown in figure 5.4 
part D where BCRP mRNA level after 15 days exposure to 1% DMSO is lower than in confluent 
control cells. Figure 6.6 part A displays results for BCRP mRNA levels in confluent Huh7 cells 
treated with BNF and shows significant increases from control with both 1 and 10 μM 
treatments. A lesser increase was seen with 100 μM BNF which, while still roughly 5-fold 
higher than control, did not reach significance. DMSO treated Huh7 cells showed significantly 
increased BCRP mRNA levels compared with control at all concentrations of BNF, and exhibited 
a concentration dependent increase over 1-100 μM BNF. This is in contrast to results from 
confluent Huh7 cells and to those from both HepG2 experiments, which showed no significant 
effect with 100 μM BNF treatment. 
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Summary 
 Although BCRP mRNA levels in confluent HepG2 cells were increased over control with 
BNF treatment, results were not significant. In DMSO-treated HepG2 cells, 10 µM BNF 
did result in a significant increase of BCRP; this was not sustained at 100 µM. 
 Significant increases in BCRP mRNA were observed after 1 and 10 µM BNF treatment 
in confluent Huh7 cells. In DMSO-treated Huh7 cells, all three BNF concentrations 
produced a significant increase, but to a lesser extent than was observed in confluent 
cells. 
6.4 – Discussion 
Overall, the effects of rifampicin, phenobarbital and BNF on MDR1, MRP2 and BCRP mRNA 
levels respectively in confluent HepG2 and Huh7 cells were those expected in a properly 
functioning hepatocyte; however, some differences in effective concentrations of inducers 
were observed. Significant increases were observed in all confluent cells after exposure to the 
appropriate compound with the exception of BNF induction of BCRP mRNA in HepG2 cells, 
which displayed a trend of increase over control but failed to reach significance. DMSO treated 
cells appeared to respond similarly to confluent cells with phenobarbital and BNF treatments 
but failed to induce MDR1 mRNA with rifampicin treatment. DMSO treatment of cells would 
ideally have led to responses to the inducing compounds occurring at concentrations closer to 
results from the literature observed in liver or primary hepatocytes. These results and 
comparisons to the literature will be analysed in more detail below. 
The effect of rifampicin on MDR1 mRNA levels was similar in HepG2 and Huh7 confluent cells, 
with 100 μM treatment increasing expression by 2-fold compared with control. In contrast to 
this neither cell line responded to rifampicin when pre-treated with 1% DMSO. In the literature 
there are several reports of rifampicin treatment on various cell lines and human hepatocytes. 
Mills et al. (Mills et al., 2004) reported a 3-fold increase in MDR1 mRNA after 10 μM rifampicin 
for 48 hours in Fa2N-4 cells, an artificially immortalised hepatocyte cell line. An increase in 
MDR1 mRNA of between 1.5- and 10-fold over control was reported after an identical 
rifampicin treatment to that by Mills et al. (Mills et al., 2004) in the HepaRG cell line (Antherieu 
et al., 2010), whilst in human liver an increase in MDR1 mRNA of 2.3-fold over control after 
10μM rifampicin for 24 hours was observed (Olinga et al., 2008). These results reveal an 
increase in MDR1 mRNA after exposure to much lower concentrations of rifampicin than 
observed here. No significant difference in MDR1 mRNA was observed here after 24 hours 
incubation with 10 μM rifampicin in either cell line with or without prior 1% DMSO treatment. 
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This suggests that confluent HepG2 and Huh7 cells are not as sensitive to induction by 
rifampicin as these other cells types and that exposure to 1% DMSO for 15 days does not 
improve the observed responses towards those seen in human hepatocytes. A longer period of 
incubation may result in induction at lower concentrations of rifampicin. 
Phenobarbital induction of MRP2 mRNA was similar in confluent and 1% DMSO treated HepG2 
and Huh7 cells. All showed a significant increase over control at 3 mM phenobarbital of 
between 2- and 3-fold. Induction of MRP2 by phenobarbital has been reported in several 
publications. For example, in HepaRG cells induction of between 1.5- and 10-fold over control 
was seen with 1 mM PB applied for 48 hours (Antherieu et al., 2010). In experiments with 
human hepatocytes, incubation with 3.2 mM PB for 96 hours produced noticeable increases in 
both RNA and protein levels of MRP2 (Courtois et al., 2002), whilst a treatment of only 50 μM 
PB for 24 hours resulted in a 12.4-fold increase in mRNA levels of MRP2 in human liver slices 
(Olinga et al., 2008). Although induction in HepaRG cells was achieved at a lower PB 
concentration than in HepG2 and Huh7 cells, the shorter incubation time used here could 
account for the difference. The publication of Courtois et al. (Courtois et al., 2002) does not 
give definitive fold changes but a similar PB concentration to that used here was used in those 
experiments. However, much larger increases in MRP2 mRNA were seen in human liver slices 
(12.4-fold) in the publication by Olinga et al. (Olinga et al., 2008) with a much lower PB 
concentration (50 μM) than was used here in HepG2 and Huh7 cells, indicating that 
hepatocytes in situ are much more sensitive to the ligand than are hepatocyte like cell lines 
and isolated hepatocytes. 
BNF did not result in significantly induced expression of BCRP mRNA at any concentration in 
confluent HepG2 cells, whereas 10 µM BNF produced a significant increase in 1% DMSO 
treated cells; however, this was not sustained. Both confluent and DMSO-treated Huh7 cells 
showed significant increases in BCRP following 1 and 10 μM BNF which were sustained only in 
DMSO-treated cells at 100 μM. Results in the literature for BCRP induction with the compound 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD or dioxin), which also acts via the AhR, showed 
mRNA and protein increases of 2- and 2.7-fold respectively in human hepatocytes (Tan et al., 
2010), a similar level of induction to that seen in this work. 
In HepG2 cells DMSO treatment appeared to improve the cellular response to AhR activation, 
as an increase was seen following 10µM BNF in DMSO-treated but not confluent cells. 
Similarly, 100µM BNF produced a significant change in DMSO-treated but not in confluent 
Huh7 cells. However, the magnitude of induction with 1 and 10 μM BNF was much larger in 
confluent Huh7 cells than in DMSO-treated cells, suggesting no simple positive effect of DMSO 
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treatment. As reports of work specifically using BNF to target the AhR in human liver were 
unavailable in the literature it is difficult to determine whether the 10-fold induction over 
control in confluent Huh7 cells is the expected result, or whether the more modest 2-fold 
increase seen in DMSO-treated cells with 1 μM BNF is the appropriate response. 
Although appropriate induction of genes by the compounds has been demonstrated for 
confluent cells of both lines (with the exception of BNF induction of BCRP mRNA in HepG2 
cells, which did not reach significance), it cannot be automatically assumed that activation of 
the single target pathway caused the observed responses. Due to built in redundancy 
mechanisms, if a compound was introduced to a cell in which the predominantly activated 
pathway was deficient or absent it would be feasible to potentially observe activation of an 
alternate nuclear receptor pathway in order to facilitate clearance of the compound. Various 
techniques have been employed to study nuclear receptor activation such as mRNA and 
protein analysis, luciferase reporter gene assays and electrophoretic gel mobility shift assays to 
determine functional motif binding (Faucette et al., 2006; Owen et al., 2006; Ripp et al., 2006). 
Differences in reported findings of which nuclear receptors are activated by compounds and 
subsequently produce gene responses can be accounted for by differences in cell types, 
sources, culture conditions, reagents and laboratory practices during experimentation as well 
as many other factors; to thoroughly define which nuclear receptor pathway was active in a 
particular cell type would need to be established in each laboratory. However, for the 
purposes required here a demonstration of gene response to a typical inducing compound was 
sufficient to demonstrate whether cells were responding positively or negatively with DMSO in 
comparison to confluent cells and published results. 
The effects of the DMSO treatment itself must also be considered as the mechanism through 
which it can potentially be used to promote differentiation or halt de-differentiation is largely 
unknown. Nuclear receptor responses could realistically be negated or impeded by DMSO; it 
has been observed previously that a DMSO concentration of 1% inhibits functional activity of 
CYP3A4 in pooled human liver microsomes (Iwase et al., 2006). Nuclear receptors also regulate 
basal expression of many of the genes they can induce as demonstrated in the case of AhR by 
Tijet et al. (Tijet et al., 2006). If DMSO does affect nuclear receptors or their subsequent 
pathways, basal gene expression may be affected as well as the ability of the cell to respond 
via that pathway.  
Overall, it can be concluded that rifampicin induction of MDR1 mRNA has been adversely 
affected by DMSO treatment in comparison to confluent cells in both cell lines and did not 
show a significant increase with 10 μM treatment observed in Fa2N-4 cells, HepaRG cells and 
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in human liver slices. This indicates that both HepG2 and Huh7 cells have less hepatocyte-like 
functionality than the aforementioned cell types and liver slices, and that DMSO treatment did 
not improve the response to lower levels of inducer. Phenobarbital induction of MRP2 mRNA 
appears to be unaffected in both cell lines by DMSO treatment and did not exhibit increased 
sensitivity to phenobarbital at lower concentrations as were observed in liver slices. BNF 
induction of BCRP remained similar in confluent and DMSO treated HepG2 cells, whilst the 
response in Huh7 cells at lower concentrations was of a lesser magnitude after DMSO 
treatment than was observed in confluent cells. However, conclusions can only be drawn 
regarding response to a particular compound rather than successful induction via a specific 
nuclear receptor pathway due to no direct analysis of nuclear receptor mobilisation, protein or 
mRNA levels being undertaken. Further analysis of these DMSO treated cells in the form of 
functional transport studies and Western blots are presented in the following chapters. 
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Receptor Protein Targets 
CAR 
CYP3A1 
CYP3A4 
CYP2B1 
CYP2B2 
CYP2B6 
CYP2C7 
CYP2C9 
CYP2C19 
UGT1A1 
UGT2B1 
GSTA1 
GSTA2 
GSTA3 
GSTM1 
MRP2 
MRP3 (hepatocytes only) 
MRP4 
OATPC 
P-gp 
PXR 
CYP3A4 
CYP2B6 
CYP2C9 
UGT1A1 
P-gp (MDR1) 
OATPC 
OATPA 
MRP2 
MRP3 
SULT2A1 
AhR 
CYP1A1 
CYP1A2 
CYP1B1 
UGT1A1 
UGT1A6 
GSTA1 
GSTA2 
GSTM 
OATPC (decrease) 
BCRP 
Table 6.1 – Protein targets of CAR, PXR and AhR. Protein targets of the three selected receptors are 
listed here; although this is not an exhaustive list, it gives and impression of the range of proteins 
that a particular receptor has been shown to affect. Data extracted from Xu et al., Dauchy et al., Tan 
et al., Tompkins et al. and Urquhart et al. (Tan et al., 2010; Tompkins et al., 2010; Dauchy et al., 
2008; Urquhart et al., 2007; Xu et al., 2005). 
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Figure 6.1 – Rifampicin induction of MDR1 mRNA levels in confluent and 15 day
1% DMSO treated HepG2 cells. Cells were grown either to confluence (A) or with
1% DMSO for 15 days (B) in 6 well plastic plates as described previously. Rifampicin,
10-100μM, was applied as described in chapter 2. RNA was harvested, processed
and assessed by qPCR for MDR1 mRNA. All data was normalised to two reference
genes. Results shown are from three experiments with a minimum of nine total
replicates for confluent cells (N = 3, n = 9) and one experiment with three replicates
for DMSO treated cells (N = 1, n = 3). Data is presented as mean ± SEM and was
analysed statistically against control by one-way ANOVA with Dunnett’s post test. *
= p < 0.05, ** = p < 0.01.
A
B
Figure 6.1 – Rifampicin induction of MDR1 m NA levels in confluent and 15 d y 1% DMSO 
treated HepG2 cells. Cells were grown either to confluence (A) or with 1% DMSO for 15 
days (B) in 6 well plastic plates as described previously. Rifampicin, 10-100 μM, was applied 
as described in chapter 2. RNA was harvested, processed and assessed by qPCR for MDR1 
mRNA. All data was normalised to two reference genes. Results shown are from three 
experiments with a minimum of nine total replicates for confluent cells (N = 3, n = 9) and 
one experiment with three replicates for DMSO treated cells (N = 1, n = 3). Liver values from 
whole liver cDNA are shown as relative to control. Data is presented as mean ± SEM and was 
analysed statistically against control by one-way ANOVA with Dunnett’s post test. * = p < 
0.05, ** = p < 0.01.  
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Figure 6.2 – Rifampicin induction of MDR1 mRNA levels in confluent and 15 day
1% DMSO treated Huh7 cells. Cells were grown either to confluence (A) or with 1%
DMSO for 15 days (B) in 6 well plastic plates as described previously. Rifampicin, 10-
100μM, was applied as described in chapter 2. RNA was harvested, processed and
assessed by qPCR for MDR1 mRNA. All data was normalised to two referencegenes.
Results shown are from three experiments with a minimum of ten total replicates
for confluent cells (N = 3, n = 10) and one experiment with three replicates for
DMSO treated cells (N = 1, n = 3). Data is presented as mean ± SEM and was
analysed statistically against control by one-way ANOVA with Dunnett’s post test. *
= p < 0.05, ** = p < 0.01.
B
A
Figure 6.2 – Rifampicin induction of MDR1 mRNA levels in confluent and 15 day 1% DMSO 
treated Huh7 cells. Cells were grown either to confluence (A) or with 1% DMSO for 15 days 
(B) in 6 well plastic plates as described previously. Rifampicin, 10-100 μM, was applied as 
described in chapter 2. RNA was harvested, processed and assessed by qPCR for MDR1 
mRNA. All data was normalised to two reference genes. Results shown are from three 
experiments with a minimum of ten total replicates for confluent cells (N = 3, n = 10) and 
one experiment with three replicates for DMSO treated cells (N = 1, n = 3). Liver values from 
whole liver cDNA are shown as relative to control. Data is presented as mean ± SEM and was 
analysed statistically against control by one-way ANOVA with Dunnett’s post test. * = p < 
0.05, ** = p < 0.01.  
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Figure 6.3 – Phenobarbital induction of MRP2 mRNA levels in confluent and 15
day 1% DMSO treated HepG2 cells. Cells were grown either to confluence (A) or
with 1% DMSO for 15 days (B) in 6 well plastic plates as described previously.
Phenobarbital, 0.5-3mM, was applied as described in chapter 2. RNA was harvested,
processed and assessed by qPCR for MRP2 mRNA. All data was normalised to two
reference genes. Results shown are from three experiments with a minimum of nine
total replicates for confluent cells (N = 3, n = 10) and one experiment with three
replicates for DMSO treated cells (N = 1, n = 3). Data is presented as mean ± SEM
and was analysed statistically against control by one-way ANOVA with Dunnett’s
post test. * = p < 0.05, ** = p < 0.01.
B
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Figure 6.3 – Phenobarbital induction of MRP2 mRNA levels in confluent and 15 day 1% 
DMSO treated HepG2 cells. Cells were grown either to confluence (A) or with 1% DMSO for 
15 days (B) in 6 well plastic plates as described previously. Phenobarbital, 0.5-3 mM, was 
applied as described in chapter 2. RNA was harvested, processed and assessed by qPCR for 
MRP2 mRNA. All data was normalised to two reference genes. Results shown are from three 
experiments with a minimum of nine total replicates for confluent cells (N = 3, n = 9) and 
one experiment with three replicates for DMSO treated cells (N = 1, n = 3). Liver values from 
whole liver cDNA are shown as relative to control. Data is presented as mean ± SEM and was 
analysed statistically against control by one-way ANOVA with Dunnett’s post test. * = p < 
0.05, ** = p < 0.01.  
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Figure 6.4 – Phenobarbital induction of MRP2 mRNA levels in confluent and 15
day 1% DMSO treated Huh7 cells. Cells were grown either to confluence (A) or with
1% DMSO for 15 days (B) in 6 well plastic plates as described previously.
Phenobarbital, 0.5-3mM, was applied as described in chapter 2. RNA was harvested,
processed and assessed by qPCR for MRP2 mRNA. All data was normalised to two
reference genes. Results shown are from three experiments with a minimum of ten
total replicates for confluent cells (N = 3, n = 10) and one experiment with three
replicates for DMSO treated cells (N = 1, n = 3). Data is presented as mean ± SEM
and was analysed statistically against control by one-way ANOVA with Dunnett’s
post test. * = p < 0.05, ** = p < 0.01.
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Figure 6.4 – Phenobarbital induction of MRP2 mRNA levels in confluent and 15 day 1% 
DMSO treated Huh7 cells. Cells were grown either to confluence (A) or with 1% DMSO for 
15 days (B) in 6 well plastic plates as described previously. Phenobarbital, 0.5-3 mM, was 
applied as described in chapter 2. RNA was harvested, processed and assessed by qPCR for 
MRP2 mRNA. All data was normalised to two reference genes. Results shown are from three 
experiments with a minimum of ten total replicates for confluent cells (N = 3, n = 10) and 
one experiment with three replicates for DMSO treated cells (N = 1, n = 3). Liver values from 
whole liver cDNA are shown as relative to control. Data is presented as mean ± SEM and was 
analys d statistically against control by one-way ANOVA with Dunnett’s post test. * = p < 
0.05, ** = p < 0.01.  
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Figure 6.5 – Beta-napthoflavone (BNF) induction of BCRP mRNA levels in confluent
and 15 day 1% DMSO treated HepG2 cells. Cells were grown either to confluence
(A) or with 1% DMSO for 15 days (B) in 6 well plastic plates as described previously.
BNF, 1-100μM, was applied as described in chapter 2. RNA was harvested,
processed and assessed by qPCR for BCRP mRNA. All data was normalised to two
reference genes. Results shown are from three experiments with a minimum of nine
total replicates for confluent cells (N = 3, n = 10) and one experiment with three
replicates for DMSO treated cells (N = 1, n = 3). Data is presented as mean ± SEM
and was analysed statistically against control by one-way ANOVA with Dunnett’s
post test. * = p < 0.05, ** = p < 0.01.
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i re 6.5 – Beta-naph fl ne (BNF) induction of BCRP mRNA lev ls in confluent and 
15 day 1% DMSO treated HepG2 cells. Cells were grown either to confluence (A) or with 1% 
DMSO for 15 days (B) in 6 well plastic plates as described previously. BNF, 1-100 μM, was 
applied as described in chapter 2. RNA was harvested, processed and assessed by qPCR for 
BCRP mRNA. All data was normalised to two reference genes. Results shown are from three 
experiments with a minimum of nine total replicates for confluent cells (N = 3, n = 9) and 
one experiment with three replicates for DMSO treated cells (N = 1, n = 3). Liver values from 
whole liver cDNA are shown as relative to control. Data is presented as mean ± SEM and was 
analysed statistically against control by one-way ANOVA with Dunnett’s post test. * = p < 
0.05, ** = p < 0.01.  
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Figure 6.6 – Beta-napthoflavone (BNF) induction of BCRP mRNA levels in confluent
and 15 day 1% DMSO treated Huh7 cells. Cells were grown either to confluence (A)
or with 1% DMSO for 15 days (B) in 6 well plastic plates as described previously.
BNF, 1-100μM, was applied as described in chapter 2. RNA was harvested,
processed and assessed by qPCR for BCRP mRNA. All data was normalised to two
reference genes. Results shown are from three experiments with a minimum of ten
total replicates for confluent cells (N = 3, n = 10) and one experiment with three
replicates for DMSO treated cells (N = 1, n = 3). Data is presented as mean ± SEM
and was analysed statistically against control by one-way ANOVA with Dunnett’s
post test. * = p < 0.05, ** = p < 0.01.
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Figure 6.6 – Beta-naphthoflavone (BNF) induction of BCRP mRNA levels in confluent and 
15 day 1% DMSO treated Huh7 cells. Cells were grown either to confluence (A) or with 1% 
DMSO for 15 days (B) in 6 well plastic plates as described previously. BNF, 1-100 μM, was 
applied as described in chapter 2. RNA was harvested, processed and assessed by qPCR for 
BCRP mRNA. All data was normalised to two reference genes. Results shown are from three 
experiments with a minimum of ten total replicates for confluent cells (N = 3, n = 10) and 
one experiment with three replicates for DMSO treated cells (N = 1, n = 3). Liver values from 
whole liver cDNA are shown as relative to control. Data is presented as mean ± SEM and was 
analysed statistically against control by one-way ANOVA with Dunnett’s post test. * = p < 
0.05, ** = p < 0.01.  
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Chapter 7 – Functional studies using Hoechst 
33342 and calcein-AM 
Chapter aim: To conduct Hoechst 33342 and calcein-AM functional studies on confluent and 
15-day DMSO-treated HepG2 and Huh7 cells, along with prolonged untreated Huh7 cells in 
order to assess function of the cells and key efflux transporters before and after DMSO 
treatment. 
7.1 – Introduction 
Hoechst 33342 is a fluorescent dye which binds to double-stranded DNA. It is often used to 
estimate cell number by nuclear staining or to assess the function of P-glycoprotein (P-gp, 
MDR1) and breast cancer resistance protein (BCRP, ABCG2), both of which efflux the 
compound from the cell. Hoechst 33342 is one of the more lipophilic members of the Hoechst 
family and enters the cell easily by diffusion through the lipid membrane. Unbound Hoechst 
dye can then be effluxed from the cell by P-gp and BCRP, with the rate of efflux being higher 
when more copies of the transporter are present (Brown et al., 2008; Ozvegy et al., 2002). 
Inhibitors of P-gp such as verapamil and cyclosporin A (CSA) (reviewed  by Perez-Tomas, Yang 
et al. and Colabufo et al. (Colabufo et al., 2010; Yang et al., 2008; Perez-Tomas, 2006)) and 
BCRP inhibitors such as Ko143 (Pick et al., 2011; Ni et al., 2010; Pick et al., 2010; Matsson et al., 
2009; Allen et al., 2002) can be applied to demonstrate that transport is indeed being 
conducted by these proteins. 
Calcein-AM is not fluorescent and enters the cell by diffusion through the lipid membrane. 
Once inside the cell it is cleaved by intracellular esterases into calcein, which is both 
hydrophilic, so it cannot diffuse out of the cell through the lipid membrane, and fluorescent. 
Before calcein-AM is cleaved it is a substrate of the P-gp and multidrug resistance associated 
protein 1 (MRP1) transporters so the addition of inhibitors such as CSA and verapamil can be 
used to increase loading of the cell (Vellonen et al., 2004). Once fluorescent calcein has been 
produced it is no longer a P-gp substrate; instead the only routes out of the cell are via MRP1 
and MRP2 transporters (Vellonen et al., 2004). These can be inhibited by ligands such as 
MK571, a potent MRP inhibitor (Matsson et al., 2009; Gekeler et al., 1995).  
Basal MDR1 (P-gp), MRP1, MRP2 and BCRP mRNA levels were analysed in chapters 3 and 5, 
and levels in DMSO-treated HepG2 and Huh7 cells along with prolonged untreated Huh7 cells 
were also assessed in chapter 5. MDR1 mRNA levels were approximately 3-fold higher in 
confluent HepG2 cells than in liver and did not change after 15 days of DMSO treatment. In 
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confluent Huh7 cells, MDR1 mRNA levels were roughly 5-fold lower than in liver, which again 
did not change with 15 days of DMSO treatment. Confluent HepG2 cells had BCRP levels 2- to 
3-fold lower than in liver, which were significantly reduced following 15 day DMSO treatment. 
Confluent Huh7 cells had BCRP mRNA levels 20- to 30-fold lower than liver but these did not 
change with DMSO treatment. MRP1 and -2 mRNA levels in confluent HepG2 cells were 
approximately 2100- to 3500-fold of those in liver and roughly 2-fold of those in liver 
respectively, neither of which changed significantly with DMSO treatment. In confluent Huh7 
cells MRP1 mRNA levels were between 10- and 90-fold of those in liver, while MRP2 mRNA 
levels were between 12- and 170-fold lower than those in liver; neither gene showed 
significant changes with DMSO treatment. These previous results demonstrate that only BCRP 
levels in HepG2 cells appear to have changed with DMSO treatment; functional experiments 
conducted here could reveal whether the lack of changes in mRNA are a true reflection of the 
effects of DMSO treatment, or whether in fact there are post-translational events occurring 
which affect expression and functional levels of the proteins. 
Efflux activity in confluent and treated cells can be determined using these two assays both by 
quantifying the amount of compound effluxed over a given period of time and by lysing the 
cells to measure the stored compound. With the Hoechst assay, cells were lysed and the 
fluorophore retained inside the cell measured. In the calcein-AM assay both calcein effluxed 
throughout the experiment and that remaining inside the cells was quantified. 
7.2 – Methods 
HepG2 and Huh7 cells were grown to confluence and, in the case of Huh7 cells, for a further 15 
days in standard growth media in 24-well plastic plates. For DMSO treatment, HepG2 and 
Huh7 cells were grown in 12-well and 24-well plastic plates respectively. This was due to 
physical limitation of the volume of media that could be applied to HepG2 cells in 24-well 
plates, which was not sufficient to sustain the cells throughout the 15 day DMSO treatment 
period. Cell culture was as described in chapter 2.2.2 and figures 2.1 and 2.2.  
Both Hoechst 33342 and calcein-AM experimental procedures are described in chapter 2.6. 
Briefly, in Hoechst experiments, cells were washed with warm Krebs solution and kept on a 
hotplate at 37oC in Krebs with or without the inhibitors CSA (10 μM), verapamil (100 μM) or 
Ko143 (10 μM) for 30 minutes. Hoechst 33342 was dissolved in water, added to Krebs solution 
at concentrations ranging from 0.1 to 30 μM and applied to cells with or without inhibitors as 
appropriate for a further 60 minutes. Cells were then washed twice in cold Krebs solution and 
lysed (buffer detailed in appendix A) before quantification of the fluorescent signal using either 
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a Perkin-Elmer LS-5 luminescence spectrometer (Perkin Elmer, Massachusetts, USA) at 
excitation wavelength 360 nm and emission wavelength 480 nm or a fluorescent plate reader 
(FLUOstar Omega, BMG Labtech, Germany) in black plastic 96-well plates using excitation filter 
355 ± 10 nm and emission filter 480 ± 20 nm. Protein quantification was by the method of 
Bradford as described in chapter 2.6 (Bradford, 1976). Data were corrected for background 
fluorescence and normalised to protein concentration for each individual well. 
Cells used in calcein-AM experiments were washed in warm Krebs solution before incubation 
with 1 nmole calcein-AM in 500 μl Krebs (final concentration of 2 μM) with or without 100 μM 
verapamil or 10 μM CSA as required for 30 minutes. Cells were washed again with warm Krebs 
solution and incubated with efflux buffer comprised of 500 μl Krebs with or without inhibitors 
(100 μM verapamil, 10 μM CSA or 20 μM MK571). Solutions were harvested and replaced 
every 20 minutes four times (total efflux time of 80 minutes) before cells were lysed overnight 
in water. Lysed cells were harvested and centrifuged at 1200 rpm (9660 x g) for 10 minutes 
after which the supernatant was collected and all samples were analysed for fluorescence 
using either a Perkin-Elmer LS-5 luminescence spectrometer (Perkin Elmer, Massachusetts, 
USA) at excitation wavelength 492 nm and emission wavelength 518 nm or on a fluorescent 
plate reader (FLUOstar Omega, BMG Labtech, Germany) in black plastic 96-well plates using 
excitation filter 480 ± 20 nm and emission filter 520 ± 10 nm. Protein quantification was by the 
method of Bradford as described previously. Data were corrected for background fluorescence 
then normalised to protein concentration for each individual well. The sum of the four efflux 
values is displayed in the figures as efflux; the lysate value is displayed separately, with the 
sum of efflux and lysate values representing the total calcein retained by cells after loading.  
Data are displayed as mean ± SEM and all statistical analyses were carried out in GraphPad 
Prism using Student’s t-test or one-way ANOVA with either Dunnett’s or Bonferroni’s post test 
where appropriate. 
8.3 – Results 
7.3.1 – Hoechst 33342 – confluent HepG2 cells 
Figures 7.1-7.5 show results for Hoechst 33342 experiments on confluent and 15 day DMSO-
treated HepG2 and Huh7 cells, along with 15 day untreated Huh7 cells. Statistical analyses of 
the data by Student’s t-test are displayed in tables 7.1-7.5. Figure 7.1 shows data from 
confluent HepG2 cells loaded with 0.1-30 μM Hoechst along with either verapamil, CSA, Ko143 
or with no inhibitor present (control); table 7.1 displays results from statistical analysis of these 
data. The different graphs in the figure display efflux data for Hoechst 33342 or along with one 
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of three inhibitors. Graphs A and B display data for the P-gp inhibitors verapamil and CSA 
respectively, while data in graph C shows the effect of Ko143, a BCRP inhibitor. Both of these 
transporters are major contributors to Hoechst efflux from cells where they are functional and 
therefore, as they are inhibited, the amount of dye remaining in the cells following loading 
should increase.  
However, statistical analysis of the data from these experiments did not show consistent 
increases in Hoechst loading by the inhibitors. Loading was slightly but significantly increased 
by verapamil at concentrations of 0.1 to 3 µM Hoechst but lost significance at 5 and 10 µM. 
CSA did not produce any significant increase in Hoechst loading and in fact resulted in a 
significant decrease in comparison to Hoechst alone at 3 and 5 µM Hoechst despite both 
verapamil and CSA being inhibitors of P-gp. The effect of Ko143 was dependent on the 
concentration of Hoechst, with small but significant increases at 0.1 and 0.5 µM Hoechst; 
however, a significant decrease in accumulation in comparison to Hoechst alone was produced 
at 5 µM Hoechst. Results for 30 µM Hoechst were excluded from the statistical analysis due to 
results which did not fit with the rest of the data, indicating a possible toxic effect on the cells. 
Of the three inhibitors, only verapamil gave results similar to those expected. However, much 
larger increases might have been expected than are observed here; Brown et al. (Brown et al., 
2008) showed an increase in Hoechst retention of almost 4-fold compared to control in human 
renal tubular cells with 1 µM Hoechst and 10 μM CSA, and a 2-fold increase compared to 
control with 1 µM Hoechst and 10 μM verapamil. These results could indicate that functional 
levels of P-gp and BCRP were low in the cells under the particular culture conditions used or 
that an alternative mechanism effluxed the Hoechst from the cell so quickly that inhibition of 
P-gp or BCRP made no difference to the overall amount retained. 
Summary 
 Verapamil inhibited efflux effectively at Hoechst concentrations of 0.1-3 µM. Ko143 
inhibited efflux only at 0.1 and 0.5 µM of Hoechst, while CSA did not effectively inhibit 
Hoechst efflux. 
7.3.2 – Hoechst 33342 – DMSO-treated HepG2 cells 
Data for Hoechst uptake experiments in HepG2 cells treated with 1% DMSO for 15 days are 
displayed in figure 7.2, with statistical analysis displayed in table 7.2. Again, the results from 
cells incubated with Hoechst alone are shown alongside results from Hoechst plus verapamil, 
CSA or Ko143. As in confluent HepG2 cells, Hoechst accumulation was not consistently 
increased with verapamil, CSA or Ko143 inhibition. Again, some small but statistically 
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significant increases in Hoechst accumulation were observed with each inhibitor; at 0.5 and 1 
μM Hoechst with verapamil, at 1 and 3 μM Hoechst with CSA and at 0.5, 1 and 3 μM Hoechst 
with Ko143. However, these increases were not sustained at higher Hoechst concentrations 
and at 30 μM Hoechst a significant reduction in loading was observed with all three inhibitors 
in comparison to control, indicating a possible toxic effect of Hoechst. The substantial 
sustained increases in Hoechst accumulation expected of the three inhibitors were not 
observed in confluent HepG2 cells and treatment with DMSO for 15 days did not improve upon 
that result. 
Summary 
 Although some increases in retained Hoechst were seen at low Hoechst 
concentrations with each inhibitor, these were not sustained.  
 DMSO treatment did not improve upon results in confluent HepG2 cells. Sustained 
inhibition of Hoechst efflux was not observed in either cell type. 
7.3.3 – Hoechst 33342 – confluent Huh7 cells 
Results for confluent Huh7 cells incubated with Hoechst 33342 either alone or with verapamil, 
CSA or Ko143 are shown in figure 7.3, with statistical analysis displayed in table 7.3. In contrast 
to results seen in confluent HepG2 cells, significant increases in Hoechst accumulation in 
comparison to control were observed at the majority of Hoechst concentrations with all three 
inhibitors. With the inclusion of verapamil, significant increases over control were observed at 
all Hoechst concentrations except 8 μM. Not only were these increases sustained over the 
whole concentration range unlike in HepG2 cells, the magnitude of increases was larger. For 
example, 3 μM Hoechst with verapamil in confluent Huh7 cells showed a statistically 
significant increase of approximately 2-fold compared to Hoechst alone, whereas in confluent 
HepG2 cells the increase with verapamil remained significant but was only approximately 1.2-
fold of levels seen with Hoechst alone. Hoechst accumulation was also significantly increased 
with CSA at all but two of the tested Hoechst concentrations (8 and 10 μM). This is vastly 
different from results obtained using HepG2 cells, where no significant increases in Hoechst 
accumulation were observed when CSA was added. Significant increases in Hoechst 
accumulation with Ko143 in Huh7 cells were observed over Hoechst alone at the majority of 
Hoechst concentrations. Again, these results were different to those in HepG2 cells as larger 
increases were seen over a wider range of Hoechst concentrations. These results indicate that 
P-gp and BCRP transporters in confluent Huh7 cells are functional and expressed at a 
sufficiently high level that their inhibition is effective in increasing the amount of retained 
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Hoechst; they also demonstrate a difference between the two cell lines at confluence in terms 
of the magnitude and consistency of the increases produced via inhibition of P-gp and BCRP. 
Summary 
 Successful inhibition of Hoechst efflux was observed with all three inhibitors over a 
range of Hoechst concentrations. 
7.3.4 – Hoechst 33342 – prolonged untreated Huh7 cells 
Results from Hoechst accumulation experiments in prolonged untreated Huh7 cells are shown 
in figure 7.4, with results of statistical analysis displayed in table 7.4. Significant increases in 
Hoechst accumulation were observed in comparison to control with the inclusion of verapamil 
between 0.1 and 5 μM Hoechst but not at the three highest concentrations. In comparison to 
results from confluent Huh7 cells the magnitude of increases here are lower; for example, at 3 
μM Hoechst verapamil inclusion in confluent Huh7 cells resulted in values approximately 2-fold 
of those in Hoechst alone, whereas here in prolonged untreated growth of Huh7 cells the 
accumulation observed under the same conditions was approximately 1.4-fold of those 
observed with Hoechst alone. The inclusion of CSA during Hoechst loading in these prolonged 
untreated Huh7 cells did not result in a sustained significant increase in Hoechst accumulation; 
only three of the eight comparisons were significant (0.1, 5 and 10 μM Hoechst). This is a 
noticeable change from results obtained in confluent Huh7 cells, where significant increases in 
accumulated Hoechst were observed with CSA in the majority of data points. These data 
indicate that a change in P-gp expression or functionality may have occurred as a result of 
prolonged untreated growth of Huh7 cells, as inhibition of Hoechst efflux via this transporter is 
less effective. However, no significant change in MDR1 mRNA, which encodes the P-gp protein, 
was observed after 15 days DMSO treatment in either cell line, or in prolonged untreated 
Huh7 cells in comparison to control (see figures 5.3 and 5.4). This could indicate that mRNA 
and protein levels did not correlate and post-translational mechanisms may be responsible for 
protein changes. 
Summary 
 Verapamil did successfully inhibit Hoechst efflux via P-gp up to 5 µM Hoechst, but no 
inhibition of efflux via P-gp with CSA was observed. 
 Prolonged untreated culture did not retain the characteristics of inhibition observed in 
confluent Huh7 cells. 
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7.3.5 – Hoechst 33342 – DMSO-treated Huh7 cells 
Results from Hoechst accumulation experiments in DMSO-treated Huh7 cells are shown in 
figure 7.5, with results of statistical analysis displayed in table 7.5. Statistically significant 
increases in Hoechst accumulation were seen with both verapamil and CSA compared to 
Hoechst alone at Hoechst concentrations of 0.1, 0.5 and 5 μM; addition of CSA also resulted in 
increased accumulation at 8 μM Hoechst. However, the magnitude of the changes observed in 
these DMSO-treated cells were smaller than those recorded previously in confluent cells with 
both verapamil and CSA; the effect of CSA was similar in prolonged untreated and DMSO-
treated cells, while inclusion of verapamil during Hoechst loading appeared to have a greater 
effect in prolonged untreated than in DMSO-treated cells. Inhibition of Hoechst efflux with 
Ko143 resulted in only one significant increase over Hoechst alone at 0.5 μM Hoechst and two 
significant decreases at 3 and 10 μM Hoechst. Although there were three concentrations at 
which inhibition resulted in a significant increase in Hoechst retention, both those and DMSO-
treated cells had a reduced response to Ko143 in comparison to that seen in confluent Huh7 
cells. The reduced effect of Ko143 could indicate that transporter levels have decreased with 
prolonged growth with and without DMSO, which Western blotting of BCRP protein in these 
cells could reveal.  
Summary 
 Although some significant inhibition of Hoechst efflux was seen with all three 
inhibitors, this was not sustained and was of a smaller magnitude than that observed 
in confluent Huh7 cells. 
 DMSO-treatment results in less inhibition of Hoechst efflux than in confluent Huh7 
cells, indicating a less representative cell model. 
7.3.6 – Calcein-AM – preliminary experiments 
Calcein-AM experiments were conducted on confluent and DMSO-treated HepG2 and Huh7 
cells and on Huh7 cells with prolonged untreated growth for up to 15 days. Briefly, cells were 
loaded with calcein-AM with the inhibitors verapamil or CSA where applicable for 30 minutes 
then washed, followed by four efflux periods of 20 minutes each in Krebs with inhibitors where 
applicable. After each efflux period the buffer was removed, kept for analysis and replaced 
with identical efflux solution. After the final efflux stage, cells were washed in cold Krebs and 
lysed in water overnight. Data displayed in figures 7.7 – 7.11 shows total calcein (all four efflux 
measurements plus lysate) and efflux separately (all four efflux measurements combined). 
Total calcein (efflux plus lysate) was analysed using one-way ANOVA with Dunnett’s post test 
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using cells incubated with calcein-AM during loading with no additional inhibitors during either 
loading or efflux as control. The results of these statistical tests are shown in figures 7.7 – 7.11. 
Efflux alone was also statistically analysed by one way ANOVA with Bonferroni’s post test, 
selected results of which are shown in tables 7.6 – 7.10. 
Figure 7.6 displays results from confluent HepG2 and Huh7 cells incubated with 1 nmol of 
calcein in 500 µl Krebs solution for 20 minutes then lysed overnight. This experiment was 
necessary to demonstrate that re-uptake of calcein, previously effluxed from the cell, was not 
significant over the time frame in which efflux was being measured. Results are shown for 
calcein uptake alongside those for calcein efflux over 20 minutes and total calcein (efflux plus 
lysate) for each cell line when loaded with calcein-AM in the presence of verapamil. As calcein-
AM is cleaved directly to calcein by esterases, the maximum amount of intracellular calcein 
possible is 1 nmol when cells are loaded with 1 nmol calcein-AM. These results showed that 
15-20% of total intracellular calcein was effluxed during the initial 20 minutes of the 
experiment, demonstrating that the maximum amount of calcein likely to be outside of the cell 
during this time is 0.2 nmol (20% of 1 nmol). Even with 5 times the likely maximum amount of 
calcein present in the extracellular fluid, the fluorescence released from lysed cells following 
20 minutes of incubation with calcein was only a fraction of that found in the efflux buffer 
after 20 minutes from cells loaded with calcein-AM, indicating that calcein is not subject to 
significant uptake during 20 minutes of efflux and the experimental conditions are 
appropriate. 
Summary 
 The experimental design is appropriate as calcein influx into the cells during the 20 
efflux period is not large enough to obscure efflux results. 
7.3.7 – Calcein-AM – confluent HepG2 cells 
Data from experiments with calcein-AM in confluent HepG2 cells are displayed in figure 7.7. 
Statistical analysis of total calcein revealed that levels were significantly raised over control 
with the addition of either verapamil or CSA to the loading buffer. Calcein fluorescence in 
efflux and lysate ranged from 1.5- to 2-fold that seen in control cells with the inclusion of 
either inhibitor. This reflects the ability of verapamil and CSA to inhibit efflux of calcein-AM via 
the P-gp transporter during loading, resulting in more calcein being generated via esterase 
cleavage of calcein-AM and retained in the cells.  
Table 7.6 displays selected results from statistical analysis of efflux values alone. Efflux data are 
displayed in figure 7.7 as the lower, darker proportion of the column. Compared to 
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measurements made in cells with verapamil present only during the loading stage, inclusion of 
any of the three inhibitors in the efflux buffer reduced calcein efflux. The most potent inhibitor 
was MK571 and the weakest was verapamil. These results agree with the known inhibitory 
actions of the inhibitors, where verapamil inhibits only MRP1 but CSA and MK571 inhibit both 
MRP1 and 2. Addition of both MK571 and CSA to the efflux buffer showed no significant 
difference in comparison to efflux with MK571 alone but significantly reduced efflux in 
comparison to CSA alone. This indicates that 20 µM MK571 inhibits MRP1 and 2 more 
effectively than 10 µM CSA. The ratio of efflux to lysate also reflected changes to inhibitors in 
the loading and efflux buffers. Control cells and those loaded with verapamil saw 60% and 66% 
of the cellular calcein effluxed respectively; addition of verapamil to the efflux buffer reduced 
this to 54% of calcein effluxed, while addition of CSA and MK571 separately caused a reduction 
in calcein efflux to 40% and 25% of total calcein respectively. These data support the statistical 
analysis and show that the inhibitors do indeed change the proportion of calcein effluxed from 
the cell when the slightly variable total calcein levels are taken into account. Overall these 
results indicate that P-gp, MRP1 and MRP2 are all functional and are expressed at a sufficiently 
high level to be useful in assessing transport and inhibition via these proteins. 
Summary 
 Addition of verapamil or CSA to loading buffer resulted in significant increases in 
calcein-AM loading (total calcein) over control (no inhibitor), demonstrating P-gp 
inhibition. 
 Verapamil, CSA and MK571 all significantly reduced calcein efflux from control. 
 Efflux of calcein via both MRP1 and -2 was demonstrated as MK571 increased cellular 
calein in comparison to verapamil during efflux. 
7.3.8 – Calcein-AM – confluent Huh7 cells 
Data from experiments using calcein-AM on confluent Huh7 cells are shown in figure 7.8. 
Statistical analysis of total calcein levels showed that the inclusion of either verapamil or CSA 
during loading significantly increased accumulated calcein in comparison to cells loaded with 
calcein-AM in the absence of inhibitors. As in confluent HepG2 cells, the addition of either 
verapamil or CSA during loading increased the calcein in both efflux and lysate to 1.5- to 2-fold 
that in control cells. This demonstrates that P-gp is functioning as expected.  
Table 7.7 displays selected results from statistical analysis of efflux values. The addition of 
either verapamil, CSA or MK571 to the efflux buffer caused reduced efflux in comparison to 
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cells similarly loaded with verapamil present but with no inhibitor included in the efflux buffer, 
indicating that inhibition of at least one MRP transporter occurred. Comparison of the effects 
of verapamil, MK571, CSA and MK571 plus CSA during efflux revealed no significant differences 
between efflux levels. This is in contrast to results for confluent HepG2 cells, where efflux 
levels were affected differently by verapamil, CSA and MK571. The lack of difference between 
verapamil and both CSA and MK571 indicates that the MRP1 transporter is dominating efflux 
of calcein in these cells as no additional effect is seen with the MRP2 inhibitors. The 
percentage of effluxed calcein in confluent Huh7 cells was 61% in control cells and 63% in cells 
loaded in the presence of verapamil, which indicates that verapamil is not retained during 
efflux after loading and that transporters continue to efflux calcein at the same rate with and 
without verapamil loading. Although this did reduce to 49% of calcein effluxed with verapamil 
in the efflux buffer, addition of CSA and MK571 in subsequent experiments resulted in 46% 
and 42% of calcein effluxed respectively. This was not the big reduction seen in HepG2 cells, 
where efflux more than halved during incubation with MK571 in comparison to verapamil. 
These data support the statistical analyses of effluxed calcein and support the conclusion of a 
lack of functional MRP2 at physiologically relevant levels in the cells. 
 Overall, these cells demonstrated the presence of functional P-gp and MRP1, but MRP2 is 
either non-functional or is expressed at such low levels that it is not contributing to calcein 
efflux at a detectable rate. This is in contrast to HepG2 cells, where all three transporters 
appear to be expressed at a sufficiently high level that the applied inhibitors had a visible 
effect. 
Summary 
 P-gp inhibition by both verapamil and CSA was observed due to increased total calcein 
during loading with these inhibitors. 
 Verapamil, CSA and MK571 all significantly reduced calcein efflux by the same degree, 
indicating that only MRP1 is functionally expressed or that MRP2 is expressed at such 
low levels that the effect cannot be observed. 
7.3.9 – Calcein-AM – DMSO treated HepG2 cells 
Data from experiments using calcein-AM on DMSO-treated HepG2 cells are shown in figure 
7.9. Statistical analysis of total calcein levels showed that the inclusion of either verapamil or 
CSA in the loading buffer resulted in a significantly higher total calcein level than was observed 
in control. As was observed in confluent HepG2 cells, inclusion of either inhibitor in the loading 
buffer lead to an increase in total calcein in the range of 1.5- to 2-fold of that in control. 
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Results here indicate that P-gp function has been retained with DMSO treatment and the 
function has not altered noticeably from that observed in confluent cells. 
Selected results from statistical analysis of efflux data are shown in table 7.8. Efflux was 
significantly reduced with the addition of MK571 and CSA to the efflux buffer when compared 
to cells loaded similarly with verapamil but with no inhibitors included during efflux, whilst the 
reduction observed with verapamil included during efflux did not reach significance. Although 
the reductions in efflux caused by MK571 in comparison to CSA and verapamil are visible on 
the graph in figure 7.9, none of these comparisons reach significance when analysed 
statistically in table 7.8. This is in contrast to results observed in confluent HepG2 cells, where 
these differences were both visually apparent and statistically significant. The percentage of 
calcein effluxed in control cells and cells loaded in the presence of verapamil is 64% and 56% 
respectively. Although the reduction in efflux with verapamil is marked at only 37%, this has 
not reached significance due to the wider spread of data than was observed in confluent 
HepG2 cells. Addition of CSA to the efflux buffer resulted in a slightly lower percentage of 
calcein effluxed at 31%, while MK571 resulted in a marked decrease at only 18%, less than half 
of that effluxed with verapamil in the buffer. These support findings from the statistical 
analyses which indicated that although the pattern of inhibition was similar to that observed in 
confluent HepG2 cells, the possible negative effects of DMSO on the ability of the cells to 
remain attached affected the data collected and in some cases prevented statistical 
significance from being achieved. 
Overall, results from DMSO-treated HepG2 cells indicate that P-gp function is retained and 
whilst the same pattern of changes is apparent regarding efflux differences with the inhibitor 
combinations, statistical significance has been lost in some cases. This is likely due to the larger 
spread of data values; although the error bars remain fairly small they are larger than those 
obtained from analysis of data from confluent cells and this may contribute to the lack of 
significance in some cases. A factor in this may be that HepG2 cells were observed to 
occasionally wash away from the well during the repeated washing and changing of solutions 
in this experimental protocol. To compensate for this a larger number of experiments were 
conducted than for confluent cells and wells with clear patches where cells had washed away 
were disregarded from analysis. Although all wells were corrected for background 
fluorescence and normalised to total protein for each well specifically, it appears that more 
variable results were obtained compared to experiments with confluent cells where cell 
attachment was not an issue. This was not as apparent in Hoechst experiments, where the 
number of washes and addition/removal of buffers are less numerous and so less likely to 
cause mechanical disruption of cell adhesion to the plastic plates. 
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Summary 
 Both verapamil and CSA increased calcein-AM loading over control, indicating that 
functional P-gp was present. 
 Inhibition of calcein efflux by CSA and MK571 was observed, but no significant 
reduction in efflux occurred with verapamil. This may be due to a proportion of cells 
becoming detatched, resulting in slightly more variable data. 
 DMSO-treated HepG2 cells are not a better model than confluent cells. 
7.3.10 – Calcein-AM – prolonged untreated Huh7 cells 
Data from experiments with calcein-AM on prolonged untreated Huh7 cells are shown in figure 
7.10. Statistical analysis of total calcein levels showed that inclusion of either verapamil or CSA 
in the loading buffer significantly increased total calcein in comparison to control. In 
comparison to results from confluent Huh7 cells, the proportion of calcein present in efflux 
buffer versus lysate has reduced in these experiments. Approximately 25% of total calcein was 
effluxed here in comparison to approximately 60% of total calcein effluxed in confluent Huh7 
cells. These results indicate that P-gp was present and functional as total calcein did increase 
with inhibition of calcein-AM efflux. However, indications are that functional levels of a calcein 
efflux protein, MRP1 or 2, have altered as a result of prolonged untreated growth in 
comparison to function in confluent cells. No detachment of cells during the experiment was 
observed. 
Table 7.9 shows selected results from statistical analysis of efflux values. Efflux was 
significantly decreased in comparison to control by the addition of MK571 to the efflux buffer, 
while neither verapamil nor CSA significantly affected efflux of calcein. MK571 also caused a 
significant reduction in calcein efflux in comparison to CSA; addition of both MK571 and CSA to 
the efflux buffer simultaneously reduced efflux significantly compared to CSA alone, indicating 
a dominant effect of MK571 over CSA. The proportion of calcein effluxed in control cells and 
cells loaded in the presence of verapamil was very similar at 34% and 30% respectively. 
Inclusion of either verapamil or CSA in the efflux buffer did not affect calcein efflux much, with 
percentages of calcein effluxed 25% and 23% respectively. However, addition of MK571 to the 
efflux buffer results in only 16% of total calcein effluxed, a marked reduction from other 
experimental conditions. These data support the statistical analyses of efflux data, showing 
that only MK571 had a marked effect on calcein efflux. 
These results indicate that although MRP-mediated efflux of calcein did occur and it could be 
effectively reduced by MK571, a potent MRP1 and 2 inhibitor, neither verapamil nor CSA were 
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effective in inhibition of MRP. This indicates that prolonged untreated Huh7 cells may not be 
responding as would be expected to CSA during efflux but did respond to P-gp inhibition by the 
compound during loading. As verapamil successfully inhibited P-gp efflux of calcein-AM, the 
lack of a significant reduction in calcein efflux via MRP1, which is inhibited by verapamil, 
indicates that efflux of calcein via MRP1 is reduced or absent. In confluent Huh7 cells 
verapamil did significantly reduce calcein efflux but no further reduction was seen with 
MK571. This could indicate a more prominent role of MRP2 in calcein efflux in these cells in 
conjunction with a reduction in MRP1 function. Indeed, it could be that MRP2 functionality has 
been revealed purely due to a severe reduction/absence of functional MRP1, with the actual 
level of functional MRP2 remaining similar to that in confluent cells. The change in the 
proportion of efflux to lysate in total calcein in these cells compared to confluent cells may 
indicate that there is a reduction in efflux via MRP, leaving more of the loaded calcein inside 
the cell.  
Summary 
 P-gp inhibition by verapamil and CSA was successful and increased total calcein. 
 MK571 did decreased inhibition of calcein efflux in comparison to control and 
verapamil, indicating that MRP2 is now playing a functional role in efflux. 
 The percentage of total calcein in the lysate has increased substantially in all 
conditions, indicating a decrease in calcein efflux which could be caused by a reduction 
in the functional levels of MRP1. 
 Prolonged untreated Huh7 cells appear to be a better efflux transporter model than 
confluent Huh7 cells. 
7.3.11 – Calcein-AM – DMSO treated Huh7 cells 
Data from experiments using calcein-AM in DMSO-treated Huh7 cells are shown in figure 7.11. 
Analysis of total calcein levels showed that inclusion of either verapamil or CSA in the loading 
buffer significantly increased total calcein in comparison to control. This indicates that P-gp is 
functional and was successfully inhibited in these cells by both verapamil and CSA. As observed 
in previous results for prolonged untreated Huh7 cells, the proportion of total calcein 
represented by efflux measurement is much lower than in confluent cells, with approximately 
80% of total calcein remaining inside the cell in control cells. 
Selected results from statistical analysis of efflux values are shown in table 7.10. MK571 
significantly reduced efflux of calcein in comparison to control, whilst inclusion of verapamil or 
CSA in the efflux buffer had no significant effect. The addition of MK571 to the efflux buffer 
230 
 
also reduced efflux significantly in comparison to efflux with verapamil or CSA. MK571 plus CSA 
in efflux significantly reduced efflux of calcein in comparison to CSA alone but no difference 
was observed in efflux from cells with MK571 alone. The percentage of calcein efflux from 
control cells and cells loading in the presence of verapamil was 25% and 20% respectively; 
addition of verapamil to the efflux buffer did not appear to affect efflux, with 19% of total 
calcein effluxed. CSA also had little effect on calcein efflux with 14% of total calcein effluxed 
from the cell. As indicated by statistical analyses, MK571 did have a significant effect on calcein 
efflux, causing a reduction in efflux to only 9% of total calcein. 
The results indicate that P-gp is functional and can be inhibited in these cells. Efflux inhibition 
results were very similar to those observed in prolonged untreated Huh7 cells and indicated an 
increased role for MRP2 during calcein efflux compared to confluent cells. As also observed in 
the prolonged untreated Huh7 cells, the decreased proportion of efflux in total calcein 
indicates that a change in MRP expression or function has been precipitated by this treatment, 
although no change in mRNA level of either MRP1 or MRP2 was observed in previous 
experiments (figure 5.4). 
Summary 
 Both verapamil and CSA increased loading of calcein-AM, demonstrated by the 
increase in total calcein over control.  
 MK571 inhibited efflux more effectively than verapamil and CSA, indicating that MRP2 
was effectively inhibited as well as MRP1, and that MRP2 was present in sufficient 
amounts in comparison to MRP1 that it was functionally effective during efflux. 
 The proportion of calcein retained in the lysate was increased over that observed in 
confluent cells, similar to results in prolonged untreated cells. This could indicate that 
functional levels of MRP1 were reduced.  
 Although this model is preferable to the confluent Huh7 cells in terms of efflux, no 
significant advantage over the prolonged untreated cells is apparent. 
7.4 – Discussion 
The Hoechst 33342 and calcein-AM assays utilised in this chapter have been described in 
various cellular systems (Brown et al., 2008; Goda et al., 2007; Schoonen et al., 2005; 
Wortelboer et al., 2005; Ifergan et al., 2004; Vellonen et al., 2004; Allen and Schinkel, 2002; 
Allen et al., 2002; Scharenberg et al., 2002). Hoechst 33342 is a lipophilic compound which 
enters the cell via diffusion across the cell membrane; once inside the cell it binds to double 
stranded DNA, with the remaining unbound compound subsequently effluxed by the 
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transporters P-gp and BCRP. Three inhibitors were used here to attempt to block this efflux: 
CSA, verapamil and Ko143. CSA enters the cell via diffusion (Leonardi et al., 2001) and inhibits 
its targets via competitive inhibition (Saeki et al., 1993); this is also the case for verapamil 
(Saeki et al., 1993). Ko143 inhibition of BCRP transport is not as clearly understood as the more 
established compounds such as verapamil and CSA; however, work published by Ozvegy-
Laczka et al. (Ozvegy-Laczka et al., 2005) demonstrated that addition of Ko143 resulted in a 
conformational change in BCRP. This was measured by binding of the 5D3 antibody to BCRP, 
which increased in accordance with certain conformational changes. Inhibition by Ko143 and 
ATP depletion within the cell gave similar results, indicating that inhibition could be due to 
disruption of the normal cycling of the transporter. Calcein-AM is a lipophilic compound which 
diffuses into cells through the cell membrane and can be effluxed via P-gp. Any calcein-AM 
remaining in the cell is transformed into calcein by intercellular esterases; this cannot diffuse 
through the membrane and is effluxed primarily by MRP1 and 2. The inhibitior MK571 was 
used here to block efflux by the MRP pathway, which is known to be a competitive inhibitor of 
MRP1, 2 and 4 as reviewed by Keppler (Keppler, 2011). The inhibitor CSA is also known to be a 
non-selective inhibitor of both MRP1 and 2 although it is a more potent inhibitor of P-gp, while 
verapamil is known to inhibit transport via MRP1 and not MRP2 (reviewed by Keppler (Keppler, 
2011)). 
7.4.1 – Hoechst 33342 experiments 
Inhibition of P-gp in HepG2 cells at confluence and after DMSO treatment was inconsistent, 
with different results obtained using verapamil and CSA. Ko143 did not produce consistent 
increases in Hoechst accumulation in either HepG2 cell type. Results obtained in confluent 
Huh7 cells were more promising and showed significant increases in Hoechst accumulation 
over a range of concentrations with all three inhibitors. These are well known inhibitors and 
have been used successfully many times; it would be expected to see successful inhibition in 
both cell lines (Pick et al., 2010; Brown et al., 2008; Goda et al., 2007; Ifergan et al., 2004; 
Vellonen et al., 2004; Allen et al., 2002; Saeki et al., 1993). The Hoechst 33342 accumulation 
assay has been used successfully in HepG2 cells previously with verapamil as an inhibitor 
(Cheng et al., 2011), which was the inhibitor that had the most effect on increasing 
accumulation in confluent HepG2 cells here. After DMSO treatment, inhibition in both cell lines 
is less effective, which may indicate an increase in P-gp and BCRP levels. To further investigate 
P-gp and two other important functional proteins, MRP1 and 2, the calcein-AM series of 
experiments were conducted. 
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7.4.2 – Calcein-AM experiments 
Measurement of calcein-AM in confluent HepG2 cells showed that verapamil and CSA both 
inhibited transport as expected, increasing the level of total calcein retained in the cell and 
indicating the P-gp activity. It was also shown that verapamil and CSA inhibited efflux, 
demonstrating MRP function to some extent but that MK571 was a more effective inhibitor, 
reducing calcein efflux significantly compared to both other inhibitors. DMSO-treated HepG2 
cells showed a similar pattern to confluent cells but some efflux inhibitors which had a 
significant effect in confluent cells were not found to significantly reduce efflux of calcein from 
the cell; however, the pattern of inhibition seen in the two cell types remained similar. Overall, 
the results for HepG2 cells indicate that P-gp, MRP1 and MRP2 are present at a level where 
function can be measured and are inhibited as expected. This points towards Hoechst 33342 
being a less informative marker in these cells as although P-gp inhibition was observed with 
verapamil in confluent cells, CSA did not produce similar results as would be expected. The 
results from both Hoechst and calcein-AM assays also indicate that some transporter function 
or effectiveness of the inhibitors may be lost with DMSO treatment; as no significant changes 
were observed in mRNA levels of any of the transporters involved here in DMSO-treated cells 
compared to confluent HepG2 cells, a form of post-transcriptional regulation is likely to be 
involved in regulating expression as was observed for BCRP in both cell lines.  
Results from calcein-AM experiments in confluent Huh7 cells indicated that P-gp is functional 
and can be inhibited successfully. However, differences in inhibition of MRP1 and 2 were 
observed in these cells in comparison to the patterns seen in both confluent and DMSO-
treated HepG2 cells. Inhibition of calcein efflux was seen with verapamil, CSA and MK571 but 
at an equal level for all, whereas in HepG2 cells, MK571 inhibited efflux more effectively than 
either verapamil or CSA. This indicates that only MRP1 was contributing to efflux of calcein in 
Huh7 cells, as verapamil, known to inhibit this transporter but be ineffective against MRP2, 
was equally as effective at inhibiting efflux as MK571, an inhibitor of both MRPs. This is 
supported by the mRNA data for these cell lines (figures 5.3 and 5.4) which showed that 
confluent HepG2 cells had an MRP2 mRNA level double that in liver, while confluent Huh7 cells 
had an MRP2 mRNA level 200-fold lower than that in liver. This very low expression of MRP2 
could explain the lack of changes in efflux of calcein with different inhibitors observed in 
confluent Huh7 cells, as MRP2 transport could be so low in comparison to MRP1 that no efflux 
could be detected.  
The data indicate that changes in transporter activity levels occur in Huh7 cells maintained in 
prolonged untreated culture or treated with DMSO. The proportion of effluxed calcein 
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dropped from roughly 60% of total calcein in confluent cells to approximately 25% and 20% in 
prolonged untreated and DMSO-treated cells respectively. This could indicate reduced levels 
of the MRP transporters. Although neither MRP1 nor 2 mRNA level changed significantly with 
either treatment in Huh7 cells, decreased MRP1 protein level could explain other differences 
also seen in these cells. In confluent cells there was no difference in effect of verapamil and 
MK571 but in both prolonged untreated and DMSO treated cells, the pattern seen in HepG2 
cells, where inhibition with MK571 was more effective than with verapamil, reappeared. This 
could be due to either lower MRP1 or higher MRP2 protein or activity reintroducing the 
balance of efflux between the two and allowing the function of MRP2 to be observed. As the 
efflux levels are much lower, it would seem that a decrease in MRP1 protein or activity is more 
likely.  
Although no other information regarding Hoechst or calcein-AM transport assays in prolonged 
DMSO-treated cells has been published, changes in levels of these transporters predicted in 
other studies can be examined with results obtained here in mind. Unfortunately, Choi et al. 
(Choi et al., 2009) examined mainly metabolising enzyme levels and no other data regarding 
transporter mRNA or protein levels in DMSO-treated Huh7 cells is available. Information from 
Sivertsson et al. (Sivertsson et al., 2010) revealed that MRP2 mRNA levels in prolonged 
untreated Huh7 cells did not change from those in confluent cells at any point during a four 
week growth period, while MDR1 mRNA levels (P-gp) increased very slightly only after four 
weeks of growth. These data agree with results observed here previously and adds weight to 
the suggestion that if protein changes are occurring, they are being controlled by a post-
translational mechanism. Antherieu et al. (Antherieu et al., 2010) and Le Vee et al. (Le Vee et 
al., 2006) both observed that changes in MDR1 and MRP2 mRNA levels were very small in 
DMSO-treated HepaRG cells from 5-28 days of culture. Le Vee et al. (Le Vee et al., 2006) 
looked at function of P-gp and MRP2 by measuring rhodamine 123 and carboxyffuorescein (CF) 
diacetate transport respectively with appropriate inhibitors in HepG2 and HepaRG cells at 
confluence, HepaRG cells after DMSO treatment and in primary human hepatocytes. Results 
indicated that P-gp function was very similar in both HepaRG cell types and in HepG2 cells, 
with P-gp activity in all three cell cultures slightly increased over that in primary hepatocytes. 
MRP2 function did decrease slightly in DMSO-treated HepaRG cells in comparison to confluent 
ones and showed a level similar to that in primary hepatocytes; HepG2 cells showed increased 
MRP2 activity in comparison to both DMSO-treated HepaRG cells and primary hepatocytes. 
This agrees with mRNA data obtained in chapter 5, where initial levels of MRP2 mRNA in 
confluent HepG2 cells were higher than those in whole liver. It has also been observed that 
functional MRP2 levels do not change in Caco-2 cells after culture with or without antibiotics 
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for up to nine weeks, demonstrating that neither prolonged untreated culture nor antibiotic 
treatment affect expression of functional MRP2 in this cell line (Prime-Chapman et al., 2005). 
Results here indicate that even if MRP2 protein function is decreased after DMSO-treatment of 
HepG2 cells, levels remain high enough that function can be detected.  
Overall, these functional experiments have produced mixed results. Both confluent and DMSO-
treated HepG2 cells gave similar results in terms of inhibition, indicating no advantage of 
DMSO treatment in HepG2 cells. Huh7 cells did have a more normal response in terms of 
expected inhibitor effect when they were grown for 15 days regardless of the presence of 
DMSO, compared with confluent cells where MRP2 functionality could not be detected. 
However, this was at the expense of a large percentage of efflux function suggesting that 
functional levels of both transporters were reduced well below the in vivo liver levels. These 
changes in functional activity were not predicted by mRNA analysis, suggesting that the effects 
seen following prolonged growth of Huh7 cells result from changes at a post-transcriptional 
level.  
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Figure 8.1 – Hoechst 33342 accumulation in confluent HepG2 cells in the presence of P-
gp and BCRP inhibitors. Cells were grown in 24-well plastic plates until confluent in
standard growth medium. Accumulation of Hoechst dye was assessed as described in
chapter 2 with Hoechst alone and with inhibitors verapamil (A), CSA (B) and Ko143 (C).
Each graph shows data from one experiment with three repeats (N = 1, n = 3) which was
representative of a further two experiments. Data displayed in parts A and C were
obtained using a FLUOstar Omega platereader (BMG Labtech) at different intensities,
while data in part B was obtained using a Perkin Elmer LS-5 luminescence spectrometer.
All data has been normalised to protein levels. Data shown is mean ± SEM with a
hyperbola line fitted. Statistical analysis of data displayed here is presented in table 8.1.
Fig r  7.  – Hoechst 342 accumulation in confluent HepG2 cells in th  presence of 
P-gp and BCRP inhibitors. Cells were grown in 24-well plastic plates until confluent in 
standard growth medium. Accumulation of Hoechst dye was assessed as described in 
chapter 2 with Hoechst alone and with inhibitors verapamil (A), CSA (B) and Ko143 (C). 
Each graph shows data from one  with three rep ats (N = 1, n = 3) which was 
representative of a further two experiments. Data displayed in parts A and C were 
obtained using a FLUOstar Omega platereader (BMG Labtech) at different intensities, 
while data in part B was obtained using a Perkin Elmer LS-5 luminescence spectrometer. 
All data has been normalised to protein levels. Data shown is mean ± SEM with a 
hyperbola line fitted. Statistical analysis of data displayed here is presented in table 7.1.  
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Hoechst 
concentration 
(μM) 
Hoechst only versus 
Hoechst plus verapamil 
Hoechst only versus 
Hoechst plus CSA 
Hoechst only versus 
Hoechst plus Ko143 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
0.1 * ↑ NS - * ↑ 
0.5 *** ↑ NS - *** ↑ 
1 ** ↑ NS - NS - 
3 * ↑ ** ↓ NS - 
5 NS - ** ↓ * ↓ 
10 NS - NS - NS - 
Table 7.1 – Statistical analysis of data from figure 7.1. Data from experiments with confluent 
HepG2 cells incubated with Hoechst 33342 alone and alongside the inhibitors verapamil, CSA and 
Ko143 are displayed in figure 7.1. Statistical analysis of this data using Student’s t-test is displayed 
here. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. 
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Figure 8.2 – Hoechst 33342 accumulation in 15 day DMSO-treated HepG2 cells in the
presence of P-gp and BCRP inhibitors. Cells were grown in 12-well plastic plates for 15
days in standard growth medium plus 1% DMSO. Accumulation of Hoechst dye was
assessed as described in chapter 2 with Hoechst alone and with inhibitors verapamil (A),
CSA (B) and Ko143 (C). Data is shown from one experiment with three repeats (N = 1, n =
3) which was representative of a total of two experiments. Data displayed in all three
parts was obtained using a Perkin-Elmer LS-5 luminescence spectrometer. All data has
been normalised to protein levels. Data shown is mean ± SEM with a hyperbola line
fitted. Statistical analysis of data displayed here is presented in table 8.2.
Figure 7.2 – Hoechst 3 42 accum lati  i    -treated HepG2 cells in the 
presence of P-gp and BCRP inhibitors. lls r  r n in 12-well plastic plates for 15 
days in standard growth medium plus 1% DMSO. Accumulation of Hoechst dye was 
assessed as described in chapter 2 with Hoechst alone and with inhibitors verapamil (A), 
CSA (B) and Ko143 (C). Data is shown from one experiment with three repeats (N = 1, n 
= 3) which was representative of a total of two experiments. Data displayed in ll t ree 
parts was obtained using a Perkin-Elmer LS-5 luminescence spectrometer. All data has 
been normalised to protein levels. Data shown is mean ± SEM with a hyperbola line 
fitted. Statistical analysis of data displayed here is presented in table 7.2.  
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Hoechst 
concentration 
(μM) 
Hoechst only versus 
Hoechst plus verapamil 
Hoechst only versus 
Hoechst plus CSA 
Hoechst only versus 
Hoechst plus Ko143 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
0.1 NS - NS - NS - 
0.5 ** ↑ NS - * ↑ 
1 *** ↑ *** ↑ *** ↑ 
3 *** ↓ ** ↑ *** ↑ 
5 NS - NS - NS - 
8 NS - NS - NS - 
10 NS - NS - NS - 
Table 7.2 – Statistical analysis of data from figure 7.2. Data from experiments with DMSO-treated 
HepG2 cells incubated with Hoechst 33342 alone and alongside the inhibitors CSA and Ko143 are 
displayed in figure 7.2. Statistical analysis of this data using Student’s t-test is displayed here. * = p 
< 0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. 
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Figure 8.3 – Hoechst 33342 accumulation in confluent Huh7 cells in the presence of P-
gp and BCRP inhibitors. Cells were grown in 24-well plastic plates until confluent in
standard growth medium. Accumulation of Hoechst dye was assessed as described in
chapter 2 with Hoechst alone and with inhibitors verapamil (A), CSA (B) and Ko143 (C).
Data is shown from one experiment with three repeats (N = 1, n = 3) which was
representative of a further two experiments. Data displayed in all three parts was
obtained using a Perkin-Elmer LS-5 luminescence spectrometer. All data has been
normalised to protein levels. Data shown is mean ± SEM with a hyperbola line fitted.
Statistical analysis of data displayed here is presented in table 8.3.
A B
C
Figure 7.3 – Hoechst 33342 accumulation in confluent Huh7 cells in the presence of P-
gp and BCRP inhibitors. Cells were grown in 24-well plastic plates until confluent in 
standard growth medium. Accumulation of Hoechst dye was assessed as described in 
chapter 2 with Hoechst alone and with inhibitors verapamil (A), CSA (B) and Ko143 (C). 
Data is shown from one xperiment with three repeats (N = 1, n = 3) which was 
representative of a further two experiments. Data displayed in all three parts was 
obtained using a Perkin-Elmer LS-5 luminescence spectrometer. All data has been 
normalised to protein levels. Data shown is mean ± SEM with a hyperbola line fitted. 
Statistical analysis of data displayed here is presented in table 7.3.  
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Hoechst 
concentration 
(μM) 
Hoechst only versus 
Hoechst plus verapamil 
Hoechst only versus 
Hoechst plus CSA 
Hoechst only versus 
Hoechst plus Ko143 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
0.1 * ↑ * ↑ *** ↑ 
0.5 ** ↑ *** ↑ ** ↑ 
1 * ↑ * ↑ NS - 
3 ** ↑ *** ↑ ** ↑ 
5 ** ↑ ** ↑ NS - 
8 NS - NS - NS - 
10 * ↑ NS - * ↑ 
30 * ↑ ** ↑ * ↑ 
Table 7.3 – Statistical analysis of data from figure 7.3. Data from experiments with confluent Huh7 
cells incubated with Hoechst 33342 alone and alongside the inhibitors verapamil, CSA and Ko143 
are displayed in figure 7.3. Statistical analysis of this data using Student’s t-test is displayed here. * 
= p < 0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. 
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Figure 8.4 – Hoechst 33342 accumulation in 15 day untreated Huh7 cells in the
presence of P-gp inhibitors. Cells were grown in 24-well plastic plates until confluent
followed by growth for a further 15 days in standard growth medium. Accumulation
of Hoechst dye was assessed as described in chapter 2 with Hoechst alone and with
inhibitors verapamil (A) and CSA (B). Each graph shows data from one experiment
with three repeats (N = 1, n = 3) which was representative of a total of two
experiments. Data displayed in part A was obtained using a FLUOstar Omega
platereader (BMG Labtech) at different intensities, while data in part B was obtained
using a Perkin Elmer LS-5 luminescence spectrometer. All data has been normalised
to protein levels. Data shown is mean ± SEM with a hyperbola line fitted. Statistical
analysis of data displayed here is presented in table 8.4.
A
B
r  7.4 – Hoechst 33 42 accum lation n 15 day untreated Huh7 cells in the presence 
of P-gp inhibitors. Cells were grown in 24-well plastic plates until conflue t followed by 
growth for a further 15 days in standard growth medium. Accumulation of Hoechst dye 
was assessed as described in chapter 2 with Hoechst alone and with inhibitors verapamil 
(A) and CSA (B). Each graph shows data from one experiment with three repeats (N = 1, n 
= 3) which was representative of a total of two experiments. Data displayed in part A was 
obtained using a FLUOstar Omega platereader (BMG Labtech) at different intensities, 
while data in part B was obtained using a Perkin Elmer LS-5 luminescence spectrometer. 
All da a has been normalised to protein levels. Data shown is m an ± SEM with a 
hyperbola line fitted. Statistical analysis of data displayed here is presented in table 7.4.  
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Hoechst 
concentration (μM) 
Hoechst only versus 
Hoechst plus verapamil 
Hoechst only versus 
Hoechst plus CSA 
Significance 
Hoechst retention 
with inhibitor 
Significance 
Hoechst retention 
with inhibitor 
0.1 *** ↑ ** ↑ 
0.5 *** ↑ NS - 
1 *** ↑ NS - 
3 ** ↑ NS - 
5 * ↑ * ↑ 
8 NS - NS - 
10 NS - * ↑ 
30 NS - NS - 
Table 7.4 – Statistical analysis of data from figure 7.4. Data from experiments with prolonged 
untreated Huh7 cells incubated with Hoechst 33342 alone and alongside the inhibitors verapamil 
and CSA are displayed in figure 7.4. Statistical analysis of this data using Student’s t-test is displayed 
here. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. 
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Figure 8.5 – Hoechst 33342 accumulation in 15 day DMSO-treated Huh7 cells in the
presence of P-gp and BCRP inhibitors. Cells were grown in 24-well plastic plates until
confluent followed by growth for a further 15 days in standard growth medium plus 1%
DMSO. Accumulation of Hoechst dye was assessed as described in chapter 2 with
Hoechst alone and with inhibitors verapamil (A), CSA (B) and Ko143 (C). Data is shown
from one experiment with three repeats (N = 1, n = 3) which was representative of a
total of two experiments. Data displayed in all three parts was obtained using a Perkin-
Elmer LS-5 luminescence spectrometer. All data has been normalised to protein levels.
Data shown is mean ± SEM with a hyperbola line fitted. Statistical analysis of data
displayed here is presented in table 8.5.
Figure 7.5 – Hoechst 33342 accumulation in 15 day DMSO-treated Huh7 cells in the 
presence of P-gp and BCRP inhibitors. Cells were grown in 24-well plastic plates until 
confluent fol o   ro t    f rt r 15  i       
D SO. Ac umulation of Hoechst dye was as essed as escrib d in chapter 2 with Hoechst 
alone and with inhibitors verapamil (A), CSA (B) and Ko143 (C). Data is shown from one 
experiment with three repeats (N = 1, n = 3) which was representative of a total of two 
experiments. Data displayed in all three parts was obtained using a Perkin-Elmer LS-5 
luminescence spectrometer. All data has been normalised to protein levels. Data shown is 
mean ± SEM with a hyp rbola line fitted. Statistical analysis of data displayed here is 
presented in table 7.5.  
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Hoechst 
concentration 
(μM) 
Hoechst only versus 
Hoechst plus verapamil 
Hoechst only versus 
Hoechst plus CSA 
Hoechst only versus 
Hoechst plus Ko143 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
Significance 
Hoechst 
retention 
with 
inhibitor 
0.1 ** ↑ * ↑ NS - 
0.5 ** ↑ *** ↑ * ↑ 
1 NS - NS - NS - 
3 *** ↓ NS - * ↓ 
5 ** ↑ ** ↑ NS - 
8 NS - *** ↑ NS - 
10 NS - NS - * ↓ 
30 NS - NS - NS - 
Table 7.5 – Statistical analysis of data from figure 7.5. Data from experiments with DMSO-treated 
Huh7 cells incubated with Hoechst 33342 alone and alongside the inhibitors verapamil, CSA and 
Ko143 are displayed in figure 7.5. Statistical analysis of this data using Student’s t-test is displayed 
here. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, NS = not significant. 
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Figure 8.6 – Calcein uptake into confluent HepG2 and Huh7 cells. A solution of 1 nmole
calcein in 500 μl Krebs was incubated with confluent HepG2 and Huh7 cells for 20 minutes to
assess whether calcein could effectively travel back into the cells during the efflux period.
These data are shown alongside those from confluent cells loaded with calcein-AM showing
calcein present in the efflux buffer after 20 minutes and the total calcein from both efflux
and lysate. Cells in each column were treated as follows:
Column Treatment
1 Krebs only (no cells)
2 & 3 HepG2 (2) and Huh7 (3) cells lysed after exposure to 1 nmole calcein for 
20 minutes
4 & 5 Efflux of calcein from HepG2 (4) and Huh7 (5) cells after 20 minutes with 
no inhibitors included in efflux buffer. Cells were initially loaded with 1 
nmole calcein-AM alongside 100 µM verapamil as described in chapters 2 
and 8.
6 & 7 Total calcein (efflux plus lysate) from HepG2 (6) and Huh7 (7) cells loaded 
with 1 nmole calcein-AM alongside 100 µM verapamil with no inhibitors 
included in the efflux buffer.
Figure 7.6 – Calcein uptake into confluent HepG2 and Huh7 cells. A solution of 1 nmole 
calcein in 500 μl Krebs was incubated with confluent HepG2 and Huh7 cells for 20 minutes 
to assess whether calcein could effectively travel back into the cells during the efflux 
period. These data are shown alongside those from confluent c lls loaded with calcein-AM 
showing calcein present in the efflux buffer after 20 minutes and the total calcein from 
both efflux and lysate. Cells in each column were treated as follows:  
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Figure 7.7 – Confluent HepG2 cells analysed for calcein-AM uptake and calcein efflux. Cells 
were grown on 24-well plastic plates until confluent. Calcein-AM experiments were conducted 
as described in chapter 2 and chapter 8. Data shown are from three experiments with a total of 
nine replicates (N = 3, n = 9) and is displayed as mean ± SEM. Statistical analysis of total calcein 
levels (efflux plus lysate) was by one-way ANOVA with Dunnett’s post test using values from 
cells loaded with calcein-AM alongside verapamil and no inhibitors in efflux as the control (first 
column). Selected data are compared in table 7.6. *** = p < 0.001.  
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Experiment 1
vs
Experiment 2
Significance
Calcein efflux 
in experiment 
2
Loading Efflux Loading Efflux
Verapamil - vs Verapamil Verapamil *** ↓
Verapamil - vs Verapamil MK571 *** ↓
Verapamil - vs Verapamil CSA *** ↓
Verapamil Verapamil vs Verapamil MK571 *** ↓
Verapamil Verapamil vs Verapamil CSA ** ↓
Verapamil CSA vs Verapamil MK571 *** ↓
Verapamil CSA vs Verapamil CSA, MK571 *** ↓
Verapamil MK571 vs Verapamil CSA, MK571 NS -
Table 7.6 – Statistical analysis of efflux data from figure 7.7. Data for confluent HepG2 cells 
incubated with calcein-AM with or without inhibitors during loading and efflux were analysed 
to show the effect of efflux inhibition. Selected results are displayed. Statistical analysis of data 
was carried out using one-way ANOVA with Bonferroni’s post-test. ** = p < 0.01, *** = p < 
0.001, NS = not significant, ↓ = decrease.  
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Figure 7.8 – Confluent Huh7 cells analysed for calcein-AM uptake and calcein efflux. Cells 
were grown on 24-well plastic plates until confluent. Calcein-AM experiments were conducted 
as described in chapter 2 and chapter 8. Data shown is from three experiments with a total of 
nine replicates (N = 3, n = 9) and is displayed as mean ± SEM. Statistical analysis of total calcein 
levels (efflux plus lysate) was by one-way ANOVA with Dunnett’s post test using values from 
cells loaded with calcein-AM alongside verapamil and no inhibitors in efflux as the control (first 
column). Selected data are compared in table 7.7. *** = p < 0.001.  
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Experiment 1
vs
Experiment 2
Significance
Calcein efflux 
in experiment 
2
Loading Efflux Loading Efflux
Verapamil - vs Verapamil Verapamil *** ↓
Verapamil - vs Verapamil MK571 *** ↓
Verapamil - vs Verapamil CSA *** ↓
Verapamil Verapamil vs Verapamil MK571 NS -
Verapamil Verapamil vs Verapamil CSA NS -
Verapamil CSA vs Verapamil MK571 NS -
Verapamil CSA vs Verapamil CSA, MK571 NS -
Verapamil MK571 vs Verapamil CSA, MK571 NS -
 
 
  
Table 7.7 – Statistical analysis of efflux data from figure 7.8. Data for confluent Huh7 cells 
incubated with calcein-AM with or without inhibitors during loading and efflux were analysed 
to show the effect of efflux inhibition. Selected results are displayed. Statistical analysis of data 
was carried out using one-way ANOVA with Bonferroni’s post-test. *** = p < 0.001, NS = not 
significant, ↓ = decrease.  
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Figure 7.9 – HepG2 cells treated for 15 days with 1% DMSO and analysed for calcein-AM 
uptake and calcein efflux. Cells were grown on 12-well plastic plates. Calcein-AM experiments 
were conducted as described in chapter 2 and chapter 8. Data shown are from five experiments 
with a minimum of  eight total replicates (N = 5, n = 8) and is displayed as mean ± SEM. 
Statistical analysis of total calcein levels (efflux plus lysate) was by one-way ANOVA with 
Dunnett’s post test using values from cells loaded with calcein-AM alongside verapamil and no 
inhibitors in efflux as the control (first column). Selected data are compared in table 7.8. *** = 
p < 0.001.  
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Experiment 1
vs
Experiment 2
Significance
Calcein efflux 
in experiment 
2
Loading Efflux Loading Efflux
Verapamil - vs Verapamil Verapamil NS -
Verapamil - vs Verapamil MK571 *** ↓
Verapamil - vs Verapamil CSA * ↓
Verapamil Verapamil vs Verapamil MK571 NS -
Verapamil Verapamil vs Verapamil CSA NS -
Verapamil CSA vs Verapamil MK571 NS -
Verapamil CSA vs Verapamil CSA, MK571 NS -
Verapamil MK571 vs Verapamil CSA, MK571 NS -
 
 
  
Table 7.8 – Statistical analysis of efflux data from figure 7.9. Data for DMSO-treatedHepG2 
cells incubated with calcein-AM with or without inhibitors during loading and efflux were 
analysed to show the effect of efflux inhibition. Selected results are displayed. Statistical 
analysis of data was carried out using one-way ANOVA with Bonferroni’s post-test. * = p < 0.05, 
*** = p < 0.001, NS = not significant, ↓ = decrease.  
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Figure 7.10 – Huh7 cells grown untreated for 15 days and analysed for calcein-AM uptake and 
calcein efflux. Cells were grown on 24-well plastic plates. Calcein-AM experiments were 
conducted as described in chapter 2 and chapter 8. Data shown are from three experiments 
with a total of nine replicates (N = 3, n = 9) and is displayed as mean ± SEM. Statistical analysis 
of total calcein levels (efflux plus lysate) was by one-way ANOVA with Dunnett’s post test using 
values from cells loaded with calcein-AM alongside verapamil and no inhibitors in efflux as the 
control (first column). Selected data are compared in table 7.9. *** = p < 0.001.  
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Experiment 1
vs
Experiment 2
Significance
Calcein efflux 
in experiment 
2
Loading Efflux Loading Efflux
Verapamil - vs Verapamil Verapamil NS -
Verapamil - vs Verapamil MK571 *** ↓
Verapamil - vs Verapamil CSA NS -
Verapamil Verapamil vs Verapamil MK571 NS -
Verapamil Verapamil vs Verapamil CSA NS -
Verapamil CSA vs Verapamil MK571 ** ↓
Verapamil CSA vs Verapamil CSA, MK571 * ↓
Verapamil MK571 vs Verapamil CSA, MK571 NS -
Table 7.9 – Statistical analysis of efflux data from figure 7.10. Data for prolonged untreated 
Huh7 cells incubated with calcein-AM with or without inhibitors during loading and efflux were 
analysed to show the effect of efflux inhibition. Selected results are displayed. Statistical 
analysis of data was carried out using one-way ANOVA with Bonferroni’s post-test. * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, NS = not significant, ↓ = decrease.  
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Figure 7.11 – Huh7 cells treated for 15 days with 1% DMSO and analysed for calcein-AM 
uptake and calcein efflux. Cells were grown on 24-well plastic plates. Calcein-AM experiments 
were conducted as described in chapter 2 and chapter 8. Data shown are from three 
experiments with a total of nine replicates (N = 3, n = 9) and is displayed as mean ± SEM. 
Statistical analysis of total calcein levels (efflux plus lysate) was by one-way ANOVA with 
Dunnett’s post test using values from cells loaded with calcein-AM alongside verapamil and no 
inhibitors in efflux as the control (first column). Selected data are compared in table 7.10. *** = 
p < 0.001.  
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Experiment 1
vs
Experiment 2
Significance
Calcein efflux 
in experiment 
2
Loading Efflux Loading Efflux
Verapamil - vs Verapamil Verapamil NS -
Verapamil - vs Verapamil MK571 *** ↓
Verapamil - vs Verapamil CSA NS -
Verapamil Verapamil vs Verapamil MK571 *** ↓
Verapamil Verapamil vs Verapamil CSA NS -
Verapamil CSA vs Verapamil MK571 ** ↓
Verapamil CSA vs Verapamil CSA, MK571 * ↓
Verapamil MK571 vs Verapamil CSA, MK571 NS -
Table 7.10 – Statistical analysis of efflux data from figure 7.11. Data for DMSO-treated Huh7 
cells incubated with calcein-AM with or without inhibitors during loading and efflux were 
analysed to show the effect of efflux inhibition. Selected results are displayed. Statistical 
analysis of data was carried out using one-way ANOVA with Bonferroni’s post-test. * = p < 0.05, 
** = p < 0.01, *** = p < 0.001, NS = not significant, ↓ = decrease.  
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Chapter 8 – Detection of proteins by Western 
blotting 
Chapter aim: To determine the absence or presence of selected proteins by Western blotting 
in confluent and DMSO-treated HepG2 and Huh7 cells. Results to be analysed in comparison to 
mRNA data to determine whether post-transcriptional regulation is affecting expression. 
8.1 – Introduction 
In this chapter results from Western blot processing of samples are displayed and analysed. 
The method for Western blotting using sodium dodecyl sulphate (SDS)-polyacrylamide gels 
was first developed by Burnette et al. (Burnette, 1981) and published in 1981. Despite being 
rejected for publication upon its first submission (Burnette, 2009), this technique was widely 
accepted and is utilised to this day for separation and identification of proteins, analysis of 
relative molecular mass and determination of relative abundance of proteins to name but a 
few applications. As the technique has been utilised, improvements and alterations to the 
initial methods have been suggested. These include choices to be made in every area including 
sample source, lysis conditions, separating and denaturing buffers, gel and membrane type, 
transfer method, blocking of the membrane post-transfer, polyclonal versus monoclonal 
antibodies, secondary antibody conjugation, detection method and quantification of protein. 
These variables will be briefly discussed here and the decisions made in terms of techniques 
used explained, followed by presentation and analysis of blots undertaken. 
Lysis buffers and techniques vary according to the original sample source used; for example, a 
whole cell lysate will require a different extraction procedure to that of a tissue sample or a 
nuclear extract. Reagents can be included to aid in extraction of proteins from the membrane 
and cytoskeleton of the cell such as SDS, NP40 and Triton X-100, all of which are considered 
denaturing detergents. More stringent buffers such as RIPA (Radio Immuno Precipitation 
Assay) can be used to further disrupt protein-protein interactions for nuclear or mitochondrial 
extracts. However, the antibodies to be used must be taken into consideration at this early 
stage as some do not recognise denatured proteins, thus rendering a buffer containing, for 
example, SDS unsuitable. Another element which improves protein recovery is the addition of 
protease inhibitors to the lysis buffer, which halt the degradation of protein. An easy addition 
to this is to carry out sample lysis on ice or at 4oC at all times, reducing the efficiency of the 
proteases. In these experiments a whole cell lysate was required. Lysis buffer, as described in 
appendix A,  included SDS, NP40, DTT and protease inhibitors to aid in protein recovery and 
during protein extraction samples were kept at 4oC or on ice at all times. 
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The antibodies to be used are an important factor to consider when preparing samples for gel 
loading. Antibodies raised against a short peptide sequence within the protein of interest 
identify a particular sequence of consecutive amino acids and require the protein to be 
denatured in order to have access to that epitope. However, other antibodies recognise an 
epitope only found in the 3D protein conformation – these require non-reducing conditions in 
both the lysis and sample loading buffers. As all antibodies used here required denaturing 
conditions (further information can be found in table 8.1), the loading buffer used was 
NuPAGE LDS sample buffer (Invitrogen) which is denaturing and is also slightly alkaline in pH, 
further contributing to ideal denaturing conditions. A 10x reducing agent containing 500 mM 
dithiothreitol (DTT) (Invitrogen) was also added to the sample loading mixture and the 
complete mixture was heated at 70oC for 10 minutes. 
While the use of pre-cast gels can be prohibitively expensive if a large number of blots are to 
be performed, they pose several advantages over self-made ones. Pre-cast gels of a single 
percentage are much more likely to have a consistent pore size throughout the gel, whereas 
ones made in the laboratory using acrylamide and bisacrylamide may set unevenly. 
Additionally, pre-cast gels using a percentage gradient, for example, ranging from 4-12% 
acrylamide,  can be purchased to enable a variety of protein sizes to be separated efficiently 
on the same gel whereas in a self-made gel only a single percentage is easy to produce. In 
these experiments pre-cast NuPAGE Novex 4-12% Bis-Tris gels (Invitrogen) were utilised. Once 
samples have been loaded onto the gel they are separated by electrophoresis. This process 
requires a buffer, the components of which are another variable in Western blotting. Gel 
migration charts which demonstrate the likely migration of proteins with various gel and 
buffer combinations are widely available, especially for pre-cast gels and buffer systems 
purchased from the same supplier. These can be used as a guide when selecting reagents and 
conditions for different sized proteins. The vast majority of running buffers contain SDS to 
sustain the denatured state of the sample proteins; this is the case in the buffer used here 
which was NuPAGE MOPS-SDS running buffer, purchased from Invitrogen. A specific 
antioxidant (NuPAGE Antioxidant, Invitrogen) is available to use with this Invitrogen system 
which migrates down the gel with the sample, maintaining proteins in a reduced form during 
electrophoresis. This product is utilised only in this system as it is carried out at a lower pH 
than other gel systems and so is not effective under different conditions. Other substances can 
be included to maintain reduction in alternative gel systems such as DTT and β-
mercaptoethanol; however, in a lower pH gel system such as is used here, these chemicals 
have a tendency to remain at the top of the gel rather than migrate with the sample. 
Electrophoresis voltages and times vary with equipment and gel or running buffer type and are 
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also dependent on the size of the protein to be detected; here a voltage of 200V was applied 
for 50-55 minutes when samples had migrated sufficiently for the range of proteins of interest. 
Once electrophoresis has been carried out protein bands can be visualised on the gel itself or 
transferred to a membrane to enable the use of antibodies for more specific identification. A 
Coomassie stain is commonly used to visualise protein separation but involves precipitation of 
the proteins, which prevents further transfer of protein to a membrane. For this reason, 
Coomassie staining of a gel is generally carried out on a duplicate of the gel, allowing one gel 
to be continued through the blotting process, or after transfer of the separated proteins to a 
membrane to check transfer efficiency. Other commonly-used protein visualising stains include 
silver staining and fluorescent stains such as the SYPRO-Ruby and Coomassie Fluor-Orange 
techniques. Since the Western blotting protocol used was well established in our laboratory 
and sample volume was limited, gel staining for protein visualisation was not carried out. 
However, in the event that ladders and visualised bands did not appear to be separating 
correctly, protein visualisation using these techniques is a viable troubleshooting step. Transfer 
of the protein can be to either a nitrocellulose or a PVDF (polyvinylidene fluoride) membrane. 
Nylon membranes are not recommended for Western blotting as these tend to produce a very 
high background protein reading. Generally, background signals are lower on nitrocellulose 
membranes and these were used here as recommended by Licor, the manufacturer of the 
Odyssey system used here for detection of antibodies. Transfer of proteins can be conducted 
in either wet or semi-dry conditions. If large proteins are to be transferred it is preferable to 
use a wet transfer procedure; however, since the majority of proteins considered in this study 
were under 100 kDa in size the semi-dry method was used as it is considerably quicker than 
wet-blotting. 
Once transfer of protein to the membrane has been achieved the membrane must be blocked 
to prevent indiscriminate binding of primary or secondary antibodies. Common examples of 
blocking agents are non-fat dry milk and BSA; however, with the Licor Odyssey detection 
system it is recommended to use a proprietary blocking buffer containing 0.1% sodium azide 
(Odyssey Blocking Buffer) to reduce background fluorescence. This has some additional 
advantages over using milk-based blocking solutions – the Odyssey buffer can be re-used and 
stored at 4oC with or without antibodies in solution and it is useful when using anti-goat 
antibodies, as these have been known to react with milk-based reagents. Both primary and 
secondary antibodies can be applied to blocked membranes using milk or blocking buffer as a 
vehicle as appropriate. 
Primary antibodies are available in polyclonal or monoclonal formats. Polyclonal antibodies are 
generated by injection of an antigen into an animal followed by collection and purification of 
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serum, whereas monoclonal antibodies are generated by clonal cells. Polyclonal antibodies 
have advantages as they can recognise multiple epitopes of an antigen, with the resultant 
signal amplification being especially useful for detection of low expression proteins. 
Production of polyclonal antibodies is much cheaper and less time consuming than that of 
monoclonal antibodies but the process can result in generation of less specific antibodies and 
high background signals. A further problem can be batch to batch variability, something which 
is not seen with monoclonal antibodies as once the production system is set up the cloned 
cells are guaranteed to produce the same antibody each time. However, this monoclonal 
specificity can be a disadvantage if the antibody fails to recognise epitopes with minor 
variations from the published amino acid sequence. In the experiments described here, a 
mixture of mono- and polyclonal antibodies were used (table 8.1). 
Antibody incubation conditions and titre are extremely wide ranging, dependent on the 
antibody itself and the target sample among other things and will often require experimental 
determination; however, a starting dilution or range of concentrations will generally be 
suggested in the information sheet provided with the antibody by most manufacturers. Here, 
most primary antibodies were initially tested at 1:1000 dilution for a minimum of 1 hour at 
room temperature followed by an overnight incubation at 4oC. The method of antibody 
visualisation depends on the marker molecule conjugated to the secondary antibody. Many 
laboratories use horseradish peroxidase (HRP) conjugated secondary antibodies as standard, 
which are usually visualised using photographic film or detected using a phosphor imager. A 
Licor Odyssey scanner which utilises fluorescently labelled secondary antibodies was used here 
to visualise bound proteins on the membrane. The conjugated labels are in the near infra-red 
range which provides advantages over traditional fluorescent probes as most biological 
systems produce little or no signal in this range, which reduces background signals and 
enhances assay sensitivity. A fluorescent system has some notable advantages over HRP, a 
major one being that two detection channels with different wavelengths are available, 
enabling simultaneous detection of two separate proteins providing they are labelled with 
different secondary antibodies with different fluorescent labels. This is very useful when 
measurement of both a reference and a target protein is required, for example in 
quantification of two similarly sized proteins. The Licor Odyssey also allows repeated scans 
with different intensities and sensitivities unique to each channel. Secondary antibodies 
utilised here were goat anti-mouse IgG (680LT labelled), donkey anti-rabbit IgG (680LT 
labelled) and donkey anti-goat IgG (800CW labelled) (Licor) and were applied at a dilution of 
1:5000 for 1 hour at room temperature (detailed in table 8.2). 
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Several primary antibodies were tested for experimental use in the work described in this 
chapter. These included antibodies to proteins which have already been analysed for mRNA 
levels in previous chapters, specifically anti-BCRP (using BXP-21 antibody), transferrin and 
albumin; antibodies to the reference proteins GAPDH and actin and to the protein ADPGK 
(ADP-dependent glucokinase). A qPCR assay for ADPGK mRNA has not been developed or used 
here but it is a member of the key hexokinase family of enzymes in the liver which catalyse the 
phosphorylation of glucose to glucose-6-phosphate, the first step in glycolysis, thus the 
presence or absence of this protein would provide useful information on the maturation status 
of the cells. Measurement of protein levels of genes tested for previously by qPCR will indicate 
whether response patterns observed at the mRNA level are being replicated in protein 
production.  
BCRP mRNA levels in both confluent and DMSO-treated HepG2 and Huh7 cells have previously 
been measured in chapters 3 and 5. In HepG2 cells BCRP mRNA levels at confluence were 
approximately 2- to 3-fold lower than those in liver, with DMSO-treatment for 15 days 
resulting in a small but significant decrease to roughly 70% of confluent levels. BCRP mRNA 
levels in confluent Huh7 cells were approximately 20- to 30-fold lower than those in liver and 
were not significantly different after DMSO-treatment. BCRP mRNA levels were also measured 
after induction with the ahryl hydrocarbon receptor (AhR) agonist beta-naphthoflavone (BNF) 
(chapter 6); results indicated no effect on BCRP mRNA level in confluent HepG2 cells, while 
DMSO-treated HepG2 cells responded to 10 µM BNF with an approximate doubling in BCRP 
transcripts. Confluent Huh7 cells showed significant induction of BCRP mRNA at both 1 and 10 
µM BNF, while after DMSO-treatment significant induction was observed with all three BNF 
concentrations (1, 10 and 100 µM). Transferrin mRNA levels at confluence and after DMSO 
treatment were analysed in both HepG2 and Huh7 cells and were presented in chapters 3 and 
4. Confluent HepG2 transferrin level was approximately 15-fold lower than liver, with DMSO 
treatment for 15 days producing an increase of approximately 6-fold over control. Confluent 
Huh7 transferrin level was approximately 11-fold lower than that in liver, while DMSO 
treatment for 15 days resulted in a significant increase to roughly 3- to 4-fold of control level. 
8.2 – Methods 
HepG2 and Huh7 cells were grown on 6-well plastic plates to confluence and subsequently 
treated for up to 20 days with 1% DMSO as previously described. Experimental layout for 
HepG2 and Huh7 cells is shown in figures 2.1 and 2.2 respectively. Protein extraction was 
carried out as described in chapter 2.7 and concentrations determined using Bradford reagent 
and read using a spectrometer at 595 nm. Precipitation and concentration of protein using 
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acetone was carried out where necessary as described in chapter 2.7. Western blotting was 
carried out using 20 μg of loaded protein per sample as described in chapter 2.7 with images 
generated using a Licor Odyssey and numerical densitometry data determined using ImageJ 
software (version 1.44p, http://imagej.nih.gov/ij). Serial dilutions of samples were carried out 
for all antibodies. Results for proteins of interest were normalised to the reference protein 
GAPDH or to a normalisation factor using both actin and GAPDH levels where applicable. 
Details of primary and secondary antibodies used can be seen in tables 8.1 and 8.2 
respectively. 
8.3 – Results 
8.3.1 – Assessment of antibodies 
Several antibodies were initially tested with protein extracted from confluent and 15 day 
DMSO treated HepG2 and Huh7 cells. Those which gave reliable and strong detection were 
BCRP (BXP-21, Abcam), ADPGK (Genetex), transferrin (TF, Genetex), actin (I-19, Santa Cruz) and 
GAPDH (Genetex); results using these antibodies are shown in figures 8.1-8.8. Other antibodies 
tried were UGT1A1 (1:30 dilution, D-16, Santa Cruz), MDR1 (1:100 dilution, C219, Abcam) and 
albumin (1:100 dilution, Abcam); unfortunately no bands could be detected with these 
antibodies even when using protein samples concentrated ten-fold over stocks. Membranes 
which failed to show signals with these antibodies were subsequently stripped using Restore 
Western Blot Stripping Buffer (Thermo Fisher Scientific, Illinois, USA) and probed with anti-
GAPDH, which consistently produced strong bands with this antibody. 
BCRP, ADPGK, TF, actin and GAPDH antibodies were tested against serial dilutions of stock 
protein (protein extracted from confluent cells) in order to determine the accuracy with which 
protein could be quantified both visually and numerically; results are shown in figures 8.1-8.3. 
The initial amount of protein loaded, 10 µl, is equal to approximately 20 µg of protein. Results 
from 1 in 2 serial dilutions of Huh7 protein from both confluent and 15 day DMSO treated cells 
probed with BCRP antibody are shown in figure 8.1. The image in part A displays results for the 
five dilutions of each protein sample, with the graph in part B showing semi-quantitative data 
extracted using ImageJ software. The band shown in the image was detected at around the 75 
kDa marker; the predicted size for BCRP is 72.3 kDa, which indicates that this antibody is 
detecting the correct protein. The intensity of the band in the image appeared to decrease 
with increasing sample dilution and became very faint in the fifth, most dilute sample from 
confluent cells. The numerical data for these results mirrors this observed decrease with 
measured BCRP level decreasing with each dilution (figure 8.1 part B). Measurement of protein 
level was fairly accurate throughout the dilution series with numerical data approximately 
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halving with each dilution. This result leads to the conclusion that this antibody is likely to be 
correctly identifying BCRP and that levels can be accurately assessed throughout a range of 
dilutions. 
Figure 8.2 shows results from 1 in 2 serial dilutions of confluent and 15 day 1% DMSO treated 
Huh7 cell lysates analysed with transferrin, ADPGK and GAPDH antibodies. The transferrin 
antibody detected three bands in Huh7 cells as shown in A and the magnified image – these 
included a doublet (TF bands 1 and 2) slightly higher than the 75 kDa molecular weight marker 
and an additional band at around 60-65 kDa (TF band 3). The expected molecular weight of 
transferrin is 77 kDa, indicating that the higher doublet contains the correct product. This 
lower band of the doublet (TF band 2) is not as clear in the lysates from confluent cells, 
however it is still faintly visible in the first sample dilution. This could indicate that this second 
band is more highly expressed with DMSO treatment, but normalisation to reference proteins 
would be required to substantiate this. As all three bands decrease similarly in intensity with 
increasing dilution it is possible that the lowest band at 60-65 kDa (band 3) is an alternatively 
spliced or degraded form of the protein or that some post-translational modification such as 
glycosylation, phosphorylation or modification of leading sequences and binding proteins has 
taken place. As it is reduced in line with decreased protein loading it could also be a non-
specific protein being detected. For quantification purposes, the higher doublet (bands 1 and 
2) was measured as separation of the two bands was difficult to accomplish accurately.  Graph 
B shows data for TF protein levels; data did not quite half from dilution to dilution but a 
noticeable difference could be quantified, particularly in the more concentrated samples.  
The molecular weight of ADPGK is 54 kDa and a very faint band of this size was seen on 
Western blots probed with anti-ADPGK antibody (figure 8.2 part A) in both protein samples, 
although it is more clearly visible in the 15 day DMSO treated cells. Since no normalisation to 
reference protein level has been conducted here, it cannot be concluded from this initial data 
whether this indicates a specific ADPGK increase or simply an overall increase in global protein. 
As only the more concentrated dilutions of each sample produced a clearly visible band, a high 
loading concentration was required for further experiments utilising this antibody. Numerical 
data (figure 8.2 part C) indicated that where bands were detected they could be accurately 
quantified with an approximate halving of protein being detected through the first three 
dilutions. 
GAPDH has a molecular weight of 37 kDa and the anti-GAPDH antibody produced a very clear 
band of this size (figure 8.2 part A) in both samples at all dilutions tested which visibly lessened 
with each dilution. Numerical data (figure 8.2 part D) showed that between the first two 
dilutions GAPDH protein detected did not quite half but a noticeable lessening of protein to 
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approximately 65% was detected. However, with subsequent dilutions the detectable change 
in protein levels by numerical assessment was not as marked, indicating that a higher protein 
loading concentration is more suitable for this antibody. 
Figure 7.3 shows results from 1 in 2 dilutions of confluent Huh7 cell lysates analysed with anti-
actin and a 1:5000 dilution of the anti-GAPDH antibody. A more dilute anti-GAPDH antibody 
was assessed due to some smearing of bands detected with the previous 1:1000 dilution, as 
this can be an indicator of over-exposure. Actin has a molecular weight of approximately 43 
kDa which matches with the band size observed in image A. The intensity of this band clearly 
diminished visibly with increasing sample dilution, which is also shown by numerical data in 
part B of figure 8.3 where each dilution shows approximately half the signal intensity of the 
previous dilution, with the exception of the final dilution where no band was detected. These 
data indicate that actin can be reliably quantified over a wide range of protein loading levels. A 
1:5000 dilution of anti-GAPDH antibody detects a band at 37 kDa as was seen previously in 
figure 8.2. However, very little change was seen between dilutions (figure 8.3 part C) where 
halving of protein level was not seen between any pair of dilutions. This indicates that a 1:5000 
dilution of GAPDH cannot be used to accurately quantify protein levels here and is less 
sensitive in terms of quantifying protein levels than the initial 1:1000 dilution used previously. 
8.3.2 – Effect of DMSO on BCRP levels 
Figure 8.4 shows results for BCRP levels in HepG2 and Huh7 cells at confluence and treated 
with 1% DMSO for up to 20 days. These membranes were also probed for the reference 
proteins actin and GAPDH to allow normalisation of numerical data with respect to protein 
loading differences and reveal potential increases in BCRP level. Part A of figure 8.4 clearly 
shows that the BCRP level in HepG2 lysates was quite low as the bands were not very strong. 
However, signal intensity at all time points was sufficient to gather numerical data. This was 
normalised to GAPDH levels and is presented in part B of the figure. This membrane was also 
probed with actin antibody, however, a faint band was only observed with the confluent cell 
sample and no actin detection was evident in protein extracts from DMSO treated cells, 
despite fairly strong GAPDH bands and evidence of BCRP expression in all samples. BCRP 
increased in comparison to confluence at all time points; approximately 4-fold and 7-fold 
increases were observed after 10 and 20 days of DMSO treatment respectively. However, the 
increase in BCRP after 15 days of treatment was lower than both of the other time points 
showing an increase of approximately 1.8-fold over the confluent cell sample. 
Figure 8.4 also shows samples from Huh7 cells at confluence and after DMSO treatment 
assessed for levels of BCRP, actin and GAPDH. The membrane image in part A clearly shows 
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strong bands with all three antibodies with all samples. Both actin and GAPDH appeared to 
stay fairly constant from confluence throughout the DMSO treatment while the BCRP level 
looked higher in DMSO-treated samples than in confluent cell lysates. Data for BCRP 
normalised using a normalisation factor representative of both actin and GAPDH levels can be 
seen in part C of this figure. An increase in BCRP was observed in all DMSO-treated samples in 
comparison to confluent levels, with expression levels 4-fold, 5-fold and 7-fold higher than 
confluence in 10, 15 and 20 day DMSO-treated samples respectively. Both visual assessment of 
the membrane image and numerical data generated indicate that BCRP expression increased 
in a time-dependent manner with DMSO treatment. 
Summary 
 DMSO-treated HepG2 cells showed increases at all time points but they were not 
sustained at comparable levels, with the level at the 15 day time point much reduced 
from those at 10 and 20 days. Actin was only detected in the confluent sample. 
 DMSO-treated Huh7 cells showed increased BCRP levels at all three DMSO treatment 
time points, which increased after each time point to a maximum of 6-fold over 
confluence. 
8.3.3 – Effect of BNF on BCRP levels 
Figure 8.5 shows results from lysates of confluent HepG2 and Huh7 cells treated with three 
concentrations of BNF and a control (experimental protocol as described previously (chapter 
6.2)), which were then analysed using anti-BCRP, anti-actin and anti-GAPDH antibodies. Images 
obtained are shown in part A. BCRP level did not appear to increase from control in either cell 
line with BNF treatment with regard to the membrane image alone. Graphs B and C show 
results for HepG2 and Huh7 samples normalised to both actin and GAPDH. Neither cell line 
showed a consistent increase or decrease from control levels with BNF treatment. 
Figure 8.6 shows results from lysates of HepG2 and Huh7 cells treated for 15 days with 1% 
DMSO and subsequently treated with three concentrations of BNF with a relevant control as 
described previously (chapter 6.2). Results from HepG2 cells (part A) revealed that neither 
GAPDH nor actin were detected in the control or 1 μM samples even though a BCRP signal was 
present. The gel electrophoresis, blotting and staining of these samples was conducted several 
times with each sample from each experiment showing the same outcome (n=6, N=2). 
Concentration of these two protein samples using acetone precipitation failed to reveal either 
actin or GAPDH protein at detectable concentrations. Consequently, normalisation could not 
be conducted for this experiment. BCRP level did appear to be higher in these samples than in 
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the 10 and 100 μM BNF treated samples but without a loading control it cannot be determined 
whether this was a true result or simply a global protein increase. BCRP, GAPDH and actin 
levels in Huh7 cells appeared to be fairly constant throughout BNF treatment. Graph B shows 
numerical data for BCRP levels in Huh7 cells normalised to both actin and GAPDH which 
revealed small decreases in BCRP in comparison to control with all concentrations of BNF. 
Summary 
 Neither HepG2 nor Huh7 cells showed an increase in BCRP protein with any 
concentration of BNF at confluence. Actin was only detected in the 100 µM sample. 
 DMSO-treated Huh7 cells did not show increased expression of BCRP with any 
concentration of BNF. BCRP levels in DMSO-treated HepG2 cells could not be 
quantified accurately due to absence of GAPDH in some samples. 
8.3.4 – Transferrin and ADPGK protein levels 
Figure 8.7 displays results for lysates from HepG2 and Huh7 cells at confluence or treated for 
10, 15 and 20 days with 1% DMSO and analysed with anti-transferrin, anti-actin and anti-
GAPDH antibodies. HepG2 cells again did not respond well to the actin antibody and no bands 
were evident in these samples (part A). Although GAPDH and TF bands were present in all 
samples they varied in intensity. Numerical data for HepG2 TF levels normalised to GAPDH 
(part B) showed a 3.5-fold increase over confluence at 10 days which was not sustained at later 
time points; after 15 and 20 days of DMSO treatment TF levels were decreased in comparison 
to the confluent sample. All three proteins were detected in Huh7 samples. Data were 
normalised to GAPDH and actin levels (part C) and showed a TF level after 10 days which was 
approximately equal to confluent cells, decreasing after 15 and 20 days to approximately 75% 
and 25% of the confluent level respectively. Interestingly, the lower 60-65 kDa band seen with 
the TF antibody in Huh7 cells was not detected in HepG2 cells indicating that it could be a 
variant of the protein or non-specific binding seen solely in these Huh7 cells. 
Figure 8.8 shows results for lysates from HepG2 and Huh7 cells at confluence or after 
treatment for 10, 15 and 20 days with 1% DMSO and analysed with anti-ADPGK, anti-actin and 
anti-GAPDH antibodies. As observed previously, HepG2 samples did not display uniform 
expression when exposed to the actin antibody; in this case actin was only seen clearly in 
confluent cells. Although GAPDH was detected in all HepG2 samples, ADPGK was only present 
in confluent cells, indicating a loss of expression of ADPGK at protein level with DMSO 
treatment in HepG2 cells. All three proteins were detected in Huh7 cell lysates; results for 
ADPGK normalised to actin and GAPDH are shown in graph B and show no large change from 
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control at 10 and 15 days of treatment, with a reduction to approximately 75% of confluent 
levels after 20 days of DMSO treatment. An additional band was visible in the confluent HepG2 
and 20 day DMSO treated Huh7 samples between those for ADPGK and actin – this could 
indicate a different form or alternative processing of ADPGK under certain conditions or could 
be the result of antibody detection of non-specific protein. 
Summary 
 HepG2 transferrin levels appeared to increase only after 10 days of DMSO treatment; 
however, some bands were very faint and data was difficult to extract from the blot. 
No actin was detected on the blot. 
 Transferrin levels in DMSO-treated Huh7 cells were stable after 10 days of DMSO 
treatment but decreased steadily at the two time points afterwards. 
  ADPGK expression in HepG2 cells was only apparent in confluent cells and was not 
observed with any DMSO treatment. GAPDH expression also decreased in the three 
DMSO samples, while actin expression was only apparent in confluent HepG2 cells. 
 ADPGK expression in Huh7 cells remained fairly stable with DMSO treatment and both 
actin and GAPDH expression was strong and consistant. 
8.4 – Discussion 
The work described in this chapter has confirmed the presence of BCRP, ADPGK and transferrin 
protein in confluent HepG2 and Huh7 cells and attempted to quantify the changes in protein 
expression in response to 1% DMSO treatment for up to 20 days. Changes in BCRP levels in 
response to BNF treatment both at confluence and after 15 days DMSO pre-treatment were 
quantified where possible in both cell lines. However, variations in protein level in response to 
treatment could not always be successfully measured due to expression of certain proteins 
being absent with certain treatments. The findings and limitations encountered during this 
work are discussed below. 
Initially it was intended to analyse data from these experiments in a similar way to that used 
previously for qPCR analysis – two reference genes/proteins would be measured and a 
normalisation factor would be derived from these data to allow more accurate representation 
of the data for the expression of the protein in question. Anti-GAPDH and anti-actin antibodies 
were applied to blotted lysates from both cell lines in order to apply this technique. However, 
a major impediment to data analysis was soon discovered with the lack of actin detection in 
some HepG2 cells, mainly those which had received a DMSO treatment. In the majority of 
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HepG2 samples GAPDH could still be detected and so normalisation to one reference protein 
was possible. However, in a limited number of samples neither GAPDH nor actin was detected 
– in this case, no normalisation of protein level was possible and so loading differences could 
not be accounted for which would make any analysis of the target protein alone questionable. 
The lack of actin detection in the majority of DMSO-treated HepG2 samples is unexplained, as 
actin is an integral protein involved in cell structure and motility which should be present in all 
cells. Actin is commonly used as a loading control for Western blotting as it should show stable 
expression. Additionally, the anti-actin antibody used here detects several different isoforms 
of the protein; considering this and the fact that actin was detected in some HepG2 samples, it 
is unlikely that HepG2 cells are expressing an undetectable isoform of the protein. It is possible 
that the protein was lost during the extraction process; however, protein was extracted from 
HepG2 and Huh7 cells simultaneously using the same methodology and solutions, and 
produced consistent yields of total protein as estimated via the Bradford assay. Since actin has 
been reliably detected in all Huh7 samples regardless of growth stage or treatment, it seems 
unlikely that this specific protein could be lost during sample processing for one cell line and 
not another. As the majority of HepG2 lysates lacking actin expression did show GAPDH and/or 
target protein expression, a general absence or loss of protein does not explain the lack of 
actin detected.  
A literature search investigating whether similar issues had occurred in other groups looking at 
prolonged exposure of cells to DMSO or loss of actin mRNA or protein expression in general 
yielded few results. A paper published in 1983 by Farmer et al. (Farmer et al., 1983) showed 
that in suspended mouse fibroblast cells (3T3 line) the amount of actin detected fell from 12% 
to 6% of total cellular protein in comparison to fibroblasts grown in contact with a surface. This 
change in actin protein occurred independently of actin mRNA levels which remained constant 
in attached and suspended cells, only increasing once cells in suspension were re-introduced 
to a contact-culture system. Another paper by the same group in 1988 looked at cytoskeletal 
mRNA and protein including that of actin in primary rat hepatocyte cultures (Ben-Ze'ev et al., 
1988). Results here indicated that growth conditions using matrigel promoted expression of 
liver-specific mRNA and proteins whilst simultaneously reducing expression of cytoskeletal 
proteins including actin. However, although actin decreases were observed, complete absence 
of expression as seen in some HepG2 samples here was not apparent. Nishimura et al. 
(Nishimura et al., 2008) observed that in C2C12 myotubes (derived from mouse skeletal 
muscle) treated with concentrations of up to 2.5% DMSO for up to 24 hours, β-actin mRNA 
expression decreased significantly in comparison to an untreated control. Indeed, significant 
decreases were also observed with 2.5% DMSO treatment for 4 and 8 hours, and with 0.5% 
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DMSO treatment for 24 hours. This publication also described results from the same 
experiments measuring GAPDH mRNA expression and found no significant differences from 
control with any concentration of DMSO after 24 hours of treatment. However, no protein 
analysis was undertaken so it remains unknown whether this change in actin mRNA translated 
directly to similar changes in protein level. It is also unknown whether these changes in 
different systems are relevant to hepatic cells. 
Several publications using mouse, rat and human hepatocytes have shown that actin is present 
at a constant and stable level (Caja et al., 2011; Glaros et al., 2010; Shay and Hagen, 2009; 
Gkretsi et al., 2007); two of these in particular show stable actin protein expression in both 
highly differentiated and more de-differentiated hepatocytes (Caja et al., 2011; Glaros et al., 
2010). Glaros et al. (Glaros et al., 2010) also showed strong actin protein expression in HepG2 
cells. Of the papers published where Western blotting or qPCR analysis have been used in cells 
which have been treated for prolonged periods of time with 1% DMSO, many have opted for 
alternatives to actin as either a protein or cDNA reference gene. However, there is no mention 
of whether this is because problems were encountered using actin or because other traditional 
reference genes such as 18S or GAPDH were utilised with no need to also measure actin. For 
example, many of the publications regarding the cell line HepaRG, which requires a 2% DMSO 
treatment for two weeks to aid differentiation, utilise qPCR with normalisation to the 
reference gene 18S (Antherieu et al., 2010; Dumont et al., 2010a; Dumont et al., 2010b; Le Vee 
et al., 2010; Tuoi Do et al., 2010; Le Vee et al., 2006). Prolonged 1% DMSO treatment of Huh7 
cells was carried out by Choi et al. (Choi et al., 2009) where analysis used qPCR with β-actin as 
the reference gene. This publication reported no unusual or adverse effects on actin 
expression at mRNA level, which agrees with results observed here where no disproportionate 
decrease or absence of actin protein expression was observed in any of the DMSO-treated 
Huh7 samples.  
Overall, no evidence has been reported previously that any growth condition or treatment, 
including DMSO, has resulted in compete loss of actin expression in a cell system as appears to 
have occurred in some HepG2 samples here. It may be that the effect observed here is a 
previously undiscovered effect of prolonged DMSO treatment on certain cell types; as 
observed by Hewitt and Hewitt in HepG2 cells (Hewitt and Hewitt, 2004), not all cells given the 
same name will remain identical due to differences in tissue culture regimes and extended 
passaging. It is also possible that there simply was not enough actin protein present in the 
HepG2 samples to be detected by Western blotting and a more sensitive technique is required, 
although fluorescent detection is one of the most sensitive methods of detecting blotted 
proteins. 
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Serial dilutions of protein samples revealed that less dilute samples produced the most reliable 
results in terms of detecting protein reduction with all of the tested antibodies, therefore in all 
subsequent experiments 20 µg of protein was loaded onto the gel. Detection of BCRP in 
confluent and DMSO-treated cells showed an increase in protein level with DMSO after 
normalisation to reference proteins in both HepG2 and Huh7 samples at all time points, 
although to a lesser extent in the 15 day DMSO-treated HepG2 sample. This is in contrast to 
mRNA levels displayed previously in chapter 5 (figures 5.3 and 5.4 part D, HepG2 and Huh7 
respectively), which showed significant decreases from control in BCRP mRNA level in DMSO 
treated HepG2 cells, and remained unchanged in Huh7 cells. The lack of correlation between 
BCRP mRNA and protein levels indicates that the apparent increase in protein level is probably 
due to a post-transcriptional mechanism stimulated or initiated by DMSO. Post-transcriptional 
regulation of BCRP has been observed previously in rat intestinal cells where a reduction in 
protein after organ damage was not mirrored by a similar mRNA reduction (Ogura et al., 2008), 
and in MCF-7 cells after oestrogen treatment (Imai et al., 2005). Pan et al. (Pan et al., 2009) 
reported that micro-RNAs (miRNAs) could successfully be used to inhibit expression of BCRP 
protein at a post-transcriptional level via modification of the 3’-UTR section of the transcript. 
Since miRNAs are expressed at certain developmental stages or in response to cellular stress, it 
is feasible to consider that DMSO treatment could be contributing to the lack of co-ordination 
between mRNA and protein levels due to both stress and the attempted push towards a more 
differentiated cell model. 
Neither cell line showed a sustained increase in BCRP when cells were treated with BNF at 
confluence. Previous data from chapter 6 (figures 6.5 and 6.6 part A, HepG2 and Huh7 
respectively) showed that mRNA levels of BCRP in BNF treated HepG2 and Huh7 cells were 
consistently higher than control if not always significant. With a DMSO pre-treatment the BNF 
effect on BCRP protein level in HepG2 cells could not be measured due to the apparent lack of 
GAPDH and actin expression which persisted even after sample concentration. However, 
looking at the BCRP band alone does not indicate that expression increased with BNF 
treatment. Pre-treatment of Huh7 cells with DMSO followed by BNF treatment did not result 
in any changes in BCRP protein; previous data from chapter 6 (figure 6.6 part B) indicated that 
significant increases in BCRP mRNA occurred with all three BNF concentrations. The reduced 
effect of the BCRP inhibitor Ko143 in treated Huh7 cells could indicate that BCRP levels have 
decreased with prolonged growth with and without DMSO in comparison to confluence 
(figures 7.3-5); however, Western blotting of BCRP protein in 15 day DMSO-treated Huh7 cells 
revealed an increase compared to confluent Huh7 cells. Again, these results for BCRP protein 
and mRNA expression do not correlate and indicate that some form of post-transcriptional 
regulation is occurring within each cell line, both at confluence and after DMSO treatment. 
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Alternatively, as both Huh7 and to a lesser extent HepG2 did show increased levels of BCRP 
protein in Western blots, this could point towards the reduced inhibition of BCRP seen in 
DMSO-treated Huh7 cells being a result of increased transporter levels which were not 
inhibited as completely as in confluent Huh7 cells. Following this, it is possible that an increase 
in P-gp protein is responsible for the reduced ability of both verapamil and CSA to inhibit 
Hoechst efflux in DMSO-treated cells. 
In a more differentiated hepatic state TF levels would be expected to increase. However, the 
only TF increase observed was unsustained and occurred after 10 days of DMSO treatment in 
HepG2 cells; this was followed by levels lower than control at subsequent time points. No 
increase in TF protein was observed in Huh7 samples. Previous assessment of TF mRNA in 
DMSO-treated cells revealed that substantial increases were seen after 15 and 20 days of 
treatment in both cell lines (figures 4.5 and 4.6). As observed with previous results for BCRP, it 
could be that some form of post-transcriptional regulation of TF is taking place. Alternatively, 
since TF is secreted from the cell it is possible that any increase in protein production cannot 
be detected due to the excess protein being transported out of the cell (Zakin, 1992).  
ADPGK plays a role in glycolysis, a key function of the liver. An increase in this protein would 
indicate a more mature cell type – unfortunately, this was not observed in either HepG2 or 
Huh7 cells. ADPGK was detected in confluent HepG2 cells along with both actin and GAPDH 
but expression of both ADPGK and actin decreased to an undetectable level or were absent 
from DMSO-treated cells, indicating a less hepatocyte-like profile in terms of ADPGK 
expression. Although Huh7 cells did express ADPGK throughout DMSO treatment, no increase 
indicative of a more mature hepatic profile was observed. The detection of a lower molecular 
weight band at approximately 45-50 kDa in the confluent HepG2 and 20-day DMSO-treated 
Huh7 samples may point towards an alternative form of the protein being detected, for 
example if cleaving of a leader sequence has occurred. It could also point towards some non-
reduced protein or modifications such as glycosylation remaining in the sample, although why 
this would occur in some samples and not others when all were treated identically is unclear. 
Overall, results from this chapter indicate no differentiation of cells towards a more hepatic 
profile in DMSO-treated cells in terms of increased transferrin or ADPGK expression. Although 
increased BCRP protein expression was detected with DMSO treatment, no increase in mRNA 
transcripts was detected in matching samples. However, data comparing mRNA levels of liver 
to confluent HepG2 and Huh7 cells did indicate that liver levels of BCRP are increased over 
those observed in these cell lines at confluence, so an increase in BCRP protein may be a 
positive indication of a more hepatocyte-like profile in some aspects of the cellular profile. 
Conversely, where BNF initiated an increase in BCRP mRNA levels it failed to increase protein 
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levels both with and without DMSO treatment. These results point strongly towards post-
transcriptional modifications being a major factor in the expression of BCRP rather than being 
driven mainly by levels of mRNA expression.  
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Antibody 
Company/ 
Number 
Peptide 
Host 
species 
Antigen 
species 
Cross-reactivity Mono/polyclonal Dilution Incubation 
Predicted 
size 
Actin (I-19) 
Santa Cruz 
(sc-1616) 
Region within 
the C-terminus 
of human actin 
(detects a broad 
range of 
isoforms) 
Goat Human 
Mouse, rat, 
human, 
zebrafish, C. 
elegans, 
drosophila and 
xenopus 
Polyclonal 1:2000 
3 hours at room 
temperature 
43 kDa 
ADPGK 
Genetex 
(GTX106029) 
Region within 
amino acids 103 
and 493 of 
human ADPGK 
Rabbit Human 
None known 
 
Polyclonal 1:500 
1 hour at room 
temperature 
followed by 
overnight at 4oC 
54 kDa 
BCRP (BXP-
21) 
Abcam 
(ab3380) 
Fusion of E. Coli 
maltose binding 
protein and 
amino acids 271 
to 396 of human 
BCRP 
Mouse Human 
None known 
 
Monoclonal 1:50 
1 hour at room 
temperature 
followed by 
overnight at 4oC 
72.3 kDa 
GAPDH 
Genetex 
(GTX100118) 
Region within 
amino acids 134 
and 145 of 
human GAPDH 
Rabbit Human 
Zebrafish 
 
Polyclonal 1:1000 
1 hour at room 
temperature 
36 kDa 
Transferrin 
Genetex 
(GTX101035) 
Region within 
amino acids 339 
and 638 of 
human 
transferrin 
Rabbit Human 
None known 
 
Polyclonal 1:500 
1 hour at room 
temperature 
followed by 
overnight at 4oC 
77 kDa 
Table 8.1 – Primary antibodies used for the detection of protein in Western blots. This table includes technical details for all primary antibodies used to 
successfully detect protein after Western blotting of lysate samples alongside dilution factors and incubation durations utilised in these experiments. 
2
7
2
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Antibody Company Host species Antigen species Label Dilution Incubation 
Anti-rabbit 
secondary 
Licor Donkey Rabbit 680LT (red) 1:5000 
1 hour at room 
temperature 
Anti-mouse 
secondary 
Licor Goat Mouse 680LT (red) 1:5000 
1 hour at room 
temperature 
Anti-goat 
secondary 
Licor Donkey Goat 800CW (green) 1:5000 
1 hour at room 
temperature 
Table 8.2 – Secondary antibodies used for the detection of protein in Western blots. This table includes technical details for all secondary 
antibodies used to successfully detect protein after Western blotting of lysate samples alongside dilution factors and incubation durations 
utilised in these experiments. 
2
7
3
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Figure 7.1 – Titration of sample for Western blot analysis using anti-BCRP. Protein was
extracted from Huh7 cells at confluence and after 15 days of treatment with 1% DMSO as
described in chapter 2. Samples were prepared, serially diluted, separated by
electrophoresis, transferred to nitrocellulose membrane and incubated with a 1:50
dilution of anti-BCRP (Abcam, USA), followed by a 1:5000 incubation with goat anti-mouse
IgG secondary antibody (Licor). The image (A) was captured using a Licor Odyssey scanner
and analysed with ImageJ software, generating the displayed graphical data (B). Data
displayed is the mean of serial dilutions from both samples with the first sample in each
set given a value of 100%. Data is representative of two serialdilutions for each sample.
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Figure 8.1 – Titration of sa ple for estern blot analysis using anti-BCRP. Protein was 
extracted from Huh7 cells at c fl ce and after 15 days of treatment with 1% DMSO as 
described in chapter 2.7. Samples were prepared, serially diluted, separated by 
electrophoresis, transferred to nitrocellulose membrane and incubated with a 1:50 
dilution of anti-BCRP (Abcam, USA), followed by a 1:5000 incubation with goat anti-mouse 
IgG secondary antibody (Licor). The image (A) was captured using a Licor Odyssey scanner 
and analysed with ImageJ software, generating the displayed graphical data (B). Data 
displayed is the mean of serial dilutions from both samples with the first sample in each 
set given a value of 100%. Data is representative of two serial dilutions for each sample.  
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Figure 7.2 – Titration of sample for Western blot analysis using anti-transferrin, anti-
ADPGK and anti-GAPDH. Protein was extracted from Huh7 cells at confluence and after 15
days of treatment with 1% DMSO as described in chapter 2. Samples were prepared,
serially diluted, separated by electrophoresis, transferred to nitrocellulose membrane and
incubated with the antibodies transferrin, ADPGK and GAPDH (Genetex, USA) at dilutions
of 1:500 (TF), 1:1000 (GAPDH) and 1:500 (ADPGK), followed by a 1:5000 incubation with
donkey anti-rabbit IgG secondary antibody (Licor). The image (A) was captured using a
Licor Odyssey scanner and analysed with ImageJ software, generating the displayed
graphical data (B, C and D). Data displayed is the mean of serial dilutions from both
samples with the first sample in each set given a value of 100%. Data is representative of
two serialdilutions for each sample.
Figure 8.2 – Titration of sample for Western blot analysis using anti-transferrin, anti-
ADPGK and anti-GAPDH. Protein was extracted from Huh7 cells at confluence and after 
15 days of treatment with 1% DMSO as described in chapter 2.7. Samples were prepared, 
serially diluted, separated by electrophoresis, transferred to nitrocellulose membrane and 
incubated with the antibodies transferrin, ADPGK and GAPDH (Genetex, USA) at dilutions 
f 1: 0 ( ), 1:1000 ( APDH) and 1:500 (ADPGK), followed by a 1:5000 incubation with 
onkey anti-rabbit Ig  secondary antibody (Licor). The i age (A) was captured using a 
Licor Odyssey scanner and analysed with ImageJ software, generating the displayed 
graphical data (B, C and D). Data displayed is the mean of serial dilutions from both 
samples with the first sample in each set given a value of 100%. Data is representative of 
two serial dilutions for each sample.  
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Figure 7.3 – Titration of sample for Western blot analysis using anti-actin and anti-
GAPDH. Protein was extracted from Huh7 cells at confluence as described in chapter 2.
Samples were prepared, serially diluted, separated by electrophoresis, transferred to
nitrocellulose membrane and incubated with the antibodies actin (Santa Cruz, USA) and
GAPDH (Genetex, USA) at diltuions of 1:5000 (GAPDH) and 1:2000 (actin), followed by a
1:5000 incubation with donkey anti-rabbit IgG secondary antibody (GAPDH) and donkey
anti-goat IgG secondary antibody (actin) (Licor). The image (A) was captured using a Licor
Odyssey scanner and analysed with ImageJ software, generating the displayed graphical
data (B and C). Data is representative of two serialdilutions for the sample.
C
Figure 8.3 – Titration of sample for Western blot analysis using anti-actin and anti-
GAPDH. Protein was extract  fr   c lls t c nfluence as described in chapter 2.7. 
Samples were pr , i lly diluted, separated by lectrophoresis, transferred to 
nitrocellulose membrane and incubated with the antibodies actin (Santa Cruz, USA) and 
GAPDH (Genetex, USA) at diltuions of 1:5000 (GAPDH) and 1:2000 (actin), followed by a 
1:5000 incubation with donkey anti-rabbit IgG secondary antibody (GAPDH) and d nkey 
anti-goat IgG secondary ntibody (actin) (Lic r). Th  image (A) was captur  using a Licor 
Odyssey scanner and analysed with ImageJ software, generating the displayed graphical 
data (B and C). Data is representative of two serial dilutions for the sample.  
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Figure 7.4 – DMSO treated HepG2 and
Huh7 cells analysed using anti-BCRP, anti-
actin and anti-GAPDH. Protein was
extracted from HepG2 and Huh7 cells at
confluence and after 10, 15 and 20 days of
treatment with 1% DMSO as described in
chapter 2.x. Samples were prepared,
separated by electrophoresis, transferred to
nitrocellulose membrane and incubated with
the antibodies BCRP (Abcam, USA), actin
(Santa Cruz, USA) and GAPDH (Genetex,
USA) at dilutions of 1:50 (BCRP), 1:2000
(actin) and 1:1000 (GAPDH). This was
followed by a 1:5000 incubation with goat
anti-mouse IgG secondary antibody (BCRP),
donkey anti-rabbit IgG secondary antibody
(GAPDH) and donkey anti-goat IgG
secondary antibody (actin) (Licor). The
images (A) were captured using a Licor
Odyssey scanner and analysed with ImageJ
software, generating the displayed graphical
data (B and C). Data for HepG2 was
normalised to GAPDH while that for Huh7
was normalised to both actin and GAPDH.
Data is representative of two experiments
with three samples in each (n = 6, N = 2).
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Figure 8.4 – DMSO treated HepG2 and Huh7 
cells analysed using anti-BCRP, anti-actin and 
anti-GAPDH. Protein was extracted from 
HepG2 and Huh7 c lls at confluence and after 
10, 15 and 20 days of tre tment with 1% 
DMSO as described in chapter 2.7. Samples 
were prepared, separated by electrophoresis, 
transferred to nitrocellulose membrane and 
incubated with the antibodies BCRP (Abcam, 
USA), actin (Santa Cruz, USA) and GAPDH 
(Genetex, USA) at dilutions of 1:50 (BCRP), 
1:2000 (actin) and 1:1000 (GAPDH). This was 
followed by a 1:5000 incubation with goat 
anti-mouse IgG secondary antibody (BCRP), 
donkey anti-rabbit IgG  seco dary antibody 
(GAPDH) and donkey anti-goat IgG secondary 
antibody (actin) (Licor). The images (A) were 
captured using a Licor Odyssey scanner and 
analysed with ImageJ software, generating 
the displayed graphical data (B and C). Data 
for HepG2 was normalised to GAPDH while 
that for Huh7 was normalised to both actin 
and GAPDH. Data is representative of two 
experiments with three samples in each (n = 
6, N = 2).  
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Figure 7.5 –HepG2 and Huh7 cells treated
with BNF and analysed using anti-BCRP,
anti-actin and anti-GAPDH. Protein was
extracted from HepG2 and Huh7 cells after
treatment with BNF at three concentrations
for 24 hours at confluence as described in
chapter 2. Samples were prepared,
separated by electrophoresis, transferred to
nitrocellulose membrane and incubated with
the antibodies BCRP (Abcam, USA), actin
(Santa Cruz, USA) and GAPDH (Genetex,
USA) at dilutions of 1:50 (BCRP), 1:2000
(actin) and 1:1000 (GAPDH). This was
followed by a 1:5000 incubation with goat
anti-mouse IgG secondary antibody (BCRP),
donkey anti-rabbit IgG secondary antibody
(GAPDH) and donkey anti-goat IgG
secondary antibody (actin) (Licor). The
images (A) were captured using a Licor
Odyssey scanner and analysed with ImageJ
software, generating the displayed graphical
data (B and C). Data for both HepG2 and
Huh7 was normalised to both actin and
GAPDH. Data is representative of two
experiments with three samples in each (n =
6, N = 2).
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Figure 8.5 –HepG2 and Huh7 cells treated 
with BNF and analysed using anti-BCRP, anti-
actin and a ti-GAPDH. rotein was extracted 
from HepG2 and Huh7 cells after tre tment 
with BNF at three concentrations for 24 hours 
at confluence as described in chapter 2.7. 
Samples were prepared, separated by 
electrophoresis, transferred to nitrocellulose 
membrane and incubated with the antibodies 
BCRP (Abcam, USA), actin (Santa Cruz, USA) 
and GAPDH (Genetex, USA) at dilutions of 
1:50 (BCRP), 1:2000 (actin) and 1:1000 
(GAPDH). This was followed by a 1:5000 
incubation with goat anti-mouse IgG 
secondary antibody (BCRP), donkey anti-
rabbit IgG  secondary antibody (GAPDH) and 
donkey anti-goat IgG secondary antibody 
(actin) (Licor). The images (A) were captured 
using a Licor Odyssey scanner and analysed 
with ImageJ software, genera g the 
displayed gr phical data (B nd C). Data for 
both HepG2 and Huh7 was normalised to 
both actin and GAPDH. Data is representative 
of two experiments with three samples in 
each (n = 6, N = 2).  
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Figure 7.6 –HepG2 and Huh7 cells treated with DMSO plus BNF and analysed using anti-BCRP,
anti-actin and anti-GAPDH. Protein was extracted from HepG2 and Huh7 cells after treatment
with 1% DMSO for 15 days followed by BNF at three concentrations for 24 hours as described in
chapter 2. Samples were prepared, separated by electrophoresis, transferred to nitrocellulose
membrane and incubated with the antibodies BCRP (Abcam, USA), actin (Santa Cruz, USA) and
GAPDH (Genetex, USA) at dilutions of 1:50 (BCRP), 1:2000 (actin) and 1:1000 (GAPDH). This was
followed by a 1:5000 incubation with goat anti-mouse IgG secondary antibody (BCRP), donkey
anti-rabbit IgG secondary antibody (GAPDH) and donkey anti-goat IgG secondary antibody
(actin) (Licor). The images (A) were captured using a Licor Odyssey scanner and analysed with
ImageJ software, generating the displayed graphical data (B). Data for Huh7 was normalised to
both actin and GAPDH. Data is representative of two experiments with two samples in each (n =
4, N = 2).
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Figure 8.6 –HepG2 and Huh7 cells treated with DMSO plus BNF and analysed using anti-BCRP, anti-
actin and anti-GAPDH. Protein was extracted from HepG2 and Huh7 cells after treatment with 1% 
DMSO for 15 days followed by BNF at three concentrations for 24 hours as described in chapter 2.7. 
Samples were prepared, separated by electrophoresis, transferred to nitrocellulose membrane and 
incubat d with the antibodies BCRP (Abcam, USA), actin (Santa Cruz, USA) and GAPDH (Genetex, USA) 
at dilutions of 1:50 (BCRP , 1:2000 (actin) and 1:1000 (GAPDH). This was followed by a 1:5000 
incubation with goat anti-mouse IgG secondary antibody (BCRP), donkey anti-rabbit IgG  secondary 
antibody (GAPDH) and donkey anti-goat IgG secondary antibody (actin) (Licor). The images (A) were 
captured using a Licor Odyssey scanner and analysed with ImageJ software, generating the displayed 
graphical data (B). Data for Huh7 was normalised to both actin and GAPDH. Data is representative of 
two experiments with two samples in each (n = 4, N = 2).  
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Figure 7.7 –HepG2 and Huh7 cells treated
with DMSO and analysed using anti-TF, anti-
actin and anti-GAPDH. Protein was extracted
from HepG2 and Huh7 cells at confluence and
after treatment with 1% DMSO for 10, 15 and
20 days as described in chapter 2. Samples
were prepared, separated by electrophoresis,
transferred to nitrocellulose membrane and
incubated with the antibodies actin (Santa
Cruz, USA), TF and GAPDH (Genetex, USA) at
dilutions of 1:2000 (actin) 1:500 (TF) and
1:1000 (GAPDH). This was followed by a 1:5000
incubation with donkey anti-rabbit IgG
secondary antibody (TF and GAPDH) and
donkey anti-goat IgG secondary antibody
(actin) (Licor). The images (A) were captured
using a Licor Odyssey scanner and analysed
with ImageJ software, generating the displayed
graphical data (B and C). Data for HepG2 was
normalised to GAPDH while data for Huh7 was
normalised to both actin and GAPDH. Data is
representative of two experiments with three
samples in each (n = 6, N = 2).
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Figure 8.7 – HepG2 and Huh7 cells treated 
with DMSO and analysed using anti-TF, anti-
actin and anti-GAPDH. Protein was extracted 
from HepG2 and Huh7 cells at confluence and 
after treatment with 1% DMSO for 10, 15 and 
20 days as described in chapter 2.7. Samples 
were prepared, separated by electrophoresis, 
transferred to nitrocellulose membrane and 
incubated with the antibodies actin (Santa 
Cruz, USA), TF and GAPDH (Genetex, USA) t 
dilutions of 1:2000 (actin) 1:500 (TF) and 
1:1000 (GAPDH). This was followed by a 
1:5000 incubation with donkey anti-rabbit IgG  
secondary antibody (TF and GAPDH) and 
donkey anti-goat IgG eco dary antibody 
(actin) (Licor). The ima s (A) were captured 
using a Licor Odyssey scanner and analysed 
with ImageJ software, generating the 
displayed graphical data (B and C). Data for  
HepG2 was normalised to GAPDH while data 
for Huh7 was normalised to both actin and 
GAPDH. Data is representative of two 
experiments with three samples in each (n = 
6, N = 2).  
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Figure 7.8 –HepG2 and Huh7 cells treated with DMSO and analysed using anti-ADPGK, anti-
actin and anti-GAPDH. Protein was extracted from HepG2 and Huh7 cells at confluence and
after treatment with 1% DMSO for 10, 15 and 20 days as described in chapter 2. Samples were
prepared, separated by electrophoresis, transferred to nitrocellulose membrane and incubated
with the antibodies actin (Santa Cruz, USA), ADPGK and GAPDH (Genetex, USA) at dilutions of
1:500 (ADPGK), 1:2000 (actin) and 1:1000 (GAPDH). This was followed by a 1:5000 incubation
with donkey anti-rabbit IgG secondary antibody (ADPGK and GAPDH) and donkey anti-goat IgG
secondary antibody (actin) (Licor). The images (A) were captured using a Licor Odyssey scanner
and analysed with ImageJ software, generating the displayed graphical data (B). Data for Huh7
was normalised to both actin and GAPDH. Data is representative of two experiments with three
samples in each (n = 6, N = 2).
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Figure 8.8 – HepG2 and Huh7 cells treated with DMSO and analysed using anti-
ADPGK, anti-actin and anti-GAPDH. Protein was extracted from HepG2 and Huh7 cells 
at conflu nce and after tr a ment with  1% DMSO for 10, 15 and 20 d ys s describ  
in chapter 2.7. Samples were prepared, separated by electrophoresis, transferred to 
nitrocellulose membrane and incubated with the antibodies actin (Santa Cruz, USA), 
ADPGK and GAPDH (Genetex, USA) at dilutions of 1:500 (ADPGK), 1:2000 (actin) and 
1:1000 (GAPDH). This was followed by a 1:5000 incubation with donkey anti-rabbit IgG  
secondary antibody (ADPGK and GAPDH) and donkey anti-goat IgG secondary antibody 
(actin) (Licor). The images (A) were captured using a Licor Odyssey scanner and 
analysed with ImageJ software, generating the displayed graphical data (B). Data for 
Huh7 was normalised to both actin and GAPDH. Data is representative of two 
experiments with three samples in each (n = 6, N = 2).  
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Chapter 9 – Concluding discussion 
The primary aim of this work was to investigate whether an in vitro system could be developed 
which could accurately predict toxicity of novel compounds in hepatocytes and provide an 
inexpensive, reliable and readily available screening system to be employed before testing in 
more expensive and difficult to obtain primary hepatocytes. To do this, the baseline expression 
of differentiation markers, transporters and enzymes in HepG2 and Huh7 human hepatic 
carcinoma  cell lines was analysed and compared to expression in whole liver. Changes in gene 
expression following induction of key metabolic pathways, Western blotting and finally 
functional assays were employed in order to determine whether any of an array of growth 
regimes and treatments resulted in differentiation of these immortalised cell lines to a more 
hepatocyte-like profile. 
A whole cell system is the most relevant one to employ when potential in vivo effects are to be 
determined. Although they lack the interactions with other cell types found in tissues and 
organs, a much clearer picture of transport and metabolic routes can be obtained than with a 
partial cell system such as microsomes. The gold standard of in vitro whole cell hepatic systems 
is the freshly isolated primary hepatocyte; however, as these are sourced directly from liver 
donors availability is unpredictable. These cells also de-differentiate rapidly in vitro so cannot 
be reliably used long-term – fresh cells are needed on a regular basis. Clearly this is a valuable 
but costly resource, one which ideally would not be used until the later stages of drug 
development if a more reliable whole cell system could be sourced. Cryopreserved 
hepatocytes can be more reliably sourced as they can be stored in liquid nitrogen until needed. 
Although these are not as expensive as primary hepatocytes, they remain substantially more 
costly than a sustainable secondary cell line and do not show the full hepatic profile observed 
in freshly obtained primary cells. Currently available secondary cell lines such as HepG2 do not 
express a full complement of hepatic proteins (Sivertsson et al., 2010; Ek et al., 2007; 
Hilgendorf et al., 2007; Olsavsky et al., 2007; Westerink and Schoonen, 2007a; Westerink and 
Schoonen, 2007b; Elizondo and Medina-Diaz, 2003) and more promising lines such as HepaRG 
(Hart et al., 2010; Jennen et al., 2010; Kanebratt and Andersson, 2008a; Kanebratt and 
Andersson, 2008b; Aninat et al., 2006; Gripon et al., 2002) have only recently become widely 
available through commercial routes and so are not yet fully characterised. This niche between 
available secondary cell lines and cryopreserved hepatocytes is one a more highly 
differentiated cell line could fill.  
Several groups have attempted to define the baseline expression of key genes for one or both 
of the two cell lines, HepG2 and Huh7, utilised in the current work (Hart et al., 2010; Sivertsson 
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et al., 2010; Choi et al., 2009; Ek et al., 2007; Hilgendorf et al., 2007; Lim et al., 2007; Olsavsky 
et al., 2007). However, as observed and documented in the literature, changes in the 
phenotype of a cell line can and do occur during use in different laboratories, possibly as a 
result of small variations in culture conditions (Hewitt and Hewitt, 2004). Although it is 
generally agreed that expression of many important enzymes and transporters is reduced in 
the HepG2 and Huh7 lines, it is not clear which most resembles the in vivo hepatocyte. For 
example, both mRNA and protein of the key metabolising enzyme CYP3A4 are reported as 
being expressed in HepG2 at levels 80-1000 fold lower than in liver and as being either 1000-
fold lower than liver or completely absent from Huh7 cells (Sivertsson et al., 2010; Ek et al., 
2007; Olsavsky et al., 2007). Expression at mRNA and protein level of several other CYPs such 
as CYP1A2 and 2E1 have also been reported as being very low or absent from HepG2 and Huh7 
cells at confluence (Choi et al., 2009; Ek et al., 2007; Lim et al., 2007; Olsavsky et al., 2007). 
mRNA expression of the major efflux transporters such as MDR1 and MRP2 appears to deviate 
less from levels observed in liver and primary hepatocytes, while mRNA levels of influx 
transporters such as OCT3 and OATPB and C have been reported as being absent or fairly close 
to liver levels (Sivertsson et al., 2010; Ek et al., 2007; Hilgendorf et al., 2007; Olsavsky et al., 
2007). Values for expression of these transporters and enzymes relative to liver measured in 
this project generally fell within the range of those cited from the literature, although as 
discussed above these are on occasion very wide-ranging.  Overall, analysis of the literature 
shows that neither cell line should be considered more hepatocyte-like than the other as both 
have substantial deficiencies in expression of metabolising enzymes and transporters, an 
observation supported by the current study where neither cell line stood out as a superior 
system with respect to basal expression levels of these key genes.  
Attempts to create a more hepatocyte-like cell using cell lines as a starting point have been 
described in the literature. Of these, two in particular have applied differentiation protocols to 
Huh7 cells similar to those employed here on both cell lines. Choi et al. (Choi et al., 2009) built 
on initial work from that group (Sainz and Chisari, 2006) where Huh7 cells were treated with 
1% DMSO in order to create a more differentiated cell model for studies of hepatitis C virus 
infection. Over the two publications, mRNA levels of certain maturation markers, transporters 
and enzymes such as albumin, CYP1A2, -2E1 and -3A4 and UGT1A1 were quantified by qPCR 
alongside functional assessment of selected enzymes. Sivertsson et al. (Sivertsson et al., 2010) 
grew both HepG2 and Huh7 cells for up to four weeks in standard media, comparable to the 
treatment described here as prolonged untreated growth. While both cell lines showed an 
increase in albumin mRNA after four weeks of growth, only Huh7 cells showed increased 
CYP3A4 mRNA, protein and activity with these remaining at initial levels in HepG2 cells. 
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Prolonged untreated growth of Huh7 cells in 3D culture for up to 26 days was also examined 
for expression of selected genes by Sainz et al. (Sainz et al., 2009). Results showed increased 
mRNA expression of maturation markers such as albumin and enzymes such as CYP3A4 and 
UGT1A1; however, these were not compared to levels in liver or primary hepatocytes. HepG2 
cells have also been grown in 3D spheroid cultures with increases in CYP1A2 activity as well as 
improved basic functional aspects of the hepatocyte such as bilirubin detoxification, urea 
synthesis and glucose consumption, although this was also accompanied by an increase in AFP 
production (Coward et al., 2009). 
Aspects of these published results, such as increased albumin and CYP3A4 mRNA expression, 
are mirrored in data described in this thesis, which demonstrates similar increases in these 
mRNAs after 15 days of untreated growth or DMSO treatment. However, although an increase 
in CYP3A4 mRNA was observed in all studies including this, the attained levels remained much 
lower than those in primary hepatocytes or human liver. Although this is not ideal, the 
increase in CYP3A4 expression seen in this work and increases in both expression and activity 
in that of Choi et al. and Sivertsson et al. (Sivertsson et al., 2010; Choi et al., 2009) suggest an 
improvement in the suitability of DMSO-treated cells and prolonged untreated growth of Huh7 
cells for use as a model in toxicity testing.    
However, a study by Antherieu et al. (Antherieu et al., 2010) using the HepaRG cell line 
showed that mRNA, protein and activity levels of some transporters and metabolising enzymes 
(which remained lowered in Huh7 and HepG2 cells following DMSO-treatment and prolonged 
untreated growth (Sivertsson 2010, Choi 2009 and this work)), were close to or even elevated 
above those in human hepatocytes cultured for one day. Although it has also been shown that 
levels in primary hepatocytes after one day of culture can be substantially lower than in fresh 
hepatocytes, this remains a much higher level of expression than observed here and in other 
studies using HepG2 and Huh7. 
The response of a cell to induction of specific pathways and receptors can elicit important 
information relating to whether it is functioning as expected. Here, comparison with results 
from the literature for induction profiles of model compounds in primary hepatocytes and liver 
slices can be utilised to determine the relative functionality of confluent and treated HepG2 
and Huh7 cells. Increases in MDR1 and MRP2 mRNA levels elicited by rifampicin and 
phenobarbital respectively were seen in liver slices at a much lower concentration of the 
ligands than in cell lines used here both at confluence and after DMSO treatment (Olinga et al., 
2008). Significant responses to rifampicin were observed with a 10 μM treatment in liver slices, 
whereas significant increases in MDR1 mRNA as a result of rifampicin induction were observed 
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in HepG2 and Huh7 cells only with a 100 μM treatment (Olinga et al., 2008). MDR1 mRNA 
increases in response to rifampicin were also observed in other cell lines (Fa2N-4 and HepaRG) 
at a similar concentration to that used in liver slices (Antherieu et al., 2010; Mills et al., 2004). 
Although all three examples from the literature showed significant responses to a lower 
concentration of rifampicin than were observed here, the magnitude of induction at these 
relevant concentrations were similar, ranging from a 2-fold increase over control in confluent 
HepG2 and Huh7 cells used here, to a 2.3-fold increase in liver slices (Olinga et al., 2008), a 3-
fold increase over control in Fa2N-4 cells (Mills et al., 2004) and an increase between 1.5- and 
10-fold over control in HepaRG cells (Antherieu et al., 2010). In contrast, with DMSO pre-
treated cells,  rifampicin resulted in a decrease in MDR1 mRNA at all concentrations tested in 
both cell lines and so did not improve upon results observed in confluent cells. These 
comparisons show that although the effective concentration of rifampicin used here is higher 
than in other studies cited in the literature, the magnitude of induction is similar which 
indicates that these cells retain the PXR pathway initiated by rifampicin if not the sensitivity.  
With phenobarbital an increase in MRP2 mRNA level has been reported in HepaRG cells, 
human hepatocyte and liver slices and was seen in experiments here with HepG2 and Huh7 
cells both at confluence and after DMSO pre-treatment. As with rifampicin, changes were 
generated at a lower concentration of phenobarbital in liver slices (50 µM) than in cell lines 
used here (3 mM) (Olinga et al., 2008). HepaRG cells also required a higher concentration (1 
mM) for a response than that used in liver slices (Antherieu et al., 2010). Courtois et al. 
(Courtois et al., 2002) used a similar phenobarbital concentration to that used here (3.2 mM) 
in primary human hepatocytes to induce both MRP2 mRNA and protein but did not specify fold 
differences observed. In both confluent and DMSO-treated HepG2 and Huh7 cells here, 
increases in MRP2 mRNA were between 2- and 3-fold higher than control; increases in HepaRG 
cells were in the same range, 1.5- to 10-fold higher than control, albeit with a slightly lower 
concentration of the ligand than that which produced an effective increase here. However, the 
increase observed with only 50 μM phenobarbital in liver slices was 12.4-fold higher than 
control, a much greater increase than observed with cells in experiments here.  These results 
show that while confluent HepG2 and Huh7 cells responded appropriately to rifampicin and 
phenobarbital, the concentrations of reagents required to induce a response indicate that the 
cells are less sensitive than liver slices and the HepaRG line. DMSO treatment did not improve 
these responses relative to liver and in the case of rifampicin, no response to the compound 
was observed after treatment in either cell line. This loss of response after DMSO treatment 
suggests that some aspect of DMSO action is interfering with the cellular response to 
rifampicin, which was functional in confluent cells. As stated earlier, it is not known exactly 
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how DMSO might act to cause maturation or other effects in cells (Aninat et al., 2006; Sainz 
and Chisari, 2006). Possible results of DMSO treatment include increased ROS scavenging (Villa 
et al., 1991), anti-apoptosis actions (Gilot et al., 2002), altered cell-cell signalling (Fiore and 
Degrassi, 1999), effects on cell membrane integrity (Melkonyan et al., 1996) and alternative 
cellular splicing (Bolduc et al., 2001). Any of these actions alone or together or others currently 
unknown could contribute to the differences resulting from DMSO treatment seen both in 
experiments here and in other cell types where it sustains primary hepatocyte maturation and 
HepaRG differentiation. 
Several factors could precipitate the difference in effects seen here with those reported 
elsewhere. Cells were cultured in different media and were derived from different sources. 
HepG2 and Huh7 cells are both derived from males with well-differentiated hepatocellular 
carcinoma, HepG2 from a 15 year old Caucasian and Huh7 from a 57 year old Japanese donor 
(Nakabayashi et al., 1982; Aden et al., 1979). HepaRG cells were derived from a female of 
unspecified age and ethnicity, also with hepatocellular carcinoma and Hepatitis C infection 
(Gripon et al., 2002). Fa2N-4 cells were derived from hepatocytes from a 12 year old female 
donor of unspecified ethnicity and were artificially immortalised using simian virus 40 large T 
antigen (Mills et al., 2004). These differences in age, gender, ethnicity and disease state all 
introduce potential differences in basal gene expression, which is why experiments using 
primary hepatocytes or liver slices often use several donors of differing age and gender; for 
example, Olinga et al. (Olinga et al., 2008) used 3 male and 3 female donors with an age range 
of 3-51 years for liver slice experiments. Although HepaRG cells are always used at confluence 
due to the prolonged growth periods required to further differentiate the cells (up to 28 days 
with 2% DMSO after high density seeding), Fa2N-4 cells were cultured in serum-free medium 
and exposed to the inducer only 48 hours after plating. Although no statement on level of 
confluence was made at this point, my experience with HepG2 and Huh7 cells suggests that 
confluence would not have been attained at the time of ligand application; however, since all 
cells grow at different rates it is possible that confluent Fa2N-4 cells were used. HepaRG cells 
were grown for up to 28 days in medium containing 10% serum and 2% DMSO; this was 
replaced by medium containing 2% serum and no DMSO 3 days before induction experiments 
were commenced, whereas here experiments were conducted in standard growth medium 
containing 10% serum and 1% DMSO. Another notable difference was that both HepaRG and 
Fa2N-4 cells were incubated with rifampicin for 48 hours (Antherieu et al., 2010; Mills et al., 
2004), while in liver slices (Olinga et al., 2008) and in experiments here RNA was extracted 
after 24 hours of treatment.  
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Differences in cell-cell communication and the expression of nuclear receptors themselves will 
also play a role in how a cell responds to an inducer. Liver slices do contain liver cell types 
other than hepatocytes (for example, stellate cells and cholangiocytes) and retain the 
extracellular matrix components which are lost with preparations containing hepatocytes only 
(Olinga et al., 2008); this could alter the reactions and the sensitivities observed in the tissue. 
HepaRG cells have been shown to have higher mRNA levels of key nuclear receptors such as 
CAR, PXR and AhR than HepG2 cells and in the case of PXR, higher than that in freshly isolated 
human hepatocytes (Aninat et al., 2006). This could account for the differences in sensitivities 
observed here; for example, levels of CAR mRNA in highly differentiated HepaRG cells are 
reported to be 30% of those in human hepatocytes, while HepG2 cells express CAR at only 
2.4% of the hepatic level (Aninat et al., 2006). These differences may themselves explain data 
discussed previously, where liver slices responded to phenobarbital, a CAR activator, at a 
concentration of 50 μM while HepaRG and HepG2 showed significant responses at 1 mM and 3 
mM respectively (Antherieu et al., 2010; Olinga et al., 2008). 
In Huh7 cells both at confluence and treated with DMSO, BCRP mRNA increased significantly 
with BNF activation of the AhR pathway at concentrations of 1 and 10 μM. In confluent HepG2 
cells no significant increase was observed with BNF treatment whereas in DMSO treated cells a 
significant increase was observed with 10 μM BNF. This could indicate that response to BNF via 
the AhR pathway was improved with DMSO treatment, but it is difficult to say conclusively that 
this is the case when significance was only observed at one concentration and not sustained 
across the concentration range. Although comparable experiments using BNF to induce BCRP 
in hepatic cells are not available, the compound TCDD has been used to activate the AhR 
pathway by Tan et al. (Tan et al., 2010) and showed a 2-fold mRNA and 2.7-fold protein 
increase in human hepatocytes. This is similar to results here, where induction of BCRP mRNA 
in DMSO-treated Huh7 cells ranged from 2- to 5-fold of control levels and in confluent Huh7 
cells ranged from 8- to 10-fold of control levels. While responses to BNF in confluent HepG2 
cells did not reach significance, the magnitude of change was 2- to 3-fold of control levels 
across the concentration range. 
Protein detection by Western blotting was also carried out for BCRP. Detection of BCRP in 
HepG2 and Huh7 cells at confluence and treated with DMSO for 10, 15 and 20 days showed 
increases in protein levels with DMSO at all time points; however, this did not correlate with 
observed mRNA data which showed significant decreases in DMSO-treated HepG2 cells and no 
significant change in either prolonged untreated or DMSO-treated Huh7 cells. Protein extracts 
from both confluent and DMSO-treated HepG2 and Huh7 cells incubated with the inducer BNF 
were also probed for BCRP. BCRP mRNA abundance was increased by BNF in both confluent 
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and DMSO-treated Huh7 cells, while results for HepG2 cells showed only one significant 
increase in BCRP mRNA at 10 μM BNF in DMSO-treated cells, with no significant changes in 
confluent HepG2 cells. Protein detection revealed that BCRP did not increase with BNF 
treatment in confluent HepG2 or Huh7 cells, or in DMSO-treated Huh7 cells. Unsatisfactory 
protein detection in DMSO-treated HepG2 cells incubated with BNF meant that protein could 
not be accurately determined here.  
These results may indicate a substantial role for post-transcriptional regulation of BCRP in both 
cell lines. Post-transcriptional regulation of this gene has been observed previously (Pan et al., 
2009; Ogura et al., 2008; Imai et al., 2005) but data looking specifically at both mRNA and 
protein upregulation of BCRP by an inducer in hepatocytes is lacking. Both Ogura et al. (Ogura 
et al., 2008) and Imai et al. (Imai et al., 2005) observed protein reduction alongside no change 
in mRNA transcript levels in rat intestinal cells and MCF-7 (human breast cancer) cells 
respectively. Pan et al. (Pan et al., 2009) showed evidence of miRNA inhibition of BCRP 
expression, also in MCF-7 cells. Since miRNA are known to be expressed at certain 
developmental stages or under conditions of cellular stress, it is feasible to consider that they 
could be active in experiments described here also.  Another possible explanation for the 
discrepancy between mRNA and protein levels of BCRP observed here is that protein levels 
have already been increased and are stabilised at a higher level after 10 -20 days of DMSO 
treatment, resulting in mRNA levels which are no longer elevated. It is also possible that 
incubation times used for BNF treatment (24 hours) were sufficient to observe an mRNA 
increase but not an increase in protein levels. Disagreement between levels of transferrin 
mRNA and protein were also observed with DMSO-treated HepG2 and Huh7 cells, where 
increases in mRNA were observed with decreases in protein at corresponding time points; 
indeed, although significant increases in transferrin mRNA were seen after 15 days of DMSO 
treatment in Huh7 cells, protein increases were not observed at either 15 or 20 days. This 
could illustrate delays in protein synthesis, although a five day lag between mRNA and protein 
increase would seem to be quite extended. However, as transferrin can be secreted from the 
cell into the medium this may be the explanation for the discrepancies observed (Zakin, 1992). 
Protein assessment from the medium may reveal an increase in transferrin, but the presence 
of serum in the medium could mask any change in secreted human transferrin. 
Assessment of BCRP and P-gp function using Hoechst 33342 and of P-gp, MRP1 and MRP2 
function using calcein-AM was carried out on confluent and DMSO-treated HepG2 and Huh7 
cells and on prolonged untreated Huh7 cells. A lack of effective inhibition in confluent HepG2 
cells by CSA and Ko143, which inhibit P-gp and BCRP respectively, was not improved upon in 
DMSO-treated cells. Verapamil, also a P-gp inhibitor, was more effective at inhibiting P-gp 
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function in confluent than in DMSO-treated HepG2 cells. Hoechst efflux by both P-gp and BCRP 
was effectively inhibited using verapamil, CSA and Ko143 in confluent Huh7 cells, but the 
effectiveness of the inhibitors was reduced after both prolonged untreated growth and DMSO 
treatment. This could be indicative of increased protein expression; in the case of BCRP, 
increased protein was observed after 15 days of DMSO treatment in both cell lines which could 
account for the reduced effectiveness of Ko143 in inhibiting Hoechst efflux in DMSO-treated 
Huh7 cells in comparison to confluent cells as more BCRP protein is present with an equal 
concentration of inhibitor. The lack of effective inhibition with CSA and Ko143 in HepG2 cells 
could be indicative of decreased expression of the respective transporters in comparison to 
Huh7 cells. mRNA data showed that the MDR1 level in HepG2 at confluence was over 2-fold 
higher than in liver, while the BCRP mRNA level was approximately half of that in liver in 
confluent HepG2 cells. Confluent Huh7 cells had an MDR1 mRNA level 8-fold lower than that in 
liver and a BCRP mRNA level 30-fold lower than in liver. This difference in potential expression 
levels between the two cell types could explain why inhibition of transporters was successful in 
Huh7 cells but not in HepG2 cells with the same ligand concentrations if protein levels in 
HepG2 were increased over those in Huh7 to such an extent that effective inhibition did not 
take place.  
Calcein-AM was used to study functional P-gp, MRP1 and MRP2 in HepG2 and Huh7 cells.  P-gp 
function was demonstrated in HepG2 and Huh7 cells at confluence, after DMSO treatment and 
after prolonged untreated growth of Huh7 cells. DMSO treatment of HepG2 cells did not alter 
activity of P-gp; when using various MRP inhibitors (CSA, verapamil and MK571) some 
significant differences to confluent cells were lost with DMSO treatment but the overall 
pattern of responses remained the same. This indicates that function of MRP1 and 2 in DMSO-
treated HepG2 cells did not change from that in confluent cells and agrees with mRNA levels 
shown here and in Sivertsson et al. (Sivertsson et al., 2010) where these three transporter 
levels remained consistent in both cell lines after 4 weeks of untreated growth.  
In confluent Huh7 cells MRP2 functional activity appeared to be very low as verapamil, an 
MRP1 inhibitor, produced the same inhibition of calcein efflux as MK571, which inhibits both 
MRP1 and 2. When calcein efflux is mediated by both MRP1 and 2 transporters, MK571 should 
have a greater inhibitory effect than verapamil, which was seen in both confluent and DMSO-
treated HepG2 cells. After both DMSO treatment and prolonged untreated growth of Huh7 
cells, the proportion of total calcein effluxed decreased from 60% in confluent cells to 20-25%. 
Additionally, the differences in efflux seen in HepG2 cells by inhibiting MRP1 alone (verapamil) 
or MRP1 and 2 together (MK571) were also seen in both prolonged untreated and DMSO-
treated Huh7 cells, indicating that a more even balance of the transporters has been achieved. 
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This could be either by MRP1 decreasing, MRP2 increasing or a combination of both; mRNA 
data indicated that the MRP1 level in confluent Huh7 cells was approximately 10-fold higher 
than liver, while the MRP2 mRNA level was approximately 200-fold lower than in liver. This 
suggests that MRP1 is expressed at a much higher level in confluent Huh7 cells. As the 
proportion of calcein effluxed was decreased following treatment it is likely that MRP1 protein 
levels or activity were decreased allowing MRP2 activity to become visible. Such changes in 
protein abundance were not predicted by a change in mRNA levels, where MRP1 and 2 mRNA 
abundances remained unchanged from control following both DMSO and prolonged untreated 
growth. In their work, Sivertsson et al. (Sivertsson et al., 2010) saw a slight increase in MDR1 
(P-gp) but no change in MRP2 mRNA; protein and functional data were not presented in this 
paper. These protein and functional data indicate a high degree of post-translational 
modification for a number of important genes in these cells which would require more analysis 
of protein generation, modification and transport to the membrane in these cells and 
collection of comparative data from primary hepatocytes in order to fully evaluate their 
potential as an effective in vitro hepatocyte model. 
Overall, the results described do not indicate that a substantially more hepatocyte-like, more 
differentiated cell type has been created from either cell line with 1% DMSO treatment or with 
prolonged untreated growth in Huh7 cells. This is disappointing as a cell with a more hepatic 
profile could be an extremely useful, relatively inexpensive whole cell system for use in early 
stage testing of new compounds in the pharmaceutical industry. Results gained here indicate 
that the effective differentiation of every aspect of a hepatic carcinoma cell would be quite 
difficult to achieve. Initial promising results gained with assessment of differentiation markers 
were not followed by sustained alteration at either mRNA or protein levels of many key 
enzymes and transporters towards levels more indicative of the in vivo hepatocyte. This leaves 
HepG2 and Huh7 cells much where they began, with no definite advantage being achieved by 
prolonged untreated growth or DMSO treatment in terms of the functionality of the cell 
system as a vehicle for assessment of toxicity.  
The HepaRG cell line is a relatively new lineage of cells generated from donated female 
hepatocarcinoma cells. This was first reported by Gripon et al. (Gripon et al., 2002) and initial 
reports of expression of key genes such as CYPs in the cells were promising (Guillouzo et al., 
2007; Aninat et al., 2006; Le Vee et al., 2006). Attempts were made to obtain some of these 
cells from the authors of the papers at the beginning of this project in October-December 2007 
but unfortunately responses were not received to e-mails from myself, Professor Barry Hirst 
(supervisor) and at least one colleague in another department of the university. Although 
initial published results for HepaRG indicated that it was a promising model for hepatic 
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function, publications at the time were not as numerous as those for HepG2 in particular. A 
search on Pubmed shows that between January 2002 and December 2007 a total of 19 
publications mention HepaRG cells; of these, ten discuss differentiation, nuclear receptor 
activation or enzyme and transporter expression and a further eight discuss infection, the 
majority with Hepatitis B virus. Over the span of this project use of these cells has become 
more widespread and they are now commercially available through Invitrogen; unfortunately 
this came too late to utilise the cells here.  
Since the commercialisation of HepaRG there have been many more publications using the 
cells – 15 from January to the end of April 2011 alone. These indicate that HepaRG is a strong 
candidate for use in drug metabolism and toxicity studies when seeded at high density and 
differentiated with 2% DMSO. In particular, the expression of many CYP enzymes has been 
confirmed at mRNA, protein and functional level by several groups; a search in Pubmed with 
the key words HepaRG and CYP3A4 produces 17 relevant publications, but HepaRG plus MDR1, 
P-gp or P-glycoprotein reveals only two matches. This is understandable as a known issue with 
other hepatic cell lines including HepG2 is the low expression of CYPs, especially CYP3A4, a key 
metabolic pathway in in vivo hepatocytes which can also be lost early after primary hepatic 
isolation (Sivertsson et al., 2010; Olsavsky et al., 2007). Nevertheless, transport proteins are 
important in metabolic studies and need to be analysed in these cells. Recent advances in the 
knowledge of the HepaRG gene expression profile have involved whole genome comparisons 
of HepaRG, HepG2 and primary human hepatocytes (Hart et al., 2010; Jennen et al., 2010). 
Hart et al. (Hart et al., 2010) showed that both the HepaRG whole genome expression profile 
and the expression profile of drug-processing genes in particular are more similar to those of a 
primary hepatocyte than are those of HepG2. Jennen et al. (Jennen et al., 2010) analysed 
whole genome expression after exposure to toxic substances and surmised that HepaRG cells 
were more suitable than HepG2 for identifying further biological consequences of toxin 
exposure, while HepG2 cells were more suitable for some cases of substance classification. 
Additional analysis of baseline genome expression in this publication agreed with Hart et al. 
(Hart et al., 2010) in that HepaRG expression was closer to that of liver and primary human 
hepatocytes than was HepG2. 
Publications are now being released which show attempts to improve HepaRG further. Darnell 
et al. (Darnell et al., 2011) have cultured HepaRG cells in a 3D bioreactor which enabled 
maintenance of the differentiated state without continued DMSO presence in the media and 
also prompted the cells to polarise similarly to the state in which they are found in vivo. 
Bednarkiewicz et al. (Bednarkiewicz et al., 2010) have experimented with eliminating the 
biliary cells found in all terminally differentiated HepaRG cell populations by increasing 
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photosensitivity and subsequently selecting specific cells for elimination by applying UV light. 
McGill et al. (McGill et al., 2011) have shown that HepaRG is a suitable model to study the 
effects of paracetamol toxicity showing comparable results to those observed in primary 
mouse hepatocytes and rodent in vivo models. However, caution must be used when looking 
into results for these cells. Ceelen et al. (Ceelen et al., 2011) noted that many of the previous 
publications analysing mRNA levels in HepaRG cells used 18S rRNA as a reference gene. Upon 
conducting analysis of the suitability of reference genes in HepaRG cells with three different 
algorithms, including the GeNorm software used here, 18S rRNA was ranked among the least 
stable by all three. This could call into question previous claims of superiority of this cell line 
based on mRNA alone, making it especially important that relevant protein and functional data 
are produced. 
Another promising avenue of research centres around transdifferentiation of pancreatic cells 
into hepatocytes. This was first reported by Shen et al. (Shen et al., 2000) where the rat 
pancreatic cell line AR42J-B13 was shown to progressively develop hepatic markers in culture 
with 1 µM dexamethasone for up to 14 days. Addition of 10 ng/ml OSM further improved the 
expression of hepatic markers such as albumin and glucose-6-phosphatase (G6P). This paper 
also demonstrated a similar effect of dexamethasone on pancreatic buds isolated from mice, 
showing that the observed generation of hepatocyte-like features was not limited to a 
particular cell line. This work has been continued further since the original publication, with 
subsequent data showing detection of CYP3A1, CYP2B1/2, glucokinase and aryl 
sulfotransferase IV by immunostaining after treatment with dexamethasone for up to 28 days 
(Tosh et al., 2002). Marek et al. (Marek et al., 2003) also analysed protein levels of various CYP 
enzymes in transdifferentiated AR42J-B13 cells by Western blotting and found that CYP 2C11, 
2A, 2E and 3A1 levels were similar to those in freshly-isolated rat hepatocytes. Continued 
analysis has revealed the presence of transferrin, UGT, CYP2E1 and carbamoyl phosphate 
synthetase-I (CPS) protein along with sensitivity to paracetamol toxicity, all of which indicate a 
hepatic phenotype (Wallace et al., 2009; Burke et al., 2006; Marek et al., 2003). Prospective 
signalling pathways involved in the transdifferentiation process have also been investigated, 
notably the transcription factor CCAAT enhancer binding protein β (C/EBPβ) and the WNT 
signalling pathway. Repression of the WNT pathway was found to be concurrent with 
increased hepatic marker expression, while increased C/EBPβ expression correlated with an 
increase in albumin and G6P; over-expression of this transcription factor reduced the number 
of ductal cells generated during the transdifferentiation process, potentially giving a more pure 
hepatic population (Al-Adsani et al., 2010; Wallace et al., 2009; Shen et al., 2000). This 
technique has also been applied to human foetal pancreatic cells, where treatment with 
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dexamethasone and fibroblast growth factor 2 (FGF2) led to increased levels of liver markers 
such as albumin and cytokeratin 19 at both mRNA and protein level (Sumitran-Holgersson et 
al., 2009). When transplanted into nude mice with chemical-induced liver injury, these 
transdifferentiated hepatocyte-like cells successfully engrafted and proceeded to differentiate 
further, indicating that this may be an option for transdifferentiation of pancreatic cells to 
hepatocytes not only for in vitro use but also with possibilities for transplantation.  
Future work 
Several possibilities for future experiments are presented in these publications with regard to 
the cell lines used here, such as extended treatment with dexamethasone alone. Although 
dexamethasone was included here in early experiments with growth factors and in prolonged 
treatments with both growth factors and DMSO (chapter 4), experiments with this compound 
alone were not carried out. It would also be interesting to see if disruption of the WNT 
pathway or over-expression of C/EBPβ induced differentiation more effectively than the DMSO 
treatments used here. 
Stem cells have been considered as a promising avenue for the creation of a sustainable source 
of hepatocyte-like cells. In theory, stem cells could be isolated from sources such as human 
embryos, umbilical cord blood, adipose tissue and bone marrow, and kept in an 
undifferentiated state until required for use. At this point, stem cells could be directed through 
the desired differentiation process, for example to endoderm followed by hepatic specification 
and maturation, by a series of specific treatments at pre-determined time points. This would 
allow the generation of hepatocyte-like cells for use when desired from a continually 
proliferating stem cell store by a standard culture procedure, resulting in an easily accessible 
and reproducible model for toxicity studies. Although attempts to induce differentiation of 
hepatocyte-like cells have been made by a number of groups, the endpoint of a cell which fully 
represents an in vivo hepatocyte has yet to be reached. Common observations are increased 
levels of hepatic markers such as albumin, AFP and G6P (Agarwal et al., 2008; Hay et al., 2008; 
Hossein Baharvand, 2008; Philippe A. Lysy, 2008; Baharvand et al., 2006; Snykers et al., 2006). 
Although such markers will increase during differentiation from a stem cell to an hepatocyte-
like cell, markers of a foetal liver phenotype such as AFP should then decrease with further 
maturation towards the true hepatic lineage (Cascio and Zaret, 1991). This increase and 
subsequent decrease in AFP was observed by Snykers et al. (Snykers et al., 2006) using rat 
BMSCs, along with detection of CYP1A1 and 2B1/2 protein, but has not been mentioned in 
many of the other publications which report only an increase in AFP (Agarwal et al., 2008; Hay 
et al., 2008; Hossein Baharvand, 2008; Philippe A. Lysy, 2008; Baharvand et al., 2006). Levels of 
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key hepatic proteins such as CYP3A4 do not reach levels observed in primary hepatocytes; Lysy 
et al. (Philippe A. Lysy, 2008) report no detection of CYP3A4 mRNA, whilst Agarwal et al. 
(Agarwal et al., 2008) report levels lower than that in HepG2 cells, which have been shown in 
work here to be much lower than those in liver. More recent publications have continued in 
this vein and attempted to develop improved differentiation protocols. Protocols used by Duan 
et al. (Duan et al., 2010) demonstrated more success using fibroblast growth factor 4 (FGF4), 
hepatocyte growth factor (HGF), bone morphogenic proteins 2 and 4 (BMP2, BMP4) and 0.5% 
DMSO, with differentiated hepatocyte-like cells shown to express several important phase I 
and II metabolising proteins such as CYP3A4, -1A2 and UGT1A1 and the transporters MRP1 and 
OATPC. Confirmation of functional expression of CYP3A4, -1A2, -2C9 and -2D6 was also 
documented and was similar to that observed in primary hepatocytes. Expression here 
appears to be an improvement over that in past differentiation regimes and this or other 
similar protocols could be a major improvement in the similarity of stem cell-derived 
hepatocyte-like cells to the in vivo ideal. 
Attempts to further improve upon this technology have been made, in particular in improving 
the culture environment of the cells. 2D growth on plastic, often with coatings of substances 
such as collagen, allows the cells to survive and differentiate to an extent but does not mimic 
the in vivo conditions. Baharvand et al. (Baharvand et al., 2006) observed that markers of 
differentiation were detected earlier and higher levels of urea production were obtained when 
hESC-derived hepatocyte-like cells were grown in a 3D environment with collagen scaffolds 
rather than a 2D one. More recently, Miki et al. (Miki et al., 2011) also observed that more 
functional maturation was seen in 3D cultured hESCs than in 2D cultured ones. These 
observations indicate that if differentiation to genuine hepatocyte-like status in a 2D system 
does prove to be unattainable, moving the differentiation process to a 3D system may give an 
additional functional boost to the cells. Alternatively, if the maturation process can be 
accelerated by moving to a 3D system, this would add to the usefulness of the cells overall. 
A common feature in the many published differentiation protocols is the use of growth factors 
in the media. Here, preliminary and extended growth factor treatments were applied to both 
HepG2 and Huh7 cells. Initial growth factor experiments, with media formulae based on final-
step maturation cocktails from the literature, were not successful as the cells proliferated 
extensively and could not be maintained successfully for the extended time periods indicated 
in other publications (10 days plus) (Agarwal et al., 2008; Hay et al., 2008; Hossein Baharvand, 
2008; Philippe A. Lysy, 2008; Jun Cai, 2007; Baharvand et al., 2006; Snykers et al., 2006; Kurash 
et al., 2004). When 1% DMSO was added to the growth factor mixtures cells could be 
maintained for longer; however, little additional effect above that of DMSO alone was seen. 
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Although the final step from multi-step protocols was applied, it could be that these hepatic 
carcinoma cells are already differentiated beyond the point at which the selected growth 
factors (HGF, OSM or HGF plus OSM all with dexamethasone and 1% DMSO) can improve upon 
the phenotype and a different maturation protocol is required to improve the cells further. 
The relevant receptors could be expressed at low levels in these cell lines, or the serum 
content of the media could be limiting the observed response due to the presence of similar 
growth factors already having had an effect. One way to limit the impact of additional factors 
in serum would be to use dialysed serum and add in hormones and growth factors as required. 
3D growth of these cell lines, with or without DMSO, may also have a maturation effect. 
Increases in albumin production and in CYP enzymes were observed in HepG2 cells cultured in 
a rotating bioreactor in comparison to those grown in 2D conditions (Chang and Hughes-
Fulford, 2009). Similar functional changes were observed by Lee et al. (Lee et al., 2009) with 
HepG2 cells grown on inverted colloid crystal (ICC) scaffolds in 96 well plates. Huh7 cells grown 
in 3D conditions using microcarrier beads in a bioreactor were shown to have increased 
expression of albumin, CYP3A4, CYP2D6 and UGT1A1 mRNAs as well as other relevant hepatic 
genes over a period of 26 days and in comparison to confluent 2D-cultured cells (Sainz et al., 
2009).These results indicate that 3D growth of the cell lines used here may elicit a more 
hepatocyte-like cell and is a future direction which could yield promising results. 
Bioartificial liver (BAL) systems consist of a combination of mechanical and biological features 
which function as a substitute during instances of liver failure. These systems incorporate living 
primary or secondary cell line hepatocytes, generally from either human or porcine sources, 
into a bioreactor system where the cells are immobilised and cultured. Blood or plasma from 
the patient is passed through the BAL system which aims to provide enough hepatic function 
to bridge the gap between liver failure and transplant or regeneration (Carpentier et al., 2009; 
Yu et al., 2009; Park and Lee, 2005; Strain and Neuberger, 2002; Cao et al., 1998; Mito, 1986). 
Current BAL systems used clinically have large scope for improvement which could be aided by 
finding a more suitable cell population. The extracorporeal liver assist device (ELAD) utilises 
the C3A cell line, which is derived from the HepG2 cell line (Ellis et al., 1996; Sussman et al., 
1994; Kelly and Darlington, 1989) and is the one of the only devices to utilise a cell line rather 
than primary hepatocytes. However, initial clinical trials showed that no distinct advantage 
was gained by use of this BAL with increases observed in plasma levels of both ammonia and 
bilirubin (Park and Lee, 2005). The reasoning behind the use of C3A was that unlike HepG2, it 
does produce urea, an essential function of the hepatocyte. However, it was assumed that this 
urea production was via the urea cycle, whereby ammonia is detoxified and urea is a by-
product. This was found to be an incorrect assumption as reported by Mavri-Damelin et al. 
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(Mavri-Damelin et al., 2008) where urea was instead produced via a mechanism independent 
of the urea cycle and the urea cycle in C3A cells is non-functional, making it unsuitable for use 
as an ammonia-detoxifying component in BAL systems. Several other systems currently in 
development utilise porcine primary hepatocytes but these present problems with 
immunorejection and the possibility of animal pathogen transmission; in clinical trials these 
have also been shown to provide no significant improvement in survival rates of patients with 
acute liver failure (Demetriou et al., 2004).  
Improving the culture conditions of the cellular component in BAL systems to promote the 
desired characteristics, whether using cell lines such as HepG2 or primary hepatocytes, may 
allow for vast improvement in the BAL without continual harvesting of human primary 
hepatocytes. For example, Coward et al. (Coward et al., 2009) demonstrated that HepG2 cells 
stably transfected with both ornithine carbamyl transferase and arginase 1, which are key 
components of the urea cycle absent from standard Hepg2 cells, followed by encapsulation in 
alginate and culture in a microgravity environment before being used in a fluidised bed 
bioreactor could efficiently carry out all metabolic, synthetic and detoxification functions 
required from a BAL device. This system would be a viable option to expand and test in a BAL 
device in a clinical setting and could potentially yield cells which would be useful in the drug 
development industry. Further experiments using these encapsulated HepG2 cells have 
attempted to cryopreserve the cells in this state, eliminating the process of encapsulation 
before use and potentially making these cells more easily available for use in BAL systems 
(Massie et al., 2011). 
So far, primary hepatocytes remain as the gold standard cellular system for assessment of drug 
toxicity. However, as outlined previously, high costs, unpredictable availability and failure to 
thrive in vitro means another system is required for early stage, routine testing. Potentially an 
improvement in the culturing conditions of primary hepatocytes could prolong their useful life; 
alternatively, a change in the culture of cryopreserved hepatocytes could result in that system 
improving. Factors which may improve expression and lifespan of these cells are similar to 
those identified for cell line culture and stem cell differentiation, such as specialised culture 
media, co-culture alongside other liver cell types and 3D culture to mimic the in vivo structure. 
Co-culture of hepatocytes with endothelial, stellate and Kupffer cells have all been shown to 
improve the function or longevity of hepatocytes in vitro (as reviewed by Dash et al. (Dash et 
al., 2009)). This is widely thought to be a result of secreted growth factors and cell-cell 
signalling; for example, HGF, which promotes hepatocyte mitosis, is synthesised by hepatic 
stellate cells and co-culture has been shown to result in continued expression of albumin and 
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CYP enzymes in hepatocytes after two months in culture (Riccalton-Banks et al., 2003). 3D co-
culture systems have also been investigated for improvements in hepatic function. An example 
of such a system is described by Kim et al. (Kim and Rajagopalan, 2010), where hepatocytes 
were cultured alongside liver sinusoidal epithelial cells using a construct designed to mimic the 
physical separation seen in vivo. This resulted in increased expression of albumin and stable 
levels of urea production after 12 days of culture, whereas hepatic monolayers showed a 65% 
decrease in albumin after 12 days of culture. Ideas such as these may be useful in cell line 
differentiation in the future, however if the aim is to use the resulting cells as early drug 
toxicity models, other mechanisms such as 3D culture alone may provide sufficient advantage 
over existing models while further development is undertaken. 
The study of liver development and regeneration processes may provide vital clues to the 
types and timing of growth factor applications required to develop a truly representative 
hepatic model. It is thought that fibroblast growth factors (FGFs) and bone morphogenic 
proteins (BMPs) along with activation of several hepatocyte nuclear factors (HNFs) are 
required for initial liver cell differentiation during early foetal liver development (Rossi et al., 
2001; Darlington, 1999). This information is reflected in attempts to differentiate stem cells in 
vitro, several of which incorporate these factors (Tuleuova et al., 2010; Agarwal et al., 2008; 
Snykers et al., 2007; Schuldiner et al., 2000). Liver regeneration relies on a large number of 
factors such as IL-6, TNFα, EGF, HGF, FGF1, TGFα, TGFβ, insulin and norepinephrine 
(Michalopoulos and DeFrances, 1997; Evarts et al., 1993). Although these generate important 
information on the required factors for differentiation, the precise manner in which they 
influence a cell to regenerate is unknown and so cannot be directly applied to in vitro 
hepatocytes, where this process could potentially be used to expand and maintain 
populations. The same is true for differentiation of liver stem cells and hepatic progenitor cells, 
which are difficult to isolate and in the case of progenitor cells, in short supply in a healthy 
liver, as reviewed in Tosh et al. (Tosh and Strain, 2005) and Sangan et al. (Sangan and Tosh, 
2010). Evidence of successful maturation of progenitor cells using co-culture with hepatic 
stellate cells was presented recently with raised expression of albumin and HNF4α and 
decreased expression of AFP and CK19 indicating a more mature hepatocyte (Chen et al., 
2009). Additional work to investigate enzyme and transporter levels in comparison to primary 
hepatocytes is required to confirm maturation and suitability for drug transport and 
metabolism studies. 
In conclusion, I suggest that greater success is more likely to be gained from attempted 
differentiation of cells which are already closer in expression to that of a true hepatocyte than 
HepG2 and Huh7 used here; perhaps an immortalised line or transdifferentiated cells which do 
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not have the inherent changes of carcinoma cells. Although analysis of the HepaRG cell line at 
this stage is not complete, available data are indicative of a cell system more comparable to 
primary hepatocytes than either the HepG2 or Huh7 lines both before and after treatment. 
More may be gained by continued evaluation and development of HepaRG rather than 
attempted refining of the models created here. Alternatively, advances in the understanding of 
the differentiation and regeneration processes may result in sufficient knowledge to enhance 
protocols for application to stem cells from various sources and allow hepatocyte-like cells to 
be reliably produced from that avenue of research. Co-cultures of hepatic cell types also 
appear to have promise in prolonging the effective life of both cryopreserved and primary 
hepatocytes; for now, primary hepatocytes remain the gold standard toxicology prediction 
model. 
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Appendix A 
Krebs and lysis buffer recipes used in experiments in chapters 7 and 8 are detailed here. All 
reagents were purchased from Sigma (Dorset, UK) unless otherwise stated. 
Krebs buffer 
NaCl   137mM 
KCl   5.4mM 
CaCl2  2.8mM 
MgSO4  1mM 
NaH2PO4 0.3mM 
KH2PO4  0.3mM 
Glucose 10mM 
HEPES  10mM 
pH to 7.4 with Tris base in 1L of deionised water 
Lysis buffer for Hoechst 33342 experiments  
EDTA (pH 8) 0.625mM 
EGTA (pH 8) 1mM 
Sucrose  0.64mM 
Tris (pH 7.6) 1mM 
Triton X-100 0.05% 
Made up to 40ml in deionised water.  
 
Protein lysis buffer (samples for Western blots) 
SDS  0.002% 
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Nonidet P-40 0.2ml 
DTT  1µM 
Complete protease inhibitor cocktail tablets – 1 per 10ml (Roche) 
Made up to 10ml with 1x PBS. 
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Appendix B 
Sigma datasheet I2521 
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